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Abstract
Juvenile CLN3 disease is a rare lysosomal storage disease, and the most common cause
of neurodegeneration in children. Since the identification of the disease gene (CLN3)
in 1995, efforts in various cellular and animal models have led to CLN3 being associ-
ated with several cellular pathologies. However, its precise molecular function remains
unknown. Furthermore, with only a limited knowledge of disease pathogenesis, there
remains a considerable need to identify therapeutic targets in order to accelerate the
development of therapies for this prematurely fatal disease.
Schizosaccharomyces pombe has proved to be a powerful and accurate model to
help elucidate the function of CLN3 by virtue of its evolutionary conserved orthologue,
btn1+. To date it has revealed both a new cellular localisation and potential functions
for btn1+.
The primary aim of this project was therefore to further exploit this fission yeast
(btn1∆) model, and use synthetic genetic array analysis (SGAs) to identify genome-
wide, genetic interactions of btn1+. It was hypothesised that defining the genetic rela-
tionships of btn1+ would provide insight into its molecular role, which in turn could be
used to infer CLN3 gene function. It was also hoped that such information could be
used to identify therapeutic targets and help refine the focus of future work in higher
eukaryotic models.
Using such an approach, this thesis provides a considerable step in our understand-
ing of the function of btn1+, and by extrapolation CLN3, by suggesting that their func-
tion likely converges with various stress response pathways. A comprehensive charac-
terization of the btn1∆ strain revealed numerous phenotypes co-incident with known
stress response mutants, suggesting that this strain indeed displays compromised stress
signalling which may contribute to disease pathogenesis.
This thesis also details a number of therapeutic targets as the genetic manipulation
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of two highly conserved mitogen activated protein kinase pathways (the cell wall in-
tegrity (CWI) pathway and stress associated protein kinase (SAPK) pathway) and the
interconnected TOR kinase complexes, are shown to rescue aspects, if not all, of the
btn1∆ phenotypes investigated. This is the most successful rescue of disease pheno-
types in any model for juvenile CLN3 disease to date.
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Chapter 1
Introduction
Juvenile CLN3 disease is the most common cause of neurodegeneration in children, and
arises due to the autosomal recessive inheritance of mutations in CLN3. Although the
causative disease gene was identified in 1995, establishing CLN3 function has, to date,
proved exceedingly difficult. In turn, a poor understanding of disease pathogenesis
has complicated therapeutic developments and there remains a considerable need for
accurate therapeutic targets.
Given the difficulties in determining CLN3 gene function, simple model systems
that lend themselves to hypothesis-free approaches can prove particularly valuable in
providing functional information. Furthermore, the development of innovative techni-
cal tools to expand the utility of such models may also prove beneficial. To this end, this
thesis details a comprehensive genetic approach performed in a Schizosaccharomyces
pombe yeast model for juvenile CLN3 disease. It also describes the initial attempts at
creating additional tools that may provide yet more benefit in the future.
The aim of this Introductory chapter is to provide an overview of the information
that was available at the onset of this work, and is needed to understand the rationale
and design of this project. Accordingly, a detailed background to the neuronal ceroid
lipofuscinoses (NCLs) and specifically juvenile CLN3 disease is provided. Known
literature regarding the structure, localisation, and possible function of CLN3 is dis-
cussed, and this information is placed within the context of why CLN3 gene function
has been especially difficult to determine. The animal models that are available for
studying this disease are also presented, with a particular focus on the importance and
utility of fission yeast. Lastly, the specific aims of the project are described.
1.1. The Neuronal Ceroid Lipofuscinoses (NCLs) 20
1.1 The Neuronal Ceroid Lipofuscinoses (NCLs)
The NCLs are a group of at least 14 genetically distinct, neurodegenerative lysosomal
storage diseases (LSDs) that exhibit the unifying feature of auto-fluorescent lipopig-
ment accumulation within the lysosomes of most cells (Haltia and Goebel, 2012; War-
rier et al., 2013; Mole and Cotman, 2015). The majority of the NCL subtypes have an
autosomal recessive mode of inheritance and predominately affect children. They also
share a number of similar clinical features, and can be broadly characterised by a loss
of vision, seizures, progressive mental and motor deterioration, and ultimately prema-
ture death (Haltia, 2003). Despite these similarities, the NCLs do however show a large
degree of clinically heterogeneity in terms of their age-of-onset and rate of progression.
Although individually rare, collectively the NCLs represent the most common
of the paediatric neurodegenerative disorders. Rare adult-onset forms have been de-
scribed, which can display either autosomal dominant or recessive inheritance, with
some lacking visual symptoms (Arsov et al., 2011; Cadieux-Dion et al., 2012; Smith
et al., 2013).
The first clinical description of any NCL is accredited to Dr. Otto Christian Sten-
gal who, in 1826, described four siblings presenting at six years with deteriorating eye
sight, progressive mental deterioration, loss of speech, epileptic fits, and premature
death. Although largely overlooked, by the early 20th century an increasing number
of familial cases of similar presentation had been recognised, all of which displayed
lipid-like accumulations within nerve cells upon autopsies (reviewed in Haltia (2006)).
These common findings led to all such cases being considered as variants of the ‘amau-
rotic family idiocies’, a term introduced in 1896 by the neurologist Dr. Bernard Sachs
(Sachs, 1896).
Over time, comparative histochemical and electron microscopy studies found that
the amaurotic family idiocies were in fact biochemically heterogeneous. While the ma-
jor storage material of the prototype amaurotic family idiocy described by Sachs was
found to be GM2-ganglioside, many other variants exhibited material resembling the
autofluorescent lipopigments ceroid and lipofuscin. Accordingly, in 1969 Drs. Wolf-
gang Zeman and Paul Dyken introduced the term ‘neuronal ceroid lipofuscinosis’ as a
histochemical classification to distinguish those diseases accumulating ceroid and lipo-
fuscin from Tay-Sachs disease and the other gangliosidoses (Zeman and Dyken, 1969).
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Figure 1.1: The various ultra-structural appearances of storage material seen in dif-
ferent NCL subtypes. [A] Granular osmiophilic deposits, as seen in infantile CLN1 dis-
ease (x10,000). [B] Curvilinear profiles, as seen in late-infantile CLN2 disease (x20,000).
[C] Fingerprint bodies as seen in juvenile CLN3 disease (x30,000). [D] Rectilinear com-
plexes as seen in variant forms of late infantile disease, arising from mutations in CLN6
(x15,000). All taken from Haltia (2003).
It was only later realised that the predominant storage material seen in the NCLs
is protein rather than lipids. Depending on the NCL subtype, the storage material is
enriched either for subunit c of the mitochondrial ATP synthase or lysosomal saposins
A and D. The proportion of the protein component varies between NCL subtypes and
appears to partially correlate with the ultra-structure of the storage material when visu-
alised by electron microscopy (Jolly and Palmer, 1995; Haltia, 2006). Four basic types
of storage pattern are described; granular osmiophilic deposits, curvilinear profiles,
fingerprint bodies, and rectilinear complexes (Figure 1.1).
In 1976, a classification system specific for the NCLs emerged that was largely
based on the age-of-onset and the characteristic ultra-structural morphology of the
storage material. This system recognised four main human NCL subtypes; infantile
(INCL), late-infantile (LINCL), juvenile (JNCL), and adult (ANCL), although disre-
garded the few known congenital cases of NCL and variant forms that became evident
in subsequent decades (Dyken, 1988).
In the early 1990s, genetic linkage studies prompted the reclassification of the
NCLs on a numerical, molecular genetic basis (Bennett and Hofmann, 1999). Then in
1995 the precise genetic basis of the NCLs began to emerge, starting when palmitoyl
protein thioesterase 1 (PPT1 or CLN1) was identified as the gene underlying infantile
NCL. In the same year, the concerted effort of the International Batten Disease Consor-
tium identified CLN3 as the gene mutated in juvenile NCL (The International Batten
Disease Consortium, 1995).
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Since that time, the number of verified human NCL genes has increased to
also include CLN2/TPP1, CLN4/DNAJC5, CLN5, CLN6, CLN7/MFSD8, CLN8,
CLN10/CTSD, and most recently CLN11/GRN (Smith et al., 2012), CLN12/ATP13A2
(Bras et al., 2012), CLN13/CTSF (Smith et al., 2013) and CLN14/KCTD7 (Staropoli
et al., 2012b). Numerous mutations and variants have been identified at each ge-
netic loci (Kousi et al., 2012; Mole and Cotman, 2015) and are listed in a recently
revised NCL Mutation and Patient Database (www.ucl.ac.uk/ncl/mutation.
shtml). It is generally accepted that other NCL genes are yet to be identified, some of
which have provisionally been given CLN designations (e.g.: CLN9).
As the understanding of the underlying genetics has developed, it has become
apparent that while a phenotype described by the age-of-onset and ultra-structure ap-
pearance typically associates with defects in one specific gene, this is far from absolute.
Rarer mutations in a given gene can instead be associated with atypical symptoms or
a protracted disease course (Mole et al., 2005). For example, mutations in CLN1 are
normally associated with infantile NCL, but some mutations can delay the onset to a
late-infantile, juvenile, or adult presentation. In response to this complexity and confu-
sion of the NCL spectrum caused by clinical, genetic and allelic heterogeneity, the most
recent refinement of the classification system is an axial system, based on the under-
lying genetics combined with key clinical and pathological features to unambiguously
place patients into the correct classical or variant NCL subtype (Kousi et al., 2012;
Williams and Mole, 2012) (Table 1.1).
Table 1.1: NCL Genes, protein names, and associated diseases. The 14 currently
known NCL genes are shown, with a description of the protein product (if known), and
the NCL subtypes they associate with. Some mutations in these genes are also associated
with other non-NCL diseases which are shown in italics within parentheses for clarity.
Adapted from Kousi et al. (2012) and Mole and Cotman (2015).
Gene Name Protein Name Disease
CLN1 /
PPT1
Palmitoyl protein
thioesterase 1
CLN1 disease, classic infantile
CLN1 disease, late infantile
CLN1 disease, juvenile
CLN1 disease, adult
Continued on next page
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Table 1.1 – Continued from previous page
Gene Name Protein Name Disease
CLN2 /
TPP1
Tripeptidyl peptidase 1 CLN2 disease, classic late infantile
CLN2 disease, juvenile
CLN2 disease infantile
CLN3 / CLN3 disease, classic juvenile
CLN3 disease, protracted
CLN3 disease, infantile
(Autophagic vacuolar myopathy)
(Retinitis pigmentosa)
(Cone-rod dystrophy)
CLN4 /
DNAJC5
Cysteine-string protein
alpha (CSPα)
Adult (autosomal dominant) NCL
disease or Parry disease
CLN5 / CLN5 disease, late infantile variant
CLN5 disease, infantile
CLN5 disease, juvenile
CLN5 disease, adult
CLN6 / CLN6 disease, late infantile variant
CLN6 disease, adult or Kufs Type A
disease
(Juvenile cerebellar ataxia)
(Teenage progressive myoclonic
epilepsy)
CLN7 /
MFSD8
Major facilitator su-
perfamily domain 8-
containing protein
CLN7 disease, late infantile variant
CLN7 disease, juvenile
(Macular dystrophy)
(Cone-rod dystrophy)
CLN8 / CLN8 disease, late infantile variant
(Progressive epilepsy with mental
retardation (EPMR))
Continued on next page
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Gene Name Protein Name Disease
CLN9 / Undetermined
CLN10 /
CTSD
Cathepsin D CLN10 disease, congenital
CLN10 disease, juvenile
CLN11 Progranulin proepithelin CLN11 disease, adult
(Frontotemporal lobar dementia (if
heterozygous))
CLN12 /
ATP13A2 /
PARK9
Lysosomal type 5 P-type
ATPase 13A2
Juvenile NCL disease
(Kufor-Rakeb syndrome)
CLN13 /
CTSF
Cathepsin F (CTSF) Adult (autosomal recessive) NCL
disease or Kufs Type B disease
CLN14 /
KCTD7
Potassium channel
tetramerisation domain
containing protein 7
Infantile NCL disease
(Progressive myoclonic epilepsy)
1.1.1 The NCL Proteins: Localisation, Function, and Interactions
As discussed above, the NCLs share the unifying features of ceroid and lipofuscin ac-
cumulation, and several clinical manifestations. Further, and perhaps most notably,
even though all identified NCL genes are ubiquitously expressed and the storage mate-
rial is seen in many tissues, the NCLs principally (although not exclusively) manifest
as diseases of the central nervous system (CNS). This arises due to the highly selective
loss of certain neurons, with populations of GABAergic interneurons, thalamocortical
projection neurons and cerebellar Purkinje neurons being particularly affected in early
disease of various NCL subtypes. There is also a loss of small neurons in the cerebral
cortical layer II and of pyramidal neurons of layer V, and a loss of neurons in the cere-
bellum and hippocampus (especially within the CA2-CA4 subfields) (Mitchison et al.,
2004; Williams et al., 2006; Anderson et al., 2012; Cooper et al., 2015). Aside from
the adult onset forms, there is also retinal degeneration, the degree of which does not
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correlate with that of cerebro- or cerebello-cortical atrophy (Williams et al., 2006).
Yet, despite these similarities, there is insufficient sequence and domain similarity
between the encoded NCL proteins to suggest they perform similar functions (Muzaffar
and Pearce, 2008). This is perhaps not surprising however, given that the NCL genes
encode a vast array of different products, including both soluble enzymes (such as
lysosomal enzymes) and membrane-bound proteins. The gene products also display
a range of subcellular localisations, including the lysosomes, endoplasmic reticulum
(ER), and Golgi (Table 1.2). Therefore, how and why a diverse number of protein
products can give rise to similar cellular and clinical pathologies remains to be fully
explained.
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Table 1.2: NCL Genes, protein function, topology, and subcellular localisation. The
14 currently known NCL genes are shown, with a description of the protein product (if
known), protein topology, and their subcellular localisation. Adapted from Kollmann
et al. (2013).
Gene Name Protein Function Protein Type Localisation
CLN1 /
PPT1
Palmitoylthioesterase;
removes palmitate
groups from S-acylated
proteins
Soluble enzyme Lysosomal matrix,
extralysosomal vesi-
cles, extracellular
CLN2 /
TPP1
Serine protease; re-
moves tripeptides from
the N-terminus of small
polypeptides
Soluble enzyme Lysosomal matrix
CLN3 Unknown Transmembrane
protein
Endosomal and lyso-
somal membranes,
presynaptic vesicles
CLN4 /
DNAJC5
Hsp70 co-chaperone
involved in endo- and
exocytosis
Soluble protein Cytosolic, associ-
ated with vesicular
membranes
CLN5 Unknown Soluble protein Lysosomal matrix
CLN6 Unknown Transmembrane
protein
ER membrane
CLN7 /
MFSD8
Major facilitator su-
perfamily member, but
substrate is unknown
Transmembrane
protein
Lysosomal mem-
brane
CLN8 Unknown Transmembrane
protein
ER/ERGIC mem-
brane
CLN9 Unknown Unknown Unknown
CLN10 /
CTSD
Aspartyl endopeptidase Soluble enzyme Lysosomal matrix,
extracellular
CLN11 Soluble enzyme Extracellular
Continued on next page
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Table 1.2 – Continued from previous page
Gene Name Protein Function Protein Type Localisation
CLN12 /
ATP13A2 /
PARK9
Unknown Transmembrane
protein
Lysosomal mem-
brane
CLN13 /
CTSF
Cysteine protease Soluble enzyme Lysosomal matrix
CLN14 /
KCTD7
Unknown Soluble protein Cytosolic, partially
associated to mem-
branes
This question remains unresolved in part because only some of the NCL genes
have been functionally characterised. Specifically, the functions of five soluble pro-
teins are known; CLN1 is a palmitoyl thioesterase (PPT1) and underlies infantile NCL
(Vesa et al., 1995), CLN2 is tripeptidyl peptidase 1 (TPP1) and underlies late-infantile
NCL (Sleat et al., 1997), CLN10 is cathepsin D (CTSD) and underlies the rare con-
genital form of NCL (Siintola et al., 2006), and CLN13 is cathepsin F and underlies
the recessive, adult onset Type B Kufs Disease Smith et al. (2013). All four of these
enzymes are present in the lysosomal matrix as detailed in Table 1.2.
CLN4 is also a soluble protein, and encodes cysteine-string protein α (CSPα), a
soluble Hsc70 co-chaperone that localises to the cytoplasm and ensures proper protein
folding. Mutations in CLN4 underlie a rare autosomal dominant adult form of NCL
commonly referred to as Parry Disease (Noskova´ and Stra´necky´, 2011; Velinov et al.,
2012). The functions of the soluble proteins CLN5, CLN11, and CLN14 are unknown.
Similarly, the functions of all membrane-bound proteins (CLN3, CLN6, CLN7, CLN8,
CLN11, and CLN12) also remain elusive (Ca´rcel-Trullols et al., 2015). The difficulties
in defining NCL gene functions have arisen in part from their low expression, difficulty
in purification, and lack of homology with other proteins of known function. However,
it has also been complicated by the finding that the ceroid and lipofuscin storage mate-
rial seen in the various NCL subtypes is not disease-specific. For example, not only is
it seen in all NCL subtypes but it is in fact also seen in other non-NCL diseases such
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as Hermansky-Pudlak syndrome (Puranen, 1990). The storage material has therefore
not helped clarify the function of the NCL genes, a benefit that is often afforded to
other classical LSDs where the type of storage material specifically reflects the lack
of a particular lysosomal hydrolase (Seehafer and Pearce, 2006; Ca´rcel-Trullols et al.,
2015).
One attractive hypothesis uniting the NCL genes is that, despite varying functions,
they might participate at different stages in a common biological process (Weimer et al.,
2002). Taking the modest heterogeneity in the protein component of storage material
between the NCL subtypes into account, it is also possible that the NCL genes function-
ally interact in several distinct but non-redundant pathways, and that these converge in
a way that when any one pathway is disrupted the result is a largely common pathology.
Whether this is achieved by physical interactions between the NCL genes was
initially explored using a yeast two-hybrid system, which failed however to find any
interactions between the NCL proteins (Zhong et al., 2000). Nonetheless, later exper-
iments have since suggested that at least some of the NCL genes do interact, either
physically or functionally.
Vesa et al. (2002) were the first to show by co-immunoprecipitation that CLN5
directly interacts with both CLN2 and CLN3 (Vesa et al., 2002). Protein-protein in-
teractions between CLN5 and both CLN2 and CLN3 have been reproduced by Lyly
et al (2009) who also reported interactions between CLN5 and CLN1, CLN6, and
CLN8 (Lyly et al., 2009). Persaud-Sawin et al. (2007) reported extensive data show-
ing that CLN3, CLN6, and CLN8 can functionally complement each other as shown
by their ability to rescue the growth and apoptotic defects observed in patient-derived
cells (Persaud-Sawin et al., 2007). Further, CLN2 was able to correct growth and apop-
tosis in CLN3-, CLN6-, and CLN8-deficient cell lines. All four proteins were also
reported to co-immunoprecipitate and co-localise. CLN1 and CLN2 were also shown
to be capable of complementing the loss of each other, and these proteins similarly
were reported to co-immunoprecipitate (Persaud-Sawin et al., 2007). Haddad et al.
(2012) has reported that CLN8 corrects growth and apoptosis phenotypes in CLN5-/-
fibroblasts (Haddad et al., 2012). Lastly, CLN2, CLN3, and CLN5 have been found
to be both spatially and temporally co-expressed (Fabritius et al., 2014). The amount
of KCTD7 (CLN14) protein is elevated in cerebellar granule cells isolated from Cln3
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deficient mice (Staropoli et al., 2012b), while others have reported defects in cathepsin
D (CLN10) (Golabek et al., 2000) and TPP1 (CLN2) activity (Vidal-Donet et al., 2013)
upon the loss of CLN3, indicative of yet more possible interactions between these pro-
teins. However, the validity of many of these reports have since been called into ques-
tion due to concerns over both experimental design and a reliance on over-expressed
proteins and antibodies of undetermined specificity, which may introduce artefacts and
non-specific interactions (Getty and Pearce, 2011; Ca´rcel-Trullols et al., 2015). Even
so, others have maintained that reports of defective pathways being common to dif-
ferent NCL proteins (i.e. apoptosis, altered lysosomal pH, oxidative stress and others)
do reflect a shared pathogenic link between certain NCL subtypes (Vidal-Donet et al.,
2013; Jones et al., 2014; Chandra et al., 2015).
Yet even if the NCL genes are functionally linked, it is still unclear why their
loss leads to a phenotype in which neurons display a specific vulnerability. Initially it
was assumed that the common ceroid and lipofuscin storage might be central to NCL
pathogenesis by being overly toxic to neurons. There is now evidence to the contrary
however, as there is no direct relationship between neuron loss and storage accumu-
lation (Cooper, 2010; Cooper et al., 2015). Efforts to induce material accumulation
do not impact on neuronal survival in culture, nor does reducing storage improve neu-
ronal survival (Cooper, 2010). Curiously however, storage reduction is commonly used
as a proxy to determine pre-clinical therapeutic success, a practise that should be ap-
proached with more caution given the lack of clear clinical relevance.
That neurons are simply more sensitive to a yet undetermined defective process
compared to other cell types remains a possibility given that these cells exert particu-
larly high metabolic demands, and are highly specialised, polarised post-mitotic cells
with limited capacity for renewal. That the NCL genes play uniquely specific roles
in neurons has also been suggested (Luiro et al., 2001; Kytta¨la¨ et al., 2006), but is not
currently supported by empirical evidence (Cooper, 2010; Getty and Pearce, 2011). Al-
ternatively, there is some evidence that for some NCL subtypes, there are other proteins
that can compensate for the missing gene outside of the CNS, but not within it. For ex-
ample, TPP1 loss can be compensated for by DPP1 (cathepsin C) in somatic tissues,
but DPP1 is not expressed within the CNS (Bernardini and Warburton, 2002). This
leads to an intriguing possibility that the differential expression of other, non-mutated
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genes underlies the neuronal specificity of the NCLs.
Although there are clear gaps in understanding, recognising the shared features
of the NCLs could reveal important biology that could accelerate the understanding
of each of the distinct subtypes. Yet a complete focus on the shared links should not
distract from the absolute need to determine the mechanistic basis of each individual
gene mutation. Further, it should not be forgotten that despite their similarities, there
are stark differences between the NCL subtypes, especially with regard to their age-of-
onset and progression. These differences are important in the clinical setting as they
dictate differential treatment and management requirements. As the focus of the work
presented in this thesis is on the most common of the NCLs, juvenile CLN3 disease, it
is discussed in more detail below.
1.2 Juvenile CLN3 Disease
The autosomal recessive juvenile CLN3 disease is the most common of the NCL disor-
ders, and accounts for approximately 50% of all cases with an incidence of 1 in 25,000
(Mole and Gardiner, 1999). It is caused by mutations in CLN3 (NM 000086.2), a 15
kb gene which encodes a 438 amino acid multi-spanning, hydrophobic transmembrane
protein of 55 or 60 kDa depending on the tissue (The International Batten Disease Con-
sortium, 1995; Ezaki et al., 2003; Mao et al., 2003a; Nugent et al., 2008). There have
been limited reports of the CLN3 protein having several splice variants (Cotman et al.,
2002; Chan et al., 2008).
80-85% of patients are homozygous for a 1 kb deletion (c.461-280 677
+382del966) that is thought to be derived from a common founder and arose from
re-combinational instability (Mitchison et al., 1997a). This deletion causes two tran-
scripts (Kitzmu¨ller et al., 2008). The first, major transcript lacks internal exons 7 and
8, which results in a frameshift and premature termination codon. The truncated pro-
tein that arises from this transcript retains the initial 153 amino acids of the wild-type
protein followed by a novel sequence of 28 amino acids. A second minor transcript
additionally lacks exon 9 due to an exon skipping event, and instead encodes for a
protein that is only missing amino acids 154–263 due to the restoration of an in-frame
RNA sequence at the novel splice site. While there are have been some reports that 1 kb
deleted transcripts are less abundant than wild-type due to nonsense-mediated decay
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mechanisms (Chan et al., 2008; Miller et al., 2013), other evidence from yeast and
mice models suggests that the encoded protein is not degraded, retains some biological
activity, and is therefore not a complete loss-of-function mutation (Kitzmu¨ller et al.,
2008; Kovacs and Pearce, 2015). This finding may explain why CLN3 mutations do
not lead to an earlier disease onset despite it being the most evolutionarily conserved
of the NCL genes, which often suggests the protein is necessary for survival.
The remaining patients are mostly compound heterozygous for the 1 kb deletion
and one of 67 currently described disease mutations (Mole and Cotman, 2015), the
most common of which is another larger deletion of 2.8 kb which removes exons 10-13.
Small indels, missense, nonsense, and splice-site mutations have all also been identified
(Mole and Cotman, 2015). The presence of one of these alternative alleles can lead to
a protracted clinical progression in which long periods free from additional decline are
seen following visual failure, presumably as the resulting protein retains more function
(Munroe et al., 1997; Wisniewski et al., 1998; Lauronen et al., 1999; Kwon et al., 2005;
Aberg et al., 2009; Sarpong et al., 2009; Adams et al., 2010). It should be noted however
that accurate genotype-phenotype correlations are difficult to make given the small
cohort of patients, the considerable phenotypic variability even among patients with
the same genotype (Schulz et al., 2010; Lebrun et al., 2011), and potential influences
from environmental factors (Ja¨rvela¨ et al., 1997). Only nine patients have been defined
who do not carry the 1 kb deletion on either disease allele (Kitzmu¨ller et al., 2008).
Novel mutations remain to be identified in some patients, such as the one case report
of a heterozygous patient with CLN3 disease, infantile whose symptoms started at four
months of age (de los Reyes et al., 2004).
1.2.1 Clinical Symptoms and Pathology
Juvenile CLN3 disease is a progressive disease, and excluding the rare adult forms,
presents with the latest age of onset of the NCLs. Juvenile CLN3 disease classically
manifests with visual failure at four to seven years of age due to retinal degeneration and
optic nerve atrophy (Bohra et al., 2000), which progresses rapidly to complete blindness
within a few years. Impaired vision typically remains the sole symptom of disease for
a few years but is then followed by refractory seizures that begin around the age of
ten and worsen with age. Gradual psychomotor deterioration becomes evident with
1.2. Juvenile CLN3 Disease 32
patients experiencing speech difficulties, a decline in verbal IQ, problems with abstract
reasoning, difficulties orientating to time, and short-term memory issues which develop
into dementia (Lamminranta et al., 2001; Schulz and Kohlschutter, 2013). The decline
in motor function typically begins at around age 12-15 years, and involves parkinsonian
type symptoms including impaired balance, rigidity, hypokinesia, stooped posture, and
shuffling gate (Williams et al., 2006). Patients also develop psychiatric problems that
impact on their quality of life, including attention deficits, aggression, anxiety, and
depression (Ba¨ckman et al., 2005; Hartmann et al., 2006; Kissenbeck et al., 2011).
Sleep problems are also reported. Patients typically die in the third decade following a
long period of complete dependence on palliative care (Haltia, 2003).
While neurological symptoms dominate in juvenile CLN3 disease, the clinical
involvement of the cardiovascular system has also been reported (Hofman et al., 2001;
Ostergaard et al., 2011). Although this finding is so far most evident for juvenile CLN3
disease, there are emerging reports of a cardiac involvement in other NCL subtypes
as well (Fukumura et al., 2012; Fidziaska et al., 2013). Additionally, recent work on
a knock-in murine model, in which the common 1 kb deletion has been introduced
(Cln3∆ex7/8 (Cotman et al., 2002)), has suggested subtle alterations in haematopoiesis
(Staropoli et al., 2012a). A study on a small cohort of female patients has reported a
high incidence of hyperandrogenism, and a lower age of menarche (Aberg et al., 2002).
Following from this, there has been a number of conflicting reports regarding whether
female patients demonstrate more severe psychiatric and cognitive symptoms than male
patients (Ba¨ckman et al., 2005; Adams et al., 2007, 2010). The most recent report has
stated that females do indeed suffer a more severe disease course, but recognises the
need for more rigorous investigation (Cialone et al., 2012).
Unlike other forms of NCL, juvenile CLN3 disease patients exhibit an autoim-
mune response against multiple brain auto-antigens (Lim et al., 2006), although the
precise aetiology and consequences of these antibodies are not fully understood. In-
terestingly, oestrogen can increase antibody production and females are more likely to
suffer from autoimmune diseases (Cutolo et al., 2006), which may explain the potential
sexual dimorphism in terms of disease progression.
Medical imaging techniques are usually normal at early stages of disease (Rain-
inko et al., 1990; Santavuori et al., 2001). Yet, cerebral and cerebellar atrophy is present
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Figure 1.2: Vacuolated lymphocytes seen in blood samples from juvenile CLN3 dis-
ease patients. [A] A semi-thin section of a buffy-coat demonstrating the presence of
vacuolated lymphocytes (arrow). Taken from Anderson et al. (2006). [B] A vacuolated
lymphocyte in a blood smear. Taken from Kohlschu¨tter and Schulz (2009).
after the age of 10-14 years (Autti et al., 1996; Jadav et al., 2014), the severity of which
positively correlates with disturbed mental and motor functions (Raininko et al., 1990;
Autti et al., 1996). At postmortem, juvenile CLN3 disease brains are typically reduced
in weight as a consequence of this atrophy. Pronounced gliosis and astrocyte activa-
tion has also been described at autopsy (Braak and Goebel, 1978, 1979; Tyynela¨ et al.,
2004).
Among the NCL subtypes, vacuolated lymphocytes (Figure 1.2) are an additional,
unique clinical hallmark for juvenile CLN3 disease, and are typically used alongside
genetic tests to aid diagnosis (Santavuori et al., 2001).
1.2.2 CLN3 Structure, Modifications, and Localisation
In order to obtain an accurate protein structure, high-resolution methods such as X-ray
crystallography, nuclear magnetic resonance (NMR) spectroscopy, and sophisticated
electron microscopy methods must be used. However, due to the low expression and
hydrophobicity of CLN3, obtaining the abundant amount of properly folded protein
necessary for such methods has so far been unachievable. Consequently, there have
been varying reports of CLN3 structure. These were based initially simply on homol-
ogy searches and molecular modelling (Janes et al., 1996; Mitchison et al., 1997b), and
later on experimental attempts using the available, although limited, biochemical tools
(Mao et al., 2003a; Ezaki et al., 2003; Kyttala et al., 2004). These studies proposed
a cytoplasmic carboxy-terminus, and between five and eight transmembrane spanning
helices, resulting in either a cytoplasmic or intralumenal facing amino terminus. These
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Figure 1.3: Early schematic of CLN3 structure. [A] Schematic includes the six trans-
membrane helices, with both amino and carboxy termini in the cytosol. Predicted N-
linked glycosylation sites (lines protruding from sequence) and phosphorylation sites
(purple circles) are shown. CaaX and lysosomal targeting sequences are also included.
[B] The truncated topology of mutated CLN3 as proposed by Ezaki et al. (2003) and also
Kyttala et al. (2004). The first 153 amino acids are properly translated along with a novel
sequence of 28 amino acids (light grey). Putative glycosylation sites and phosphorylation
sites are shown as in [A]. Both adapted from Phillips et al. (2005) but do not show the
amphipathic helix in the third lumenal domain, or take the presence of a second splice
variant into account.
experimental predictions were subsequently used to constrain more sophisticated bioin-
formatics tools, leading to a generally accepted six transmembrane model with cytoso-
lic facing N- and C-termini, and an amphipathic helix in the third lumenal domain
(Nugent et al., 2008) (Figure 1.3). Hydrophilicity plots have also indicated that CLN3
is an integral membrane protein (Mao et al., 2003a).
Most recently, Fo¨rster Resonance Energy Transfer microscopy (FRET) has been
used to determine the topology of human CLN3 tagged either internally with eGFP or
myc-tag, or with a near C-terminal eGFP and one myc-tag near the N-terminus which
act as FRET donor-acceptor pairs (Ratajczak et al., 2014). The function of 11 such
clones was assessed by their ability to traffic to the lysosome, and their ability to clear
lysosomal storage in cultured Cln3-mutant murine cells. Functional clones were used
to transiently transfect HeLa cells, and the resultant FRET data used in a membrane
prediction algorithm, also using previous experimental data to serve as a constraint.
1.2. Juvenile CLN3 Disease 35
This approach supports the consensus six transmembrane domain and cytosolic N- and
C-termini model, but differs in its positioning of the transmembrane domains as well
as the size of the lumenal loops. Importantly, these differences would predict a vastly
different topology for the truncated CLN3 arising from the most common 1 kb deletion.
As shown in Figure 1.3, the previous model predicted that mutated CLN3 would retain
three transmembrane domains, but that this would result in the C-termini facing the
opposing side of the membrane from wild-type CLN3. Conversely, this newer model
instead predicts just two transmembrane domains with the consequence that both the N-
and C-termini would remain cytoplasmic facing (Figure 1.4). This has led the authors
to speculate that this may have interesting consequences in terms of understanding the
residual function seen in mutant CLN3, and its role in disease pathology. The vast ma-
jority of disease-causing missense mutations reside on the lumenal face of CLN3 (Mao
et al., 2003a), and mutational analysis performed in yeast has supported the hypothesis
that this lumenal region may have a significant role in normal function.
As eluded to in Figures 1.3 and 1.4, certain structural motifs suggest that CLN3
undergoes several putative post-translational modifications, including glycosylation,
phosphorylation and lipid modifications (Phillips et al., 2005). More specifically, there
are four putative N-glycosylation sites, two putative O-glycosylation sites, and two pu-
tative glycosaminoglycan sites (Ja¨rvela¨ et al., 1998; Golabek et al., 1999). Mutational
analysis in COS7 cells has confirmed that CLN3 undergoes N-linked glycosylation at
asparagine residues 71 and 85, yet at steady state the glycosylated protein represents
only a minor CLN3 fraction (Storch et al., 2007). As discussed below, CLN3 is ob-
served to localise to the lysosome, but this glycosylation is not needed for lysosomal
targeting (Storch et al., 2007). Nonetheless, deletion of the glycosylation sites 71-74
and 310-313 adversely impacts the growth rate and increases apoptosis of immortalised
lymphoblast cells (Persaud-Sawin et al., 2002). CLN3 also has ten serines and three
threonines that could act as potential sites for phosphorylation. There is some in vitro
evidence that CLN3 is phosphorylated (Michalewski et al., 1998, 1999), yet the in vivo
validation and significance of this still remains unclear (Phillips et al., 2005). Despite
initial predictions that CLN3 contains a N-myristoylation site at the amino terminus,
which is conserved in the yeast and Dictyostelium discoideum homologues (Phillips
et al., 2006; Huber et al., 2014), in vivo studies have yet to confirm myristoylation of
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Figure 1.4: Revised schematic of CLN3 structure developed from recent FRET data.
[A] Schematic of a recently revised CLN3 topology based on FRET data. Schematic
includes the six transmembrane helices, with both amino and carboxy termini in the cy-
tosol. Red and green circles are myc and eGFP insertions respectively used as FRET
donor-acceptor pairs. Glycosylation sites (green squares), other modified sites (blue dia-
monds), and the CaaX propetide (grey circles) are shown. Lysosomal targeting sequences
are also included. [B] The truncated topology of mutated CLN3 as proposed by Rata-
jczak et al. (2014). The first 153 amino acids are properly translated along with a novel
sequence of 28 amino acids (grey diamonds). Glycosylation and other modification sites
are shown as in [A]. Both adapted from Ratajczak et al. (2014).
CLN3. CLN3 was also predicted to contain a CaaX motif at the C-terminus, which acts
as the consensus site for farnesylation (a type of prenylation). Interestingly, although
this site is also conserved in various models, others have since failed to find a CaaX
motif in the human CLN3 sequence (Phillips et al., 2005). Nonetheless, prenylation of
CLN3 has been observed in vitro (Kaczmarski et al., 1999) and has been reported to
be required for the efficient sorting of CLN3 to the lysosomes, especially in neuronal
cells (Storch et al., 2007). CLN3 also contains three lysosomal targeting motifs; two
canonical dileucine motifs (one in the second cytoplasmic loop (LI), the other at the C-
terminus (LL)), and a putative targeting motif consisting of a methionine and glycine
residue separated by 9 amino acids (M(X)9G) (Ja¨rvela¨ et al., 1998; Kyttala et al., 2004;
Storch et al., 2004; Kytta¨la¨ et al., 2005). Lastly, CLN3 is described as containing a
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sequence structurally homologous to galactosylceramide (GalCer) lipid raft-binding
domains. Lipid rafts are plasma membrane microdomains rich in glycosphingolipids
and cholesterol, and it has been suggested CLN3 may traffic to lipid rafts via Rab4-
and Rab11-positive endosomes and also act to transport GalCer to lipid rafts (Persaud-
Sawin et al., 2004).
Yet, despite the identification of certain targeting motifs, the precise subcellular lo-
calisation of CLN3 remains unclear. In addition to its low expression and hydrophobic-
ity, full-length CLN3 is toxic when expressed in bacterial systems (Kaczmarski et al.,
1997) and oocyte membranes, and shows a high degree of cross-species conservation.
Therefore, the development of a suitable monoclonal antibody to substantiate CLN3 lo-
calisation has been difficult. Instead, studies have largely relied on tagged/fusion CLN3
proteins (which may or may not accurately reflect native function), or have driven the
exogenous expression of CLN3 from strong over-expression promoters and detected
its localisation using peptide antibodies of questionable specificity. Only one paper has
validated a CLN3-specific peptide antibody by mass-spectrometry (Ezaki et al., 2003),
and this antibody is not commercially available. Many have raised concerns that a re-
liance on such methods may introduce artefacts, and indeed there is disparity between
reports regarding CLN3 localisation (Pearce, 2000; Phillips et al., 2005; Getty et al.,
2013). In fact, CLN3 (or its orthologues) has been seen in the plasma membrane (Mar-
graf et al., 1999), (Mao et al., 2003b), cytoplasm (Margraf et al., 1999), and almost
every subcellular compartment including the nucleus (Margraf et al., 1999), mitochon-
dria (despite not containing a mitochondrial sorting motif) (Katz et al., 1997), Golgi
(Golabek et al., 1999; Kida et al., 1999; Kremmidiotis et al., 1999; Codlin and Mole,
2009; Kama et al., 2011), ER (Ja¨rvela¨ et al., 1998; Kremmidiotis et al., 1999), and
endosomal/lysosomal compartments (Ja¨rvela¨ et al., 1998; Golabek et al., 1999; Kida
et al., 1999; Ezaki et al., 2003; Mao et al., 2003b; Storch et al., 2007). On review of
the available data, it is generally now accepted that in mammalian cells, CLN3 traffics
and functions through the ER and Golgi to the plasma membrane and finally resides
as an integral lysosomal membrane protein (Pearce, 2000; Phillips et al., 2005). Ef-
forts have also been focused on the localisation of CLN3 specifically in neurons, where
it has again been seen in the nucleus (Margraf et al., 1999), cytoplasm (Margraf et al.,
1999), and lysosomes (Kyttala et al., 2004) as well as pre-synaptic vesicles (Luiro et al.,
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2001), synaptosomes (Luiro et al., 2001), and at least by some in the synaptic vesicles
(Ja¨rvela¨ et al., 1999; Haskell et al., 2000). Truncated CLN3 protein, arising from the
1 kb deletion, lacks the lysosomal targeting motifs and has been shown to be retained
in the ER in baby hamster kidney (BHK) cells and primary neuronal cultures (Ja¨rvela¨
et al., 1999). The consequence of other missense mutations on localisation has been ex-
tensively characterised in both budding (Haskell et al., 2000) and fission yeast (Haines
et al., 2009). These studies agree that while point mutations clearly affect CLN3 func-
tion, they generally do not affect its localisation.
Similarly, the tissue expression pattern has been challenging to determine. CLN3
is however now well known to be ubiquitously expressed (Kollmann et al., 2013), and
mRNA levels are reported to be highest in gastrointestinal and glandular/secretory tis-
sue (Chattopadhyay and Pearce, 2000). Antibody staining on human tissue has found
CLN3 to be expressed in the grey matter, specifically in astrocytes, the capillary en-
dothelium, and neurons (Margraf et al., 1999). The development of a Cln3-deficient
reporter mouse that expresses β -galactosidase from the native Cln3 promoter (Eliason
et al., 2007) has also provided information on the spatial and temporal expression of
Cln3. Using this mouse, the predominant distribution of Cln3 reporter neurons are in
the visual, limbic, and subcortical motor structures of the brain, which correlates well
with the clinical symptoms of juvenile CLN3 disease (Ding et al., 2011). Yet despite
this correlation, Cln3 expression in these neural regions is most evident only during the
first month of post-natal development and is subsequently expressed at relatively low
levels, a finding that is also seen in other NCL subtypes (Mitchison et al., 2004).
1.2.3 Animal Models, Cellular Pathology, and Potential Function
Despite being one of the first NCL genes to be identified, the precise function of CLN3
remains to be defined. Protein function can often be inferred from sequence similari-
ties with other proteins whose function is known. However, although CLN3 is highly
conserved between species, it shares no homology with other characterised proteins
at either the nucleotide or amino acid level (The International Batten Disease Con-
sortium, 1995; Taschner et al., 1997). Alternatively, an analysis of its structure may
prove useful. An in silico prediction of CLN3 homologues using PSI-BLAST has
previously suggested CLN3 is distantly related to a family of equilibrative nucleoside
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transporters (ENTs) (Baldwin et al., 2004), leading to the speculation that CLN3 may
also act as a transporter. More recent algorithms suggest CLN3 has a domain struc-
ture consistent with members of the major facilitator superfamily (MFS) (Cotman and
Staropoli, 2012); one of the two largest families of membrane transporters that in-
cludes small-solute uniporters, symporters, and antiporters. Most MFS members have
12 transmembrane domains, and although CLN3 is likley to only have six, there is
evidence that over-expressed myc-tagged CLN3 can form homodimers (Storch et al.,
2007). Whether endogenous CLN3 can do the same is unknown. It is interesting to
note however that CLN7 (MFSD8), mutations in which cause a variant late-infantile
form of NCL, is a predicted MFS member albeit with unknown substrate specificity
(Siintola et al., 2007). At least one patient with a CLN7 mutation has presented with
vacuolated lymphocytes (Siintola et al., 2007), a finding generally thought to specifi-
cally arise from CLN3 mutations. CLN12 also has predicted transport functions, and as
a type 5 P-type ATPase is thought to transport cations, heavy metals, and/or lipids (van
Veen et al., 2014). Although the sequence similarities suggesting CLN3 is a transporter
are weak, budding yeast lacking the CLN3 orthologue (BTN1) show a defect in vac-
uolar arginine transport (Kim et al., 2003). Decreased arginine transport has similarly
been reported in patient isolated lysosomes (Ramirez-Montealegre and Pearce, 2005),
and mice lacking a functional copy of Cln3 (Chan et al., 2009). Sequence analysis
using the Pfam server has also identified a weak match between a fatty acid desaturase
domain and a 14 amino acid N-terminal sequence of the CLN3 protein (Narayan et al.,
2006b). Remarkably, given the weak similarity, Narayan et al. (2006) reported that
CLN3 has desaturase activity and converts membrane-associated palmitoylated pro-
teins to palmitoleated derivatives. Further still, it was reported that CLN3 represented
a founding member of a new class of enzymes that perform such proteolipid modifica-
tions, and that its absence gives rise to neurological symptoms (Narayan et al., 2006b,
2008). However, while these studies suggest that CLN3 influences the ∆-9 desaturation
of palmitoylated proteins, it is not clear whether CLN3 has inherent catalytic activity or
instead associates with another unidentified catalytic protein present in the lysate used
in these studies. Studies to characterise the desaturase activity of purified or recombi-
nant CLN3 are needed, but are currently still lacking.
As CLN3 is highly evolutionarily conserved in all eukaryotes except plants, it is
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probable its function is fundamental. Its conservation has therefore allowed much of the
current CLN3 knowledge to be experimentally determined from numerous model or-
ganisms, including budding and fission yeast (Pearce and Sherman, 1997; Gachet et al.,
2005), the social amoeba Dictyostelium discoideum (Huber et al., 2014), Caenorhab-
ditis elegans (de Voer et al., 2005), Drosophila melanogaster (Tuxworth et al., 2009),
and zebrafish (also reviewed in (Phillips et al., 2006; Bond et al., 2013)). There are
also four genetically distinct murine models. The first mouse model to be made was
a knock-out model created by replacing the start codon and the first six exons with a
neomycin cassette insertion (Cln3∆ex1-6 mice) (Mitchison et al., 1999). RT- PCR con-
firmed the absence of Cln3 transcripts in homozygous mutant mice, and therefore this
model is commonly referred to as the Cln3-/- mouse model. A second knock-out model
was created by the insertion of a neomycin cassette to replace exons 7-8 (Cln3ex7/8neo
mice) (Katz et al., 1999). Two knock-in models are also available, and have already
been mentioned. One was developed using Cre/lox technology to initially knock-in
a ‘floxed’ PGKneo cassette to replace exons 7 and 8. These mice were subsequently
bred with Cre recombinase mice to induce the excision of the cassette in their progeny,
thereby creating the Cln3∆ex7/8 knock-in mice which models the most common juve-
nile CLN3 mutation (Cotman et al., 2002). Lastly, the Cln3 knock-in reporter mouse,
described above, is available that not only lacks Cln3 expression but allows the normal
expression of Cln3 to be assessed via β -galactosidase activity (Cln3LacZ/LacZ) (Elia-
son et al., 2007). The Cln3-/- knockout and Cln3∆ex7/8 knock-in mice have been most
commonly used, and both display features consistent with human disease. They do
however show some differences in terms of the age-dependency, extent, and regional
specificity of glial activation and neuronal loss, as well as the onset and progression of
neurological symptoms (Kovacs and Pearce, 2015).
Efforts from these diverse models, combined with studies using patient-derived
cell lines, have been valuable by delineating cellular pathologies that might in turn be
used to predict gene function. Much of the early focus was directed to the role of the
storage material that accumulates upon CLN3 mutation. Subunit c of mitochondrial
ATPase is the major protein component of the storage material in juvenile CLN3 dis-
ease, which appears as a fingerprint profile within either a lysosomal residual body, as a
component within large membrane-bound lysosomal vacuoles, or in combination with
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curvilinear/rectilinear profiles (Mole et al., 2005). The accumulation of subunit c of mi-
tochondrial ATPase is not a result of increased expression of the genes that encode it,
nor does the stored protein have a different encoded sequence compared to that seen in
healthy mitochondria (Palmer et al., 1995). The cause of its accumulation is therefore
unclear, especially since juvenile CLN3 patients show either normal or increased ac-
tivity of several lysosomal enzymes including cathepsin D (Cao et al., 2006) and TTP1
(Mitchison et al., 1999; Sleat et al., 1998) respectively, both of which have been im-
plicated in the degradation of this protein (Kominami, 2002; Goebel and Wisniewski,
2004). Of potential interest however, these findings have been disputed by others who
report defects in cathepsin D processing and maturation (Golabek et al., 2000; Fossale
et al., 2004; Metcalf et al., 2008) and a decrease in TPP1 activity (Vidal-Donet et al.,
2013) in CLN3-deficient models. Interestingly, TPP1 expression in induced pluripotent
stem cells (iPSCs) derived from juvenile CLN3 patients is significantly reduced com-
pared to control cells, yet is significantly increased in neural progenitor cells (NPCs)
derived from the same iPSCs (Lojewski et al., 2013). It is plausible therefore that lyso-
somal enzyme expression in CLN3 disease patients is dependent on cell type and/or
development stage.
Regardless, and as discussed above, that this storage may play a direct role in dis-
ease pathogenesis is however becoming increasingly disregarded. Yet, given patients
also display reduced ATP-synthase activity and ATP levels (Das and Kohlschu¨tter,
1996; Das et al., 2001), it has instead been postulated that mitochondrial dysfunction
may contribute to juvenile CLN3 disease pathogenesis (Jolly et al., 2002). Morpholog-
ical and functional changes in the mitochondria of patients and mice models have been
reported (Jolly et al., 2002; Fossale et al., 2004; Luiro et al., 2006) and mitochondrial
dysfunction has been shown to precede subunit c deposition in a cerebellar neuronal
granular cell line derived from Cln3∆ex7/8 knock-in mice (Fossale et al., 2004). Using
patient derived lymphoblasts, it has also been shown that the loss of functional CLN3
is accompanied by altered expression of mitochondria-related metabolic molecules,
including pyruvate dehydrogenase (PDH), ATP citrate lyase (ACL), and phospho-
enolpyruvate carboxykinase (PEPCK) (Kang et al., 2013). Most recently, Lojewski
et al. (2013) have performed an extensive characterisation of NPCs derived from iPSCs
developed from juvenile CLN3 disease patients (Lojewski et al., 2013). In support of
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others, they found 15%-25% of mitochondria showed morphological disturbances, in-
cluding distended mitochondria, a disruption of the internal architecture, and a loss of
cristae. This was even more apparent in iPSC-derived mature neurons, where approx-
imately half of all mitochondria displayed reduced cristae. Defects in mitochondria
could conceivably underlie the neuronal and retinal vulnerability, given that these cell
types exert high metabolic demands and are rich in mitochondria (Niven and Laugh-
lin, 2008). Emerging evidence implies that mitochondrial dysfunction and/or abnormal
morphology is also a common theme in various cardiovascular diseases (Ballinger,
2005; Ong and Hausenloy, 2010), and so could also underlie the cardiovascular find-
ings in juvenile CLN3 disease.
A number of other cellular processes are defective in cells or models lacking
CLN3, leading to the speculation that CLN3 might ordinarily be involved in their func-
tion. CLN3 has consequently been linked to various processes, including lysosomal
acidification and homeostasis (Pearce et al., 1999b; Golabek et al., 2000; Holopainen
et al., 2001; Codlin et al., 2008a), autophagy (Cao et al., 2006; Behrends et al., 2010;
Vidal-Donet et al., 2013), cytoskeletal organisation (Luiro et al., 2006), membrane traf-
ficking (Fossale et al., 2004; Kama et al., 2011; Rusyn et al., 2008; Tecedor et al.,
2013), protein trafficking (Metcalf et al., 2008), lipid synthesis/modification (Hobert
and Dawson, 2007), cell volume regulation (Stein et al., 2010), osmoregulation (Hu-
ber et al., 2014), oxidative stress (Tuxworth et al., 2011), cell migration (Getty and
Pearce, 2011), and apoptosis (Narayan et al., 2006a; Wu et al., 2014), possibly via the
suppression of sphingolipid production (Puranam et al., 1997, 1999; Persaud-Sawin
et al., 2002, 2004). However, the mechanistic link between these individual pathologi-
cal defects and the underlying CLN3 mutation have not been precisely defined. It also
remains unclear which of these cellular defects are directly related to CLN3 mutations,
and which are simply secondary to its loss and represent a consequence or compen-
satory mechanism of an established disease. Evidence that fission yeast lacking the
CLN3 orthologue btn1+ have defects in the location and structure of Golgi compart-
ments could explain why so many apparently disparate pathways are affected upon
CLN3 loss (Codlin and Mole, 2009). As for all NCLs, why such cellular pathologies
would result in a specific loss of neurons is not known.
While there remain many unanswered questions, recent years have seen an im-
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portant development in the understanding that defects in non-neuronal cells precede
neuronal loss and the onset of symptoms. Specifically, the Cln3-/- knock-out mouse
model displays non-symptomatic and subtle astrocytic and microglial activation at 5
months of age, whereas the loss of hippocampal interneurons only becomes evident at
14 months (Pontikis et al., 2004). Morphological staining has shown that the Cln3∆ex7/8
knock-in model instead shows widespread astrocyte hypertrophy and microglial acti-
vation as early as postnatal day 7. The loss of neurons, specifically within the tha-
lamocortical system, was only observed at 6-8 months (Pontikis et al., 2005). Fur-
thermore, primary microglia isolated from these Cln3∆ex7/8 mice are primed towards a
pro-inflammatory phenotype, and are hyper-responsive to multiple inflammatory stim-
uli (Xiong and Kielian, 2013). These mice also show a transient increase in astro-
cyte hemi-channel activation in regions that subsequently go on to show neuronal loss
(Burkovetskaya et al., 2014). Although the precise relevance of these findings remains
to be clarified, astrocyte and glial activation is now reproducibly shown to predict the
distribution of neuronal loss in a variety of NCL models (Pontikis et al., 2004; Oswald
et al., 2005; Kuronen et al., 2012; Schmiedt et al., 2012). Compromised glia biology,
rather than defects within the neurons, may therefore play an important role in medi-
ating disease pathogenesis, as suggested for other LSDs (Keatinge et al., 2015; Rama
Rao and Kielian, 2015).
1.2.4 CLN3 Interactions
When gene function remains obscure, its interactome and/or that of its protein product
can provide useful information. Accordingly, several groups have attempted to iden-
tify protein-protein interactions, or have performed transcript profiling, in an effort to
provide further insight into the pathways CLN3 may be involved in.
As discussed above, CLN3 interactors include CLN5 (Vesa et al., 2002; Lyly et al.,
2009), although the significance of this is unclear given the function of CLN5 is also
unknown. Three adaptor protein complexes, AP-1, AP-2, and AP-3, have also been re-
ported to bind the dileucine motif (LI) present in the cytoplasmic loop of CLN3 in vitro
(Kytta¨la¨ et al., 2005), despite the same authors previously stating that this LI motif does
not fulfil the positional criteria needed for AP-1 and AP-3 to recognise dileucine mo-
tifs (Kyttala et al., 2004). AP-1 and AP-3 in particular have been reported to facilitate
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the endosomal/lysosomal targeting of CLN3 (Kytta¨la¨ et al., 2005), yet confirmation of
this physical interaction has not been demonstrated by others (Storch et al., 2004). The
significance of the interaction with AP-2 is unclear, as AP-2 has a role at the plasma
membrane in clathrin-mediated endocytosis and CLN3 is not targeted to lysosomes via
this mechanism (Kytta¨la¨ et al., 2005). Others have reported that CLN3 immunoprecip-
itate from bovine brain homogenate contains a number of proteins including β -actin,
calmodulin complexes, a ribosomal protein, and a lipid raft marker Flotillin-1 (Rakheja
et al., 2004). No controls were used however to confirm the specificity of these find-
ings, although CLN3 does contain a potential lipid raft-binding domain (Persaud-Sawin
et al., 2004) and co-localises to lipid rafts (Persaud-Sawin et al., 2007). Others have
reported that lipid rafts have altered lipid content, morphology, and buoyancy in the
absence of functional CLN3 (Hobert and Dawson, 2007; Rusyn et al., 2008).
CLN3 also physically interacts with the microtubule binding protein Hook1 (Luiro
et al., 2004) as well as active GTP-bound Rab7 and its effector, Rab7-interacting lyso-
somal protein (RILP) (Uusi-Rauva et al., 2012). The disruption of such interactions
could be predicted to cause defects in autophagosome transport, preventing their fusion
with the lysosome and therefore explaining why autophagosome maturation is impaired
in juvenile CLN3 disease patients and mice models. CLN3 has been further implicated
in the microtubular system due to its interaction with non-muscle myosin IIB (Getty
et al., 2011). The loss of Cln3 function in Cln3-/- primary mouse embryonic fibroblasts
results in defects in myosin distribution, migration, and morphology, presumably as a
consequence of its disrupted interaction with non-muscle myosin IIB. Further, the inhi-
bition of non-muscle myosin-II in wild-type cells with blebbistatin can phenocopy the
loss of Cln3 (Getty et al., 2011).
CLN3 is also thought to interact with the plasma membrane-associated cytoskele-
tal and endocytic fodrin, and the associated Na+, K+ ATPase (Uusi-Rauva et al., 2008).
Fodrin is a heterotetrameric complex of two α and two β chains that binds the plasma
membrane and tethers membrane protein complexes to the actin cytoskeleton. Na+, K+
ATPase maintains chemical gradients at the cell surface by pumping Na+ out and K+
into the cell. Fodrin cytoskeleton abnormalities are seen in Cln3-/- mouse brains and
patient-derived fibroblasts, and although the pumping activity of Na+, K+ ATPase is
normal, there are defects in its basal subcellular distribution (Uusi-Rauva et al., 2008).
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This is consistent with the observed fodrin defects given that Na+, K+ ATPase relies
on fodrin for its plasma-membrane association (De Matteis and Morrow, 2000), and
suggests that CLN3 may interact with these two partners in a multi-protein complex.
Fodrin and Na+, K+ ATPase are multifunctional proteins, and their disruption upon
CLN3 deficiency could explain a number of disease-associated phenotypes. For exam-
ple, fodrin binds synaptic vesicles via synapsin I to ensure proper synaptic transmission
(Zimmer et al., 2000). Na+, K+ ATPase is involved in the regulation of glutamatergic
neurotransmission (Rose et al., 2009), endosomal pH (Cain et al., 1989), and endocytic
membrane trafficking (Feldmann et al., 2007). Fodrin and Na+, K+ ATPase defects
could therefore explain why patients and/or animal models show defective neurotrans-
mission, glutamate receptor-mediated excitotoxicity, altered endosomal/lysosomal pH
homeostasis, and defective endocytosis.
CLN3 has been reported to have anti-apoptotic effects (Puranam et al., 1999;
Narayan et al., 2006a), and is up-regulated in certain cancers (Rylova et al., 2002;
Zhu et al., 2014). Its anti-apoptotic effect may be mediated in part by its reported C-
terminal interaction with calsenilin, which acts to limit its role as mediator of Ca2+
induced cytotoxicity (Chang et al., 2007). Calsenilin protein levels are increased in
the brains of Cln3 knock-out mice and CLN3 knock-down cell lines, and such models
are more susceptible to Ca2+ mediated cell death. Conversely, calsenilin protein levels
are decreased when CLN3 is over-expressed, which leads to protection against Ca2+
mediated apoptosis. This finding also suggests that calsenilin expression levels may be
negatively regulated by CLN3.
Lastly, CLN3 is reported to directly interact with Shwachman-Bodian-Diamond
syndrome protein (SBDS) (Vitiello et al., 2010). Interestingly, SBDS is also ubiqui-
tously expressed and highly conserved (Boocock et al., 2006), but Shwachman-Bodian-
Diamond syndrome does not share clinical features with the NCLs but rather is char-
acterised by skeletal and haematologic abnormalities, exocrine pancreatic dysfunction,
defects in immunity and a susceptibility to recurrent infections, and an increased risk
of leukaemia (Boocock et al., 2003). The CLN3-SBDS interaction appears to be evo-
lutionarily conserved, as a small portion of the orthologous proteins in budding yeast
(Btn1p and Sdo1p respectively) also interact (Vitiello et al., 2010). SBDS is a mul-
tifunctional protein that plays a suspected role in certain stress responses (Ball et al.,
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2009). Using budding yeast it was suggested that Sdo1p may inhibit Btn1ps functional
modulation of the vacuolar-ATPase during pH stress (Vitiello et al., 2010). As Sdo1p
also participates in ribosomal maturation, the authors also suggested the existence of
a novel mechanism whereby the ribosome can monitor and maintain the status of the
vacuole/lysosome in response to an environmental insult, such as a change in pH.
Behrends et al. (2010) have performed a high-throughout proteomic analysis to
define a global view of the autophagy interaction network (Behrends et al., 2010). As
part of this work, the authors used CLN3 as a primary bait to identify protein complexes
by mass spectrometry (LC-MS/MS). They identified 42 high-confidence candidate in-
teraction partners (HCIPs), although did not go on to validate these particular findings.
The most recent effort to expand the CLN3 physical interactome employed a tandem
affinity purification coupled to mass spectrometry (TAP-MS) strategy and identified 58
interacting partners; 42 of which were novel and 13 of which were shared by CLN5
(Scifo et al., 2013). This approach also verified the interaction with Na+, K+ ATPase
(Uusi-Rauva et al., 2008), and 16 of the proteins also identified by Behrends et al.
(2010). The authors stated that the identified interactions supported the involvement
of CLN3 in transmembrane transport, lipid homeostasis, and neuronal excitability, in
addition to G-protein signalling and protein folding/sorting in the ER.
Given the differing function of these interaction partners, it is presumed that CLN3
does not interact with them all at once, but instead does so in a dynamic manner.
Precisely how these interactions might be controlled in a temporal or spatial man-
ner is however unclear, as is their significance with respect to the CNS (Getty and
Pearce, 2011). Most importantly, there are a number of concerns that these reported
physical interactions may be false positives. Defining the physical interactome of hy-
drophobic proteins such as CLN3 is challenging as they are difficult to solubilise and
prone to non-specific interactions. Accordingly, the techniques used to determine the
above CLN3 interaction partners, including yeast-two-hybrid, the alternative CytoTrap
two-hybrid system (from Stratagene) and mass spectrometry, require validation by co-
immunoprecipitation and co-localisation, both of which are difficult due to the low en-
dogenous expression of CLN3 and the paucity of adequate antibodies. Adding yet more
complexity is the identification of a highly similar protein called CLN3-like, which is
up-regulated in the brains of patients and Cln3-/- knock-out mice (Narayan et al., 2004).
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CLN3-like is identical to CLN3 over the first 284 amino acids, and produces a 33 kDa
protein which can cross-react with certain CLN3 antibodies. There are concerns there-
fore that some interaction partners may not be specific to CLN3, but rather interact
with this CLN3-like protein instead, the function and relevance of which is unknown.
Lastly, it should also be realised that a number of these studies were restricted to the
identification of proteins that bind the hydrophilic domains of CLN3, rather than the
full length protein.
A number of genetic interactions have also been identified, which act to comple-
ment these proteomic approaches. The tissue specific over-expression of CLN3 causes
a degenerative phenotype in the Drosophila eye (Tuxworth et al., 2009). This pheno-
type is reminiscent of a Notch loss-of-function phenotype, and led to the identification
of genetic interactions between CLN3 and both the Notch and Jun N-terminal kinase
(JNK) signalling pathways (Tuxworth et al., 2009). Specifically, CLN3 over-expression
causes reduced Notch signalling and increased JNK signalling. A link between CLN3
and Notch signalling is supported by the finding that Notch2 receptor expression is
significantly increased in the Cln3-/- mouse cerebellum (Weimer et al., 2009). The
Drosophila eye phenotype has also been used as the basis for a modifier screen, which
revealed that deletion of the mago nashi allele (in flies over-expressing CLN3) acts as
a phenotypic enhancer, meaning that it usually antagonises CLN3. mago nashi is an
RNA-binding protein, and a conserved component of the exonexon junction complex
(EJC) that regulates RNA stability (Kataoka et al., 2001). In the developing oocyte of
Drosophila, this gene also plays a role in RNA and organelle transport, and cell polarity
(Micklem et al., 1997; Newmark et al., 1997). In a subsequent screen for genes that
modify the eye phenotype when co-expressed with CLN3, it was found that CLN3 co-
operatively interacts with multiple components of stress signalling pathways (Tuxworth
et al., 2011). Interactions were also identified between CLN3 and other RNA-binding
proteins (RBPs), which suggests CLN3 might be similarly involved in the regulation of
RNA biogenesis, metabolism, and localisation.
Genome-wide expression profiling has been performed in the budding yeast model
for juvenile CLN3 disease, which completely lacks the CLN3 orthologue BTN1+
(Pearce et al., 1999a). Only two genes displayed altered expression compared to wild-
type cells; HSP30, a plasma membrane heat-shock protein that is also known to down-
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regulate plasma membrane H+-ATPase and BTN2, an orthologue of the human Hook1
protein. This latter finding is interesting given CLN3 is also shown to physically inter-
act with Hook1, as described above. Transcript profiling has also been performed in a
small cohort of patients, all of which were homozygous for the 1 kb deletion yet dis-
played varying rates of disease progression (Lebrun et al., 2011). This analysis revealed
just five genes that were dysregulated in all cases, making them potential biomarkers.
Stratification upon rate of disease progression allowed the identification of 13 genes
which are predicted to be disease modifiers. Comparative gene expression analyses
have also been performed in various tissues of murine models. Initially, whole brains
of 10 week old Cln3-/- knock-out mice were compared to wild-type (Elshatory et al.,
2003). 14 genes were described as having>1.5 fold change in expression; two were re-
lated to neurotransmitter release and two to glutamate utilisation. Another report in the
same year reported the findings of a microarray performed on just the cerebellum of 10
week old Cln3-/- knock-out mice (Brooks et al., 2003). 756 genes were reported to dis-
play a reproducible change in expression of 2 fold or more. These were divided into 14
functional categories, including trafficking, signalling or cell growth, cell structure, cell
adhesion, proteolysis or inhibition of proteolysis, neuronal cell development and func-
tion, lipid metabolism, immune or inflammatory response, energy metabolism, detoxi-
fication or stress, cytoskeleton, cell death, vascular and blood, amino acid metabolism,
and unknown. Later, 285 genes with altered expression in 10 week old Cln3-/- knock-
out mice retinas were reported (Chattopadhyay et al., 2004). This data was compared
to that produced for the cerebellum in order to identify gene expression changes that
are specific to the eye. 18 genes were found to be altered specifically in the eye, 13
of which were down-regulated. Three of these were found to be part of mitochon-
drial complexes, leading the authors to speculate that altered mitochondrial function in
eye may lead to disease development (Chattopadhyay et al., 2004). Lastly, microar-
ray profiling has most recently been performed on primary cortical neuron cultures of
Cln3-/- knock-out E16.5 embryos (Luiro et al., 2006). Three major cellular pathways
were deemed to be affected, revealing disturbances in mitochondria, cytoskeleton, and
synaptic functions. Unlike the other reports, this report also provided functional data
to support subtle defects in glucose energy metabolism, microtubule organisation, and
synaptic transmission in Cln3-/- knock-out mice.
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While these microarray experiments have highlight common pathways, it is in-
teresting to note than no single affected gene has been reproducibly reported from all
four different reports (Jalanko et al., 2006). Further, it is generally accepted that under-
standing the physiological relevance of these genes in disease development, or CLN3
function, requires more extensive work.
1.2.5 Therapeutic Options for Juvenile CLN3 Disease
Currently there are no curative treatments for any NCL subtype, and approved medical
interventions for juvenile CLN3 disease remain exclusively symptomatic and pallia-
tive. For example, anticonvulsants such as lamotrigine and valproate are used to man-
age epilepsy symptoms (Aberg et al., 2000a), although others (such as carbamazepine)
may cause an exacerbation of symptoms in some patients (Vercammen et al., 2003;
Schulz et al., 2013). Psychotrophic drugs can also be beneficial for limiting the psy-
chological symptoms (Ba¨ckman et al., 2001), although sleep disturbances may prove
more difficult to manage (Ha¨to¨nen et al., 1999). Levodopa may be useful, at least in
some patients, for reducing the parkinsonion motor symptoms (Zweije-Hofman et al.,
1982; Aberg et al., 2001). Following a marked improvement in the symptoms of two
sisters, pallidotomy and deep brain stimulation has been raised as a possible treatment
for NCL related dystonic storm (severe episodes of generalised muscle contractions)
(Elkay et al., 2009). Although effective, the extremity of this approach clearly reflects
the urgent need for less invasive therapies that can slow or prevent disease progression.
For LSDs that arise from an enzyme deficiency, enzyme replacement therapy
(ERT) is the most logical and, in some cases, successful treatment. However, as CLN3
is a non-soluble transmembrane protein, ERT is not an option for juvenile CLN3 dis-
ease. Unfortunately, ERT has yet to prove successful even for the treatment of NCL
subtypes which do manifest through an enzymatic defect, reflecting the difficulties in
bypassing the blood-brain barrier (BBB) and administrating the enzyme to the CNS.
Curative options for juvenile CLN3 disease are similarly complicated by the need to
achieve persistent and therapeutic levels of pharmaceuticals across the BBB, which
will be a necessity due to the predominance of neurological symptoms. The lack of
an in-depth understanding of gene function and disease pathophysiology also largely
prevents rational, target-driven drug development strategies. Yet, even when a potential
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drug is identified, the rarity of juvenile CLN3 disease also poses problems for clinical
trial subject recruitment. This in turn reduces the feasibility of randomised controlled
trials which are reliant on large sample sizes. Lastly, although a clinical rating scale is
available (Marshall et al., 2005), an incomplete understanding of disease natural his-
tory can make evaluating the success of a drug difficult (Kohan et al., 2011; Augustine
et al., 2013; Sondhi et al., 2013).
However, a number of case series and therapeutic trials (of varying design) were
performed in the 1970s and 1980s to evaluate the potential benefit of supplementing
patients with antioxidants, including vitamin C, vitamin E, methionine, BHT, B2, B6,
and sodium selenite (Santavuori and Moren, 1977; Santavuori et al., 1985, 1988, 1989;
Naidu et al., 1988). Antioxidant therapy was rationalised following an observation
based on 12 patients that patient derived erythrocytes had reduced glutathione peroxi-
dase activity which could be corrected by selenium supplementation (Westermarck and
Sandholm, 1977). Together with the finding of lipid peroxides within the autofluo-
rescent storage material, it was thought that disease pathology might arise from an im-
paired ability to protect lipids from oxidative damage. The general findings of these tri-
als were that antioxidants might slow disease progression, but did not stop it. Although
decreased peroxidase activity in patients is now disputed, antioxidant therapy is com-
monly used as part of NCL disease management (Hobert and Dawson, 2006). There
have similarly been trials investigating the role of polyunsaturated fatty acid (PUFA)
supplementation, although the initial trial was inconclusive (Bennett et al., 1988). A
subsequent study by the same group did however report that PUFA supplement might
be used to halt disease progression (Bennett et al., 1994), although no follow-up studies
have since been performed.
Haematopoietic stem cell transplant (HSCT; and previously referred to as bone
marrow transplants) have proved helpful in reducing the symptoms of some LSDs that
affect visceral organs (Kim, 2014). HSCT is most relevant for LSDs that arise from a
lysosomal enzyme deficiency, as the engraftment of healthy monocytes can provide a
source from which to secrete the enzyme lacking in the host. Despite a lack of logical
basis, one patient with juvenile CLN3 disease received HSCT in the late 1990s, but
to no effect (Lake et al., 1997). HSCT has also, to date, been ineffective for NCLs
subtypes that arise from a lack of a soluble enzyme (PPT-1 in infantile NCL, and TPP-
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1 for late infantile NCL) due to difficulties in crossing the BBB (Hobert and Dawson,
2006).
Later, cell culture studies suggested that flupirtine, a non-opioid analgesic, could
inhibit apoptosis and prevent death in CLN3 deficient lymphoblasts and post-mitotic
neurons (Dhar et al., 2002). Despite this promise, a 2011 secondary analysis based
on parent surveys concluded that while parents felt that self-administered flupirtine
treatment delayed disease progression, a more objective evaluation using clinical rating
scales did not agree (Cialone and Augustine, 2011).
There are however some ongoing experimental therapies that may be more promis-
ing. For example, the demonstration of functional auto-antibodies against various brain
auto-antigens (Lim et al., 2006) has recently formed the basis of several distinct ther-
apeutic efforts in murine models. Specifically, auto-antibodies against glutamic acid
decarboxylase (GAD65) result in reduced γ-aminobutyric acid (GABA) levels and ele-
vated glutamate within the brain and sera of Cln3-/- knock-out mice and patients (Chat-
topadhyay et al., 2002; Pearce et al., 2004; Pears et al., 2005). Increased extracellular
glutamate level could enhance both AMPA and NMDA receptor activity, leading to
seizures, excitotoxicity, and neuronal damage. Indeed, cerebellar granule cells from
Cln3-/- knock-out mice have a selectively increased sensitivity to AMPA-type gluta-
mate receptor-mediated toxicity (Kova´cs et al., 2006), recently reported to arise due to
significantly increased surface levels of AMPA receptors in the cerebellum, cortex, and
striatum (Kova´cs et al., 2015). Cerebellar granule cells from the Cln3∆ex7/8 knock-in
mouse model are similarly sensitive to both AMPA- and NMDA-type glutamate re-
ceptor over-activation (Finn et al., 2011). Encouragingly, attenuating AMPA receptor
activity using a single intraperitoneal injection of a non-competitive AMPA antagonist
results in an immediate improvement of motor skills in one-month-old Cln3-/- knock-
out mice (Kova´cs and Pearce, 2008), and a delayed yet prolonged improvement in
six/seven-month-old mice (Kova´cs et al., 2011). Both AMPA and NMDA receptor an-
tagonists have since been shown to significantly improve the motor skills of Cln3-/-
knock-out mice in an age-dependent manner (Kova´cs et al., 2012). Interestingly, this
study found that while NMDA antagonists were effective in reducing motor symptoms
in six/seven-month-old mice, it had no effect on one-month old mice. An important
outcome of these studies is therefore the realisation that the timing of treatment admin-
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istration may affect its efficacy and clinical outcome.
An alternative approach to the presence of brain auto-antibodies has been to use
immunosuppressant drugs. Initially, a small trial was performed involving eight pa-
tients who received intermittent, medium doses of prednisolone (Aberg et al., 2008).
Although the results were encouraging, it was deemed necessary to perform a larger
trial to verify the results and more robustly assess adverse effects. Since then how-
ever, immune suppression using Mycophenolate motefil (commercially known through
Roche Pharmaceuticals as CellCept), has been shown to decrease circulating auto-
antibodies, decrease neuroinflammation, and improve motor skills in Cln3-/- knock-out
mice (Seehafer et al., 2011). These studies have formed the basis for an ongoing phase
II randomised and placebo controlled trial designed to assess the safety and tolerabil-
ity of CellCept in 30 children with juvenile CLN3 disease (ClinicalTrials.gov identifier
NCT01399047).
Gene therapy for neurological diseases is complicated as viral vectors are typically
unable to cross the BBB and therefore require direct CNS administration. Furthermore,
as CLN3 is a non-secreted protein, gene administration is limited only to the cells that
are directly transduced by the vector, whereas widespread transduction is likely needed
(Sondhi et al., 2013). Nonetheless, encouraging results have recently been reported in
the Cln3∆ex7/8 knock-in mouse model (Sondhi et al., 2014). Neonatal mice received
direct brain administration of a serotype rh.10 adeno-associated virus vector express-
ing the human CLN3 cDNA (AAVrh.10hCLN3). After 18 months, CLN3 transgene
expression was detected in various locations throughout the brain and resulted in sig-
nificantly reduced storage material, significantly decreased gliosis, and a trend towards
an improved neuron count (Sondhi et al., 2014). Although phenotypic measures were
not assessed, this report does suggest that gene therapy may be a safe and effective
strategy for juvenile CLN3 disease.
Yet, although promising, these experimental therapeutic strategies are preliminary
and there remain many unanswered questions. An important consideration is that with-
out a full understanding of disease pathogenesis, the development of a neuronal specific
treatment may only act to reveal other symptoms which could then dominate and con-
tinue to cause morbidity and mortality.
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1.2.6 Links to Other Diseases
As the most common of the NCLs, further delineating CLN3 gene function may inform
the understanding of the other NCL subtypes, for reasons detailed above. However, it
may also have impacts on other diseases. For example, CLN3 mutations have also
been linked to some cases of autophagic vacuolar myopathy (Cortese et al., 2014) and
nonsyndromic retinal dystrophy (Coppieters et al., 2014; Wang et al., 2014) (also see
Table 1.1). Further, CLN3 expression is dysregulated in Smith-Magenis syndrome,
Down syndrome, Fragile X syndrome, Prader-Willi syndrome (Girirajan et al., 2009)
and in patients with Graves ophthalmopathy (Chen et al., 2008b). Intriguingly, CLN3
may be required for HIV infection (Brass et al., 2008).
Furthermore, the NCLs provide an invaluable model in which to define the path-
ways needed for normal neurodevelopment, and their simple Mendelian genetics make
them an ideal paradigm for more complex and common neurodegenerative diseases.
Indeed, juvenile CLN3 disease shares a number of cellular deficits with common, age-
related neurodegenerative diseases, despite resulting in varying clinical symptoms. As
described elsewhere in this Introduction, juvenile CLN3 disease shows defects in lyso-
somal function and autophagy, Golgi fragmentation, mitochondrial deficits and oxida-
tive stress, glutamate excitotoxicity and neuroinflammation, all of which are similarly
seen in other neurodegenerative diseases (Nakagomi et al., 2008; Nixon et al., 2008;
Osellame and Duchen, 2013). Another shared feature is the accumulation of abnor-
mal protein deposits. For example, autofluorescent lipopigments accumulate in normal
aged neurons and in other pathologies such as Alzheimer’s and Parkinson’s disease
(Seehafer and Pearce, 2006; Sulzer et al., 2008). Furthermore, juvenile CLN3 disease
patients display defective processing of the amyloid precursor protein (Wisniewski
et al., 1990a,b; Golabek et al., 2000), a characteristic feature of Alzheimers disease
(Selkoe, 2001). They also display altered levels of α-synuclein (Kang et al., 2014) and
decreased dopamine transporter density in the striatum (Aberg et al., 2000b), both of
which are features of Parkinson’s disease (Shulman et al., 2011). Such commonalities
can be taken to be suggestive of converging pathways of neurodegeneration (Durren-
berger et al., 2014), therefore what can be learnt in one disease may be applicable to
others.
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1.3 Yeast as a Model Organism
As already explained, there are a number of animal models for juvenile CLN3 disease.
Given the exact scientific question being asked, each model offers distinct advantages
and limitations, and so improvements in the understanding of juvenile CLN3 disease
will undoubtedly come from the concerted effort of all available models. Yet despite
extensive efforts, there remains an incomplete understanding of CLN3 function and in-
volvement in CLN3 disease pathogenesis, and so much can still be learnt from simple
model organisms such as yeast. The two most commonly used yeast species are Sac-
charomyces cerevisiae (budding yeast) and Schizosaccharomyces pombe (fission yeast).
Despite superficial similarities, these species are highly diverged from one another, with
S. pombe diverging from budding yeast around 330-420 million years ago (Wood et al.,
2002). This evolutionary distance is as distant from each other as from higher eukary-
otes, making these models far from redundant with each other (Forsburg, 1999, 2007).
Although S. pombe lagged behind S. cerevisiae as an experimental system, both now
benefit from an extensive collection of molecular tools available for their study. Im-
portantly, and notwithstanding their simplicity, a distinct advantage of yeast as a model
system is that numerous basic pathways and mechanisms are evolutionarily conserved
with higher eukaryotes. As a result, both yeast species can be informative predictors
of human gene function and have productively been used to model even complex dis-
ease processes, including neurodegeneration (Mager and Winderickx, 2005; Brandis
et al., 2006; Gitler, 2008; Miller-Fleming et al., 2008; Winderickx et al., 2008; Pereira
et al., 2012; Tenreiro et al., 2013; Voisset et al., 2014; Wiley et al., 2014; Lasserre et al.,
2015). Indeed, using both yeast to study the same biological problem can be a pow-
erful approach, and there are both budding and fission yeast models of juvenile CLN3
disease. However, as this work specifically uses the fission yeast model, this will be
discussed in more detail below.
1.3.1 The Fission Yeast Model for Juvenile CLN3 Disease
S. pombe is a rod-shaped unicellular eukaryote that has a well-annotated genome, is
highly amenable to genetic manipulation, and reproduces in a genetically stable way
with a short generation time. With just 4912 genes over three chromosomes, S. pombe
has the smallest number of protein-coding genes amongst eukaryotes, resulting in lit-
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tle redundancy or specialisation (Wood et al., 2002). It has a single CLN3 orthologue,
btn1+, which encodes a predicted transmembrane protein of 396 amino acids that is
30% identical and 48% similar to CLN3 (Figure 1.5). Complementation assays have
confirmed these genes are functional homologues (Gachet et al., 2005; Codlin et al.,
2008a), and support that CLN3 is presumed to have a fundamental molecular func-
tion. Importantly, S. pombe has a large number of small, acidic vacuoles (typically
50-80 per cell) which are equivalent to human lysosomes (Bone et al., 1998; Takegawa
et al., 2003), making it highly relevant to the study of juvenile CLN3 disease. Indeed,
cells which lack the entire btn1+ coding sequence (btn1∆ cells) display larger and less
acidic vacuoles than wild-type (Gachet et al., 2005), a feature that recapitulates the
less acidic lysosomal phenotype of patient fibroblasts (Holopainen et al., 2001; Vidal-
Donet et al., 2013) and cell lines depleted of CLN3 by RNAi (Kitzmu¨ller et al., 2008).
The over-expression of N-terminally tagged GFP-btn1+ and GFP-CLN3 constructs in
btn1∆ cells can complement these defects in vacuolar homeostasis. That btn1∆ cells
have defects in vacuolar function, as opposed to simply morphology, is supported by
the finding that btn1∆ cells secrete carboxypeptidase Y (Cpy1), which is indicative of
a moderate defect in the vacuole sorting of this hydrolase (Codlin and Mole, 2009).
This was found to arise from delayed trafficking of Vps10, the sorting receptor for
Cpy1, through the endoplasmic reticulum and its inability to exit the Golgi and cor-
rectly traffic to the trans-Golgi network (TGN) and vacuole. Btn1 is also implicated in
an additional Vps10 independent pathway of Cpy1 sorting (Codlin and Mole, 2009).
Ectopic expression studies using GFP-btn1+ have shown that at steady-state, Btn1
localises to, and can function from, a pre-vacuolar compartment considered to be the
Golgi (Codlin and Mole, 2009), which is consistent with its localisation in budding
yeast (Kama et al., 2011). After promoter shut-off, Btn1 traffics unusually slowly to the
vacuolar membrane via a Rab GTPase Ypt7 dependent endocytic route, in agreement
with the observed location of CLN3 (Gachet et al., 2005). btn1∆ cells are viable under
normal laboratory conditions but exhibit pleiotropic phenotypes that not only support
a role for Btn1 in vacuole homeostasis, but also endocytosis, cell wall deposition and
maintenance, glycolysis, and amino acid metabolism (Gachet et al., 2005; Codlin et al.,
2008b,a; Codlin and Mole, 2009; Pears et al., 2010). That Btn1 is involved in various
pathways is consistent with the finding that it affects the number, morphology, and
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Figure 1.5: Evolutionary conservation of CLN3 and Btn1. Human CLN3 protein
is shown aligned to the Btn1 homologues in Saccharomyces cerevisiae (shown here as
ScBtn1p) and Schizosaccharomyces pombe (shown here as SpBtn1). Shading indicates
identical (dark) or similar (grey) residues. Missense mutations that are conserved from
CLN3 to Btn1, and have been modelled in fission yeast, are shown by red boxes. Figure
adapted from Gachet et al. (2005) and Phillips et al. (2006).
location of the Golgi apparatus in addition to trafficking through this compartment
(Codlin and Mole, 2009).
Specifically, btn1∆ cells are longer and slower growing than wild-type cells. Pre-
vious work has described a significantly higher septation index and incidence of binu-
cleate cells under normal growth conditions, indicative of defects in the cell cycle and
cytokinesis (Gachet et al., 2005). All of these growth defects are exacerbated further
by growth at the non-permissive temperature of 37◦C, where btn1∆ cells additionally
exhibit monopolar growth, lose their rod-like shape and eventually lyse (Codlin et al.,
2008b,a). This is preceded by aberrant Myo1 localisation leading to an inability to cor-
rectly polarise sterol-rich domains to the plasma membrane, and is associated with ab-
normal formation and polarisation of F-actin patches and defective endocytosis (Codlin
et al., 2008b). As observed by electron microscopy, the cell wall and secondary septum
are also significantly thicker in btn1∆ cells, suggesting defects in cell wall develop-
ment. Indeed, btn1∆ cells are sensitive to zymolyase, an enzyme that targets one of the
main components of the fission yeast cell wall, β -glucan. These cell wall defects are
also thought to contribute to the delayed cytokinesis phenotype (Codlin et al., 2008a).
Lastly, the swelling and cell lysis phenotypes seen at 37◦C are completely rescued by
the addition of the osmolyte sorbitol, a finding that is common in cell wall mutants (Ga-
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chet et al., 2005). Importantly, the results of these studies indicate a multi-functional
role for Btn1 as while the vacuolar and cytokinesis defects are linked by a common pH
dependent pathway, the inability to maintain polarised growth and correctly deposit cell
wall material are a result of Btn1 action in a separate pH-independent pathway (Codlin
et al., 2008a). Work in this yeast therefore provided the first evidence that juvenile
CLN3 disease is more than a pH-related lysosomal disorder.
btn1∆ cells also display a number of metabolic defects (Pears et al., 2010). Using
1H NMR spectroscopy on both cell extracts and media supernatant to detect metabo-
lites, a number of distinguishing metabolic differences have been detected between
wild-type and btn1∆ cells. For example, btn1∆ cells show a decrease in extracellu-
lar glucose but an increases in extracellular ethanol and alanine labelling compared to
wild-type. As S. pombe preferentially generates ATP via aerobic alcoholic fermen-
tation, converting glucose into ethanol and glycerol, this altered metabolic profile is
suggestive of an increased glycolytic flux.
The vacuole is acidified by the action of H+-ATPases which reside on intracellular
membranes and pump protons out of the cytosol. This action is coupled to the hydrol-
ysis of cytosolic ATP, and in yeast the ATPase is regulated by glucose. As btn1∆ cells
have less acidic vacuoles than wild-type, it has been suggested that an up-regulation
of the vacuolar-type H+-ATPase (v-ATPase) to compensate for increased vacuolar pH
places a high energy demand on cells, and causes an increased glycolytic flux (Pears
et al., 2010). Interestingly, the swelling and lysis phenotype seen at 37◦C is worsened
in rich YES media compared to minimal media (Codlin et al., 2008b) but is rescued
by supplementing glycolytic substrates but not non-fermentable carbon sources. This
finding has been used to affirm that the metabolic defects seen in btn1∆ cells are a result
of altered glycolytic flux as opposed to an increase in the TCA cycle rate. It has also
been speculated that perturbed amino acid metabolism in btn1∆ cells is also associated
with vacuolar impairment (Pears et al., 2010).
Several aspects of these phenotypes, including altered vacuole pH and metabolic
defects, could conceivably have detrimental influences on neurons (for example by
impairing neurotransmitter trafficking (Gachet et al., 2005; Pears et al., 2010)) high-
lighting the clinical relevance of this work and suitability of S. pombe as a NCL model.
Furthermore, all residues affected by CLN3 mutations are present in btn1+. Modelling
1.4. Identifying Genetic Interactions in Fission Yeast 58
CLN3 disease mutations in Btn1 has provided valuable insight into the consequences
of such mutations on protein trafficking and function (Gachet et al., 2005; Codlin et al.,
2008b; Kitzmu¨ller et al., 2008; Haines et al., 2009). An extensive effort was recently
made to ectopically express Btn1 harbouring all known disease-causing missense and
common deletion mutations on a btn1∆ background (Haines et al., 2009). The effect of
these mutations was assessed by the ability of the mutant proteins to rescue four previ-
ously established marker phenotypes of btn1∆ cells; increased vacuole size, increased
cell curving at 37◦C, increased septation index, and monopolar growth at 37◦C - all of
which can be rescued by wild-type Btn1 and CLN3. The mutant protein arising from
an allele equivalent to the common 1 kb deletion was found to be able to rescue the
increased vacuole size, adding further support to the notion that this mutation retains
some function. No mutant protein could rescue all four phenotypes, although each was
able to rescue one or more phenotypes to a variable extent. Importantly, modelling
different CLN3 mutations in btn1+ affected the yeast phenotype in a way that corre-
lated with the known disease phenotype of patients carrying the equivalent mutation,
meaning the yeast model can be used to accurately predict the severity of CLN3 dis-
ease mutations. This therefore further establishes fission yeast as an accurate model for
juvenile CLN3 disease despite its simplicity.
Lastly, there is now a growing body of literature describing fission yeast as a suit-
able model for other neurodegenerative diseases (Brandis et al., 2006; Wiley et al.,
2014), ageing (Roux et al., 2010), and drug discovery (Delneri, 2010; Sun et al., 2012).
This S. pombe model is therefore well placed to provide a highly comprehensive means
to investigate both the pathogenesis and potential treatments of juvenile CLN3 disease.
1.4 Identifying Genetic Interactions in Fission Yeast
A disease phenotype does not arise from the loss of a gene acting in isolation, but rather
from the loss of its action in the context of a cellular network of interactions. Whereas
some interactions are physically direct (e.g. protein-protein interactions) others can
be more abstract (e.g. genetic interactions). Both can be informative however, and
integrating these two types of information has proven to be extremely powerful in un-
derstanding complex biological phenomenon in a variety of systems (Vidal et al., 2011;
Kemmeren et al., 2014).
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Some physical interaction partners are known for CLN3, yet as discussed at great
length already, the lack of suitable antibodies raises concerns over the validity of at
least some of these physical interactions. Microarray expression profiling provides in-
formation on which genes are altered in a given scenario, and such data is also available
for juvenile CLN3 disease. Yet the pattern of gene expression does not always reflect
protein levels or gene function (Chen et al., 2012), nor does it inform on whether the
changes are contributing to the disease state or reflect a compensatory mechanism.
Alternatively, genetic interactions may prove more useful in delineating the func-
tion of CLN3. Genetic interactions are defined as the phenomenon whereby mutations
in two genes produce a phenotype that is unexpected in light of the individual effect
of each mutation (Mani et al., 2008). These can be additive such that the resultant
phenotype is more severe than expected (i.e. synergistic or so-called called synthetic
interactions) or they can be suppressive/alleviating interactions, where the resultant
phenotype is in fact less severe than expected. As the contribution to a phenotype is
dependent upon the particular digenic allele combination, genetic interactions can be
used to identify functional relationships among genes. When the function of a gene is
unknown, this information can help place it into its biological context.
Yeasts are ideal models in which to identify genetic interactions, and overcome
some substantial limitations often encountered in other systems. They are typically
maintained in a haploid life cycle, which facilitates the recovery of what would be re-
cessive alleles in diploid organisms, while their compact genome reduces the likelihood
that a gene knock-out will be masked by redundant genes. Genetic manipulations are
also both heritable and highly stable in yeast, providing another distinct benefit over
transformed mammalian cell lines. When taken together with the ease of handling sta-
tistically relevant cell numbers, yeast also provide the means to systematically identify
genetic interactions at a genome-wide level. This level of genomic interrogation is not
possible, or vastly more difficult, in higher eukaryotes. For example, over 200 million
pairwise tests would be required to identify all synthetic lethal interactions in humans,
which is a prohibitively large experimental burden (Jacunski et al., 2015). Importantly,
there is now a growing body of literature that supports the notion that genetic interac-
tions are conserved among species (Dixon et al., 2008; Koch et al., 2012; Ryan et al.,
2012).
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1.4.1 Synthetic Genetic Arrays (SGAs)
The development of an open reading frame (ORF) deletion library, commercially avail-
able through Bioneer Inc (the Bioneer Deletion Mutant Library) (Kim et al., 2010), has
been central to genome-wide efforts in fission yeast. This resource allows the global
analysis of gene function, and interactions, rapidly and with ease. Building on work
pioneered in budding yeast, a particularly popular way to use this resource has been to
perform synthetic genetic array (SGA) analysis (Tong et al., 2001; Boone et al., 2007).
SGAs are performed on the principle that double mutants can be used to identify genetic
interactions in which a single gene of interest is central. First, a query strain harbouring
a gene disruption is crossed with an ordered array of the deletion mutants in the Bioneer
library. Through a series of replica-pinning procedures (usually performed robotically)
the double mutants can be selected, and digenetic interactions are identified in these
meiotic progeny by performing large-scale mutant phenotyping (Figure 1.6). Due to its
simplicity, the most frequently analysed phenotype is the growth rate, or fitness, of the
resultant double mutant strains which can be determined by colony size when grown
on solid agar. Negative interactions are identified when two mutations are additive,
and cause a stronger fitness defect than expected based on the growth phenotypes of
the individual mutations (i.e. the colony size of the double mutant is smaller than ex-
pected). In extreme cases, two single mutants may be viable and yet the combination
of mutations leads to cell death in a process known as synthetic lethality. Importantly,
as the double mutants are arranged in a precisely ordered manner (i.e. the location of
each mutant is known) synthetic lethal strains can be identified despite a complete lack
of cell growth. Negative interactions are typically observed for genes that act in sep-
arate pathways but carry out similar or compensatory functions (Braberg et al., 2014).
Conversely, positive interactions are identified when the double mutant is healthier than
expected, based on the phenotypes of the individual mutations (i.e. the colony size of
the double mutant is larger than expected). Although perhaps counter-intuitive, such
interactions can arise between genes that act in concert within the same non-essential
pathway or complex (Braberg et al., 2014), or can reveal a suppression mechanism.
Importantly, when using an SGA approach, the query gene can be explored in
a hypothesis-free manner. This offers a particular advantage when gene function is
unclear and the phenotypes resulting from its mutation are broad and complex, as is
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Figure 1.6: SGA process. [A] A query strain (i.e. btn1∆) is mated to the Bioneer Col-
lection, which contains deletion mutants of all non-essential genes arranged in an ordered
array. [B] Through a number of routine culturing steps (described in more detail in the
Materials and Methods), the diploids are allowed to sporulate and germinate. [C] Double
mutant progeny are selected by virtue of the antibiotic-resistance selection cassettes used
for gene deletion in both the query strain (NatMX6 cassette) and the Bioneer collection
(KanMX4 cassette). [D] The double mutants are allowed to grow under normal growth
condition for a defined time before plates are imaged and scored for fitness. More details
are provided in the Materials and Methods.
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the case with btn1+/CLN3. Further still, when used with a query gene associated with
disease, these interactions can be used not only to help define function, but also to
identify suppressors that might be suitable therapeutic targets.
1.4.2 Alternatives to SGAs: Transposon-Based Mutagenesis
Despite their wide use, deletion libraries are not however without limitations. They
are restricted to the analysis of complete null alleles of non-essential genes only, and
clearly completely lack mutants of essential genes. Further, approximately 10% of the
fission yeast collection is suspected of retaining copies of non-essential genes targeted
for deletion (Spirek et al., 2010; Guo et al., 2013), a similar number as previously re-
ported for the budding yeast library (Hughes et al., 2000). Others are not complete
deletions, with over 120 strains retaining more than 50% of the coding sequence (Kim
et al., 2010). Whether such partial deletions are functionally null alleles is not clear.
Furthermore, there are concerns regarding the number of additional mutations (un-
linked to the deletion cassette) that may have arisen when generating numerous strains
simultaneously. Mutations that alter (as oppose to abolish) gene function, affect ex-
pression levels or disrupt functional non-coding regions can also result in informative
phenotypes, but are also missing from the deletion collection. Accordingly, a pheno-
typic analysis of mutants developed by an insertional mutagenesis technique offers an
attractive alternative to systemically developed deletion sets.
One such insertional mutagenesis technique is to use linear PCR-derived selection
cassettes. These are capable of inserting randomly into the fission yeast genome by
non-homologous recombination, and do so most commonly at single locations (Chua
et al., 2000). The random nature of insertion sites ensures the mutagenic event is not bi-
ased towards known ORFs, allowing this approach to additionally disrupt un-annotated
genes and non-coding regions. Further, a greater variety of mutant alleles, extending
beyond null alleles, can be obtained such that essential genes may also be functionally
disrupted. For example, insertions in the 5’ and 3’ region of a gene can change pro-
tein expression levels by compromising promoter function and mRNA stability. Two
genome-wide, insertional mutant libraries have been developed based on the insertion
of linear ura4+ cassettes (Armstrong et al., 2007; Chen et al., 2012). Both overcome
a principle limitation of the deletion library by including hypo- and hypermorphic al-
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leles, disruptions to essential genes, and disruptions in non-coding regions. Although
SGAs have been performed with success using these insertional based libraries, they
are also limited by the need to purchase the libraries and equipment, and the need to
temporally separate biological replicates to gain power which can often make this ap-
proach prolonged and costly. The fundamental need for mating is also a substantial
disadvantage as query strains that are sterile or have meiotic defects typically perform
badly in such screens. Even when strains are not sterile, many meiotic genes also have
other functions, but negative interactions involving these genes can not be interrogated.
An easier approach to defining genetic interactions on a genome-wide scale is to
directly create the second site mutation on a specific genetic background i.e. in the
context of a pre-existing gene deletion or mutation. Although this can also be achieved
using linear PCR-derived cassettes, identifying which region has been disrupted by its
insertion can be challenging. In theory, this is achieved by sequencing the junction
between the ura4+ cassette and the genome to map the insertion site. However, linear
cassettes often create complex junctions that make them refractory to inverse PCR and
complicate mapping achieved by more sophisticated sequencing methods. It has been
noted that in many cases, transforming ura4+ fragments either develop terminal trunca-
tions or become concatemeric before integrating (Tatebayashi et al., 1994; Chua et al.,
2000; Rodrı´guez-Gabriel et al., 2003; Davidson et al., 2004; Armstrong et al., 2007;
Chen et al., 2012). In other cases, mitochondrial DNA co-integrates with the trans-
formed fragment, further complicating or precluding the ability to map the genomic
location of the insertion (Decottignies, 2005; Chen et al., 2012). Chemical mutagens
or ultraviolet radiation often introduce more than one mutation, and extensive linkage
analysis is required to interpret the phenotypic consequences.
Instead, transposon-mediated mutagenesis may provide a more suitable and com-
prehensive means to rapidly generate mutagenesis libraries on any strain background,
in a cost-effective manner and with tolerable labour investment.
DNA transposons are specialised sequences that are capable of non-replicative
movement within a host genome (Hermann et al., 2014). Highly ubiquitous in nature,
their inherent mutagenic properties have resulted in transposon-based systems being
well established for a variety of molecular applications, in multiple model organisms.
In an experimental setting, a transposon can be modified to carry almost any sequence
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cargo, provided it is flanked by transposon-specific sequences (termed terminal inverted
repeats (TIRs)) that are recognised by the transposase enzyme necessary to mediate its
movement.
Two transposon systems have been developed for S. pombe; one based on the
Hermes transposon from the housefly Musca domestica (Evertts et al., 2007) and a
second on the piggyBac transposon from the cabbage looper moth Trichoplusia ni (Li
et al., 2011). Both have been reported to show a broad distribution of insertion sites
across the three yeast chromosomes. Work with the piggyBac transposon has illustrated
that transposon mutagenesis is capable of resulting in null, hypomorphic, and gain-of-
function mutations. Together, these characteristics mean that transposons can be used
to create near-saturating mutagenesis libraries to facilitate screens to identify genetic
interactions.
Methods based on these transposons share numerous benefits with non-
homologous integration; namely the largely random insertion site pattern, paucity
of multiple insertions within single cells, the ability to create a wide range of mutation
types, and that the disruption mutation is physically tagged with a known sequence.
Most importantly however, transposons integrate as single, unmodified copies mak-
ing the transposon-genome boundaries substantially more defined than those achieved
with linear PCR cassettes. This makes the identification of the insertion site com-
paratively trivial, and overcomes a major drawback associated with non-homologous
recombination approaches.
Proof-of-principle experiments using transposon-based mutagenesis have been
performed in wild-type fission yeast for single gene phenotyping in order to assign
a measure of gene requirement or dispensability under specific conditions (Park et al.,
2009; Li et al., 2011; Guo et al., 2013). So far however, its use for identifying genetic
interactions has predominately been used in prokaryotes, including S. pneumoniae (van
Opijnen et al., 2009) although there is one paper detailing its application in Candida
albicans (Bharucha et al., 2011). The development of such an approach, when applied
to a disease model, will therefore provide a complementary yet competitive resource to
conventional SGAs using the Bioneer deletion library.
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1.5 Aims: Rationale and Significance
Despite extensive efforts, focused experiments performed to date have proved insuffi-
cient to define CLN3 function or its involvement in juvenile CLN3 disease pathogen-
esis, and there remains a significant need for protective therapeutic targets. The basis
of this work is therefore founded on the assumption that a more comprehensive and
hypothesis-free approach might be better placed to address the current gaps in under-
standing.
The primary aim of this project is to use the S. pombe model to facilitate genome-
wide SGA screens to identify genes that improve or worsen the fitness of cells lack-
ing btn1+. The hypothesis is that the identification of such genetic interactors will be
instructive about the basic biology and disease-specific pathways of btn1+, and by ex-
trapolation CLN3. A wider aim is that such information may also be used to identify
accessible drug targets to inform rational and mechanistically-based therapeutic devel-
opments which are clearly lacking for juvenile CLN3 disease. It is also hoped that
an improved understanding of btn1+/CLN3 function might have important inferences
into the function of other uncharacterised NCL genes, and help dissect the mechanisms
involved in more common neurodegenerative diseases, such as Alziehmer’s and Parkin-
son’s.
A secondary aim of this work is to begin to extend and develop a transposon-based
mutagenesis system using the Hermes transposon to complement the SGA approach to
finding genetic interactions.
Chapter 2
Materials and Methods
2.1 Routine Molecular Biology Methods
All routine reagents were supplied from Sigma-Aldrich (Dorset, England) and were of
analytical grade unless stated otherwise.
2.1.1 Competent Bacteria
Competent E. coli DH5α bacteria were created using the rubidium chloride (RbCl)
method as described in Sambrook and Russell (2001).
2.1.2 Bacterial Transformations
100 µl of chemically competent cells, created as described above, were thawed on
ice. Approximately 1 ng of plasmid DNA was added to cells, and incubated on ice
for 5 mins. The cell-DNA mixture was subsequently exposed to a 42◦C heat shock
for 2 mins, before being returned to ice for a further 5 mins. 100 µl of SOC media
was added, and cells were incubated at 37◦C for 30 mins before being plated on LB
agar with the appropriate antibiotic (typically ampicillin at a final concentration of 100
µg/mL). Plates were incubated at 37◦C for 24 hrs to allow colonies to form.
2.1.3 Plasmid Preparation and Storage
All plasmid preparations were performed using either the Qiagen Miniprep or Max-
iprep kits, as per manufacturers instructions (QIAGEN, Manchester, UK). Plasmids
were eluted in a volume of EB buffer (10 mM Tris-Cl, pH8.5) as dictated by manufac-
turers instructions, and stored either at 4◦C for short-term use or -20◦C for longer term
storage.
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The pREP1.rho5+ construct used in this work was obtained from Professor
Kentaro Nakano (University of Tsukuba, Tsukuba, Japan); pREP41x.rho1+ and
pREP41x.pmp1+ were both from Professor Pilar Pe´rez (The Institute of Functional
Biology and Genomics, University of Salamanca, Spain); pREP1.wis1DD-3HA6His
from Professor Kaz Shiozaki (Nara Institute of Science and Technology, Ikoma, Japan);
pREP41x.rhb1D60K from Dr Elizabeth Henske (Dana-Farber/Harvard Cancer Center,
Brookline, MA); pREP41x.gad8+ from Dr Ronit Weisman (The Open University of
Israel, Tel Aviv); and the pREP41x.pmr1+ construct was obtained from Dr Takayoshi
Kuno (Kobe University, Kobe, Japan). The pREP41x.GFP-btn1+ construct used in this
study has been described previously (Gachet et al., 2005).
2.1.4 DNA Sequencing
Plasmid DNA, PCR amplicons, and all sequencing primers were sent externally
to SourceBioscience (www.lifesciences.sourcebioscience.com) for se-
quencing. Chromatograms and sequences were visualised using Serial Cloner v2.5 for
Mac.
2.2 Routine Yeast Methods
2.2.1 Yeast Strains
Standard nomenclature has been used to describe the genotype of all S. pombe strains
discussed in this work. Fission yeast gene names are expressed as a three letter, italic
name followed by a number and a plus (+) for wild type. Gene deletions are initially
described and denoted by lower-case letters representing the disrupted gene, followed
by two colons and the gene marker used for targeted replacement (e.g. yfg1+::NatMX6).
Throughout the main body of the text however, gene deletions are referenced using a
delta (∆) following the gene name (e.g. yfg1∆). Fission yeast protein names are in Ro-
man text with a capitalised first letter (Yfg1). In some cases where a common name has
not been assigned, fission yeast systematic names are instead used (e.g. SPAC17C9.14).
When referring to budding yeast genes, wild-type alleles are expressed as italicised
capital letters (YFG1) and mutants in lower case. Budding yeast protein names are in
capitalised Roman text. A list of all yeast strains used in this work is given in Table
2.1.
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Table 2.1: Yeast strains. The yeast strains used in this work are detailed, including a
description of their genotype and source.
Strain Name Genotype Source
972h- h-, (prototrophic wild-type) Laboratory strain
SP5 h+, ura4-D18, leu1-32 Laboratory strain
SP19 h+, btn1::NatMX6, ura4-D18, leu1-
32
This work
SP23 h-, ura4-D18, leu1-32, ade6-210 Kazu Tomita,
UCL, London
SP38 h-, ura4-D18, leu1-32, ade6-210,
his-
Laboratory strain
SP29 h-, btn1::NatMX6, ura4-D18, leu1-
32, ade6-210
This work
SP30 h-, btn1::NatMX6, ura4-D18, leu1-
32, ade6-210
This work
SP35 h-, btn1::NatMX6, ura4-D18, leu1-
32, ade6-210, his-
This work
SP36 h-, btn1::NatMX6, ura4-D18, leu1-
32, ade6-210, his-
This work
SP37 h-, btn1::NatMX6, ura4-D18, leu1-
32, ade6-210, his-
This work
klp5+::KanMX6 h-, klp5+::KanMX6 Takashi Toda, London
Research Institute
klp6+::KanMX6 h-, klp6+::KanMX6 Takashi Toda, London
Research Institute
sxa1∆ SPAC26A3.01::KanMX4, ura4-D18,
leu1-32, ade6-M210
Bioneer
Collection
npc2∆ h+, SPAPB8E5.04c::KanMX4, ura4-
D18, leu1-32, ade6-M210
Bioneer
Collection
Continued on next page
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Table 2.1 – Continued from previous page
Strain Name Genotype Source
lvs1∆ h+, SPBC28E12.06c::KanMX4,
ura4-D18, leu1-32, ade6-M210
Bioneer
Collection
atp13a2∆ h-, SPCC1672.11c::KanMX6, ura4-
D18, leu1-32, his-, ade6-M210
Laboratory Strain
pmr1∆ h+, SPBC31E1.02c::KanMX4, ura4-
D18, leu1-32, ade6-M210
Bioneer
Collection
btn1-1kb∆ h+, btn1+::btn1-1kb∆, ura4-D18,
leu1-32, his-
Laboratory strain
btn1E240K h+, btn1+::btn1E240K, ura4-D18,
leu1-32, his-
Laboratory strain
2.2.2 Routine Yeast Media
Yeast extract (YE) and supplemented yeast extract (YES) media were made as previ-
ously described by Moreno et al. (1991) and listed below. Plates of solid media were
made with the addition of 2% agar. All media reagents were supplied by Formedium
(Norfolk, UK).
YE (per litre):
Yeast Extract 5 g
Glucose 30 g
YES (per litre):
Yeast Extract 5 g
Glucose 30 g
Adenine 500 mg
Uracil 500 mg
Leucine 500 mg
Histidine 500 mg
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Edinburgh minimal media (EMM) was also made as previously described (Moreno
et al., 1991). Where necessary, and detailed in the main text, thiamine was added to
EMM media at a final concentration of 50 µg/ml to repress expression from the no-
message-in-thiamine (nmt1) promoter (Maundrell, 1990).
EMM (per litre):
NH4Cl 5 g
Na2HPO4 2.2 g
Potassium hydrogen phthalate 3 g
Adenine (if required) 500 mg
Uracil (if required) 250 mg
Leucine (if required) 250 mg
Histidine (if required) 250 mg
Glucose (20% w/v stock) 50 ml
Salts (50x stock; see below) 10 ml
Vitamins (1000x stock; see below) 500 µl
Minerals (10,000x stock; see below) 50 µl
Salt Stock (50x) (per litre):
MgCl2.6H2O 52.5 g
CaCl2.2H2O 0.735 g
KCl 50 g
Na2SO4 2 g
Vitamins Stock (1000x) (per 100 ml):
Nicotinic acid 1 g
Inositol 1 g
Pantothenic acid 0.1 g
Biotin 0.001 g
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Minerals Stock (10,000x) (per 100 ml):
Citric acid 1 g
Boric acid 0.5 g
MnSO4.H2O 0.5 g
ZnSO4.7H2O 0.4 g
Molybidic acid 0.305 g
FeCl3.6H2O 0.2 g
KI 0.1 g
CuSO4.5H2O 0.04 g
Amino acids (AA) media was made as previously reported (Davey et al., 1995), and is
described below.
AA (per litre:):
Drop-Out Mix (see below) 1.5 g
Yeast Nitrogen Base (without amino acids or (NH4)2SO4) 1.7 g
Amino Acid Supplements (see below) 500 mg
(NH4)2SO4 5 g
Glucose 24 g
Bacto agar 20 g
Drop-Out Mix:
Alanine 2 g Pheylalanine 2 g
Arginine 2 g Proline 2
Asparagine 2 g Serine 2 g
Aspartic acid 2 g Threonine 2 g
Cystine 2 g Tryptophan 2 g
Glutamine 2 g Tyrosine 2 g
Glutamic acid 2 g Valine 2 g
Glycine 2 g Myo-inositol 2 g
Lysine 2 g Para-amino benzoic acid 0.4 g
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Amino Acid Supplements (Components as required):
Adenine 0.5 g
Uracil 0.5 g
Leucine 0.5 g
Histidine 2 g
Methionine 2 g
Prior to all physiological assays, cells were grown overnight in 10 ml EMM with the
appropriate supplements, at 30◦C and 230 rpm to mid-log phase. Liquid YES and agar
plates were used for non-selective, vegetative growth. AA agar plates were used for
selective purposes following yeast transformations (protocol described below). Strains
carrying plasmids were stored at 4◦C on selective AA agar plates to ensure plasmid
retention. Strains without plasmids were stored at 4◦C on YES agar plates. For long-
term storage, strains were frozen at -80◦C in YES or selective EMM liquid media and
25% glycerol.
Cell concentration measurements were based on optical density readings at 600
nm (OD600) using a Ultrospec 2000 spectrophotometer (Pharmacia Biotech) and ad-
justed for a 1:10 dilution in water. An OD600 of 0.1 was taken to correspond to 2x106
cells/ml.
All centrifugation steps were performed at 2000 rpm and for 5 mins unless stated
otherwise.
2.2.3 Yeast Strain Construction by Targeted Gene Replacement
The btn1+::NatMX6 strains were constructed by targeted gene replacement using the
long template PCR approach method described by Bahler et al (1998) (Ba¨hler et al.,
1998). Primers for gene replacement and subsequent confirmation were designed using
the Pombe PCR Primer Programs (PPPP; www.bahlerlab.info/resources)
and ordered through EuroFins (www.eurofins.co.uk).
The NatMX6 cassette was amplified from a pFA6A construct (Hentges et al., 2005)
using the Expand Long Template PCR System (Roche, West Sussex, UK) according to
manufacturers instructions, and the primers btn1delete For and btn1delete Rev (de-
tailed in Table 2.2). The PCR amplicon was size selected and gel purified using the
2.2. Routine Yeast Methods 73
QIAGEN Gel Extraction kit (QIAGEN, Manchester, UK), and eluted in 12 µl sterile
water to concentrate the DNA. The full volume was used to transform wild-type cells
using the lithium acetate method described below. Following the transformation, cells
were plated onto YES agar to allow expression of the NatMX6 cassette. After approxi-
mately 24 hrs, cells were replica plated onto YES containing 100 µg/ml nourseothricin
(Formedium, Norfolk, UK) for selection. Stable transformants were confirmed by
colony purification onto YES + 100 µg/ml nourseothricin, then maintained on YES
agar plates at 4◦C. The replacement of btn1+ by NatMAX6 was confirmed by PCR
using gene specific primers on yeast genomic DNA (btn1ORF For, btn1ORF Rev,
btn1flank For, btn1flank Rev, NatMX For, and NatMX Rev (all detailed in Table 2.2)).
2.2.4 Yeast Transformations
Cells were transformed using the lithium acetate (LiAc) method described by Okazaki
et al. (1990) with slight modification. Cells were grown overnight, harvested by cen-
trifugation and washed once in 1 ml LiAc (adjusted to pH4.9 with acetic acid). Cells
were re-suspended to 1x109 cells/ml in LiAc (pH4.9) and incubated at 30◦C, without
shaking, for 30 mins. During this time, 0.5–5 µg plasmid or purified PCR-derived
DNA was mixed with 290 µl 50% polyethylene glycol (PEG) in 0.1 M LiAc, pH 4.9
(PEG-Li), and also equilibrated to 30◦C. 100 µl of cells were subsequently added to
the PEG-Li-DNA mix, and incubated at 30◦C, without shaking, for a further 50 mins.
Cells were heat shocked at 42◦C for 10 mins, then collected by centrifugation. Pelleted
cells were suspended in 200 µl sterile water and plated onto selective media. Success-
ful transformants were selected by single-colony isolation and maintained on selective
AA agar plates at 4◦C.
2.2.5 Preparation of Yeast Genomic DNA
Genomic DNA was extracted from yeast cultures using the protocol described by Hoff-
man and Winston (1987). Cells were grown overnight in 20 ml YES media, harvested
by centrifugation then re-suspended in 500 µl sterile water and transferred to a 2 ml
safe-lock tube. Cells were again harvested by centrifugation (13,000 rpm for 30 secs)
and re-suspended in residual water. 200 µl breaking buffer (2% Triton X-100, 1% SDS,
100 mM NaCl, 10 mM Tris pH 8.0, 1 mM EDTA) and 200 µl 1:1 phenol:chloroform
was added. 0.3 g acid-washed glass beads were added, and cells were lysed by vigor-
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ous vortexing for 3 mins. 200 µl TE Buffer (10 mM Tris, 1 mM EDTA, pH 8.0) was
then immediately added and tubes were centrifuged for 5 mins at 13,000 rpm, 4◦C. The
aqueous layer was transferred to 1 ml of ice-cold 100% ethanol and mixed by inversion.
Precipitated DNA was harvested by centrifugation for 10 mins at 13,000 rpm, 4◦C. The
supernatant was aspirated, and the DNA pellet washed once with 200 µl 70% ethanol.
The DNA was allowed to air dry then re-suspended in 50 µl TE Buffer before being
stored at 4◦C.
2.2.6 PCR Screens using Yeast Genomic DNA
PCR reactions on yeast genomic DNA were performed using GoTaq Polymerase
(Promega, Southampton, UK) according to manufacturers instructions. PCR products
were checked for size by running on a 1% agarose gel at 120 V for approximately 40
mins.
2.3 Synthetic Genetic Arrays
Synthetic genetic arrays (SGAs) were performed by Dr Charalampos Rallis (Univer-
sity College London, UK) using a protocol based on that described by Dixon et al.
(2008). Four btn1∆ query strain isolates (SP29, SP30, SP35, and SP37) were mated
to a 384 strains/plate array of single deletion mutants (the Bioneer Deletion Mutant
Library, (v2.0)) using the Singer RoToR robot (S. pombe settings). Cells were then
allowed to sporulate at 25◦C for 3 days, before being transferred to 42◦C for 3 days in
order to enrich for spores by eliminating vegetative cells. Following this heat treatment,
spores were transferred to YES lacking antibiotics and allowed to germinate for 2 days
at 30◦C. Recombinant double mutant haploids were subsequently selected by pinning
the cells to YES containing the antibiotics G418 and nourseothricin (both Formedium,
Norfolk, UK). During this step, cells were copied from a 384 to a 1536 strains/plate
format such that each mating resulted in four colonies. After 3 days growth at 30◦C,
agar plates were imaged using a MultiDoc-It Imaging System (UVP). Images were pro-
cessed for analysis using Gitter, an image analysis R package (Wagih and Parts, 2014).
A control SGA using ade6+::NatMX4 as a query was performed simultaneously. The
ade6∆ mutant does not alter the fitness of the deletion collection, and arising double
mutants are used to determine Bioneer strain fitness and for colony size normalisation
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(see below).
Using Excel (version 14.3.3 for Mac), the colony sizes produced by Gitter were
normalised to the median colony size of each plate to account for within-plate positional
growth effects and differential plate growth. Mean values for the 4 colonies resulting
from each mating were used to establish the ratio of query (btn1∆) colony size to control
(ade6+::NatMX4) colony size. Ratios from the four btn1∆ isolates used for the screen
were subsequently used to calculate a mean ratio. Using this mean value, colony-size
ratio scores of <0.8 were defined as negative interactions, and ratios of >1.2 as posi-
tive interactions. Genetic interactions under normal conditions were scored from two
independent biological experiments, separated temporally to minimise potential batch
effects (Baryshnikova et al., 2010). Only interactions common to both replicates were
considered robust enough for further follow-up. Negative and positive interaction sets
were tested for Gene Ontology (GO) enrichment using the AnGeLi: Analysis of Gene
Lists software (Bitton et al (2015), submitted). SGA data sets were compared against
all protein coding genes for biological process and molecular function GO categories.
Multiple testing was adjusted for by using the False discovery rate (FDR) and p <0.01
was taken as significant (default settings). AnGeLi results were corroborated using
the ‘protein annotation through evolutionary relationship’ (PANTHER) classification
system (Mi et al., 2013).
To aid comparisons across data sets of other known CLN3 interactors, all hits
were converted to fission yeast systematic names for convenience using either the
g:Orth function of the web-based g:Profiler platform (Reimand et al., 2007) or manu-
ally using the web-based YOGY platform (Penkett et al., 2006) and Pombase database
(www.pombase.org). Comparisons were made using the web-based list compari-
son tools available through the Bioinformatics and Research Computing page from the
Whitehead Institute (http://jura.wi.mit.edu/bio/). CLN3 interaction data
sets were compiled using BioGRID, GeneMania, and STRING with others manually
added after a review of the literature if neccessary.
2.4 Yeast Stress Conditions
The yeast strains used in this work were phenotypically characterised by being sub-
jected to various environmental stress conditions as predominately detailed in Chapter
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4 (p. 108). The media used for this work are detailed in this section, while the experi-
mental approaches are detailed below.
The media used for glucose limitation experiments were made as previously de-
scribed (Rorbach et al., 2008), and shown below.
Glucose / Glycerol Media (per litre:)
Yeast Extract 10 g
Peptone 5 g
Adenine 80 mg
Glucose or Glycerol 30 g
Ethanol 30 ml
Agar 20 g
For experiments involving nitrogen limitation, EMM was prepared by omitting ammo-
nium chloride (NH4Cl). Experiments to investigate the impact of elevated heat were
performed using standard YES agar incubated at either 30◦C (as a control) or 37◦C.
Sorbitol was added to a final concentration of 2 M for some experiments. For cell wall
stress experiments, caspofungin was made as a 2.5 mg/ml (2.3 mM) stock in H2O, and
added to YES media at a final concentration of 5 µg/ml (4.5 µM). For oxidative stress
experiments, H2O2 was added to YES media at a final concentration of 0.75 mM. For
salt induced hyper-osmotic stress experiments, KCl or NaCl was added to YES me-
dia at a final concentration of 1.5 M and 0.8 M respectively. Hypotonic treatment
was assessed by two methods. In the first, cells were grown to mid-log stage in YES
medium plus 1.2 M sorbitol and subsequently transferred to the same medium without
sorbitol. A second approach involved growing cells overnight in YES media, then sup-
plementing the culture with an equal volume of YES with 2.4 M sorbitol (creating a
final sorbitol concentration of 1.2 M). This culture was incubated at 30◦C for a further
4 hrs before being diluted 20-fold with water to induce to the hypo-osmotic shock. For
replication stress experiments, hydroxyurea (HU) was added to YES agar at a final con-
centration of 2.5 mM from a 1 M stock in DMSO. Methyl-methane sulfonate (MMS)
was added to YES at a final concentration of 0.04% and camptothecin (CPT) at a final
concentration of 3 µM from a 10 mM stock in methanol.
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For the rescue experiments described in Chapter 5 (p. 129), cyclohexamide (CHX)
and G418 were added to YES agar at a final concentration of 0.1 µM. Guanabenz (GB)
was added to a final concentration of 1 µM from a 10 mM stock in DMSO.
As used in Chapter 6 (p. 151) Mn2+-free media was prepared as EMM but by
omitting MnCl2 and MnSO4 from Salt and Mineral stocks respectively. Ca2+ free me-
dia was prepared as EMM but CaCl2 was omitted and the calcium panthothenate in the
Vitamin stocks (listed above as pantothenic acid) was replaced by sodium pantothenate.
Experiments which involved exposing yeast cells to excess manganese or calcium were
performed by adding MnCl2 and CaCl2 to EMM at a final concentration of 50 mM and
100 mM respectively.
2.5 Microscopy and Image Analysis
2.5.1 Viability Assays
For stress conditions evaluated in liquid media, cell viability assays were performed
as follows. Cells were grown overnight in EMM to mid-log phase, then used seed 20
ml experimental cultures at an initial OD600 of 0.1. Every 24 hrs, 1 ml aliquots were
removed and process for imaging. 10 µl calcofluor white (Sigma, Dorset, UK) was
added to stain the total cell population, and 15 µl of the cell impermeant nucleotide
stain propidium iodide (Sigma, Dorset, UK) was added to stain dead cells. Cells were
incubated with stains for 10 mins at room temperature, protected from light. Cells
were harvested by centrifugation and washed once in phosphate-buffered saline (PBS).
Cells were visualised immediately, without fixation, using a 40x oil-immersion objec-
tive and either a Hamamatsu C4742-95 digital camera fitted to a Zeiss Axioskop mi-
croscope, or a QImaging QIClick digital camera fitted to a Zeiss AxioImager. Images
were recorded using OpenLab software (PerkinElmer). At least 500 cells were scored
for viability per data set using ImageJ software. Viability was calculated as the number
of alive cells (Nalive) to the total number counted (Ntotal) and expressed as a percentage
((Nalive/Ntotal)*100).
2.5.2 Morphological Response Assays
To assess the morphological response of cells to various conditions, cells were grown
overnight in EMM to mid-log phase. Cells were subsequently collected by centrifu-
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gation, washed once in sterile water, and re-suspended in experimental media at 30◦C
for a time period as dictated in the Results section. 1 ml aliquots were subsequently
stained with 10 µl calcofluor white (Sigma, Dorset, UK) to identify the total cell popu-
lation, and incubated for 10 mins at room temperature, protected from light. Cells were
harvested by centrifugation and washed once in PBS. Cells were visualised immedi-
ately, without fixation, using a 63x oil-immersion objective on a Leica SPE2 confocal
microscope. Images were recorded using LASAF software (Leica Microsystems). To
determine cell morphology (specifically cell elongation), cells were segmented using
the BOA plugin of the quantitative imaging of membrane proteins (Quimp) package,
itself available as a plugin for ImageJ (Bosgraaf et al., 2009). Cell elongation was de-
termined using the equation 1 - (4 pi area)/perimeter2. At least 50 cells were scored per
data set.
2.5.3 Vacuole Size
Cells were grown overnight in EMM to mid-log phase. 1 ml of culture was
collected by centrifugation and re-suspended in 50 µl of YES and 1 ul N-(3-
triethylammoniumpropyl)-4-(6-(4-diethylamino) phenyl) hexatrienyl pyridinium di-
bromide (FM4-64) (Invitrogen, Paisley, UK). Cells were incubated at 30◦C, without
shaking, for 20 mins. Cells were then harvested by centrifugation, re-suspended in 5
ml YES media and incubated at 30◦C, with shaking, for a further 1.5 hrs. Cells were
again harvested by centrifugation and washed once in 1 ml EMM media. Cells were
visualised immediately, without fixation, using a 63x oil-immersion objective on a Le-
ica SPE2 confocal microscope. Images were recorded using LASAF software (Leica
Microsystems). The diameter of each vacuole visible in one focal plane of a cell was
measured using ImageJ software. At least 300 vacuoles were measured per data set.
2.5.4 Cell Length
Cells were grown overnight in EMM to mid-log phase. 1 ml aliquots were subsequently
stained with 10 µl calcofluor white (Sigma, Dorset, UK) to identify the total cell popu-
lation, and incubated for 10 mins at room temperature, protected from light. Cells were
harvested by centrifugation and washed once in PBS. Cells were visualised immedi-
ately, without fixation, using a 40x oil-immersion objective on a Leica SPE2 confocal
microscope. Images were recorded using LASAF software (Leica Microsystems). Cell
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length was measured using ImageJ software. At least 500 cells were measured per data
set.
2.6 Plate Assays
For stress conditions that were investigated on solid media, cell growth assays were
performed as follows. Cells were grown overnight in EMM to mid-log phase, then
harvested by centrifugation (2000 rpm for 5 mins), washed once in 10 ml sterile water,
and re-suspended to 1x108 cells/ml in sterile water. Five 10-fold serial dilutions were
made, and 10 µl aliquots from each spotted onto plates. Plates were imaged after 3
days growth at 30◦C, except for glycerol plates which were imaged afer 7 days.
2.7 Transposon-Mutagenesis Library Preparation
2.7.1 Strains and Constructs
Yeast strains SP5 (wild-type) and SP19 (btn1+::NatMX6) were used to prepare the
experimental mutagenesis libraries used for the high-throughput sequencing work.
Yeast strain SP5 was used in all proof-of-principle experiments. klp5+::KanMX6) and
klp6+::KanMX6 strains were used for thiabendazole (TBZ; SIGMA-Aldrich, Dorset,
UK) resistance validation tests, and were provided by Dr Takashi Toda (Cancer Re-
search UK, London Research Institute, UK).
The Hermes constructs have been described in (Evertts et al., 2007) and were a
kind gift from Dr Henry Levin (Eunice Kennedy Shriver National Institute of Child
Health and Human Development, Rockville, MD). pHL2577 is a pSP2 shuttle vector
derivative and was used as a donor for the Hermes transposon, which consists of a
KanMX6 cassette flanked by Hermes terminal inverted repeats (TIRs). This plasmid
also contains the URA3 coding sequence for selection. pHL2651 is a similar plasmid,
except the Hermes transposon contains the NatMX6 cassette in place of the KanMX6
cassette. The Hermes transposase enzyme was provided to cells under the control of
the Rep81X nmt1 promoter (pHL2578). The Hermes transposase enzyme recognises
the Hermes TIR, and mobilises the transposon from the donor plasmid to mediate its
insertion into the yeast genome. A detailed description of these plasmids is provided in
Chapter 7 (Figure 7.1).
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2.7.2 Transformation of Hermes constructs
Cells were transformed with pHL2577 using the lithium acetate method described
above, and selected on AA agar lacking uracil. Single colonies were used in a sec-
ond transformation to introduce either the pHL2578 plasmid or pREP41x to create a
vector-only negative control strain. Transformants were selected on AA agar plates
lacking both uracil and leucine. Single colonies were used immediately in a transposi-
tion reaction to generate the mutagenesis libraries.
2.7.3 Transposition Induction and Library Construction
Cells carrying Hermes plasmids, or the negative control strain, were used to seed a
5 ml EMM culture lacking uracil and leucine, supplemented with 50 µg/ml thiamine.
Thiamine is added at this stage to suppress the expression of the transposase enzyme, in
order to reduce the risk of attaining transposition events in early progenitor cells. After
24 hrs, this culture was washed four times in EMM lacking uracil and leucine to remove
thiamine. Removing thiamine permits the expression of the transposase enzyme from
the nmt81 promoter. These cells were used to inoculate a 50 ml EMM culture lacking
uracil, leucine and thiamine to an initial OD600 of 0.05. This culture was maintained
in log-phase and passaged until approximately 25 generations had been reached, as
determined using OD600 measurements and the formula n = [ln(ODF/ODI)]/0.693;
where n is the number of cell generations and ln is the natural log (Park et al., 2009).
During library construction, the transposition frequency was monitored by plat-
ing dilutions of cells onto AA + 1 mg/ml 5-fluoroorotic acid (5-FOA) (Formedium,
Norfolk, UK), and YES + 1 mg/ml 5-FOA + 0.5 mg/ml G418 (Formedium, Norfolk,
UK). This allowed the percentage of cells lacking pHL2577 but harbouring genomic
insertions to be calculated by dividing the number of G418 resistant colonies by the
total number of 5-FOA tolerant colonies. The transposition frequency was expressed
relative to generation number.
After 25 generations, cells were grown for an additional 24 hrs in AA liquid me-
dia + 1 mg/ml 5-FOA from an initial OD600 of 0.25 to select against cells carrying
the pHL2577 donor plasmid. These cells were subsequently used to inoculate a 500
ml culture of YES + 1 mg/ml 5-FOA + 0.5 mg/ml G418 to an initial OD600 of 0.5.
This step selects cells that have lost the original donor plasmid (pHL2577) but remain
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resistant to G418 due to the retention of the KanMX6 cassette at a genomic location.
Once the culture had reached an OD600 of five, 100 µl aliquots were plated on YES
agar. After 24 hrs these were replica-plated onto YES + 0.5 mg/ml G418 and AA agar
lacking uracil to ensure the majority of cells were insertional mutants and no longer
carried the pHL2577 donor plasmid.
Cells from ten 50 ml aliquots were collected by centrifugation, re-suspended in
YES + 25% glycerol and stored at -80◦C.
For each strain, three biological replicate libraries were independently constructed.
2.8 Transposon-Mutagenesis Proof of Principle Screens
In a screen for mutagenesis-derived strains deficient in adenine biosynthesis, cells were
spread onto YE agar plates at a density of approximately 1000 colonies per plate. Plates
were incubated at 30◦C for 3 days then visually inspected for pink or red colonies. In a
screen for mutagenesis-derived mutants resistant to TBZ, an aliquot of the final libraries
was diluted to 1x108 cells/ml, and 100 µl spread onto YES agar + TBZ.
TBZ was made as a 20 mg/ml stock solution in DMSO, and added to YES media
to a final concentration of 40 µg/ml. Plates were incubated at 30◦C for 3 days. Colony
numbers were estimated using ImageJ and the colony counter plug-in. For both screens,
cells from the negative control strain were also plated for comparison.
2.9 Mutagenesis Library Passage and Genomic DNA
Extraction
Frozen aliquots from independently created libraries were thawed into 50 ml EMM
complete media. DNA was extracted from 3x108 cells. This was taken as time point
T=0.
1.5x108 cells were inoculated into 75 ml EMM complete media to an initial
OD600 of 0.1. This culture was grown such that mutants from each library were com-
petitively grown under defined conditions. After approximately 24 hrs, 1.5x108 cells
were transferred to a fresh 75 ml EMM complete culture. Passaging was continued for
ten days, with cultures being maintained in log phase. DNA was extracted from 3x108
cells every two days to give time points T=2, 4, 6, 8 and 10.
All DNA extractions were performed using the MasterPure Yeast DNA Purifica-
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tion Kit (EpiCentre, Cambridge, UK). DNA was quantified using a Qubit dsDNA HS
Assay Kit (Invitrogen, Paisley, UK), and DNA quality was assessed by Nanodrop 1000
spectrometer (Thermo Fisher Scientific, Loughborough, UK) to determine absorbance
ratios (samples with a 260/280 ratio of 1.8 and a 260/230 ratio of 1.8 - 2.2 were con-
sidered to be pure).
2.10 Illumina DNA Library Preparation
The high-throughput sequencing approach used in this work is based on a protocol
previously developed by Dr Dan Jeffares (University College London, London), with
some modifications. All oligonucleotides were ordered through SourceBioscience and
PAGE purified, and detailed in Table 2.2.
3 µg genomic DNA from each sample was sheared to an average size of 200 bp
using a Covaris S2 ultrasonicator (Covaris, Woburn, MA) in a final volume of 120 µl
TE buffer (Quail et al., 2008). 40 µl of sheared DNA (approx. 1 µg) was subsequently
digested with 20 units KpnI-HF (NEB, Hitchin, UK) in a final volume of 50 µl for
2 hrs. This step was incorporated to remove any pHL2577 plasmid which contains
the Hermes transposon and may have still been present in genomic preparations. Di-
gested DNA was purified using 1.8x Agencourt AMPure XP beads (Beckman-Coulter,
Danvers, MA) and re-suspended in 50 µl sterile water. 48 µl of purified DNA was
subsequently end-repaired using the NEB End Repair Module (NEB, Hitchin, UK)
according to manufacturers instructions. End-repaired DNA was purified using 1.8x
Agencourt AMPure XP beads and re-suspended in 27 µl sterile water.
Forked linkers (Linker 1 and Linker 2, see Table 2.2) were annealed to a final con-
centration of 10 µM in annealing buffer (10 mM Tris pH 7.5, 1 mM EDTA, 50 mM
NaCl) by heating to 90◦C, then slowly cooling to room temperature over 1 hr. 10 µl
of annealed linkers were ligated to 25 µl purified DNA in a 50 µl reaction using the
NEBNext Quick Ligation Module (NEB, Hitchin, UK), according to manufacturers in-
structions. Linker-ligated DNA was purified using 1.8x Agencourt AMPure XP beads
and re-suspended in 22 µl sterile water. Linker oligonucleotides were ordered through
Integrated DNA Technologies (www.idtdna.com). Linker 2 was designed to in-
clude a 5’ phosphorylation modification (to allow it to be a substrate for DNA ligase)
and a 3’ amino group modification in order to prevent linker-linker ligation.
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To specifically enrich for fragments containing the Hermes transposon, 20 µl
linker-ligated DNA was amplified using NEBNext High-Fidelity 2x PCR Mix (NEB,
Hitchin, UK) with a universal forward primer designed to bind the ligated linker (Her-
mesEnrich For), and a sample specific reverse primer designed to bind within the Her-
mes right terminal inverted repeat (TIR) sequence (HermesEnrich For). This reverse
primer contained a defined 10 bp barcode designed using the TagGD software package
(Costea et al., 2013). This barcode provides sample identify, and allows libraries to be
multiplexed prior to sequencing. A random 16 bp sequence was also incorporated into
the reverse primer to act as a unique molecular identifier (UMI) (Kivioja et al., 2012).
This UMI acts to distinguish biologically unique insertions over PCR derived amplifi-
cations, and is explained in more detail in Chapter 7 (p. 171). Cycling conditions for
this PCR step were as follows: 98◦C for 30 secs, then 20 cycles of 98◦C for 10 secs,
65◦C for 30 secs, 72◦C of 30 secs followed by a final extension at 72◦C for 5 mins.
Both primers were ordered through EuroFins (www.eurofins.co.uk).
Following this first round of PCR, DNA was purified using 1.5x Agencourt AM-
Pure XP beads and re-suspended into 22 µl sterile water. 2 µl was used in a sec-
ond round of PCR to attach Illumina flow cell adapters using commercially available
primers as provided in the NEBNext Multiplex Oligos for Illumina (Index Primers Set
1) kit (New England Biolabs, Hitchin, UK). Cycling conditions were as above. PCR
amplicons were purified using 1.5x Agencourt AMPure XP beads and re-suspended
into 20 µl sterile water. The size and molarity of final libraries were determined us-
ing an Agilent High-Sensitivity DNA Analysis Chip on the 2100 Bioanalyzer platform
(Agilent Technologies, Santa Clara, CA).
2.11 Illumina DNA Sequencing
DNA libraries were pooled together, further processed for cluster generation, and used
in paired-end sequencing runs on the Illumina MiSeq machine by the University Col-
lege London Genomics core facility.
2.12 Bioinformatic Analysis
All bioinformatic analysis was performed by Dr Dan Jeffares (University College Lon-
don) with contributions from Namrata Saha.
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2.13 Statistical Analysis
All statistical tests were performed in Prism 6 for Mac OS X (GraphPad Software, Inc).
To identify significant differences between strains for vacuole diameter, cell length, and
morphological responses, a one-way ANOVA followed by Tukey post-hoc corrections
was performed (unless just two strains were compared, in which case an independent t-
test was used). The viability assays were compared using a two-way ANOVA followed
by Tukey post-hoc corrections. Data is presented as the mean ± the standard error
of the mean (SEM) of at least three independent experiments unless stated otherwise.
Significance was defined as p<0.05. All graphs were generated in Prism 6 for Mac OS
X, and figures compiled in Inkscape.
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Table 2.2: Oligonucleotide list. The name, purpose, and sequence of the oligonu-
cleotides used in this work. ORF = open reading frame.
Name Target/Purpose 5’ - 3’ Sequence
btn1delete For Bold section binds pFA6a plasmid, remainder is
complemetary to genomic sequence flanking the
btn1 ORF. Used to replace the btn1 ORF with the
KanMX6 cassette
ACTTTACAAAAGTCTACTATCGTATTGCCGGTTCAAACT
AAAATTTATGACCTCAGTTTCTACTAAATATAGTACGAA
TCCGGATCCCCGGGTTAATTAA
btn1delete Rev Bold section binds pFA6a plasmid, remainder is
complemetary to genomic sequence flanking the
btn1 ORF. Used to replace the btn1 ORF with the
KanMX6 cassette
TATTGAAGCACTTAGCACACTAATGGAAGAAACGTCATA
GGTTAACTCTCAATATAATGGAGATGTGCGCACTCACTA
TTGAATTCGAGCTCGTTTAAAC
btn1ORF For Binds first 20 nucleotides of the btn1 ORF. Used
to confirm the deletion of the btn1 ORF.
ATGATTAAATTGAGGTTAAC
btn1ORF Rev Binds last 20 nucleotides of the btn1 ORF. Used to
confirm the deletion of the btn1 ORF.
TCAAGTTAAGGCACACCAAT
btn1flank For Binds 0.2 kb upstream of the btn1 ORF. Used to
confirm the deletion of the btn1 ORF.
TTTGAACCTGACAACATTACCG
Continued on next page
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Table 2.2 – Continued from previous page
Name Target/Purpose 5’ - 3’ Sequence
btn1flank Rev Binds 0.2 kb downstream of the btn1 ORF. Used
to confirm the deletion of the btn1 ORF.
GCATAGAATGCACAGCAGAAAG
NatMX For Binds the first 20 nucleotides of the ORF within
the NatMX6 cassette. Used to confirm the deletion
of thebtn1 ORF.
ATGGGTACCACTCTTGACGA
NatMX Rev Binds the last 20 nucleotides of the ORF within the
NatMX6 cassette. Used to confirm the deletion of
thebtn1 ORF.
TTAGGGGCAGGGCATGCTCA
Linker 1 Used to introduce a known sequence to the DNA
created from mutagenesis libraries to facilitate Il-
lumina sequencing.
TTCAGACGTGTGCTCTTCCGATCTCTCCGCTTAAGGGAC
Linker 2 Used to introduce a known sequence to the DNA
created from mutagenesis libraries to facilitate Il-
lumina sequencing.
(Phosphate modification)-GTCCCTTAAGC
GGAG-(Amino modification)
Continued on next page
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Table 2.2 – Continued from previous page
Name Target/Purpose 5’ - 3’ Sequence
HermesEnrich For Binds to linker sequence described above. Used to
enrich for mutagenesis library fragments contain-
ing the Hermes transposon.
TTCAGACGTGTGCTCTTCCGATCTCTCC
HermesEnrich Rev Binds to the Hermes sequence. Used to enrich for
mutagenesis library fragments containing the Her-
mes transposon. See text for details about barcode
sequence.
CACGACGCTCTTCCGATCT-barcode-
CCTGTGGCTTGTTGAAGTTCTC
Chapter 3
Synthetic Genetic Arrays: Identifying
Genetic Interactions
3.1 Introduction
Synthetic genetic arrays (SGAs) provide an unbiased, yet systematic, genome-wide ap-
proach to define the genetic interactions of a query gene. Genetic interactions revealed
by such an approach have the potential to provide information about gene function and,
importantly in the case of a disease gene, can highlight genes or processes that can be
used to suppress the loss of a disease gene. As explained in the Introduction (p. 19), the
main premise of this body of work was to apply SGA analysis to reveal both functional
information of btn1+, and also to reveal therapeutic targets that might be suitable for
juvenile CLN3 disease.
3.1.1 Chapter Aims
This chapter initially details the construction of btn1∆ strains suitable for the SGA
screens, then provides an overview of the genes found to interact with btn1+. In par-
ticular, this chapter will focus on interactions that fall within a set of conserved, inter-
connected stress pathways that were considered to be particularly relevant in btn1∆
cells. As the importance of these pathways was only discovered as part of this work,
this initial Results chapter also serves to provide the necessary introductory material
on mitogen-activated protein kinase (MAPK) signalling and the Tor kinase complexes
(TORC).
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3.2 Strain Construction
3.2.1 Rationale
The fission yeast mutant strains available in the Bioneer Deletion Mutant Library were
systematically constructed using targeted mutagenesis to replace each target open read-
ing frame (ORF) with the KanMX4 cassette which confers resistance to the antibiotic
G418. This approach was first performed in a diploid host strain before haploid mu-
tants, expressing the h+ allele at the mating type locus, were isolated. The genotype
of these Bioneer mutant strains consequently confers some restrictions on the query
strains (i.e. btn1∆) genotype; namely that the mating type locus has the h- allele and
that there is a dominant selectable marker other than KanMX4 to facilitate the selection
of double mutant progeny. This is most commonly achieved by linking the query gene
deletion to the NatMX6 selection cassette which confers resistance to the antibiotic
nourseothricin.
Previously published work using S. pombe as a model for juvenile CLN3 disease
has used a strain constructed by the targeted replacement of btn1+ with the leu2+ coding
sequence (btn1+::leu2+) (Gachet et al., 2005). This strain is therefore not suitable for
SGA analysis as it both lacks an antibiotic selection cassette and additionally has the
h+ mating type allele. Consequently, to facilitate this work, additional btn1∆ strains
were constructed.
A PCR-mediated gene deletion strategy was employed (Ba¨hler et al., 1998) to re-
place the btn1+ coding sequence with the NatMX6 cassette (Figure 3.1). btn1∆ strains
were made from the SP23 and SP38 wild-type backgrounds, both expressing the nec-
essary h- allele.
3.2.2 PCR-mediated Gene Deletion
The NatMX6 cassette was amplified from pFA6a-NatMX6 using 100 base-pair primers
(btn1delete For and btn1delete Rev; see Materials and Methods Table 2.2 for primer
sequences). The 20 most 3’ nucleotides of both the sense and antisense oligonu-
cleotides are specific to the pFA6a template. The remaining 80 nucleotides are ho-
mologous to genomic sequences either immediately upstream of the btn1+ start codon
(sense oligonucleotide) or immediately downstream of the btn1+ stop codon (antisense
oligonucleotide). Consequently, the resulting PCR amplicon contains the NatMX6 cas-
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Figure 3.1: PCR-mediated gene deletion strategy used to construct btn1∆ yeast
strains. [A] The NatMX6 cassette was amplified from a pFA6a construct using primers
designed to introduce 80 base pairs of sequence homologous to genomic regions that
flank the btn1+ ORF. [B] The purified PCR amplicon was transformed into wild-type
yeast strains. The PCR fragment is integrated into the yeast chromosome by homologous
recombination directed by the regions of homology at the terminal ends of the amplicon.
[C] The resulting strain has the NatMX6 cassette in place of the btn1+ ORF in the en-
dogenous btn1+ locus. Positive transformants were selected in the presence of 100 µg/ml
nourseothricin and confirmed by PCR screens.
sette nested between terminal ends corresponding to chromosomal sequences that flank
the btn1+ ORF. These terminal ends serve to promote the integration of the NatMX6
cassette into the btn1+ locus by homologous recombination, removing the entire btn1+
ORF in a one-step disruption process (Figure 3.1).
Stable transformants were confirmed by colony purification onto YES +
nourseothricin agar. Genomic DNA was subsequently extracted from various re-
isolated nourseothricin-resistant transformants, and used as the template in several
discrete PCR reactions to confirm the successful integration of the NatMX6 transform-
ing product.
One reaction employed a sense primer designed to bind the first 20 nucleotides
of the btn1+ ORF (btn1ORF For) and an antisense primer designed to bind approxi-
3.2. Strain Construction 91
mately 0.2 kb downstream of the btn1+ ORF (btn1flank Rev). A similar reaction was
performed but with the binding locations of the primers reversed - that is, the sense
primer bound approximately 0.2 kb upstream of the btn1+ ORF (btn1flank For) while
the antisense primer bound the last 20 nucleotides of the btn1+ ORF (btn1ORF Rev;
see Materials and Methods Table 2.2 for primer sequences). Using these complemen-
tary approaches, a PCR product could be amplified from genomic DNA extracted from
wild type cells but not from genomic DNA extracted from btn1::NatMX6 transformants
(data not shown), indicative of the loss of btn1+.
The successful integration of NatMX6 into the btn1+ locus was shown in a
similar manner, using primers designed to bind the NatMX6 gene within the cas-
sette (NatMX For and NatMX Rev; see Materials and Methods Table 2.2 for primer
sequences) and the same flanking primers as described above (btn1flank For and
btn1flank Rev). This time, an amplification product was only seen when genomic DNA
extracted from btn1+::NatMX6 transformants was used as a template (Figure 3.2 A).
Lastly, to ensure strains had not retained btn1+ in an ectopic region, a PCR reac-
tion was performed using primers designed only to amplify the btn1+ ORF, regardless
of its genomic context (btn1ORF For and btn1ORF Rev). Again, only genomic DNA
extracted from wild-type strains produced an amplification product (Figure 3.2 B), con-
firming that no btn1∆ strains had retained the btn1+ ORF.
3.2.3 Phenotypic Analysis
Using this approach, a total of five independent btn1∆ strains suitable for SGA anal-
ysis were created; two from the SP23 background (SP29 and SP30) and three from
the SP38 background (SP35, SP36, and SP37). Each were characterised using a num-
ber of phenotypes previously defined in the btn1+::leu2+ strain (Gachet et al., 2005);
increased cell length, increased vacuole diameter, and a heat sensitivity. Interestingly
however, during these initial characterisation attempts it was noted that while some
isolates recapitulated the btn1+::leu2+ strain, others showed a varying penetrance of
these phenotypes, and one isolate remained indistinguishable from the parental wild-
type under all conditions tested. Most notably, it was also revealed that the majority of
these btn1∆ isolates were phenotypically different from parental strains with regards to
nutrient auxotrophies, and therefore also from their supposed genotype.
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Figure 3.2: Checking btn1∆ yeast strains by PCR. [A] PCR performed using primers
NatMX For and btn1flank Rev to show the presence of the NatMX6 cassette in the btn1
locus. [B] PCR performed using primers btn1ORF For and btn1ORF Rev to show the
absence of the btn1+ open reading frame (ORF) following targeted gene replacement with
the NatMX6 cassette.
Rigorous PCR screens established that these isolates have not retained the full
btn1+ coding sequence so the cause of this disparity is unclear. Such phenotypic differ-
ences in independent isolates are not reported in the literature, but through discussions
with colleagues and from experience with other strains, it is not considered to be a
common artefact of strain construction. This finding was therefore deemed to be im-
portant, and so the phenotypic characterisation of these strains and possible reasons for
this phenomenon are discussed in more detail in Appendix 1.
Given the complete confidence that, regardless of the disparate phenotypes, each
btn1∆ isolate truly lacked the btn1+ ORF, four of the five isolates (two from each ge-
netic background: SP29, SP30, SP35, and SP37) were used for SGA screens, as dis-
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cussed in more detail below.
3.3 SGA Reveals Genetic Interactions
234 negative and 516 positive interactions were found in an initial SGA screen per-
formed under normal growth conditions as described in the Materials and Methods.
309 negative and 672 positive interactions were found from a second independent bi-
ological screen, temporally separated from the first by several weeks. A total of 131
negative interactions and 331 positive interactions were found to be common to both
independent biological screens (Appendix 2 and Figure 3.3), and only these were con-
sidered robust enough for follow-up analysis and validation. As an important validator
of using yeast to model human disease, 67.9% of the negative interactions (n = 89), and
66.8% of the positive interactions (n = 221), were found to be orthologous to human
genes.
The results from the SGA were initially compared to known CLN3 interactions
identified from large-scale proteomic approaches (Behrends et al., 2010; Scifo et al.,
2013) and several more focused experiments (Luiro et al., 2004; Chang et al., 2007;
Uusi-Rauva et al., 2008; Vitiello et al., 2010; Getty et al., 2011). An obvious caveat
in this approach is that genetic interactions have been compared to protein interactions
identified in organisms other that yeast. Nonetheless, genetic interactions often pre-
dict physical ones (Forsburg, 2001; Boone et al., 2007), and an overlap may highlight
particular areas of interest. However, only one negative interaction found through the
SGA been previously reported; the translational activator GCN1L1 (Scifo et al., 2013)
(gcn1+ in fission yeast). Two positive interactions have been previously reported; the
ketoreductase HSD17B12 (Scifo et al., 2013) (ifa38+) and SEC61A1 (Scifo et al., 2013)
(SPBC19G7.17 in fission yeast), a gene that in humans plays a role in the insertion of
secretory and membrane polypeptides into the endoplasmic reticulum.
The SGA results were also compared to known juvenile CLN3 disease biomark-
ers that have been collated from murine microarray data (Elshatory et al., 2003; Luiro
et al., 2006) and patients (Lebrun et al., 2011). No overlap between this data set and
either the negative or positive SGA interactions were identified. Lastly, results were
also compared to genes that are dysregulated at the expression level in various neu-
rodegenerative diseases, and therefore represent a common transcriptional signature of
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Figure 3.3: Total SGA hits. Two independent SGAs were performed (separated tempo-
rally by several weeks), each using four independent btn1∆ strains. A total of 131 negative
interactions and 331 positive interactions were found to be common to both independent
biological screens, and only these were considered robust enough for follow-up analysis
and validation as described in more detail in the text. The top panel shows the negative
interactions (red), and the bottom shows positive interactions (green).
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neurodegeneration (Durrenberger et al., 2014; Li et al., 2014). The transcription elon-
gation factor TCEA2 (tfs1+), protein phosphatase regulatory subunit PPP1R2 (glc9+),
and protein phosphatase catalytic subunit PPP3CB (ppa3+) have all been reported to
be down-regulated in neurodegeneration (Li et al., 2014) and were all negative interac-
tors of btn1+. Conversely, the peroxisomal biogenesis factor PEX19 (SPAC17C9.14 in
fission yeast) and the DNA replication subunit RPA3 (ssb3+) are also down-regulated
in neurodegeneration (Li et al., 2014), but the fission yeast orthologues were found to
positively interact with btn1+, suggesting that the down-regulation of these genes may
be a protective mechanism.
3.4 Genetic Interactions Reveal a Link between btn1+
and Stress Response Pathways
Using the AnGeLi gene ontology (GO) enrichment program to compare the 131 genes
in the SGA negative interaction data set with all known S. pombe protein coding genes,
no biological processes or molecular function annotations were found to be enriched.
However, negative interactions from each of the individual biological SGA replicates
were found to be enriched for the response to stress. When the genes annotated as stress
response from individual replicates were compared with the final negative interaction
data set, a large proportion (n = 44; 33.59%) were indeed found to be annotated as in-
volved in stress response signalling or regulated in a stress-responsive manner (Figure
3.4). Further, although it did not reach significance, PANTHER reported a 2.12-fold
enrichment in stress responses; 17.56% compared to an expected 8.27% genome fre-
quency, further supporting that stress response genes were a predominant feature of the
negative interaction data set.
More specifically, a number of the negative interactions were identified to be com-
ponents of two distinct mitogen-activated protein kinase (MAPK) signalling pathways
present in fission yeast; the stress-associated protein kinase (SAPK) and cell wall in-
tegrity (CWI) pathways. A number of other negative interactions were found that are
known to be involved in downstream processes regulated by these stress response path-
ways (Figure 3.4). Negative genetic interactions often occur between genes that act in
different pathways but nonetheless perform similar or compensatory functions (Braberg
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et al., 2014). The results presented here therefore suggest that the function of btn1+,
and by extrapolation CLN3, may converge with that of various stress response genes or
pathways.
Interestingly, the positive interaction data set was also found to be lacking any
significant enrichment in GO terms when assessed using AnGeLi. Nonetheless, a vast
number of positive interactions were found that support the hypothesis that btn1+ is
involved in stress responses, and these are explain in more detail below. Finally, core
components of the connected Tor kinase complexes (TORC1 and TORC2) were also
found to interact with btn1+ in a pattern that again supports a role for btn1+ in stress
response (Figure 3.4, and explained below).
3.4.1 btn1+ Interacts with Members of MAPK Stress Signalling
Pathways
MAPK pathways are highly conserved signal transduction mechanisms that are vital for
eukaryotic cells to recognise and respond to extra-cellular changes. The fundamental
architecture of these pathways includes diverse upstream mechanisms for detecting a
stressor which then relay a signal to a linear module of three sequentially acting protein
kinases; the MAP kinase (MAPK), the MAP kinase kinase (MAPKK), and the MAP
kinase kinase kinase (MAPKKK, or MEK). Upon activation by a specific stressor, this
MAPK cascade ultimately orchestrates adaptive changes in gene expression.
Budding yeast, plant, and animal cells show a largely stress-specific MAPK acti-
vation strategy where certain stressors are signalled through a dedicated MAPK path-
way (Madrid et al., 2006). However, in contrast to budding yeast which have at least
six MAPK cascades (Chen and Thorner, 2007), fission yeast only have three MAPK
pathways - the SAPK, CWI, and pheromone response pathway (which is not discussed
further in this work). While the MAPK pathways are molecularly distinct from each
other, the existence of just three pathways anticipates the need for extensive cross-talk
modulation. This is reflected not only in that the SAPK and CWI are often triggered
by the same stressor (as shown in Figure 3.4) but also in shared regulatory links and a
shared target transcription factor, Atf1, as detailed more extensively below.
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Figure 3.4: SGA hits reveal a link to stress response pathways. Manual curation of the
SGA data revealed a vast proportion of negative interactions fell within stress response
pathways; the Cell Wall Integrity pathway (CWI), the Stress Associated Protein Kinase
pathway (SAPK), and the Tor kinase complexes (TORC1/2)). Figure shows the genes in-
volved in these pathways, their sub-cellular localisation, any cross-talk (explained further
in Chapters 3 and 4), and down-stream processes. Red gene names are negative inter-
actions with btn1+, green are positive interactions, and grey are genes involved in the
pathways but not found to interact with btn1+.
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3.4.1.1 The Stress-Associated Protein Kinase Pathway
The SAPK plays a vital role in the general cellular response to stress, and accordingly
responds to variety of stressors including hyperosmotic stress (Shiozaki and Russell,
1995; Shiozaki and Russel, 1996), presence of heavy metals (Degols et al., 1996), high
and low temperatures (Samejima et al., 1997; Nguyen and Shiozaki, 1999; Soto et al.,
2002), UV irradiation (Degols and Russell, 1997), hyper-gravity (Soto et al., 2007),
increased hydrostatic pressure (George et al., 2007), nutrient stress (Shiozaki and Rus-
sell, 1995; Petersen and Nurse, 2007), and oxidative stress (Degols et al., 1996; Madrid
et al., 2004) (Figure 3.4).
The MAPK component of the SAPK pathway is Sty1 (also named Spc1 or Phh1)
which shows high homology to mammalian p38 kinase and the mammalian specific c-
Jun N-terminal kinases (JNK). Sty1 is directly phosphorylated by the MAPKK Wis1 at
both threonine-171 and tyrosine-173 (Millar et al., 1995; Shiozaki and Russell, 1995)
in the TGY- motif (similarly to p38 and JNK in higher eukaryotes cells). Conversely,
Wis1 can be phosphorylated by either Wis4 (also Wak1) (Shieh et al., 1997) or Win1,
which shows 60% identity with Wis4 (Shieh et al., 1998; Samejima et al., 1998).
In unstressed cells, Sty1 is predominately in the cytoplasm. Conversely, upon a
stress trigger and phosphorylation by Wis1, Sty1 reversibly accumulates in the nucleus
where it associates with a variety of targets (Pe´rez and Cansado, 2010). The primary
target of Sty1 is the basic leucine zipper (bZIP) transcription factor Atf1, which is con-
stitutively nuclear and orthologous to the ATF-2 transcription factor in higher eukary-
otics (Wilkinson et al., 1996; Shiozaki and Russel, 1996). As determined by microarray
analysis, activated Sty1-Atf1 induces the expression of various genes, the majority of
which respond to almost all stress conditions and are consequently termed the ‘core
environmental stress response’ (CESR) genes (Chen et al., 2003). Pcr1, also a bZIP
transcription factor, is similarly required for the transcriptional activation of most (al-
though not all) Sty1-dependent genes; its action being mediated both via the formation
of a heterodimer with Atf1 and independently (Sanso´ et al., 2008). A third bZIP tran-
scription factor, Pap1, also lies downstream of Sty1 (Toone et al., 1998) and plays a
particularly important role in the response to oxidative stress (Quinn et al., 2002). Ev-
idence for the direct phosphorylation of Pap1 by Sty1 (as seen for Atf1) is however
ambiguous and appears unlikely (Quinn et al., 2002; Papadakis and Workman, 2014).
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The SAPK pathway also controls progression through the cell cycle, and sty1∆ cells
have a cell cycle defect at the G2/M transition. This is not thought to be mediated
via Atf1 (Shiozaki and Russel, 1996) but rather through the interaction of Sty1 with
a number of other proteins, including the MAPK-activated protein kinase Srk1 (Smith
et al., 2002; Lo´pez-Avile´s et al., 2005). Ordinarily Sty1 is bound to Srk1, but in re-
sponse to stress Sty1 phosphorylates Srk1 at threonine 463 of the regulatory domain
(Lo´pez-Avile´s et al., 2008). In turn, activated Srk1 dissociates from Sty1 and is able
to phosphorylate and inhibit the Cdc25 phosphatase, which causes its accumulation
in the cytoplasm and the arrest of the cell cycle at the G2/M transition (Lo´pez-Avile´s
et al., 2005, 2008). Srk1 regulates Cdc25 to delay mitotic entry during a normal cell
cycle and in response to nongenotoxic stress, but not in response to replication arrest
or DNA damage (Lo´pez-Avile´s et al., 2005). More recently however, Atf1 has been
shown to promote the G2/M transition, and its over-expression to accelerate mitosis
(Bandyopadhyay et al., 2014; Bandyopadhyay and Sundaram, 2015).
Lastly, the fission yeast SAPK pathway also plays a role in supporting protein
synthesis and translational adaptation to environmental stress. Generally, a global re-
duction in protein synthesis is observed in response to stress, which is thought to allow
cells to conserve resources as they induce the gene expression changes required to re-
sist or tolerate stress damage. This block in translation is ordinarily transient, and the
translational control of at least some specific mRNAs is required for survival during
stress. Various mutants of the SAPK pathway however show a greater reduction in
protein synthesis (Dunand-Sauthier et al., 2005) and reduced translation recovery (Asp
et al., 2008) compared to wild-type cells. In part this is due to the SAPK negatively
regulating α subunit of eukaryotic initiation factor 2 (eIF2α) activity. The disruption
of Wis1, Sty1, Atf1, or Pap1 causes the increased phosphorylation of the α subunit of
eukaryotic initiation factor 2 (eIF2α) due to the continued action of either the eIF2α
kinases Hri2 or Gcn2 depending on the precise stressor experienced (Dunand-Sauthier
et al., 2005; Berlanga et al., 2010). Sty1 may also mediate a role in translational adap-
tation via its interactions with the eukaryotic initiation factor 3a (eIF3a) and eukaryotic
elongation factor 2 (eEF2) (Asp et al., 2008).
Little is known about the upstream sensor mechanisms that relay stress condi-
tions to the SAPK kinase module, expect in the case of oxidative stress (Pe´rez and
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Cansado, 2010). The response to oxidative stress requires a multi-step phosphorelay
module, which contains two homologous sensor histidine kinases (Mak2 and Mak3), a
histidine-containing phosphotransfer protein (Mpr1/Spy1), and the response regulator
Mcs4 (Shieh et al., 1997; Nguyen et al., 2000). Upon exposure to H2O2, both Mak2
and Mak3 autophosphorylate, and the phosphate group is transferred by Mpr1/Spy1
to Mcs4 at Asp412 which is sufficient to transduce the signal and activate the MAPK
cascade. The glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (Tdh1,
or GAPDH) is also essential for phosphorelay signalling, and in its absence the in vivo
association between Mpr1 and Mcs4 is lost, and Sty1 activation is compromised (Mori-
gasaki et al., 2008). The response regulator Mcs4 is also required for Sty1 activation
in response to other stressors although in these situations its phosphorylation is not re-
quired, so is thought to function independently from the phosphorelay module via an
as-of-yet unknown mechanism (Buck et al., 2001; Soto et al., 2002, 2007; Morigasaki
and Shiozaki, 2013). The basal activity of the SAPK pathway, and its inactivation
following stress, is regulated through the removal of the activating phosphate groups
added by Wis1. This is regulated by the tyrosine phosphatases Pyp1 and Pyp2 (Mil-
lar et al., 1995; Degols et al., 1996), as well as the serine-threonine phosphatases Ptc1
and Ptc3 (Nguyen and Shiozaki, 1999), and Ptc4 specifically upon oxidative stress (Di
et al., 2012). The stress-induced expression of pyp1+, pyp2+, and ptc1+ is regulated in
a Sty1-Atf1 dependent manner, providing a negative feedback loop.
btn1+ was found to negatively interact with both wis4+ and wis1+, encoding the
MAPKKK and MAPKK of the SAPK pathway respectively. The transcription factor
pap1+, which lies downstream of Sty1 and plays an important role in the tolerance to
oxidative stress, was also found to be a negative interactor of btn1+. As these genes
interact negatively with btn1+, it would suggest that an activated SAPK pathway is
required when btn1+ is absent. Indeed, 13.66% of the positive interaction data set (n
= 44) were found to be genes that are ordinarily down-regulated by the SAPK path-
way (‘CESR-down’ genes), and therefore support the hypothesis that the appropriate
activity of the SAPK pathway is beneficial to btn1∆ cells. Counter-intuitive to this hy-
pothesis however was the finding that tdh1+ also positively interact with btn1+, despite
being required for the response to oxidative stress. This may however be explained
due to Tdh1 having other functions, including a role in the glycolytic pathway (Tristan
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et al., 2011), indicative of the complexity in interpreting genome-wide data. srk1+ also
interacted positively with btn1+, although this is perhaps not surprising given its role in
inhibiting the cell cycle. btn1+ was also found to positively interact with eft202+, one
of the two genes encoding the eukaryotic elongation factor 2 (eEF2).
3.4.1.2 The Cell Wall Integrity Pathway
The CWI pathway, which is orthologous to the extracellular signal-regulated kinases
ERK1/2 (p42/p44) in animal cells, also responds to a variety of stressors including
hypo- and hyper-osmotic stress, glucose starvation, elevated temperatures, cell wall
damage, and oxidative stress (Sengar et al., 1997; Madrid et al., 2006; Barba et al.,
2008; Madrid et al., 2013) (Figure 3.4). The main MAPK module is linear and non-
branched, and includes Mkh1 (the MAPKKK), Pek1/Shk1 (MAPKK), and Pmk1/Spm1
(MAPK), all of which physically interact to form a ternary complex (Loewith et al.,
2000). Mkh1 and Pek1 are cytoplasmic proteins and also found at the septum, whereas
Pmk1 is localized both cytoplasmically and within the nucleus. During cytokinesis,
Pmk1 is also found at the mitotic spindle and septum (Madrid et al., 2006).
Upon activation by stress Pmk1, like Sty1, is also seen to phosphorylate Atf1
(Takada et al., 2007) in addition to the highly conserved RNA-binding protein Nrd1
(Satoh et al., 2009). Via its downstream targets, the CWI pathway regulates cell wall
integrity, cell morphology, and cytokinesis (Toda et al., 1996; Zaitsevskaya-Carter and
Cooper, 1997; Satoh et al., 2009), in addition to ion homeostasis (Toda et al., 1996),
vacuole fusion (Bone et al., 1998), the response to genotoxic stress (Broadus and Gould,
2012), and stress granule formation (Satoh et al., 2012) (Figure 3.4).
In response to a stress stimulus, Mkh1 is activated by specific members of the GT-
Pase Rho family. Rho GTPases cycle between active GTP-bound and inactive GDP-
bound conformations, giving them the colloquial name ‘molecular switches’ (Sten-
mark, 2009). Although GTPases have intrinsic GTPase activity, GTPases also rely on
specific regulators to allow conformational cycling; the guanine nucleotide exchange
factors (GEFs) mediate their activation while the GTPase-activating proteins (GAP)
proteins terminate their activity by promoting intrinsic GTPase activity (Barr and Lam-
bright, 2010). Rho proteins are also negatively regulated by guanine nucleotide disso-
ciation inhibitors (RhoGDIs).
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S. pombe has six Rho GTPases; cdc42+ and rho1+, rho2+, rho3+, rho4+, and
rho5+, of which rho1+ and cdc42+ are essential genes. Rho1 and Rho2 GTPases (the
orthologues of mammalian RHOA, B, and C) have direct roles in the co-ordinated
regulation of cell wall biosynthesis and actin organisation which is required for cell
integrity, polarised growth, cytokinesis, and septation. Both GTPases act via physical
interactions with Pck1 and Pck2, the two protein kinase C (PKC) orthologues present
in fission yeast (Arellano et al., 1999). Specifically, Rho1 participates in the genera-
tion of the main cell wall polymer (β -1,3 glucan, which accounts for 50 - 54% of total
polysaccharides) through its interaction with Pck2 (Arellano et al., 1999; Sayers et al.,
2000), but also by directly acting as the regulatory subunit of β -1,3 glucan synthase
(Arellano et al., 1996). Rho1 is further required to ensure the correct polarisations of
the actin cytoskeleton (Arellano et al., 1997; Nakano et al., 1997, 2005). Through its
interaction with Pck2, Rho2 regulates α-1,3 glucan synthesis, the other main structural
polymer of the S. pombe cell wall (Calonge et al., 2000).
More recently Rho1, Rho2, and both PKC orthologs have been shown to act as
upstream positive regulators of the CWI pathway. Rho2 was the first GTPase found to
positively regulate Pmk1 signalling, a function that is again mediated via its interaction
with Pck2 (Ma et al., 2006). The over-expression of rho2+ is toxic to wild-type cells
(Hirata et al., 1998), but not in cells lacking pck2+ or cells lacking core components of
the CWI cascade (Calonge et al., 2000), suggesting the toxic effects of rho2+ are me-
diated through the hyper-activation of the CWI pathway. However, cells lacking rho2+
still show a detectable level of Pmk1 phosphorylation (Barba et al., 2008; Madrid et al.,
2013), as do rho2∆pck2∆ double mutants (Barba et al., 2008). This indicates that while
the MAPK module of the CWI pathway is strictly linear, the upstream signalling el-
ements that transduce stress signals to regulate Pmk1 activity must be branched. The
first indication that Rho1 also acts upstream of the CWI pathway came from the find-
ing that the over-expression of rgf1+ (a Rho1 specific GEF), rho1+, and rho1-G15V
(a constitutively active allele) results in increased Pmk1 phosphorylation compared to
wild-type cells (Garcia et al., 2009). Later, a mutant expressing a genomic, hypoac-
tive version of Rho1 (rho1-596 allele) was isolated (Viana et al., 2013). Intriguingly,
this strain was also shown to have increased basal Pmk1 phosphorylation compared to
control cells. However, Pmk1 activation was not enhanced in response to stress stimuli
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compared to wild-type cells, leading the authors to state that Rho1 is not a negative
regulator of the CWI pathway. Instead, it was proposed that increased Pmk1 phospho-
rylation was a protective mechanism in response to cell wall damage caused by reduced
Rho1 levels. Indeed, the same authors have since reported that Rho1 GTPase is a pos-
itive regulator of the CWI pathway and drives Pmk1 activation through both Pck1 and
Pck2 (Sa´nchez-Mir et al., 2014). Current literature shows that both Rho1 and Rho2
support Pmk1 activity during vegetative growth primarily through Pck2 (Barba et al.,
2008; Sa´nchez-Mir et al., 2014). The response to osmotic stress is solely dependent
on Rho2-Pck2 whereas other stressors are only partially reliant on Rho2 (Barba et al.,
2008). Both Rho2 and Rho1 (via either Pck1 or Pck2) have since been shown to be
required for the response to cell wall stress (Sa´nchez-Mir et al., 2014).
rho5+ is a functional paralogue of rho1+ (Nakano et al., 2005), and is also capable
of directly activating the β -1,3 glucan synthase (Rinco´n et al., 2006). Rho5 also phys-
ically associates with Pck1 and Pck2, and importantly for this work, is the most recent
GTPase to be shown to activate CWI signalling along with Rho4 (Doi et al., 2015).
Neither Rho3 nor Cdc42 participate in CWI signalling (Ma et al., 2006; Madrid et al.,
2006). Of note, what proteins detect and signal stress from the cell wall to the Rho
GTPase components of the CWI pathway is not known (Barba et al., 2008; Cruz et al.,
2013).
To limit CWI signalling, Pmk1 is also de-phosphorylated by Pyp1, Pyp2, Ptc1, and
Ptc3. The dual-specificity phosphatase Pmp1 is however the main negative regulator
of the Pmk1 MAPK pathway (Sugiura et al., 1998). pmp1+ expression levels do not
alter during stress, but rather the stability of the mRNA is increased via an interaction
with the RNA-binding protein Rnc1, whose activity is up-regulated by Pmk1-mediated
phosphorylation (Sugiura et al., 2003).
Although no MAPK components of the CWI were revealed as btn1+ interactors,
the upstream regulator rho5+ was found to interact negatively with btn1+ as were
a number of genes involved in downstream processes (Figure 3.4). This suggests
that, as for the SAPK pathway, activation of the CWI pathway is required in the ab-
sence of btn1+ and that limiting its activity is detrimental to btn1∆ cells. This is fur-
ther supported by the RNA binding protein rnc1+ positively interacting with btn1+.
As explained above, Rnc1 promotes the negative regulation of Pmk1 signalling, and
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Pmk1 phosphorylation is absent when Rnc1 is over-expressed and enhanced in rnc1∆
cells (Sugiura et al., 2003). Consequently, rnc1+ deletion in btn1∆ cells may act
to increase CWI signalling which may underlie the positive interaction of these two
genes. Nonetheless, the RhoGDI rdi1+ also negatively interacted with btn1+ while the
RhoGEF for Rho1/Rho5 rgf1+ (Mutoh et al., 2005) interacted positively with btn1+.
These findings are in contrast to the hypothesis that CWI signalling is beneficial to
btn1∆ cells, but may simply reflect the complexity of stress response pathways, the
multifacetated roles for Rho1, the need for Rho GTPases to cycle, and the noise that is
inevitable with genome-wide approaches.
3.4.2 btn1+ Interacts with Members of Tor Kinase Complexes
As in humans, the presence of two distinct multi-protein Tor complexes has been
demonstrated in fission yeast (Otsubo and Yamamato, 2008). However, while there
is a sole mammalian TOR (mTOR) catalytic subunit present in both complexes, fis-
sion yeast contains two Tor kinases that form functionally distinct Tor complexes.
Thus, in fission yeast, the TORC1 contains Mip1 (the mammalian Raptor homologue),
Wat1/Pop3 (the mLST8 homologue and common to both complexes), Tco89, Toc1, and
the Tor2 kinase (named somewhat confusingly for the order in which it was discovered
in fission yeast rather than for the complex it associates with). The TORC2 complex
is comprised of Ste20 (the Rictor homologue), Wat1/Pop3, Sin1, Bit61 (PRR5 homo-
logue), and Tor1 kinase (Otsubo and Yamamato, 2008). S. pombe TORC1 and TORC2
are controlled by the small GTPases Rheb1 (Urano et al., 2007) and Ryh1 (a human
Rab6 orthologue) (Tatebe et al., 2010) respectively. TORC1 activity is in turn mediated
through the phosphorylation of its downstream target Psk1 (a SK6 homologue) and
its subsequent target (ribosomal protein S6 (Rps6)) (Nakashima et al., 2010, 2012).
TORC2 activity is mediated by the downstream effector kinase Gad8, a member of the
AGC family and a multi-copy suppressor of loss of TORC2 (Matsuo et al., 2003).
The two TORC complexes are antagonistic to each other with regards to func-
tion, and undergo mutual repression (Weisman et al., 2007; Ikai et al., 2011). More
specifically, TORC1 positively controls cell growth, and under favourable conditions
negatively regulates catabolic and stress response processes such as G1 arrest, sexual
development, amino acid uptake, and autophagy (Alvarez and Moreno, 2006; Matsuo
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et al., 2007). Conversely, yet like the MAPK pathways, the TORC2 complex is required
to promote cellular survival under stress (Kawai et al., 2001; Weisman and Choder,
2001; Matsuo et al., 2003; Tatebe et al., 2010), and cross-talk between the MAPK and
TORC pathways reveals an additional level of complexity with respect to fission yeast
stress response mechanisms. For example, Sty1 activation under nutrient stress is me-
diated by TORC2 (Perez and Rinco´n, 2010), and TORC2 also regulates pck2+ synthesis
to result in Pmk1 activation under cell wall stress and glucose limitation (Madrid et al.,
2015). With regards to stress responses, TORC1 inhibition promotes both CWI and
SAPK signalling (Hartmuth and Petersen, 2009). In budding yeast, RHO1 both acti-
vates the CWI pathway and inhibits TORC1 under heat, oxidative, and cell wall stress
(Loewith, 2010; Yan et al., 2012; Takahara and Maeda, 2013). Together the current
understanding of the TORC and MAPK pathways builds an - albeit simplified - pic-
ture where MAPK and TORC2 act in concert to promote tolerance to stress, whereas
TORC1 is ordinarily repressed under stress conditions.
btn1+ was found to negatively interact with tor1+ (TORC2), corroborating a pre-
vious finding that BTN1 and the budding yeast tor1+ orthologue TOR2 also show a
genetic interaction (Costanzo et al., 2010). This consistency across both yeast species
is suggestive of an evolutionary conserved, and therefore a particularly important, in-
fluence for this Tor kinase in cells lacking btn1+/CLN3. TORC2 is also necessary for
the tolerance to replication stress (Schonbrun et al., 2009, 2013), and several genes in-
volved in genome stability (atl1+, msh1+, rdl1+, flm2+, mh201+, and pku80+) were also
found to negatively interact wih btn1+ (Figure 3.4 and Appendix 2).
The tco89+ component of the TORC1 complex was found to positively interact
with btn1+. This suggests that while reducing TORC2 function in cells already lacking
btn1+ is detrimental, reducing TORC1 activity is in fact beneficial; a finding that is
consistent with the mutual antagonism of these Tor kinase complexes. Furthermore,
TORC1 activity promotes cellular growth by promoting ribosome biogenesis, transla-
tion, and transcription. Upon TORC1 inhibition these processes are similarly inhibited,
so it is therefore interesting to note that 20 of the 44 (45.5%) CESR down-regulated
genes (described above to positively interact with btn1+) were identified to be struc-
tural ribosomal proteins. Another 8 of the CESR down-regulated genes were found to
be involved in ribosome biogenesis, and another 4 in transcription or mRNA stability.
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Together with the positive interaction with eft202+ as mentioned above, this suggests
that a reduction in protein synthesis is advantageous to btn1∆ cells, supporting the
hypothesis that reducing TORC1 activity would be benefical. TORC1 activity also in-
hibits autophagy by the phosphorylation of Atg13, an initiator of autophagy (Takahara
and Maeda, 2013). That TORC1 signalling is potentially detrimental to btn1∆ cells is
supported by btn1+ negatively interacting with atg14+ and atg12+, both of which are
required for autophagosome formation.
3.5 Summary
This chapter serves to describe both the strain construction and genome-wide approach
that forms the foundation of this project. The SGA performed with btn1∆ strains re-
vealed 131 negative and 331 positive interactions that were used for follow-up analysis.
Negative interactions often occur between genes that perform compensatory functions,
while positive interactions can reveal connections between members of the same pro-
tein pathway, or different pathways that act in concert. Positive interactions also reveal
suppression mechanisms, and so can be particularly informative about protective path-
ways that may have therapeutic potential.
Comparing the SGA data with known CLN3 physical interactions and gene expres-
sion data revealed a notable lack of direct overlap. Genetic interactions are therefore
not redundant with physical interactions and consequently, this work has emphasised
the real potential for SGAs in simple organisms to reveal novel information about gene
function. Importantly, the substantial number of genes that have known human ortho-
logues suggests that such information is truly relevant for the study of juvenile CLN3
disease.
Although no GO terms were found to be significantly enriched, the pattern of in-
teractions revealed during the SGA suggest that the function of btn1+ may be required
to support appropriate stress signalling. This is based on the observation that btn1+ neg-
atively interacts with members of the highly-conserved MAPK stress signalling path-
ways and the kinase of TORC2, in addition to various genes involved in downstream
processes. It is further supported by a number of positive interactions with genes that
are ordinarily down-regulated by the SAPK pathway, and with a core component of
TORC1 which is similarly repressed under stress. A previous microarray finding that
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btn1+ is up-regulated under certain stress conditions is in agreement with these data
and a proposed role for btn1+ in stress responses (Chen et al., 2003).
If this proposed role is correct, it can be predicted that an absence of btn1+ would
lead to compromised stress responses and to the manifestation of stress-related phe-
notypes, as seen in mutants lacking known stress response proteins, many of which
are now known to genetically interact with btn1+. Furthermore, if a second mutation
affecting stress response pathways is sufficient to impede on btn1∆ fitness even under
normal conditions, it holds to reason that the augmentation of these pathways might be
protective and reveal therapeutic targets. These hypotheses are explored in the follow-
ing chapter.
Chapter 4
Phenotypic Characterisation of btn1∆
Cells Reveals Compromised Stress
Responses
4.1 Introduction
As detailed in the previous chapter, the SGA results obtained as part of this work sug-
gest that btn1+ function may converge with that of various stress response genes. Con-
sequently, it can be predicted that stress responses may be impaired in cells lacking
btn1+. Indeed, previous work has shown that the disruption of btn1+ manifests with
various phenotypes that may reflect dysfunctional stress signalling, including depo-
larised growth and eventual lysis at 37oC (Codlin et al., 2008b), multiple septa which is
indicative of delayed cytokinesis (Gachet et al., 2005), morphological alterations such
as thickened cell walls and septa, and a hypersensitivity to β -1,3 glucanases (Codlin
et al., 2008a). These phenotypes have been considered to arise as pleiotropic effects
of btn1+ loss, and have been linked to at least two different defective processes, one
pH-dependent and one not (Codlin et al., 2008a). However, these phenotypes are also
consistently seen in mutants of MAPK and TOR signalling (Madrid et al., 2006; Ikai
et al., 2011),
If stress signalling is compromised in cells lacking btn1+, it can be expected that
btn1∆ cells may share a number of additional phenotypes, aside from these heat and
cell wall defects, that are co-incident with mutants of other stress response genes found
to interaction with btn1+.
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4.1.1 Chapter Aims
This Results chapter aims to supplement the previous chapter by providing some addi-
tional background information about the MAPK and Tor pathways, and their complex
pattern of cross-talk, under specific stress conditions. This will be followed by an ex-
tensive characterisation of btn1∆ cells under these same conditions, the overall aim
being to validate the hypothesis that wider stress response processes are compromised
in cells lacking btn1+. Of note, although four independent btn1∆ isolates were used
for the SGA screens, all validation and follow-up work discussed in this work was
performed in one strain (SP29, but referred to from here simply as btn1∆).
4.2 btn1∆ Cells Show a Sensitivity to Elevated Heat and
Cell Wall Defects
Heat stress signals through the CWI cascade to result in pmk1+ activation (Toda et al.,
1996; Sengar et al., 1997), and requires the activity of the upstream protein kinase C
orthologue pck2+ (Barba et al., 2008). Conversely, although heat stress also results
in sty1+ activation, this occurs in a manner that is independent from Wis1 phosphory-
lation, and instead arises from the inhibition of the Pyp1 tyrosine phosphatase which
ordinarily inhibits Sty1 (Samejima et al., 1997; Nguyen and Shiozaki, 1999). Nonethe-
less, heat stress induces responses mediated by both MAPK pathways. Accordingly,
mutants of the CWI and SAPK pathways both show heat sensitivities. rho5∆ cells
show decreased Pmk1 phosphorylation upon heat stress compared to wild-type cells
(Doi et al., 2015), although whether such cells show reduced growth in elevated tem-
perature has not been reported. TORC2-Gad8 activity is also required for thermotol-
erance, and mutants in this complex similarly show reduced growth at 37◦C (Kawai
et al., 2001; Matsuo et al., 2003; Tatebe et al., 2010). Although TORC2 function is less
well understood than TORC1, especially in higher systems, TORC2 has recently been
confirmed to also mediate the heat stress response in Drosophila (Jevtov et al., 2015).
Little is known about TORC1 activity during heat stress in S. pombe, although it has
been shown to be transiently repressed in budding yeast (Loewith, 2010; Takahara and
Maeda, 2013), through RHO1 activity (Yan et al., 2012) and sequestration in stress
granules (Takahara and Maeda, 2012b).
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Figure 4.1: btn1∆ cells Show an osmoremedial heat sensitivity. [A] 10-fold serial di-
lutions of wild-type (WT), btn1∆, and btn1∆ + pREP41x.GFP-btn1+ logarithmic cultures
were spotted onto YES plates and incubated at either 30◦C or 37◦C for 3 days. The most
concentrated spot contains 1x106 cells. v = empty pREP41x vector as a control. [B]
Wild-type (WT) and btn1∆ logarithmic cultures were spotted onto YES and YES plates
containing 2 M sorbitol and incubated at 37◦C for 3 days. Images are representative of 3
independent experiments.
Consistent with previous observations (Codlin et al., 2008b,a), the btn1∆ strain
constructed as part of this work also shows an overt heat sensitivity (Figure 4.1 A). The
temperature sensitivities of TORC2 and CWI pathway mutants is osmoremedial; that
is it can be rescued by the addition of sorbitol to create a hyper-tonic environment and
prevent cell lysis. This finding is also recapitulated in btn1∆ cells (Figure 4.1 B), as
also previously reported (Codlin et al., 2008a).
The finding that a heat sensitivity can be osmotically stabilised, as seen here, is
often indicative of an inability to maintain a functional cell wall. While the complete
deletion of rho1+ is non-viable, mutants that display reduced Rho1 GTPase activity
show severe cell wall defects (Viana et al., 2013). As a rho1+ paralogue, rho5∆ cells
similarly show cell wall defects as revealed by a sensitivity to β -glucanases (Doi et al.,
2015); enzymes such as zymolyase that have a detrimental effect on the cell wall by
hydrolysing the β -1,3 glucan network. Further, Pmk1 activates the transcription fac-
tor Atf1 in response to cell wall damage where it regulates the expression of a small
number of genes (Takada et al., 2007, 2010). Unsurprisingly, mutants lacking compo-
nents of the CWI pathway have cell wall defects and are sensitive to zymolyase (Toda
et al., 1996) and caspofungin, an echoinocandin antifungal which inhibits β -1,3 glucan
synthase (Sa´nchez-Mir et al., 2014). Unlike many of the other stressors described in
this chapter, cell wall damage does not appear to induce TORC2 activity (Kawai et al.,
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Figure 4.2: btn1∆ cells show a sensitivity to cell wall stressors. 10-fold serial dilutions
of wild-type (WT), btn1∆, and btn1∆ + pREP41x.GFP-btn1+ logarithmic cultures were
spotted onto YES containing 5 µg/ml caspofungin (CSP) and incubated at 30◦C for 3
days. The most concentrated spot contains 1x106 cells. v = empty pREP41x vector as a
control. Vehicle = H2O. Images are representative of 3 independent experiments.
2001; Cohen et al., 2014). However, in budding yeast at least, cell wall damage does
result in TORC1 repression in a manner that is mediated by RHO1 (Yan et al., 2012;
Takahara and Maeda, 2013).
It has been previously reported that btn1∆ cells, like CWI mutants, show a sen-
sitivity to zymolyase (Codlin et al., 2008a). That btn1∆ have defects in the structural
integrity of the cell wall was also reproduced in the course of this work as btn1∆ cells
were found to also be sensitive to caspofungin (Figure 4.2). This phenotype was res-
cued by the over-expression of pREP41x.GFP-btn1+.
4.3 btn1∆ Cells Show a Sensitivity to Oxidative Stress
Although H2O2 can act as an important signalling molecule, oxidative stress can arise
when the level of H2O2 (or other reactive oxygen species (ROS)) overwhelms cellular
elimination mechanisms. Oxidative stress is detrimental to cells through the develop-
ment of direct and indirect damage to various macromolecules including DNA, pro-
teins, and lipids. Consequently, oxidative stress is linked to numerous disease states,
including neurodegeneration (Uttara et al., 2009). Adequate redox homeostasis is there-
fore vital, and the response of S. pombe to oxidative stress is now largely well under-
stood (Ikner and Shiozaki, 2005; Vivancos et al., 2006; Papadakis and Workman, 2014)
and known to be highly conserved in higher eukaryotes (Ikner and Shiozaki, 2005).
H2O2 results in Sty1 and Atf1 phosphorylation in a dose dependent manner via
two sensing mechanisms (Quinn et al., 2002). This in turn leads to the Atf1-dependent
differential expression of over 3000 genes (Chen et al., 2003), although the precise
expression profile is also highly influenced by H2O2 concentration (Chen et al., 2008a).
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For example, at 0.5 mM H2O2, over 90% of genes that comprise the core environmental
stress response (CESR) group are expressed in a Sty1-Atf1 dependent manner (Chen
et al., 2003, 2008a). At 6 mM H2O2, only 53% of these genes remain expressed (Chen
et al., 2008a). Conversely, the transcription factor pap1+, which displayed a negative
interaction with btn1+, is required only in response to low levels of H2O2 (0.07-0.25
mM) (Quinn et al., 2002), where it rapidly activates the transcription of a small number
of genes, including several antioxidants (Toone et al., 1998; Chen et al., 2008a; Calvo
et al., 2012). Nonetheless, given these roles in oxidative stress resistance, sty1∆, atf1∆,
and pap1∆ mutants all show reduced growth in the presence of H2O2.
Pmk1 phosphorylation is also observed with high concentrations of H2O2 (>1
mM), and other pro-oxidants like DEM or Paraquat (Madrid et al., 2006; Sa´nchez-Mir
et al., 2012). Despite this, pmk1∆ cells are largely tolerant, in terms of growth ability, to
H2O2 (Madrid et al., 2006; Chen et al., 2008a). The precise role of pmk1+ in oxidative
stress therefore requires clarification, although it may be that it performs a role at the
post-translational level to support SAPK activity (Chen et al., 2008a). Importantly
however, the phosphorylation of Pmk1 when exposed to H2O2 is independent of rho2+
(Barba et al., 2008). Although not confirmed, it can be speculated that rho1+ (the
essential paralogue of rho5+, which was revealed as a negative interactor of btn1+)
may instead relay oxidative stress to Pmk1. Consequently, Rho1 may be particularly
important for tolerance to oxidative stress, as in budding yeast (Lee et al., 2011).
TORC1 activity, which can be monitored by the phosphorylation status of its
downstream target Pks1 (SK6 homologue) and its subsequent target (ribosomal protein
S6 (Rps6)), is inhibited under oxidative stress (Nakashima et al., 2010, 2012). This
is consistent with findings in various other models including mammalian cells (Patel
et al., 2002; Sengupta et al., 2010). Lastly, and conversely, tor1+ (TORC2) activity is
required for the response to oxidative stress and tor1∆ cells are unable to grow on high
concentrations of H2O2 (5 mM) (Weisman and Choder, 2001).
The ability of btn1∆ cells to grow under oxidative stress was assessed by serial
dilutions on solid agar. This revealed that btn1∆ cells are sensitive to H2O2 at a con-
centration of 0.75 mM (Figure 4.3), although can tolerate lower concentrations (data
not shown). This concentration is consistent with those that require a functional Sty1-
Atf1 signalling pathway, as detailed above.
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Figure 4.3: btn1∆ cells show a sensitivity to H2O2. 10-fold serial dilutions of wild-type
(WT), btn1∆, and btn1∆ + pREP41x.GFP-btn1+ logarithmic cultures were spotted onto
YES containing 0.75 mM H2O2 and incubated at 30◦C for 3 days. The most concen-
trated spot contains 1x106 cells. v = empty pREP41x vector as a control. Images are
representative of 3 independent experiments.
btn1∆ cells were also investigated for their tolerance to FTY720, a sphingosine
1-phosphate receptor agonist derived from a chemical modification of myriocin which
is capable of stimulating the endogenous accumulation of ROS (Hagihara et al., 2014).
Fission yeast defective in the Wis1-Sty1 cascade and Atf1 signalling are sensitive to
FTY720, and show inhibited growth on solid media containing 10-20 µM of the drug
(Hagihara et al., 2014). However, btn1∆ cells showed no such growth defect under any
concentration of FTY720 up to that which prevented the growth of wild-type cells (30
µM) (data not shown). This finding could suggest that btn1∆ cells are more sensitive to
extracellular sources of ROS rather than those produced endogenously. The finding that
the addition of the antioxidant N-acetyl-cysteine (NAC) to media lacking glucose does
not prevent cellular death (see below) suggests that endogenous ROS can be tolerated
more so than other stressors and supports the latter hypothesis.
4.4 btn1∆ Cells Show a Sensitivity to Nutrient Limita-
tion
4.4.1 Nitrogen Limitation
Wild-type S. pombe cells show a remarkable alteration in both their physiology and
cell size upon nitrogen withdrawal. Within the first 8 hours following its withdrawal,
fission yeast cells undergo approximately two cell divisions before arresting in G1. This
increase in cell number is however associated with a reduction in cellular volume, and
the resulting cells are shorter than vegetatively growing cells and lose their rod-shape
morphology to become round (Shimanuki et al., 2007). Providing cells of the opposite
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mating type are available, these cells are competent to leave the G1 state and undergo
meiosis. However, when cells of the opposite mating type are absent, cells lose their
ability to mate, and 12 hours after nitrogen withdrawal instead commit to the G0 state
(Yanagida et al., 2011). G0 cells do not display any growth (an increase in cell volume)
or division, but are metabolically active and can remain viable in this quiescent phase
for months even in the complete absence of nitrogen (Sajiki et al., 2013).
tor1+, as part of TORC2, is particularly important for this response to nitrogen
starvation (Kawai et al., 2001; Weisman and Choder, 2001). TORC2 activity ordinarily
remains active during nitrogen starvation (Hatano et al., 2015). Under this condition,
tor1∆ and gad8∆ mutants do not display the characteristic shortening, and are unable
to arrest at G1 and undergo meiosis, leading to sterility and a rapid loss of viability
(Kawai et al., 2001; Matsuo et al., 2003).
Conversely, TORC1 is inactive under nitrogen replete conditions (Nakashima
et al., 2010, 2012) and plays an antagonistic role to TORC2 under nitrogen limited
conditions. Initial suggestions that TORC1 is ordinarily repressed at times of nitrogen
limitation came from a number of observations that tor2 temperature sensitive (ts) mu-
tants, and strains carrying tor2+ under a repressible nmt promoter, phenotypically re-
semble wild-type cells that are starved of nitrogen; that is small, round, G0/G1 arrested
cells (Uritani et al., 2006; Weisman et al., 2007). The same is observed in mutants of
rhb1+ which encodes the upstream activator of TORC1 Rheb1 (Weisman et al., 2007).
Microarray analysis of tor2-ts mutants has also revealed that Tor2 suppression (i.e.
TORC1 inactivation) induces the expression of known nitrogen starvation-responsive
genes and permease/transporter genes (Matsuo et al., 2007). Later, the discovery that
the TORC1 dependent phosphorylation of Psk1 and Rps6 rapidly becomes undetectable
following nitrogen starvation confirmed that TORC1 is inactivated under nitrogen limi-
tation (Nakashima et al., 2010, 2012; Hatano et al., 2015). TORC1 inactivation permits
autophagy to occur, which allows the recycling of intracellular nitrogen to support qui-
escence and sexual differentiation (Kohda et al., 2007; Mukaiyama et al., 2009). Most
recently, it has been shown that TORC1 negatively regulates the nuclear accumulation
of the Gaf1 transcription factor under nitrogen sufficient conditions (Laor et al., 2015).
Under nitrogen limitation, TORC1 repression permits the dephosphorylation and nu-
clear translocation of Gaf1, where it regulates the expression of nitrogen stress-induced
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genes. gaf1+ was found to be a negative genetic interactor with btn1+ as part of this
work.
Extensive work has revealed numerous genes that are up-regulated following ni-
trogen starvation (Mata et al., 2002, 2007; Sajiki et al., 2013). Pap1 expression is
induced upon nitrogen starvation (Kim et al., 2008) where it regulates the expression
of several genes needed to tolerate nitrogen starvation, including sty1+ (Kang et al.,
2011). Many of the other genes up-regulated upon nitrogen starvation show significant
overlap with genes defined as CESR-induced genes (Chen et al., 2003) and therefore
require Sty1-Atf1 signalling (Song et al., 2009; Kristell et al., 2010). Additionally, Sty1
activation upon nitrogen starvation is required for cell shortening (Petersen and Nurse,
2007; Sajiki et al., 2009; Yanagida et al., 2011) and has a key role in promoting con-
jugation through the Atf1-dependent induction of ste11+ (Takeda et al., 1995; Shiozaki
and Russel, 1996). Interestingly, sty1∆ cells are able to undergo the two divisions as
seen in wild-type cells upon nitrogen starvation (Sajiki et al., 2009). However, this is
not associated with a change in cell morphology and sty1∆ cells are additionally un-
able to arrest in G1 or undergo mating, and ultimately lose viability when starved of
nitrogen (Shiozaki and Russel, 1996; Sajiki et al., 2009). These phenotypes are simi-
larly observed in wis1∆ (Zaitsevskaya-Carter and Cooper, 1997; Sajiki et al., 2009) and
atf1∆ cells (Kanoh et al., 1996). It has also been suggested that the coupling of cell size
to nutrient availability is mediated through cross-talk between the Tor and Sty1 path-
ways, as TORC1 inhibition in wild-type cells exposed to nutrient starvation promotes
an increase in Sty1 signalling due to Pyp2 down-regulation (Petersen and Nurse, 2007;
Hartmuth and Petersen, 2009).
In fission yeast, Pmk1 is not phosphorylated by nitrogen starvation, suggesting
that the CWI pathway is dispensable for tolerance to nitrogen limitation (Madrid et al.,
2006). It is interesting to note however, that upon nitrogen stress in budding yeast,
RHO1 leads to the down-regulation of TORC1 (Yan et al., 2012) and in fission yeast
rho5+ is up-regulated upon nitrogen starvation (Rinco´n et al., 2006) although the sig-
nificance of this remains unclear.
The response of btn1∆ cells to nitrogen limitation was determined by assessing the
viability of cells cultured in EMM and EMM lacking the sole nitrogen source NH4Cl
(EMM - N) every 24 hours for 72 hours. Both wild-type and btn1∆ cells (containing
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pREP41x vectors as a control) remained close to 100% viable in EMM media over
the 72 hour time course. Similarly, and as expected, nitrogen deprived wild-type +
pREP41x cells also remained close to 100% viable over this time-course (Figure 4.4
A). However, a repeated measures two-way ANOVA revealed a significant difference
in mean viability between strains in the different media conditions (F(5, 12) = 12.50; P
= 0.0002). Post-hoc tests using the Tukey correction determined that 24 hours follow-
ing nitrogen withdrawal, btn1∆ cells were already displaying a significant reduction in
viability compared to wild-type cells in the same condition (79.43 ± 2.52% vs 95.73
± 1.68%; P ≤ 0.01) and to btn1∆ cells cultured in EMM containing a nitrogen source
(79.43 ± 2.52% vs 97.20 ± 1.2%; P ≤ 0.001) (Figure 4.4 A). The viability of btn1∆
cells in EMM - N remained significantly reduced compared to wild-type cells in the
same condition at all subsequent time points (Figure 4.4 A)).
At 48 hrs, the viability of btn1∆ cells in EMM - N was significantly reduced com-
pared to the viability displayed at 24 hours (68.83 ± 8.49% vs 79.43 ± 2.52% respec-
tively; P ≤ 0.05), although did not show any significant further change by 72 hours
(73.73 ± 0.10%) suggesting that these cells may plateau at this level of viability. The
over-expression of GFP-btn1+ from a pREP41x expression vector fully rescued the
ability of btn1∆ cells to survive in media lacking nitrogen (Figure 4.4 A).
The ability of btn1∆ cells to arrest in G1/G0, as illustrated by a reduction in cell
elongation, was determined using a measure of cell circularity and given an arbitrary
score of between 0 and 1, where 0 represents a perfectly round cell (Figure 4.4 B + C).
A one-way ANOVA revealed that there were statistical differences in cell elongation
between cells cultured in EMM and those cultured in EMM - N (F(5, 18) = 10.58; P ≤
0.0001). A Tukey post-hoc test revealed that 24 hours following nitrogen withdrawal,
wild-type cells had undergone a significant reduction in cell elongation (0.29± 0.03 vs
0.18 ± 0.006; P ≤ 0.05.) Conversely, btn1∆ cells did not show a significant reduction
in elongation (0.34 ± 0.03 vs 0.31 ± 0.03 in EMM - N; P = ns). The timing of this
finding coincides with a loss of viability, as discussed above. Over-expression of GFP-
btn1+ from a pREP41x vector fully rescued this phenotype, as these cells also showed a
significant reduction in cell elongation 24 hours following nitrogen withdrawal (0.32±
0.02 vs 0.18 ± 0.01; P ≤ 0.01). There was no significant difference in cell elongation
size between wild-type and GFP-btn1+ expressing cells in media lacking nitrogen (0.18
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Figure 4.4: btn1∆ cells show growth defects under nitrogen limitation. [A] Wild-type
(WT), btn1∆, and btn1∆ + pREP41x.GFP-btn1+ cells were cultured in EMM or EMM
lacking the sole nitrogen source NH4Cl (EMM - N) for 72 hrs. Viability was assessed
every 24 hrs using calcofluor-white to identify the total cell population, and the cell im-
permeable stain propidium iodide to identify dead cells. Viability was calculated as the
number of alive cells (Nalive) to the total number counted (Ntotal) and expressed as a per-
centage ((Nalive/Ntotal)*100). A total of 500 cells were counted per data set, and the graph
shows the mean ± SEM of 4 independent experiments. Statistical differences were iden-
tified by a repeated measures two-way ANOVA and post-hoc Tukey analysis (** = P ≤
0.01, **** = P ≤ 0.0001). Asterisks refer to significant differences between btn1∆ cells
in media lacking nitrogen and WT cells under the same condition. v = empty pREP41x
vector as a control. [B] Wild-type (WT), btn1∆, and btn1∆ + pREP41x.GFP-btn1+ cells
were also assessed for morphological changes 24 hrs after nitrogen withdrawal. This was
expressed using a measure of cell elongation on a scale of 0 - 1, where 0 represents a per-
fectly round cell (1 - (4 pi area)/perimeter2). 30 cells were measured for each condition,
and the graph shows the mean ± SEM of 4 independent experiments. Statistical differ-
ences were identified by a one-way ANOVA and post-hoc Tukey analysis (* = P ≤ 0.05,
** = P ≤ 0.01). v = empty pREP41x vector as a control. [C] Representative micrographs
of the cell morphology phenotype assessed in [B]. Scale bars = 10 µm.
4.4. btn1∆ Cells Show a Sensitivity to Nutrient Limitation 118
± 0.006 vs 0.18 ± 0.01 respectively; P = ns and Figure 4.4 B + C).
4.4.2 Glucose Limitation
Glucose is the fundamental source of carbon and energy in eukaryotes. S. pombe pref-
erentially generates ATP via the aerobic alcoholic fermentation of glucose rather than
through respiration. In fact, even under fully aerobic conditions, fission yeast show only
low-levels of respiratory metabolism (making them ‘Crabtree positive’(Flores et al.,
2000)) as glucose represses the necessary enzymes (Zuin et al., 2008). While standard
media contains 2-3% glucose, measures to inhibit respiration have no impact on sur-
vival in media containing levels as low as 0.2% glucose (Takeda et al., 2015). Indeed,
fission yeast are largely resilient to reduced glucose concentrations, and can maintain
normal division even when glucose levels are reduced to one twentieth of that normally
found in culture media (Pluskal et al., 2011).
However, and unlike budding yeast, fission yeast lack the enzymes that comprise
a functional glyoxylate cycle. Therefore, upon complete glucose withdrawal, fission
yeast undergo a rapid nutritional stress as they are unable to use the ethanol produced
during the preceding glucose fermentation as an energy source for respiration (the so
called ‘diauxic shift’) (Yanagida, 2009).
Glucose limitation activates both the SAPK (Shiozaki et al., 1997; Madrid et al.,
2004) and CWI pathway (Madrid et al., 2006; Barba et al., 2008), although the pre-
cise mechanism by which glucose availability is signalled to the CWI remains unclear
(Madrid et al., 2013). Although the kinetics of activation differ, complete adaptation to
glucose withdrawal nonetheless requires both pathways to be operational, indicative of
functional cross-talk between these pathways under this stress condition. More specif-
ically, Pmk1 activation, which is only observed upon complete glucose withdrawal, re-
inforces Sty1 activity and promotes the expression of sty1+-atf1+ dependent genes, in-
cluding fbp1+ which codes for the gluconeogenic enzyme fructose-1,6-bisphosphatase
(Madrid et al., 2013). Low glucose also stimulates the Sty1 pathway in a MAPKKK
independent manner via the inhibition of the Pyp1 phosphatase (Zhou et al., 2010).
Mutants lacking either sty1+ or the transcription factor atf1+ are unable to grow on
non-fermentable carbon sources due to an inability to induce fbp1+. pmk1∆ mutants
also show growth defects upon glucose withdrawal, albeit more subtly than sty1∆ cells
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(Madrid et al., 2013).
As for nitrogen limitation, the TOR complexes also play antagonistic roles un-
der glucose limitation. Glucose starvation results in TORC1 inactivation, again as ev-
idenced by a rapid reduction of Psk1 and Rps6 phosphorylation (Nakashima et al.,
2010, 2012). tor1+ (i.e. TORC2) mutants are unable to grow in glucose limited media
(Yanagida et al., 2011; Saitoh et al., 2015), indicative of a TORC2 requirement in this
condition. Surprisingly however, cells in fact experience a decrease in the TORC2-
dependent phosphorylation of Gad8 in response to glucose deprivation (Cohen et al.,
2014) which arises due to a concomitant decrease in the levels of the GTP-bound (ac-
tive) form of Rhy1 (Hatano et al., 2015), the upstream regulator of TORC2 (Tatebe
et al., 2010). A possible explanation for this apparent paradox is that TORC2 activity
does however re-activate to initial levels within 30 minutes of glucose starvation, in a
Rhy1 independent manner (Hatano et al., 2015). Another possible reason why tor1∆
cells lose viability under glucose limitation is that TORC2 activity is needed to posi-
tively regulate the CWI in this condition by enhancing the de novo synthesis of pck2+
which is required for CWI activation (Madrid et al., 2015). However, others have in
turn shown that the CWI (in a Rho2-dependent manner) down-regulates TORC2-Gad8
signalling (Cohen et al., 2014). Taken together, it is intriguing to speculate that highly
complex regulatory mechanisms, which include both positive and negative feedback,
are in place which allow cells to ‘fine-tune’ TORC2 and CWI activity to permit growth
under a range of different glucose conditions (Madrid et al., 2015; Hatano et al., 2015).
Regardless of the precise complexity, the proper activity of these pathways is clearly
required for viability upon glucose starvation.
The ability of btn1∆ cells to respond to glucose limitation was assessed by com-
parative spot assays using media containing either glucose or the alternative carbon
source glycerol. Ethanol was added to the latter media to promote glycerol assimila-
tion (Matsuzawa et al., 2010; Klein et al., 2013).
As fully expected, wild-type and btn1∆ strains were both viable and grew in a com-
parable manner on glucose-containing media (Figure 4.5 A). In glycerol-containing
media, fission yeast are able to undergo obligate respiratory growth, and oxidative
phosphorylation becomes the main source of energy production (Zuin et al., 2008).
Therefore, as also expected, wild-type cells were able to grow on plates containing
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Figure 4.5: btn1∆ cells show growth defects under glucose limitation. [A] 10-fold
serial dilutions of wild-type (WT), btn1∆, and btn1∆ + pREP41x.GFP-btn1+ logarithmic
cultures were spotted onto glucose or glycerol containing media and incubated at 30◦C
for 3 days (glucose) or 10 days (glycerol). The most concentrated spot contains 1x106
cells. v = empty pREP41x vector as a control. Image is representative of 3 independent
experiments. [B] + [C] Wild-type (WT), btn1∆, and btn1∆ + pREP41x.GFP-btn1+ cells
were also assessed for morphological changes 6 hrs after growth in glycerol media. This
was expressed using a measure of cell elongation on a scale of 0 - 1, where 0 represents
a perfectly round cell (1 - (4 pi area)/perimeter2). 30 cells were measured for each con-
dition, and the graph shows the mean ± SEM of 4 independent experiments. Statistical
differences were identified by a one-way ANOVA and post-hoc Tukey analysis (*** = P
≤ 0.001, **** = P≤ 0.0001). v = empty pREP41x vector as a control. Scale bars in panel
[C] = 10 µm. Data in panels [B] and [C] were provided by Dr Michael Bond.
glycerol, although they divide slower than on glucose plates (Figure 4.5 A). However,
btn1∆ cells showed a pronounced defect in their ability to grow on glycerol-containing
plates (Figure 4.5 A). This phenotype was fully rescued by the over-expression of
pREP41x.GFP-btn1+ (Figure 4.5 A). Assays performed in liquid media confirmed that
the lack of growth on glycerol media was due to a loss of viability as opposed to cellular
quiescence (data not shown).
In low-glucose media, wild-type S. pombe cells maintain their doubling time but
divide at a shorter cell length (Ikai et al., 2011; Yanagida et al., 2011). The extent of
the shortening is not as stark as seen under nitrogen limitation, but is an adaptive mea-
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sure presumably enacted to maintain a normal doubling time despite nutrient limitation
(Pluskal et al., 2011). tor1∆ mutants remain elongated when starved of glucose (Weis-
man et al., 2007; Ikai et al., 2011). This is a notably rare phenotype, as the only other
mutant reported to display this persistent elongation phenotype is a strain lacking the
Ca2+/calmodulin-dependent-like gene ssp1+ (Hanyu et al., 2009).
Given the observed loss of viability, btn1∆ cells were also assessed for their profi-
ciency to reduce cell length upon growth in glycerol (Figure 4.5) using the same method
as described for nitrogen above. A one-way ANOVA revealed that there were statisti-
cal differences in cell elongation between strains cultured in the differing media (F(5,
18) = 41.83; P <0.0001). Tukey post-hoc comparisons showed that wild-type cells are
significantly shorter in glycerol containing media compared to glucose (0.28 ± 0.007
vs 0.19 ± 0.005; P ≤ 0.001). The length of btn1∆ cells did show a modest reduction in
glycerol, but this did not reach significance (0.34 ± 0.006 in glucose containing media
vs 0.29 ± 0.01 in glycerol; P = ns). GFP-btn1+ expression re-established the ability of
cells to reduce their length in glycerol (0.39 ± 0.01 vs 0.25 ± 0.02; P ≤ 0.0001).
In fission yeast, glucose deprivation and the switch to oxidative phosphorylation
induces a mild oxidative stress due to mitochondrial-derived ROS production. This
promotes the nuclear accumulation of Pap1, which then acts in concert with the al-
ready active SAPK pathway to promote cellular survival upon glucose removal (Madrid
et al., 2004). Together, Atf1 and Pap1 result in the expression of genes, including gpx1+
(glutathione peroxidase) and ctt1+ (cytoplasmic catalase), which help reduce the intra-
cellular accumulation of H2O2. In certain conditions, Pmk1 is also needed for ROS
clearance (Wang et al., 2010).
Mitochondrial mutants are particularly compromised for growth on glycerol due
to increased ROS production (Zuin et al., 2008). Although mitochondrial function
has been largely un-addressed in the yeast models of juvenile CLN3 disease, defective
mitochondria is a feature of other NCL models (Jolly et al., 2002). It is therefore
possible that increased endogenous oxidative stress, or an inability to respond to it,
contributes to the loss of btn1∆ viability in glycerol.
However, the addition of 30 mM N-acetyl-cysteine (NAC; a scavenger for per-
oxide radicals) to glycerol media did not improve viability of btn1∆ cells when as-
sessed over 72 hours (Dr Michael Bond, data not shown). It would therefore appear
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that the death of btn1∆ cells when starved for glucose is unrelated to endogenous ox-
idative stress, a finding that is consistent with their tolerance to FTY720 (described
above). Notably, Pmk1 and Sty1 activation due to glucose limitation is specifically due
to the lack of this particular carbon source rather than endogenous oxidative stress, as
pre-incubation with antioxidants also has no effect on the activation of either kinase
(Madrid et al., 2004, 2013). btn1∆ cells, like TORC2 and CWI mutants, therefore ap-
pear to have a fundamental inability to tolerate glucose deprivation that is unlikely to
solely reflect the development of endogenous oxidative stress.
4.5 btn1∆ Cells Do Not Show a Sensitivity to Osmotic
Stress
Changes in osmotic status affect the turgor and volume of yeast cells, but also ad-
versely affect the intracellular environment and cause organelle damage. Under condi-
tions of hyper-osmotic stress, this is avoided by the actions of sty1+ and atf1+ (Shiozaki
and Russel, 1996; Wilkinson et al., 1996; Degols et al., 1996; Zaitsevskaya-Carter and
Cooper, 1997) which induce the transcriptional up-regulation of various osmoadaptive
genes (Chen et al., 2003) including glycerol-3-phosphate dehydrogenase (gpd1+) (Aiba
et al., 1995; Ohmiya et al., 1995). gpd1+ is involved in the first step of glycerol produc-
tion, an inert osmolyte that increases internal osmolarity and promotes the uptake of
water from the cells environment. SAPK signalling, via atf1+, is also required for the
recovery from hyper-osmotic stress induced changes to the cell wall and cytoskeleton
(Robertson and Hagan, 2008). SAPK and atf1+ mutants show growth defects in high
osmolarity media produced by the addition of sorbitol, NaCl, or KCl (Wilkinson et al.,
1996; Madrid et al., 2006).
Unlike Sty1, Pmk1 is phosphorylated after both hypo- and hyper-osmotic stress
(Sengar et al., 1997; Madrid et al., 2006; Barba et al., 2008). In the case of hyper-
osmotic stress, the deactivation of Pmk1 requires sty1+-atf1+ signalling (Madrid et al.,
2006), indicative of yet more cross-talk between these pathways. Interestingly however,
and in contrast to SAPK mutants, Pmk1 mutants are only sensitive to high osmolarity
media created by the addition of KCl, despite Pmk1 also becoming phosphorylated by
NaCl and sorbitol (Madrid et al., 2006).
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TORC2 activity is similarly required for tolerance to hyper-osmotic stress induced
by salts (NaCl and KCl) or sorbitol (Kawai et al., 2001; Weisman and Choder, 2001;
Matsuo et al., 2003; Ikeda et al., 2008; Tatebe et al., 2010). As with other conditions de-
tailed here, and consistent with the mutual antagonism of the TOR complexes, TORC1
activity is inhibited under osmotic stress (Nakashima et al., 2010).
A particularly important physiological response to osmotic stress involves the vac-
uoles. Pre-existing vacuoles rapidly undergo fusion in response to a hypo-tonic envi-
ronment, presumably to sequester water and restore osmotic homeostasis to the cytosol
(Bone et al., 1998). This morphological change requires pmk1+ and sty1+, and is dis-
rupted in mutants lacking these kinases (Bone et al., 1998; Sa´nchez-Mir et al., 2012).
Intriguingly however, vacuole fusion does not require Sty1 phosphorylation or protein
synthesis, but does require atf1+ (Bone et al., 1998). In times of hyper-tonic stress,
vacuole fission is not observed in wild-type cells, but does occur in Rab GTPase ypt4
mutants which have larger vacuoles under normal conditions (Bone et al., 1998). Vac-
uole fission in ypt4 mutants paradoxically still requires pmk1+ and sty1+, although in
this case does not rely on atf1+ (Bone et al., 1998). Mutants lacking various components
of TORC2 also show vacuole fragmentation which is associated with hypersensitivity
to osmostress (Tatebe et al., 2010).
It has previously been reported that btn1∆ cells have enlarged vacuoles, which is
accompanied with an increase in pH (Gachet et al., 2005). That btn1+ is required for
vacuole homeostasis, and that its deletion causes an increase in vacuole diameter, was
reproduced in the course of this work as shown in Figure 4.6. This phenotype was
rescued by the over-expression of pREP41x.GFP-btn1+.
Therefore, given these observed vacuole defects and negative interactions with
stress signalling components, it was hypothesised that btn1∆ would also show a sensi-
tivity to osmotic changes. Since sorbitol can rescue the heat phenotypes of the btn1∆
strain (Figure 4.1), it was instead tested for it’s response to salt-induced osmotic stress.
Although high salinity media induces both osmotic and ionic stress, NaCl and KCl
salts are nonetheless commonly used experimental osmolytes. The response of btn1∆
cells to hypo-osmotic stress was assessed by two differing protocols (detailed in the
Materials and Methods, and Figure 4.7).
Surprisingly however, btn1∆ cells did not appear sensitive to either hypo- or hyper-
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Figure 4.6: btn1∆ cells show enlarged vacuoles. [A] Wild-type (WT), btn1∆, and btn1∆
+ pREP41x.GFP-btn1+ cells were grown overnight in EMM and stained with FM4-64 to
visualise the vacuoles. The diameter of 300 vacuoles was determined per data set, and
the graph shows the mean ± SEM of four independent experiments. Statistical differ-
ences were identified by a one-way ANOVA and post-hoc Tukey analysis (*** = P ≤
0.001, **** = P ≤ 0.0001). v = empty pREP41x vector as a control. [B] Representative
micrographs of the vacuole phenotype assessed in [A]. Scale bars = 10 µm.
osmotic stress (Figure 4.7). Some strains are sensitive to hyper-osmotic stress only
when assayed in minimal media, not rich YES media (Zaitsevskaya-Carter and Cooper,
1997). Although not shown, btn1∆ cells also grew in a manner comparable to wild-type
when NaCl and KCl were added to EMM solid agar.
4.6 btn1∆ Cells Do Not Show a Sensitivity to Replica-
tion Stress
Sty1 and Atf1 are activated following exposure to both UV and ionizing radiation, and
sty1∆ mutants are hypersensitive to DNA damage caused by such methods (Degols and
Russell, 1997; Watson et al., 2004). Pap1 can also confer resistance to DNA damage,
although this does not appear to be dependent on Sty1 (Belfield et al., 2014). Cells de-
fective in TORC2 signalling, including tor1∆ and gad8∆ cells, are also subtly sensitive
to UV radiation (Schonbrun et al., 2009) although are resistant to ionizing radiation
(Schonbrun et al., 2013). These cells do however display a more evident sensitivity
to chronic replication stress, caused by hydroxyurea (HU), methyl-methane sulfonate
(MMS), and camptothecin (CPT) (Schonbrun et al., 2009, 2013). HU reversibly in-
hibits ribonucleotide reductase which is required for nucleotide synthesis, therefore
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Figure 4.7: btn1∆ cells do not do not show growth defects under osmotic stress.
[A] Wild-type (WT) and btn1∆ cells were grown overnight in YES + 1.2 M sorbitol,
then shifted to YES without the osmotic stabiliser. Cell viability was assessed 8 hrs
later using calcofluor-white to identify the total cell population, and the cell imperme-
able stain propidium iodide to identify dead cells. Viability was calculated as the number
of alive cells (Nalive) to the total number counted (Ntotal) and expressed as a percentage
((Nalive/Ntotal)*100). A total of 500 cells were counted for each condition, and the graph
shows the mean ± SEM of four independent experiments. An unpaired t-test found no
significant differences between the strains (P = 0.0512). [B] The ability of btn1∆ cells
to withstand hypo-osmotic stress was also assessed by diluting a YES + 1.2 M sorbitol
culture 20-fold with water. Cell viability was assessed after 1 hr using the method de-
scribed for panel [A]. A total of 500 cells were counted for each condition, and the graph
shows the mean ± SEM of four independent experiments. Again, btn1∆ cells did not
show a statistically significant change in viability compared to wild-type (WT) cells as
determined by an unpaired t-test (P = 0.379). [C] + [D] Wild-type (WT) and btn1∆ cells
were streaked onto YES containing 0.8 M NaCl or 1.5 M KCl to determine their toler-
ance to hyper-osmotic stress. Plates were incubated at 30◦C for 3 days and images are
representative of three independent experiments.
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Figure 4.8: btn1∆ cells do not show growth defects under chronic replication stress.
10-fold serial dilutions of wild-type (WT) and btn1∆ logarithmic cultures were spotted
onto YES containing either 2.5 mM hydroxyurea (HU), 0.004% methyl-methane sul-
fonate (MMS) or 3 µM camptothecin (CPT) and incubated at 30◦C for 3 days. The
most concentrated spot contains 1x106 cells. Images are representative of 3 independent
experiments.
HU causes a depletion of dNTPS which in turn slows DNA replication and causes
replication fork stalling. MMS is an alkylating agent which physically blocks replica-
tion fork elongation (Groth et al., 2010). Lastly, CPT is a cytotoxic quinoline alkaloid
which inhibits the DNA enzyme topoisomerase I, leading to replication fork collision
(Liu et al., 1996).
Given that tor1+ and pap1+ were found to negatively interact with btn1+, as were
a number of genes involved in DNA repair (atl1+, msh1+, rdl1+, flm2+, mh201+, and
pku80+; refer to Appendix 2), btn1∆ cells were similarly tested for their ability to
tolerate increasing doses of HU, MMS, and CPT.
Initially btn1∆ cells were tested for viability using concentrations known to af-
fect tor1+ mutants; 2.5 mM HU, 0.004% MMS (Schonbrun et al., 2009) and 3 µM
CPT (Schonbrun et al., 2013). At these concentrations btn1∆ cells remained viable
and showed no obvious growth disparity compared to wild-type cells (Figure 4.8). Al-
though at 5 mM HU, btn1∆ cells seemed to display a very subtle sensitivity, this was not
overly consistent and did not appear to be dose-dependent (data not shown). btn1∆ cells
remained indistinguishable from wild-type cells at increasing MMS and CPT doses un-
til growth was prevented at the same dose as for wild-type cells (data not shown).
4.7 btn1∆ Cells Do Not Show the vic Phenotype
Inhibiting calcineurin activity (either by genetic knock-out or using the immunosup-
pressant FK506) causes a hypersensitivity to chloride ions, and calcineurin and Pmk1
play antagonistic roles in Cl- homeostasis (Sugiura et al., 1998). Exploiting this inter-
action has led to the identification of several components of Pmk1 MAPK signalling, as
mutations in CWI genes affords the ability to grow in the presence of immunosuppres-
sant and chloride ions (the so-called vic phenotype) (Ma et al., 2006; Doi et al., 2015).
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This phenotype is specifically shared by CWI mutants, including cells lacking pmk1+,
pek1+, mkh1+, pck2+, rho2+, and rho5+ mutants. The vic phenotype is not observed in
SAPK mutants (Ma et al., 2006).
btn1∆ cells were similarly tested for their ability to grow on media containing
FK506 and MgCl2. Both btn1∆ and wild-type cells failed to grow under these condi-
tions (data not shown). This suggests that while btn1+ may influence, or show some
functional overlap with CWI signalling, it is not a direct component of this pathway.
4.8 Summary
The results obtained from the SGA performed as the basis of this work, and described
in Chapter 3 (p. 88), suggest that btn1+ function may converge with that of various
stress response pathways; specifically MAPK and Tor pathways. By extension, it was
hypothesised that cells lacking btn1+ might show sensitivities to stress conditions, and
therefore share phenotypes with mutants of known, and conserved stress-response path-
ways. In support of this hypothesis, this chapter has shown that cells lacking btn1+ do
indeed show an overt inability to tolerate several forms of environmental stress in which
MAPK and Tor signalling is ordinarily required.
These include a sensitivity to elevated temperature which is likely associated with
cell wall defects, both of which have been described and discussed previously. Novel
findings include morphological defects and a loss of viability upon both glucose and
nitrogen limitation, and a sensitivity to oxidative stress. The association of these phe-
notypes with the absence of btn1+ was confirmed by their rescue upon re-expression of
GFP-btn1+ from a pREP41x vector. btn1∆ cells were not however found to be sensi-
tive to osmotic stress despite having enlarged vacuoles, or to DNA damage. Although
there is not a strict global inability to respond to stress, the number of different stressors
that do affect the btn1∆ strain could be taken to imply that the loss of btn1+ results in
an inability to respond to stress per se, as opposed to a specific stressor, and that this
molecular defect may underlie the pathogenesis of juvenile CLN3 disease.
Given that btn1∆ cells show sensitivities to conditions which ordinarily require
functional MAPK and Tor signalling, it can also be speculated that manipulating such
pathways may be beneficial in cells lacking btn1+. If so, this could help further validate
the suggestion that dysfunctional stress responses underlie the pathogenesis of juvenile
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CLN3 disease, and highlight therapeutic targets. The hypothesis that manipulating
stress-response pathways will be protective in btn1∆ cells is explored in the following
chapter.
Chapter 5
Manipulating Stress Response
Pathways Rescues btn1∆ Phenotypes
5.1 Introduction
The data presented in the previous two chapters provide a convincing argument for
btn1+ being required for stress signalling, and that the response to environmental stress
is compromised in its absence. Accordingly, the manipulation of known stress re-
sponse pathways (i.e. those that are shown to genetically interact with btn1+) could be
predicted to result in observable benefits to btn1∆ cells. If corroborated, such a finding
would act to both validate the hypothesis that a lack of functional btn1+ leads to dys-
functional stress signalling, and reveal pathways that could be therapeutically targeted
to alleviate the symptoms seen in patients.
5.1.1 Chapter Aims
The aim of the work described in this chapter is to test the ability of various genetic
and pharmacological manipulations of stress signalling pathways to rescue btn1∆ phe-
notypes. Of the phenotypes described in Chapter 4 (p. 108), the following were chosen
as readouts to assess the effectiveness of experimental manipulations: heat sensitivity
(as this has previously been published and is a highly reproducible phenotype), enlarged
vacuoles (as this can be used as a proxy for the lysosomal dyshomeostasis of patient
cells), and the novel viability and morphology defects seen under nutrient limitation.
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5.2 Manipulating the Cell Wall Integrity Pathway
5.2.1 Rho1 and Rho5 GTPases Rescue btn1∆ Phenotypes
As described in Chapter 3 (p.88), rho5+ and various genes that lie downstream of the
CWI pathway are negative interactors with btn1+. This would suggest that absent or
reduced CWI is detrimental to cells lacking a functional btn1+, and so conversely that
up-regulating CWI signalling may be protective. The up-regulation of the CWI path-
way in btn1∆ cells was achieved both by the ectopic over-expression of rho5+ and of
its essential paralogue rho1+.
5.2.1.1 Rho1 and Rho5 have Differential Effects on the Heat Sensitiv-
ity and Vacuole Diameter of btn1∆ Cells
The ability of the Rho GTPases to rescue the heat sensitivity of btn1∆ cells was inves-
tigated using spot assays. btn1∆ cells transformed with pREP41x.rho1+ were indistin-
guishable from wild-type cells when grown at the non-permissive temperature of 37◦C,
indicating that Rho1 was able to fully rescue the heat sensitivity exhibited by btn1∆
(Figure 5.1 A). However, the over-expression of pREP1.rho5+ did not rescue the heat
phenotype (Figure 5.1 B). Given that these Rho GTPases are paralogues, the cause for
this disparity was initially unclear. However, btn1∆ cells show some morphological
and septation defects as a result of the loss of btn1+ (Codlin et al., 2008b). It appeared
that pREP1.rho5+ enhanced these defects (data not shown), consistent with the pub-
lished effects of rho5+ over-expression in wild-type cells (Nakano et al., 2005). As
previously described, there is a link between the heat-sensitivity and septation defects
of btn1∆ cells (Codlin et al., 2008b), and therefore that rho5+ over-expression was un-
able to rescue this heat phenotype is not unexpected. That pREP41x.rho1+ was able
to rescue the heat sensitivity, despite being a functional paralogue of rho5+, is likely
due to a dosage effect. In the context of these experiments, rho5+ was expressed to
high levels from a full-strength nmt1 promoter, whereas endogenous rho5+ expression
is low (Nakano et al., 2005). Conversely, rho1+ was expressed from a medium strength
promoter in the pREP41x construct, and rho1+ endogenous expression is ordinarily
seen at higher levels than rho5+.
The ability of the Rho GTPase paralogues to rescue the increased vacuole diam-
eter phenotype was also measured. In this case, as vacuole diameter is a quantitative
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Figure 5.1: Rho GTPases rescue the btn1∆ heat sensitivity. [A] 10-fold serial dilutions
of wild-type (WT), btn1∆, and btn1∆ + pREP41x.rho1+ logarithmic cultures were spotted
onto YES plates and incubated at either 30◦C or 37◦C for 3 days. The most concentrated
spot contains 1x106 cells. v = empty pREP41x vector as a control. [B] 10-fold serial
dilutions of wild-type (WT), btn1∆, and btn1∆ + pREP1.rho5+ logarithmic cultures were
spotted onto YES plates and incubated at either 30◦C or 37◦C for 3 days. The most
concentrated spot contains 1x106 cells. v = empty pREP41x vector as a control. Images
are representative of 3 independent experiments.
phenotype, the effect of over-expressing the Rho GTPases in wild-type cells was also
assessed. The expression of pREP41x.rho1+ resulted in significant differences in vac-
uole diameter between the strains as revealed by a one-way ANOVA (F (3, 12) = 53.55;
P <0.0001). Post-hoc Tukey corrections showed that, as shown in Chapter 4 (p.108),
btn1∆ cells had significantly larger vacuoles compared to wild-type cells (0.42 ± 0.01
µm vs 0.28 ± 0.0078 µm; P ≤ 0.0001) (Figure 5.2 A + C). The over-expression of
pREP41x.rho1+ significantly reduced vacuole diameter in both the wild-type (0.28 ±
0.0078 µm vs 0.21 ± 0.016 µm; P ≤ 0.05) and btn1∆ cells (0.42 ± 0.01 µm vs 0.32
± 0.01 µm; P ≤ 0.001) (Figure 5.2 A + C). Importantly however, the vacuole diameter
of btn1∆ cells expressing pREP41x.rho1+ was not significantly different from wild-
type cells (0.28 ± 0.0078 µm vs 0.32 ± 0.01 µm; P = ns). Although pREP41x.rho1+
also reduces vacuole size in wild-type cells, this particular finding was encouraging
given that the native wild-type diameter is the normal (or ‘healthy’) state, and restoring
vacuole/lysosomal diameter to this value would be the aim of an effective therapy.
The expression of pREP1.rho5+ also resulted in significant differences in vacuole
diameter as revealed by a one-way ANOVA (F (3, 12) = 108.3; P <0.0001) (Figure 5.2
B + C). Similar to the effect of pREP41x.rho1+, post-hoc Tukey corrections revealed
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Figure 5.2: Rho GTPases rescue the btn1∆ vacuole enlargement. [A] Wild-type (WT),
WT + pREP41x.rho1+, btn1∆, and btn1∆ + pREP41x.rho1+ cells were grown overnight
in EMM and stained with FM4-64 to visualise the vacuoles. The diameter of 300 vacuoles
per data set was determined, and the graph shows the mean ± SEM of four independent
experiments. Statistical differences were identified by a one-way ANOVA and post-hoc
Tukey analysis (* = P≤ 0.05, *** = P≤ 0.001, **** = P≤ 0.0001). v = empty pREP41x
vector as a control. [B] Wild-type (WT), WT + pREP41x.rho5+, btn1∆, and btn1∆ +
pREP1.rho5+ cells were cultured and vacuoles analysed as for [A]. [C] Representative
micrographs of the vacuole phenotype of WT, btn1∆, btn1∆ + pREP41x.rho1+, btn1∆ +
pREP1.rho5+ assessed in [A] + [B]. Scale bars = 10 µm.
that the over-expression of pREP1.rho5+ reduced vacuole diameter in both wild-type
(0.28 ± 0.0078 µm vs 0.17 ± 0.012 µm; P ≤ 0.0001) and btn1∆ cells (0.42 ± 0.01
µm vs 0.19± 0.012; P≤ 0.0001). However, in this case, the mean vacuole diameter of
btn1∆ + pREP1.rho5+ cells was significantly smaller than wild-type cells containing an
empty pREP41x vector (0.28 ± 0.0078 µm for wild-type vs 0.19 ± 0.012; P ≤ 0.001).
This over-correction of vacuole size (relative to the ‘healthy’ wild-type state) may
reflect a strong dose-dependence of the Rho GTPase paralogues, and supports that
dosage differences also likely underlie the disparate ability to rescue the heat sensi-
tivity as described above. It is of interest that a dose-dependence relationship between
btn1+ and vacuole size has been reported previously as ectopic GFP-btn1+ expression
correlates with vacuolar size (Gachet et al., 2005). Notably, the ability of GFP-btn1+
to rescue the btn1∆ heat phenotype also appears sensitive to dosage (this work, data
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not shown). It follows that these two phenotypes in particular may be sensitive to both
btn1+ and rho1+/rho5+ GTPase dosage.
As an aside, it should be noted that the aim of these experiments was not to directly
compare Rho5 and Rho1 over-expression, but rather only to examine if up-regulating
the CWI could restore btn1∆ phenotypes to wild-type. That the Rho GTPases were
expressed under different promoters is therefore not considered to be an important lim-
itation of this work, especially given the more concordant effects seen under other
conditions as discussed below.
5.2.1.2 Rho1 and Rho5 Rescue the Nutrient Sensitivities of btn1∆
Cells
The ability of Rho1 and Rho5 to rescue the loss of btn1∆ viability under nutrient limita-
tion was assessed either in liquid media (nitrogen limitation) or on solid agar (glycerol).
The expression of pREP41x.rho1+ had a significant effect on strain viability in
EMM lacking NH4Cl (EMM - N) as assessed by a two-way ANOVA (F (5, 18) = 5.564;
P = 0.0029). A post-hoc Tukey’s multiple comparisons test confirmed that wild-type
cells cultured in EMM - N remained close to 100% viable over the entire time-course,
and showed no significant difference compared to wild-type cells grown in nitrogen
replete media (Figure 5.3 A). The addition of pREP41x.rho1+ to wild-type cells had no
impact on viability compared to wild-type cells containing a control empty pREP41x
vector under any condition.
btn1∆ cells showed a significant loss of viability at both 48 hrs and 72 hrs when
cultured in EMM - N compared to btn1∆ cells in normal EMM media, and compared to
wild-type cells in EMM - N (Figure 5.3 A). However, at 48 hrs btn1∆ + pREP41.rho1+
cells in EMM - N showed a significantly higher viability compared to btn1∆ cells con-
taining an empty pREP41x vector under the same condition (99.38 ± 0.23% vs 86.73
± 3.92%; P ≤ 0.01). At this time point, the viability of btn1∆ + pREP41.rho1+ cells
in EMM - N was not significantly different from wild-type cells in EMM - N (99.38 ±
0.23% vs 97.40 ± 2.33%; P = ns). At 72 hrs, btn1∆ + pREP41.rho1+ cells in EMM -
N continued to show a significantly higher viability compared to btn1∆ cells in EMM
- N (96.10 ± 2.20% vs 76.70 ± 4.09%; P ≤ 0.0001), and similarly remained non-
significantly different from wild-type in EMM - N (96.10 ± 2.20% vs 98.25 ± 0.76%
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for wild-type; P = ns) indicating that Rho1 can also fully rescue this nutrient sensitivity
phenotype.
The expression of pREP1.rho5+ also had a significant effect on strain viability in
EMM - N as assessed by a two-way ANOVA (F (5, 18) = 6.306; P = 0.0015). Tukey
post-hoc tests showed that at 48 hrs, btn1∆ + pREP1.rho5+ cells in EMM - N showed
a significantly higher viability compared to btn1∆ cells containing an empty pREP41x
vector under the same condition (97.75 ± 0.76% vs 86.73 ± 3.92%; P ≤ 0.01). The
same was observed at 72 hrs (97.60 ± 0.35% vs 76.70 ± 4.09% for btn1∆ cells; P ≤
0.0001). btn1∆ + pREP1.rho5+ in EMM - N did not show a significant difference in
viability compared to wild-type cells in EMM - N at any time point (Figure 5.3 B).
Given that both Rho1 and Rho5 fully rescued the loss of viability when starved of
nitrogen, it was also assessed whether Rho1 could restore the ability of btn1∆ to un-
dergo the characteristic cell shortening ordinarily observed in this condition. As cells
over-expressing pREP1.rho5+ displayed some morphological defects (see text above),
morphological analysis on this strain proved difficult and is not included here. A one-
way ANOVA revealed statistical differences in cell elongation between cells cultured
in EMM and those in EMM lacking nitrogen (F (5, 18) = 21.31; P <0.0001). A Tukey
post-hoc test revealed that 24 hrs following nitrogen withdrawal, wild-type cells con-
taining an empty pREP41x vector had undergone a significant reduction in cell elon-
gation (0.29 ± 0.03 vs 0.15 ± 0.01; P ≤ 0.001) whereas btn1∆ cells had not (0.34 ±
0.003 vs 0.35 ± 0.03; P = ns), consistent with data presented in Chapter 4 (p.108).
btn1∆ cells over-expressing pREP41x.rho1+ did however show a significant reduction
in cell length (0.32 ± 0.01 vs 0.16 ± 0.02 in EMM - N; P ≤ 0.001), revealing that
Rho1 can rescue both the viability and morphological response to nitrogen withdrawal
(Figure 5.3 C).
Both Rho1 and Rho5 also fully rescued the ability of btn1∆ cells to grow on the
non-fermentable carbon source glycerol (Figure 5.4 A + B). When pREP41x.rho1+
was assessed for its ability to rescue the morphological response to glycerol, a one-
way ANOVA revealed statistical differences in cell elongation between cells cultured
in glucose and those in glycerol containing media (F (5, 18) = 15.21; P <0.0001)
(Figure 5.4 C + D). As for the response to nitrogen limitation, Tukey post-hoc com-
parisons revealed that upon glucose limitation, wild-type cells containing an empty
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Figure 5.3: Rho GTPases rescue the btn1∆ sensitivity to nitrogen limitation. [A] +
[B] Wild-type (WT), btn1∆, btn1∆ + pREP41x.rho1+ or btn1∆ + pREP1.rho5+ cells were
cultured in EMM or EMM lacking the sole nitrogen source (NH4Cl) for 72 hrs. Viability
was assessed every 24 hrs using calcofluor-white to identify the total cell population, and
the cell impermeable stain propidium iodide to identify dead cells. Viability was calcu-
lated as the number of alive cells (Nalive) to the total number counted (Ntotal) and expressed
as a percentage ((Nalive/Ntotal)*100). A total of 500 cells were counted per data set, and
the graph shows the mean ± SEM of 4 independent experiments. Statistical differences
were identified by a repeated measures two-way ANOVA and post-hoc Tukey analysis
(* = P ≤ 0.05, *** = P ≤ 0.001, **** = P ≤ 0.0001). Asterisk’s refer to significant
differences between btn1∆ cells in media lacking nitrogen and WT cells under the same
condition. v = empty pREP41x vector as a control. [C] Wild-type (WT), btn1∆, and
btn1∆ + pREP41x.rho1+ cells were also assessed for morphological changes 24 hrs after
nitrogen withdrawal. This was expressed using a measure of cell elongation on a scale of
0 - 1, where 0 represents a perfectly round cell (1 - (4 pi area)/perimeter2). 30 cells were
measured for each condition, and the graph shows the mean ± SEM of 4 independent
experiments. Statistical differences were identified by a one-way ANOVA and post-hoc
Tukey analysis (*** = P ≤ 0.001). v = empty pREP41x vector as a control. [D] Repre-
sentative micrographs of the cell morphology phenotype assessed in [C]. Scale bars = 10
µm.
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pREP41x vector displayed a significant reduction in cell elongation (0.28 ± 0.02 vs
0.16 ± 0.01; P ≤ 0.01). btn1∆ cells did not display the same reduction, and cell elon-
gation in glycerol media was not significantly reduced compared to glucose containing
media (0.33± 0.02 vs 0.30± 0.03 in glucose; P = ns). However, the over-expression of
pREP41x.rho1+ fully restored the ability of btn1∆ cells to undergo this morphological
response (0.29 ± 0.01 vs 0.15 ± 0.01 in glycerol media; P ≤ 0.01).
5.2.2 Pmp1 Exacerbates btn1∆ Phenotypes
Although both Rho1 and Rho5 are bona fide upstream regulators of the CWI pathway,
both also have more direct roles with respect to cell wall organisation and actin po-
larisation. These processes are also defective in btn1∆, so in order to substantiate the
involvement of CWI signalling in btn1∆ phenotypes (as opposed to direct roles of these
GTPases), the effects of down-regulating the CWI pathway was also investigated. The
dual-specificity phosphatase Pmp1 is the primary negative regulator of Pmk1 activity
(Sugiura et al., 1998). pmp1+ was therefore over-expressed in an attempt to reduce
Pmk1 signalling, and test the hypothesis that this would exacerbate btn1∆ phenotypes
in a similar manner to deleting upstream CWI regulators as observed during the SGA.
The over-expression of pREP41x.pmp1+ had no discernible effect on the viabil-
ity of either wild-type nor btn1∆ cells cultured under normal conditions. However,
a two-way ANOVA revealed that the expression of pREP41x.pmp1+ did have a sig-
nificant effect viability when strains were cultured in EMM - N (F (7, 24) = 61.95;
P <0.0001) (Figure 5.5 A). Post-hoc Tukey corrections revealed that the addition of
the pREP41x.pmp1+ construct further reduced the viability of btn1∆ cells cultured in
EMM - N, and this was found to reach statistical significance by 24 hrs (77.52± 3.06%
vs 88.48 ± 2.86%; P ≤ 0.01). The viability of btn1∆ + pREP41x.pmp1+ in EMM - N
remained significantly reduced compared to btn1∆ cells in the same condition at all fur-
ther time points assayed (Figure 5.5 A). The over-expression of pREP41x.pmp1+ did
not however affect the viability of wild-type cells cultured in the absence of nitrogen.
That Pmp1 over-expression exacerbates the nitrogen phenotype suggests that the
rescue elicited by Rho5/Rho1 as described above occurs in a Pmk1 dependent manner,
rather than through a more direct role of these GTPases. This was somewhat unex-
pected given there is little evidence linking the CWI pathway to the nitrogen stress
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Figure 5.4: Rho GTPases rescue the btn1∆ sensitivity to glucose limitation. [A] +
[B] 10-fold serial dilutions of wild-type (WT), btn1∆, btn1∆ + pREP41x.rho1+ or btn1∆
+ pREP1.rho5+ logarithmic cultures were spotted onto glucose or glycerol containing
media and incubated at 30◦C for 3 days (glucose) or 10 days (glycerol). The most con-
centrated spot contains 1x106 cells. v = empty pREP41x vector as a control. Image is
representative of 3 independent experiments. [C] Wild-type (WT), btn1∆, and btn1∆ +
pREP41x.rho1+ cells were also assessed for morphological changes 6 hrs after growth in
glycerol media. This was expressed using a measure of cell elongation on a scale of 0
- 1, where 0 represents a perfectly round cell (1 - (4 pi area)/perimeter2). 30 cells were
measured for each condition, and the graph shows the mean ± SEM of 4 independent
experiments. Statistical differences were identified by a one-way ANOVA and post-hoc
Tukey analysis (** = P ≤ 0.01). v = empty pREP41x vector as a control. [D] Representa-
tive micrographs of the cell morphology phenotype assessed in [C]. Scale bars = 10 µm.
Data in panel [D] was provided by Dr Michael Bond.
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response in fission yeast. Indeed, it is interesting to note that Pmp1 expression in wild-
type cells does not phenocopy btn1∆ with respect to viability in a nitrogen limited envi-
ronment. Nonetheless, the finding that Rho5/Rho1 over-expression not only improved
viability but also corrected the highly specific morphological response to nitrogen with-
drawal, and that Pmp1 over-expression reduced viability in EMM - N media, suggests
that the CWI can play a role in the response to nitrogen limitation, at least in the context
of the btn1∆ model. Although the precise mechanism for how this occurs in unclear,
these data may reflect lateral communication between the CWI and SAPK signalling,
which is known to be required for the response to nitrogen withdrawal. Further, CWI
signalling in budding yeast down-regulates TORC1 signalling, which is similarly re-
quired to tolerate this stress and may also occur in fission yeast.
A one-way ANOVA also revealed that pREP41x.pmp1+ had a significant effect on
vacuole diameter (F (3, 12) = 34.10; P ≤ 0.0001). Post-hoc Tukey corrections revealed
that pREP41x.pmp1+ had no effect on the vacuole diameter of wild-type cells (0.24 ±
0.01 µm vs 0.23 ± 0.02 µm for wild-type; P = ns), but led to a significant increase
in the vacuole diameter of btn1∆ cells (0.80 ± 0.08 µm vs 0.52 ± 0.04 µm for btn1∆
cells; P ≤ 0.01) (Figure 5.5 B + C).
5.3 Manipulating the Stress Associated Protein Kinase
Pathway
The interactors identified from the SGA largely support that reduced SAPK signalling,
in addition to CWI signalling, is detrimental to cells lacking a functional btn1+. In
order to up-regulate the activity of the SAPK pathway in btn1∆ cells, a constitu-
tively active wis1 allele was ectopically expressed from the pREP1.nmt1 promoter
(pREP1.wis1DD). Wis1DD is an allele in which the Ser 469 and Thr 473 codons have
been substituted to encode aspartic acid residues to mimic phosphorylation (Shiozaki
et al., 1998), and cells expressing Wis1DD show an increase in Sty1 activity (Shiozaki
et al., 1998; Hartmuth and Petersen, 2009).
5.3.1 Wis1DD Rescues the Vacuole Diameter of btn1∆ Cells
A one-way ANOVA followed by post-hoc Tukey corrections revealed that the over-
expression of pREP1.wis1DD was able to rescue the vacuole diameter of btn1∆ cells
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Figure 5.5: Pmp1 exacerbates btn1∆ phenotypes. [A] Wild-type (WT), WT +
pREP41x.pmp1+, btn1∆, and btn1∆ + pREP41x.pmp1+ cells were cultured in EMM (not
shown for clarity) or EMM lacking the sole nitrogen source (NH4Cl) for 72 hrs. Viability
was assessed every 24 hrs using calcofluor-white to identify the total cell population, and
the cell impermeable stain propidium iodide to identify dead cells. Viability was calcu-
lated as the number of alive cells (Nalive) to the total number counted (Ntotal) and expressed
as a percentage ((Nalive/Ntotal)*100). A total of 500 cells were counted per data set, and
the graph shows the mean ± SEM of 4 independent experiments. Statistical differences
were identified by a repeated measures two-way ANOVA and post-hoc Tukey analysis
(** = P ≤ 0.01, **** = P ≤ 0.0001). Asterisk’s refer to significant differences between
btn1∆ + pREP41x.pmp1+ cells in media lacking nitrogen and btn1∆ + v cells under the
same condition. v = empty pREP41x vector as a control. [B] Wild-type (WT), btn1∆, and
btn1∆ + pREP41x.pmp1+ cells were grown overnight in EMM and stained with FM4-64
to visualise the vacuoles. The diameter of 300 vacuoles per data set was determined, and
the graph shows the mean± SEM of four independent experiments. Statistical differences
were identified by a one-way ANOVA and post-hoc Tukey analysis (** = P ≤ 0.01). v =
empty pREP41x vector as a control.
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Figure 5.6: Wis1DD rescues the btn1∆ vacuole enlargement. [A] Wild-type (WT),
WT + pREP1.wis1DD, btn1∆, and btn1∆ + pREP1.wis1DD cells were grown overnight
in EMM and stained with FM4-64 to visualise the vacuoles. The diameter of 300 vacuoles
per data set was determined, and the graph shows the mean ± SEM of four independent
experiments. Statistical differences were identified by a one-way ANOVA and post-hoc
Tukey analysis (* = P≤ 0.05). v = empty pREP41x vector as a control. [B] Representative
micrographs of the vacuole phenotype of strains assessed in [A]. Scale bars = 10 µm.
(F (3, 12) = 10.11; P = 0.0013) (Figure 5.6). btn1∆ + pREP1.wis1DD cells had signif-
icantly smaller vacuoles compared to btn1∆ control cells (0.31 ± 0.05 µm vs 0.49 ±
0.03 µm; P ≤ 0.05), but not compared to wild-type cells (0.31 ± 0.05 µm vs 0.31 ±
0.02 µm for wild-type; P = ns). pREP1.wis1DD seemingly also reduced the vacuole
size of wild-type cells, although this did not reach statistical significance (0.21 ± 0.04
µm vs 0.31 ± 0.02 µm; P = ns).
5.3.2 Wis1DD Does Not Rescue the Heat or Nutrient Sensitivities
of btn1∆ Cells
Given the positive effect on vacuole size, Wis1DD was also investigated for its ability
to rescue the heat and nutrient sensitivities of btn1∆. However, the over-expression of
pREP1.wis1DD was found to be unable to rescue the heat sensitivity of btn1∆ cells
(Figure 5.7 A). pREP1.wis1DD was also unable to improve viability in the absence of
glucose (Figure 5.7 B) or nitrogen (Figure 5.7 C). Rather, a two-way ANOVA followed
by Tukey post-hoc correction revealed that pREP1.wis1DD reduced the viability of
btn1∆ cells even under normal conditions (F (2, 9) = 57.69; P <0.0001) (Figure 5.7
D). After 24 hrs, btn1∆ cells carrying an empty pREP41x vector were 98.5 ± 0.76%
viable whereas the viability of btn1∆ + pREP1.wis1DD had fallen to 76.22± 1.78% (P
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≤ 0.0001). Similar values were also seen for both strains at both 48 and 72 hrs (Figure
5.7 C). pREP1.wis1DD over-expression did not however have any effect on wild-type
when grown under normal conditions (data not shown) nor did it further exacerbate the
loss of btn1∆ viability in EMM - N media (Figure 5.7 C).
These data indicate that the up-regulation of SAPK signalling in a broad sense
may be insufficient to rescue btn1∆ phenotypes. Although several negative interactions
were found within this pathway, a number of positive ones were also revealed which
may be suggestive of a more complex interaction between btn1+ and the SAPK path-
way than observed with the CWI pathway. That Wis1DD over-expression reduced the
viability of btn1∆ but not wild-type in normal conditions, despite being recovered as
a negative interactor of btn1+, may be taken to support this hypothesis. Alternatively
however, there are a number of reports from the literature that suggest the specific use
of the Wis1DD allele to manipulate SAPK signalling may not have been an optimal
approach. Firstly, Sty1 activity in cells expressing the constitutively active wis1DD
allele is reduced if compared to its activity when wild-type cells are exposed to ox-
idative or osmostress (Shiozaki et al., 1998). This raises the possibility that this allele
may not be capable of increasing SAPK signalling to a level that is necessary to rescue
btn1∆ phenotypes. Secondly, Sty1 activation in response to stress is usually transient,
and the intensity of the response is heavily dependent on the nature and magnitude of
external stimulus (Pe´rez and Cansado, 2010). Although in obvious contrast to the pre-
vious consideration, it is therefore also possible that the use of a wis1DD allele was too
strong, and a more physiological relevant means of up-regulating the SAPK pathway
may elicit a larger positive effect on btn1∆ cells. Thirdly, constitutive Sty1 hyper-
activation, caused either by pyp1+ deletion or the wis1DD allele, causes a decrease in
Pmk1 phosphorylation (Madrid et al., 2007) which through this work is thought to be
detrimental to btn1∆ cells. The wis1DD construct may therefore have had an undesir-
able effect on CWI signalling, which may be an alternative explanation for the loss of
btn1∆ + pREP1.wis1DD viability under normal conditions, and the lack of rescue under
stress conditions. Lastly, with specific respect to the heat phenotype, sty1+ activation
in response to heat stress does not ordinarily occur as a result of Wis1 phosphorylation
but rather from the inhibition of Pyp1 (Samejima et al., 1997; Nguyen and Shiozaki,
1999). It is possible that manipulating SAPK signalling by targeting Pyp1 may there-
5.3. Manipulating the Stress Associated Protein Kinase Pathway 142
WT + v
btn1Δ + v
btn1Δ + wis1DD
30oC 37oC[A]
WT + v
btn1Δ + v
btn1Δ + wis1DD
Glucose Glycerol[B]
WT + vbtn1Δ + vbtn1Δ + wis1DD
0 24 48 720
20
40
60
80
100
Time (hrs)
WT + v
WT + v - N
btn1Δ + v
btn1Δ + wis1DD
btn1Δ + v - N
btn1Δ + wis1DD - N
0 24 48 720
20
40
60
80
100
Time (hrs)
Via
bil
ity
 (%
)
Via
bil
ity
 (%
)
[C] [D]
**** **** ****
Figure 5.7: WisDD does not rescue the other btn1∆ phenotypes. [A] 10-fold serial di-
lutions of wild-type (WT), btn1∆, and btn1∆ + pREP1.wis1DD logarithmic cultures were
spotted onto YES media and incubated at 30◦C for 3 days. [B] 10-fold serial dilutions of
wild-type (WT), btn1∆, and btn1∆ + pREP1.wis1DD logarithmic cultures were spotted
onto glucose or glycerol containing media and incubated at 30◦C for 3 days (glucose) or
10 days (glycerol). The most concentrated spot of [A] and [B] contains 1x106 cells. v
= empty pREP41x vector as a control. Images are representative of 3 independent ex-
periments. [C] Strains were cultured in EMM or EMM lacking the sole nitrogen source
NH4Cl (EMM - N) for 72 hrs. Viability was assessed every 24 hrs using calcofluor-white
to identify the total cell population, and the cell impermeable stain propidium iodide to
identify dead cells. Viability was calculated as the number of alive cells (Nalive) to the total
number counted (Ntotal) and expressed as a percentage ((Nalive/Ntotal)*100). A total of 500
cells were counted per data set, and the graph shows the mean ± SEM of 4 independent
experiments. [D] Data from strains cultured in EMM is repeated for clarity. Statistical
differences were identified by a repeated measures two-way ANOVA and post-hoc Tukey
analysis (**** = P ≤ 0.0001). Asterisk’s refer to significant differences between btn1∆
+ pREP1.wis1DD cells and btn1∆ + v cells cultured under normal conditions. v = empty
pREP41x vector as a control.
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fore have been more helpful in this context. Furthermore, when exposed to heat stress,
cells expressing Wis1DD show a block of mitotic onset until the stress has been dealt
with (Hartmuth and Petersen, 2009). It is known, through this and previous work, that
btn1∆ cells lose viability under heat stress although this phenotype is typically assayed
as reduced cellular growth on solid agar. Any block in cell division caused by the over-
expression of wis1DD, regardless of whether it was accompanied by improved viability
or not, would not be easily observed if assayed on solid agar as done here.
5.4 Manipulating TOR Kinase Signalling
As detailed in Chapter 3 (p.88), core components of both TORC1 and TORC2 were
found to interact with btn1+. Furthermore, these interactions occurred in a pattern that
is consistent with the mutual repression of the TOR complexes, and indicated that re-
ducing TORC1 but increasing TORC2 activity might be beneficial to btn1∆ cells. Ac-
cordingly, the inhibition of TORC1 was achieved by the over-expression of a dominant
negative version of the upstream activator Rhb1 GTPase (rhb1D60K) (Van Slegtenhorst
et al., 2004). The increase in TORC2 signalling was achieved by the over-expression
of the downstream effector kinase Gad8, which is a multi-copy suppressor of loss of
TORC2 (Matsuo et al., 2003). This work (and that using rapamycin described below)
was performed by Dr Michael Bond, but is presented here in brief due to its relevance
to the SGA findings, and since these pathways are involved in the response to stress
conditions under which btn1∆ lose viability.
5.4.1 Genetic Manipulations of TOR Kinase Signalling Rescues the
Vacuole Diameter of btn1∆ Cells
A one-way ANOVA followed by post-hoc Tukey corrections revealed pREP41x.rhb1D60K
significantly reduced btn1∆ vacuole size (0.40 ± 0.04 µm vs 0.65 ± 0.03 µm; P ≤
0.001) as did pREP41x.gad8+ (0.45 ± 0.03 µm vs 0.65 ± 0.03 µm; P ≤ 0.01). The
over-expression of both constructs reduced btn1∆ vacuole diameter to a value that was
non-significantly different from wild-type cells containing vector alone (0.39 ± 0.01
µm; P = ns).
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5.4.2 Genetic Manipulations of TOR Kinase Signalling have Dif-
ferential Effects on Heat and Nutrient Sensitivities of btn1∆
Cells
The over-expression of pREP41x.rhb1D60K was also found to fully rescue the heat
sensitivity of btn1∆ cells. However, in this instance gad8+ over-expression had no
effect on the ability of btn1∆ to grow at 37◦C.
Similarly, the genetic manipulations of the two distinct TOR complexes
elicited differential effects on the tolerance of btn1∆ cells to nutrient limitations.
pREP41x.rhb1D60K over-expression fully restored the ability of btn1∆ cells to grow
on glycerol as a carbon source. A one-way ANOVA revealed that this was also ac-
companied by a significant rescue of the morphological response to this condition (F
(7, 32) = 37.92; P ≤ 0.0001). As before, btn1∆ cells with an empty vector showed
a non-significant change in elongation from 0.32 ± 0.02 in glucose to 0.28 ± 0.01
in glycerol. In btn1∆ + pREP41x.rhb1D60K cells however, the elongation measure
significantly fell from 0.29 ± 0.02 to 0.18 ± 0.01 (P ≤ 0.0001) which was consistent
to that observed in wild-type cells (0.28 ± 0.01 in glucose to 0.19 ± 0.01 in glycerol;
P ≤ 0.001). pREP41x.rhb1D60K also fully rescued growth in media lacking nitrogen,
with such cells remaining over 95% viable throughout the experimental time course.
Interestingly, although pREP41x.gad8+ did not rescue growth on glycerol, a one-
way ANOVA revealed that this construct was able to significantly rescue the morpho-
logical response to glucose withdrawal (F (7, 32) = 37.92; P≤ 0.0001). Although btn1∆
cells over-expressing gad8+ were more elongated when grown in glucose compared to
wild-type cells (0.36 ± 0.01 vs 0.28 ± 0.01; P ≤ 0.001), btn1∆ + pREP41x.gad8+
cells were able to show a reduction in elongation when grown in glycerol (0.36 ± 0.01
in glucose vs 0.19 ± 0.01 in glycerol; P ≤ 0.0001). In glycerol containing media,
the elongation measure for btn1∆ + pREP41x.gad8+ cells was not longer significantly
different from wild-type cells grown under the same condition.
Lastly, pREP41x.gad8+ had no effect on the viability of btn1∆ cells when grown
in the absence of nitrogen, revealing that such cells still have defects in their ability to
fully adapt to nutrient limitation. The effects of manipulating the TOR pathways on the
morphological response to nitrogen were not assessed.
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5.4.3 Pharmacological Inhibition of TORC1 Signalling Rescues
btn1∆ Phenotypes
These data reveal that both the over-expression of rho1+, and of a dominant negative
rhb1 allele, are able to fully rescue all assessed phenotypes of btn1∆ cells. Given these
profound genetic rescues, these pathways may be particularly good therapeutic targets.
Therefore, it was deemed important to attempt to recapitulate these rescues via a phar-
macological approach using rapamycin and/or caffeine, both of which are canonically
known to inhibit TORC1 signalling. Interestingly however, especially in the context
of this work, both drugs can also induce Rho1/CWI signalling in budding yeast (Yan
et al., 2012) and therefore the two manipulations found to be most beneficial by genetic
means could be potentially achieved using a single pharmacological approach.
Rapamycin acts by forming an intracellular complex with immunophilin FKBP12,
the fission yeast orthologue of which is Fkh1p (Weisman et al., 2001). This com-
plex subsequently binds with the FRB (FKBP12-rrapamycin binding) domain in Tor2
to preferentially inhibit TORC1 activity (Wullschleger et al., 2006; Nakashima et al.,
2010). However, in sharp contrast to other organisms, rapamycin does not inhibit vege-
tative growth in fission yeast (Weisman et al., 1997; Takahara and Maeda, 2012a). The
reasons for this remain unclear, although rapamycin is able to affect cellular processes
such as sexual development, amino acid uptake, and mitotic onset (Weisman et al.,
1997; Weisman and Choder, 2001; Petersen and Nurse, 2007). Caffeine also decreases
TORC1 activity in fission yeast by acting as a competitive inhibitor of ATP binding
(Takahara and Maeda, 2012a), as it does in budding yeast (Reinke et al., 2006; Wanke
et al., 2008) and mammals (Sarkaria et al., 1999). Although rapamycin and caffeine dif-
ferentially affect fission yeast cellular processes, both function in a TORC1-dependent
manner and combined drug treatment often enhances the resulting phenotypes (Rallis
et al., 2013). For example, while rapamycin alone does not induce autophagy in wild-
type fission yeast (Uritani et al., 2006; Mukaiyama et al., 2009), dual treatment with
rapamycin and caffeine does (Takahara and Maeda, 2012a).
Wild-type and btn1∆ cells were incubated in either rapamycin or caffeine alone, or
in the presence of both drugs for six hours before vacuole diameters were determined
and analysed by a one-way ANOVA. Incubation with rapamycin alone had no signifi-
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cant effect on the vacuole diameter of wild-type cells (0.31 ± 0.002 µm in rapamycin
vs 0.37 ± 0.05 µm; P = ns) nor was it able to rescue the vacuole size of btn1∆ cells
(0.56 ± 0.04 µm in rapamycin vs 0.58 ± 0.04 µm; P = ns). However, while caffeine
also had no significant effect on wild-type cells (0.32 ± 0.03 µm in caffeine vs 0.37 ±
0.05 µm; P = ns), incubation in the presence of caffeine did significantly reduce btn1∆
vacuole size (0.37 ± 0.01 µm in caffeine vs 0.58 ± 0.04 µm; P ≤ 0.01) to a value
that was no longer significantly different from wild-type vacuoles. Culturing cells in
the presence of both rapamycin and caffeine did appear to reduce vacuole size further
than individual treatments in both strains, although this did not reach significance in
any case. Although genetically inhibiting TORC1 using the dominant-negative Rhb1
reduced vacuole size, the finding that rapamycin alone can not recapitulate this is not
unexpected. Firstly, as described above rapamycin alone does not fully inhibit TORC1
in fission yeast (Takahara and Maeda, 2012a), nor in-fact in mammalian cells (Edinger
et al., 2003). More specifically, a similar finding has recently been reported in mam-
malian cells whereby the suppression of TORC1 using catalytic inhibitors was found to
activate lysosomal function, whereas the same could not be achieved using rapamycin
which is an allosteric inhibitor (Zhou et al., 2013). Rapamycin treatment alone did how-
ever fully rescue the ability of btn1∆ cells to grow at the non-permissive temperature
of 37◦C, and on glycerol as an alternative carbon source.
5.4.4 Translational Inhibition Partially Rescues btn1∆ Phenotypes
One of the effects of down-regulating TORC1 function is to suppress protein synthesis.
As described in Chapter 3 (p.88), btn1+ shows a positive interaction with one of the
two genes encoding the eukaryotic elongation factor 2 (eEF2; eft202+) in addition to
a number of structural ribosomal proteins and proteins involved in ribosome biogene-
sis. Together this could suggest that the beneficial effects of TORC1 inhibition in the
btn1∆ strain may be more specifically related to a reduction in translation. Interest-
ingly, the CWI pathway and ER stress response are also coordinated in budding yeast
(Krysan, 2009). In turn, this may be a more precise yet particularly important process
to therapeutically target.
This hypothesis was initially explored by using sub-inhibitory concentrations of
the antibiotics G418 and cycloheximide to suppress protein synthesis by blocking elon-
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gation. Both antibiotics had an appreciable effect on cell growth 37◦C (Figure 5.8 A
+ B). However, neither were considered to offer a complete rescue as btn1∆ cells still
grew considerably slower than wild-type, requiring approximately seven days incuba-
tion to reach the same level of growth achieved by wild type cells after three.
Translation is also down-regulated as part of the response to ER stress in order
to reduce the total protein load of the ER. This reduction in protein synthesis is ulti-
mately achieved by the phosphorylation of α-subunit of eukaryotic translation initia-
tion factor-2 (eIF2α). In this state, eIF2 is unable to undergo nucleotide exchange to
its active GTP-bound form, leading to a global reduction in protein synthesis. The use
of pharmacological agents to prevent the dephosphorylation of eIF2α (thus prolong-
ing reduced protein synthesis) have proved useful in reducing the symptoms in animal
models of prion disease (Tribouillard-Tanvier et al., 2008) and amyotrophic lateral scle-
rosis (ALS) (Jiang et al., 2014). One such agent, guanabenz, was found to improve the
growth of btn1∆ cells when grown at 37◦C (Figure 5.8 C), but again only did so par-
tially. It was however unable to rescue the growth of btn1∆ on glycerol containing
media or reduce vacuole size (data not shown).
These data suggest that reducing global translation may offer some benefit in the
absence of btn1+, and that a translational burden contributes to at least some of the phe-
notypes described. However, given the genetic inhibition of TORC1 described above
led to a more complete rescue of btn1∆ phenotypes, it can be speculated that a therapy
solely targeting a protein synthesis would be inferior to one targeting the diverse range
of TORC1 activities. This is discussed in more detail in the Discussion chapter (p.
194).
5.5 Summary
The SGA results and detailed characterisation of btn1∆ cells presented in the previ-
ous chapters led to the hypothesis that btn1+ is required for stress signalling. As a
continuation of this hypothesis, this Results chapter explored whether the focused ma-
nipulation of stress-response pathways was sufficient to phenotypically restore btn1∆
cells to wild-type.
Given the pattern of interactions revealed by the SGA, it was postulated that the
up-regulation of MAPK signalling might be beneficial in the absence of btn1+. The
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Figure 5.8: Translational inhibition rescues btn1∆ heat sensitivity. 10-fold serial di-
lutions of wild-type (WT) and btn1∆ logarithmic cultures were spotted onto YES media
containing [A] 0.1 µM cyclohexamide (CHX), [B] 0.1 µM G418, or [C] 1µM guanabenz
(GB) and incubated at 37◦C for 3 days. Vehicle = DMSO. The most concentrated spot
contains 1x106 cells. Images are representative of 3 independent experiments.
CWI pathway was augmented by the over-expression of two upstream GTPase regula-
tors; Rho5 (a negative interactor of btn1+) and its essential paralogue Rho1. Further-
more, the CWI was also independently down-regulated by the over-expression of the
main negative regulator of this pathway; the dual-specificity phosphatase Pmp1. Rho5
was able to rescue the majority of btn1∆ phenotypes, whereas Rho1 led to a com-
plete rescue of all phenotypes. The over-expression of Pmp1 led to an exacerbation of
the nitrogen limitation and vacuole size phenotypes, strengthening the speculation that
the Rho GTPases were eliciting their positive effect via CWI signalling. These data
provide convincing evidence for the involvement of compromised CWI signalling in
btn1∆ phenotypes, and encouragingly demonstrate that this pathway may be a suitable
therapeutic target.
The SAPK pathway was up-regulated using the constitutively active form of wis1+
(wis1DD), which was also uncovered as a negative interactor of btn1+. This allele was
able to reduce vacuole size in btn1∆ cells, although was not able to restore any other
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phenotypes. It is possible therefore that this pathway has a less important, or more
intricate, influence on btn1∆ phenotypes compared to the cell wall integrity MAPK
pathway. This could also explain the somewhat paradoxical finding of both negative
and positive interactions within this pathway. Alternatively, a lack of rescue may be in-
dicative of experimental shortcomings as discussed above. More comprehensive work
using a wild-type wis1+ allele, or alternative genetic and pharmacological approaches,
will be needed to further corroborate the involvement of SAPK signalling in the phe-
notypes of btn1∆ cells.
The involvement of the two TOR complex pathways was also briefly presented
and discussed. Although these pathways are tightly coupled to one another (albeit
antagonistically), manipulating the distinct complexes led to differential effects. Im-
portantly however, the data presented here suggests that TORC1 signalling also has a
particular influence on btn1∆ cells as the over-expression of a dominant negative Rhb1
allele to inhibit TORC1 signalling led to a complete rescue of all btn1∆ phenotypes
investigated. Confirming that this pathway is also an accessible drug target, pharmaco-
logical approaches to inhibit TORC1 (or more specifically the downstream process of
translation) also led to varying rescues of the btn1∆ phenotype. The implications for a
potential therapy are discussed in more detail in the Discussion chapter (p. 194).
That the augmentation these pathways was able to rescue aspects, if not all, of the
phenotypic defects associated with the btn1∆ strain supports the hypothesis that com-
promised or dysfunctional stress responses underlie the various phenotypes described
in the previous chapter. In particular, compromised CWI and hyperactive TORC1 sig-
nalling appear to play particularly influential roles in the manifestation of the stress-
related phenotypes. This is based on the findings that over-expressing rho1+ to increase
CWI signalling, and a dominant negative rhb1+ allele to inhibit TORC1, led to a com-
plete rescue all of the btn1∆ phenotypes investigated. Both manipulations are the most
complete rescue of phenotypes that has been achieved in any juvenile CLN3 disease
model to date. Whether defects in these pathways could conceivably underlie other
disease phenotypes reported in the literature will be discussed later.
By extrapolation, these data potentially support a role for aberrant ERK1/2 and
hyperactive TORC1 signalling in the pathogenesis of juvenile CLN3 disease, and reveal
that these pathways may make good therapeutic targets. Means to validate this work in
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mammalian systems is also discussed more fully in the Discussion chapter (p. 194).
However, the molecular mechanism by which the loss of btn1+ could lead to com-
promised stress signalling has so far not been addressed. Yet a number of intriguing
similarities between the btn1∆ strain and a strain lacking the Ca2+/Mn2+ ATPase pmr1+
became apparent during the course of work. Supported by a number of other literature
findings, the following chapter explores whether the parallels between these two strains
are able to offer any mechanistic insight into the molecular function of btn1+.
Chapter 6
SGA Results Suggest Clues to btn1+
Function
6.1 Introduction
This work has provided persuasive genetic data, supported by functional information,
to support the hypothesis that dysfunctional stress signalling arising from the loss of
btn1+ might be involved in the pathogenesis of juvenile CLN3 disease. However, the
precise mechanism by which btn1+ loss leads to compromised stress signalling has not
been addressed by data presented in the previous chapters. During the course of this
work however, intriguing parallels between btn1∆ and fission yeast lacking pmr1+ were
observed that may provide some mechanistic insight.
pmr1+ is a P2-type secretory pathway Ca2+ ATPase (SPCA) which functions to
transport Ca2+ and Mn2+ ions with high affinity from the cytoplasm into compartments
of the secretory pathway (Okorokova-Fac¸anha et al., 2003). It therefore serves a dual
purpose; to supply these ions to the secretory pathway where they facilitate the pro-
cessing and trafficking of proteins, and also to clear them from the cytosol to prevent
them reaching toxic levels. In fission yeast, GFP-Pmr1 has been observed at the ER
(Cortes et al., 2004) and Golgi (Maeda et al., 2004), and shares its role with the vacuo-
lar Ca2+ ATPase, Pmc1, which also acts to deplete cytosolic Ca2+ (Cortes et al., 2004;
Furune et al., 2008). As a reminder, Btn1 is also seen in the membranes of the Golgi
and vacuole.
Like btn1+, pmr1+ is not essential but its deletion leads to a number of pleiotropic
phenotypes, most of which are also shared with btn1∆. These include defects in actin
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organisation, thicker septa, cell separation defects and a slower cell cycle, growth and
morphology defects at 37◦C (which can be restored with 1.2 M sorbitol), and a sensitiv-
ity to cell wall digesting agents indicating that pmr1+ is required for cell wall integrity
(Cortes et al., 2004; Furune et al., 2008). There is functional conservation between
fission and budding yeast pmr1+ homologues (Maeda et al., 2004), and the deletion
of budding yeast PMR1 also leads to a number of phenotypes reminiscent of btn1∆.
These include cell polarity defects (Garcı´a-Rodrı´guez et al., 2012), vacuole morphol-
ogy defects (Callewaert et al., 2015), and the missorting and secretion of the vacuolar
protein carboxypeptidase Y (CPY) (Du¨rr et al., 1998). Importantly in the context of
this work, the deletion of PMR1 also results in hyperactive TORC1 signalling (Devasa-
hayam et al., 2006). The same authors have since demonstrated that a highly specific
role of Pmr1 in the transport of Mn2+ into the Golgi is required to inhibit TORC1 sig-
nalling (Devasahayam et al., 2007). Pmr1 homologues have therefore been shown to
be required both for proper cell wall integrity and TORC1 inhibition, the two processes
that have been shown in this work to also be most ostensibly compromised in btn1∆.
These phenotypic similarities therefore led to the speculation that Btn1 may perform a
similar role to Pmr1 in the homeostasis of calcium and/or manganese ions, perhaps by
also acting as a transporter given that both proteins also localise to membranes of the
secretory system.
Indeed, there is evidence from mammalian models that supports a potential role for
CLN3 as a transporter. As discussed in the Introduction (p. 19), CLN3 has previously
been considered to be a transporter by virtue of topological similarities to equilibrative
nucleoside transporters and members of the major facilitator superfamily. In support of
such a role, the BTN1∆ budding yeast model shows defects in vacuolar arginine trans-
port which is rescued by the over-expression of human CLN3 and is also recapitulated
in mammalian models. Furthermore, the disruption of the murine CLC-3 member of
the CLC chloride channel family results in phenotypes that resemble a NCL phenotype
(Yoshikawa et al., 2002).
Interestingly, there is also now an emerging body of evidence to more specifically
suggest CLN3 may act as a mediator of Ca2+/Mn2+ homeostasis. CLN3 has been re-
ported to regulate intracellular free calcium levels through its C-terminus in SH-SY5Y
neuroblastoma cells (Chang et al., 2007). Further work in these cells showed that var-
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ious calcium channel blockers are capable of significantly reducing an increase in in-
tracellular calcium seen upon CLN3 siRNA knock-down (An Haack et al., 2011). The
functional and potentially clinical significance of this report has since been confirmed,
as one such channel antagonist (amlodipine) can prevent apoptosis by reversing the ele-
vation in calcium seen in primary rat neurons lacking Cln3 (Warnock et al., 2013). Most
recently, alterations in the sub-cellular pools of Ca2+ and store-operated Ca2+ uptake
have been reported in Cln3∆ex7/8 neuronal cell lines, leading to further speculation that
CLN3 is required for intracellular Ca2+ homeostasis (Chandrachud et al., 2015). Lastly,
using the levels of a Golgi-resident protein GPP130 as a proxy for Mn2+ concentration,
it has been shown that the Golgi uptake of Mn2+ is also impaired upon CLN3 deletion
or mutation in mammalian cell lines (Dr Davide Marotta, unpublished). Of note, while
btn1+ and pmr1+ were not found to genetically interact in this work, this does not mean
that they do not perform similar functions. Intriguingly however, BTN1+ and PMR1+
do negatively interact in budding yeast (Costanzo et al., 2010).
6.1.1 Chapter Aims
This penultimate Results chapter is based on a working hypothesis that btn1+, like
pmr1+, is involved in Ca2+ and/or Mn2+ homeostasis. It is further hypothesised that
in the absence or mutation of btn1+, defects in the homeostasis of these ions lead to
compromised CWI signalling and hyperactive TORC1 signalling as also seen in pmr1∆,
which in turn lead to the manifestation of the pleiotropic phenotypes exhibited by btn1∆
reported during this work or previously. This is summarised in Figure 6.1. Accordingly,
the aim of this Chapter is to test the hypothesis that Btn1 participates in Ca2+ and/or
Mn2+ homeostasis, and that its molecular function is to act as a transporter for these
ions.
6.2 btn1∆ Cells are Hypersensitive to Excess Mn2+
pmr1∆ cells show reduced growth and viability in EMM media lacking Ca2+ (Cortes
et al., 2004) and in the presence of 10 mM EGTA, a calcium chelator (Maeda et al.,
2004). pmr1∆ cells are also sensitive to high Mn2+ concentrations (Maeda et al., 2004),
and show a loss of viability due to the accumulation of excess Mn2+ in the cytosol.
If btn1+ and pmr1+ are performing similar roles with respect to the transport of these
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Figure 6.1: Working hypothesis detailing the proposed role of btn1+. The pheno-
typic similarities of btn1∆ and pmr1∆ cells (supported by background literature as de-
tailed in the text) led to a working hypothesis that btn1+is involved in Ca2+ and/or Mn2+
homeostasis. In turn, it is proposed that defects in the homeostasis of these ions leads to
compromised cell wall integrity (CWI) signalling and hyperactive TORC1 signalling, and
ultimately the pleiotropic phenotypes of btn1∆ cells, which have been either previously
reported or revealed during the course of this work.
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ions into the secretory pathway, then it would be expected that the btn1∆ strain would
similarly show a sensitivity to alterations in the concentration of Ca2+ and Mn2+ ions.
To test this idea, the viability of btn1∆ was assessed in the absence of each ion inde-
pendently, and in the presence of excess Ca2+ or Mn2+ ions.
However, unlike the pmr1∆ strain, btn1∆ cells did not show a statistically signif-
icant sensitivity to the loss of Ca2+ (Figure 6.2 A). Likewise, the addition of 10 mM
EGTA did not reduce the growth of btn1∆ cells when assayed on solid media (Figure
6.2 B). btn1∆ cells also did not show any statistical difference from wild-type cells
when cultured in EMM containing an 1000-times increase in Ca2+ (100 mM), which is
consistent with findings in pmr1∆ also (Maeda et al., 2004) (data not shown).
Similarly, neither strain displayed any loss of viability upon the removal of Mn2+,
which is also consistent with previous reports for pmr1∆ (Furune et al., 2008) (data
not shown). However, btn1∆ cells did show a significant loss of viability in response
to excess Mn2+ (Figure 6.3) as revealed by a two-way ANOVA (F (5, 12) = 128.1; P
<0.0001).
Post-hoc Tukey tests revealed that at the level of Mn2+ used (50 mM), wild-type
cells showed a significant decrease in viability by 24 hrs (77.68 ± 2.20% vs 95.67 ±
1.37% in normal EMM media; P ≤ 0.01). However, the extent to which btn1∆ cells
lost viability was distinctly greater, and the viability of btn1∆ cells 24 hrs following
Mn2+ addition was significantly reduced compared to wild-type cells in the same con-
dition (44.87 ± 3.55% vs 77.68 ± 2.20%; P ≤ 0.0001). A within-column analysis
revealed that following the initial loss of viability exhibited at 24 hrs, wild-type cells
did not show any further significant loss in viability over the time-period investigated.
Conversely, btn1∆ cells did not show this plateau, and progressively lost viability over
the experimental time course. Indeed, the difference in btn1∆ viability between 48 hrs
and 72 hrs in excess Mn2+ reached statistical significance (37.11 ± 4.15% vs 21.22 ±
3.92%; P ≤ 0.01). Importantly, at all time points investigated btn1∆ cells remained
significantly different from wild-type under the same condition, indicating that btn1+
is required for the appropriate response to excess Mn2+. Of note, although it has been
reported that pmr1∆ cells are sensitive to excess Mn2+, no significant decrease in via-
bility relative to wild-type cells was observed here when assayed in liquid media. The
reason for this is unclear, but a sensitivity was achieved on solid agar (see below).
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Figure 6.2: btn1∆ is not sensitive to alterations in Ca2+. [A] Wild-type (WT), btn1∆,
and pmr1∆ cells were cultured in EMM or EMM lacking Ca2+ for 72 hrs. Viability was
assessed every 24 hrs using calcofluor-white to identify the total cell population, and the
cell impermeable stain propidium iodide to identify dead cells. Viability was calculated
as the number of alive cells (Nalive) to the total number counted (Ntotal) and expressed
as a percentage ((Nalive/Ntotal)*100). A total of 500 cells were counted per data set, and
the graph shows the mean ± SEM of 3 independent experiments. Statistical differences
were identified by a repeated measures two-way ANOVA and post-hoc Tukey analysis
(**** = P ≤ 0.0001). Asterisk’s refer to significant differences between pmr1∆ cells in
media lacking calcium and WT cells under the same condition. [B] 10-fold serial dilutions
of wild-type (WT), btn1∆, and pmr1∆ logarithmic cultures were spotted onto YES agar
containing 10 mM EGTA and incubated at 30◦C for 3 days. The most concentrated spot
contains 1x106 cells. Images are representative of 3 independent experiments.
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The addition of MnSO4 as opposed to MnCl2 resulted in the same loss of btn1∆
viability (data not shown), indicating that the sensitivity is related to the Mn2+ ion rather
than increased Cl2. Indeed, btn1∆ cells did not show a sensitivity to CaCl2 (as above)
or other chloride salts including MgCl2 (data not shown).
All following experiments are based on the statistically significant phenotypic dif-
ferences observed between wild-type and btn1∆ at 24 hrs following the addition of
50 mM Mn2+. This phenotype is fully rescued by the over-expression of GFPbtn1+,
validating that this phenotype arises due to btn1+ deletion (Figure 6.3).
6.2.1 Mn2+ Hypersensitivity is Disease Specific
An increasing body of evidence suggests that altered biometal homeostasis is yet
another shared pathological feature of several neurodegenerative diseases, including
Alzheimer’s disease, Parkinson’s disease, and motor neuron disease (White et al.,
2015). Similarly, calcium dyshomeostasis in particular is not an uncommon finding
in lysosomal storage disorders, raising the possibility that the Mn2+ hypersensitivity
exhibited by btn1∆ cells may be a secondary consequence of btn1+ loss. To inves-
tigate this hypothesis, the response of several other disease-modelling yeast strains
to excess Mn2+ was also evaluated. These included the fission yeast models for two
other NCL subtypes; CLN10 disease (sxa1∆) and a strain lacking the orthologue of
ATP13A2/CLN12 (atp13a2∆) which is associated with a juvenile onset NCL but more
commonly with Kufor-Rakeb syndrome (KRS), a rare parkinsonian phenotype with a
juvenile onset (Bras et al., 2012). Also investigated were fission yeast models for the
LSDs Niemann Pick C disease (npc2∆) and Chediak-Higashi Syndrome (lvs1∆), which
arises from mutations in a lysosomal trafficking regulator protein.
A one-way ANOVA followed by post-hoc Tukey tests revealed that, as stated pre-
viously, btn1∆ cells show a significant loss of viability after 24 hrs in 50 mM Mn2+ rel-
ative to wild-type (32.03 ± 0.69% vs 77.10 ± 6.80%; P ≤ 0.0001). However, no other
strain showed a significant difference compared to wild-type cells when cultured in the
presence of excess of Mn2+ (Figure 6.4). These findings could be taken to indicate that
the Mn2+ sensitivity seen in the btn1∆ strain arises as a more direct consequence of
btn1+ loss rather than a secondary effect that is common to multiple neurodegenerative
diseases.
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Figure 6.3: btn1∆ is hypersensitive to excess Mn2+. [A] Wild-type (WT), btn1∆, and
pmr1∆ cells were cultured in EMM or EMM containing 50 mM Mn2+ for 72 hrs. Viability
was assessed every 24 hrs using calcofluor-white to identify the total cell population,
and the cell impermeable stain propidium iodide to identify dead cells. Viability was
calculated as the number of alive cells (Nalive) to the total number counted (Ntotal) and
expressed as a percentage ((Nalive/Ntotal)*100). A total of 500 cells were counted per data
set, and the graph shows the mean ± SEM of 3 independent experiments. Statistical
differences were identified by a repeated measures two-way ANOVA and post-hoc Tukey
analysis (**** = P ≤ 0.0001). Asterisk’s refer to significant differences between btn1∆
cells in media containing manganese and WT cells under the same condition. [B] Wild-
type (WT), btn1∆, and btn1∆ + pREP41x.GFP-btn1+ cells were cultured in EMM (not
shown for clarity) or EMM containing 50 mM Mn2+ for 24 hrs. Viability was assessed as
for [A]. v = empty pREP41x vector as a control. Statistical differences were identified by
a one-way ANOVA and post-hoc Tukey analysis (**** = P ≤ 0.0001).
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The yeast vacuole is a major site for ion homeostasis, and plays a fundamental
role in the storage and detoxification of heavy metals in order to reduce the risk of
metal-mediated damage to other cellular compartments. Mn2+ homeostasis is therefore
unsurprisingly disrupted in mutants affecting vacuole biogenesis and vacuolar acidifi-
cation, and strains that are unable to sequester Mn2+ show an increased cellular sensi-
tivity towards manganese. It is therefore interesting to note that these other strains do
not show a Mn2+ sensitivity despite all but atp13a2∆ having enlarged vacuoles, which
can be suggestive of vacuolar defects (Figure 6.4). In turn, it can be taken that the Mn2+
sensitivity of btn1∆ does not arise solely due to defects at the level of the vacuole, and
that other defects likely underlie this phenotype.
6.2.2 Mn2+ Hypersensitivity is Disease Relevant
Work in this fission yeast model has previously concluded that the most common CLN3
mutation, an intragenic 1 kb deletion, retains some residual function. This was ini-
tially based on reports that the over-expression of btn1 modelling this mutation (btn1-
1kb∆) can fully rescue the increase in vacuole diameter seen in the btn1∆ null model
(Kitzmu¨ller et al., 2008). This allele was subsequently however shown to be insufficient
to rescue the polarity defects and increased septation index of btn1∆ cells, revealing
that it does not retain full function (Haines et al., 2009). As part of this later work,
it was found that the expression of btn1+ modelling a rare missense mutation (GFP-
btn1E240K) was the only mutation able to significantly reduce the number of cells that
were bent or curved after 4 hrs at 37◦C (Haines et al., 2009). This allele corresponds
to the p.Glu295Lys missense mutation in humans, and when in heterozygosity with the
1 kb deletion has been reported to lead to a mild phenotype with a protracted disease
course (Aberg et al., 2009). Therefore, Haines et al. (2009) concluded that the ability
of this mutant Btn1 to rescue the cell curvature phenotype might reflect a significant
retention of function. Interestingly, recent work on a strain expressing an integrated
GFP-Btn1E240K allele from the endogenous promoter (rather than ectopic expression
from a plasmid) has confirmed this ability to rescue cell curvature, but also revealed
that this allele can in fact fully rescue vacuole size and septation index (Dr Mariana
Vieira, unpublished). This work therefore supports that this allele likely retains more
function than btn1-1kb∆, hence its association with a mild disease phenotype. The
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Figure 6.4: Mn2+ hypersensitivity is disease specific. [A] Wild-type (WT), btn1∆,
sxa1∆, atp13a2∆, npc2∆, and lvs1∆ cells were cultured in EMM (data not shown for clar-
ity) or EMM containing 50 mM Mn2+ for 24 hrs. Viability was assessed using calcofluor-
white to identify the total cell population, and the cell impermeable stain propidium iodide
to identify dead cells. Viability was calculated as the number of alive cells (Nalive) to the
total number counted (Ntotal) and expressed as a percentage ((Nalive/Ntotal)*100). A total
of 500 cells were counted per data set, and the graph shows the mean ± SEM of 3 inde-
pendent experiments. Statistical differences were identified by a one-way ANOVA and
post-hoc Tukey analysis (** = P ≤ 0.01). [B] Wild-type (WT), btn1∆, sxa1∆, atp13a2∆,
npc2∆, and lvs1∆ cells were grown overnight in EMM and stained with FM4-64 to vi-
sualise the vacuoles. The diameter of 300 vacuoles was determined per data set, and the
graph shows the mean ± SEM of 4 independent experiments. Statistical differences were
identified by a one-way ANOVA and post-hoc Tukey analysis (** = P ≤ 0.01, **** = P
≤ 0.0001).
6.2. btn1∆ Cells are Hypersensitive to Excess Mn2+ 161
WT btn1Δ btn1-1kbΔ btn1E240K
0
20
40
60
80
100
Via
bil
ity
 (%
)
**
**
*
Figure 6.5: Mn2+ hypersensitivity is disease relevant. Wild-type (WT), btn1∆, btn1-
1kb∆, and btn1E240K strains were cultured in EMM (data not shown for clarity) or EMM
containing 50 mM Mn2+ for 24 hrs. Viability was assessed using calcofluor-white to iden-
tify the total cell population, and the cell impermeable stain propidium iodide to identify
dead cells. Viability was calculated as the number of alive cells (Nalive) to the total num-
ber counted (Ntotal) and expressed as a percentage ((Nalive/Ntotal)*100). A total of 500
cells were counted per data set, and the graph shows the mean ± SEM of 4 independent
experiments. Statistical differences were identified by a one-way ANOVA and post-hoc
Tukey analysis (* = P ≤ 0.05), ** = P ≤ 0.01).
ability of these two alleles (expressed endogenously without a GFP tag) to resist Mn2+
toxicity was therefore also investigated, and compared to wild-type and the complete
null btn1∆ strain.
As shown in Figure (6.5), a one-way ANOVA revealed significant differences be-
tween the various btn1 mutants with respects to the Mn2+ sensitivity (F (3, 12) = 10.10;
P = 0.0013). Post-hoc Tukey corrections revealed a significant difference in the viabil-
ity between wild-type and btn1-1kb∆ cells after being exposed to 50 mM Mn2+ for 24
hrs (72.3 ± 2.4% vs 37.30 ± 7.1%; P ≤ 0.01). The btn1∆ and btn1-1kb∆ strains were
however statistically indistinguishable (34.48 ± 6.8% for btn1∆ vs 37.30 ± 7.1%; P =
ns), indicating that any residual function the 1 kb mutant allele has does not extend to
an ability to rescue this particular phenotype.
In contrast, the btn1E240K strain showed a significant improvement in viability
over the btn1∆ null strain following 24 hrs in 50 mM Mn2+ (58.6± 2.4% vs 34.48 ±
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6.8%; P ≤ 0.05). Although the viability of the btn1E240K mutant remained lower
than wild-type, this difference was not statistically significant (58.6± 2.4% vs 72.3 ±
2.4%). More extensive work should be performed to determine if this allele is truly
capable of a wild-type response to excess manganese, or whether it is perhaps only
capable of a more limited, intermediate response as it is tempting to speculate from the
raw values. These data do however demonstrate that the 1 kb and E240K alleles re-
spond differentially to excess manganese, which could explain the association of their
human counterparts with a severe or mild disease phenotype respectively. Whether this
is specific to manganese toxicity or all environmental stressors should be explored in
future work to help determine the specificity of Mn2+ sensitivity to disease pathogene-
sis.
Lastly, although it was not confirmed in the course of this work, both the 1 kb
and E240K mutations have previously been reported to restore vacuole size to wild-
type. Therefore, that the 1 kb allele was not also able to rescue the Mn2+ sensitivity
supports the above hypothesis that this phenotype is unlikely to be a direct consequence
of impaired vacuole function.
6.3 Pmr1 Partially Rescues btn1∆ Phenotypes
If the hypothesis that Btn1 performs a similar molecular role to Pmr1 is correct, it can
be predicted that the over-expression of pmr1+ will complement the loss of btn1+. This
hypothesis was investigated by testing the ability of Pmr1 to rescue the phenotypes
explored in the previous chapter; enlarged vacuole diameter, heat sensitivity, and a lack
of growth following nutrient withdrawal.
6.3.1 Pmr1 Rescues the Vacuole Diameter of btn1∆ Cells
A one-way ANOVA followed by Tukey post-hoc corrections revealed that the over-
expression of pmr1+ from a medium strength pREP41x promoter was able to re-
store vacuole size (F (3, 12) = 23.78; P <0.0001 and Figure 6.6 A + B). btn1∆ +
pREP41x.pmr1+ cells had a significantly reduced vacuole diameter compared to btn1∆
cells carrying an empty pREP41x plasmid as a control (0.30± 0.02 µm vs 0.48± 0.03
µm; P≤ 0.001). The vacuole size of btn1∆ + pREP41x.pmr1+ cells was not statistically
different from wild-type (0.30 ± 0.02 µm vs 0.24 ± 0.02 µm; P = ns), indicating that
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Figure 6.6: pmr1+ rescues the btn1∆ vacuole enlargement. [A] Wild-type (WT), WT
+ pREP41x.pmr1+, btn1∆, and btn1∆ + pREP41x.pmr1+ cells were grown overnight in
EMM and stained with FM4-64 to visualise the vacuoles. The diameter of 300 vacuoles
was determined per data set, and the graph shows the mean ± SEM of 4 independent
experiments. Statistical differences were identified by a one-way ANOVA and post-hoc
Tukey analysis (*** = P ≤ 0.001, **** = P ≤ 0.0001). [B] Representative micrographs
of the vacuole phenotype of strains assessed in [A]. Scale bars = 10 µm.
Pmr1 is sufficient to fully rescue this phenotype. pmr1+ over-expression had no dis-
cernible effect on the diameter of wild-type vacuoles (0.29 ± 0.01 µm vs 0.24 ± 0.02
µm for wild-type; P = ns and Figure 6.6 A + B). Furthermore, although PMR1 deletion
in budding yeast leads to alterations in vacuole morphology, the isolated deletion of
fission yeast pmr1+ (pmr1∆) did not negatively affect vacuole diameter as revealed by
an un-paired t-test (P = 0.84, data not shown).
This is therefore the first genetic manipulation explored in this work that can res-
cue the vacuole diameter of btn1∆ cells without also having a noticeable effect on wild-
type cells. Unfortunately, why vacuoles are enlarged in btn1∆ remains unclear, which
complicates the interpretation of how Pmr1 over-expression can rescue this phenotype
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despite having no obvious effect in wild-type fission yeast. Interestingly however, the
increased vacuole size in btn1∆ cells has previously been linked to alterations in vac-
uolar pH (Iwaki et al., 2004; Gachet et al., 2005)), and vacuolar-type H+-transporting
ATPase (v-ATPase) mutants also closely phenocopy PMR1∆ budding yeast mutants,
despite the latter being able to maintain normal vacuolar and prevacuolar pH (Yadav
et al., 2007). Future work might benefit from exploring whether pmr1+ elicits its bene-
fit on btn1∆ cells by affecting the pH of the vacuoles. This might also help clarify why
pmr1+ can only restore some phenotypes (detailed below), as btn1+ has previously been
suggested to have roles in both pH-dependent and pH-independent processes (Codlin
et al., 2008a).
6.3.2 Pmr1 Does Not Rescue the Heat or Nutrient Sensitivities of
btn1∆ Cells
pREP41x.pmr1+ was subsequently tested for its ability to rescue the heat and nutrient
sensitivities exhibited by btn1∆ cells. These phenotypes are considered to arise due to
defective TOR and CWI pathway signalling (as discussed in Chapters 4 and 5); the two
pathways in which Pmr1 has also been shown to participate. If impaired manganese
and/or calcium transport into the secretory pathway lies upstream of the stress response
defects of btn1∆, addressing any defects in ion homeostasis might offer an alterna-
tive means by which to rescue these phenotypes compared to the more direct genetic
manipulations of the CWI and TORC1 pathways explored in the previous chapter.
Yet, and despite rescuing the increased vacuole diameter phenotype, Pmr1 was
unable to rescue the heat or glucose limitation sensitivities exhibited by btn1∆ (Fig-
ure 6.7 A + B). A two-way ANOVA followed by Tukey corrections also revealed that
pREP41x.pmr1+ failed to exert any beneficial effect on btn1∆ cells when starved of
nitrogen (Figure 6.7 C). Together this would suggest that although btn1+ appears nec-
essary for the tolerance to excess Mn2+, defects in the transport and homeostasis of this
ion (at least within the secretory system) are unlikely to underlie the stress response
defects exhibited by btn1∆.
Perhaps more surprisingly, pREP41x.pmr1+ was also unable to rescue the novel
Mn2+ hypersensitivity of btn1∆ cells (Figure 6.8 D). Although the fission yeast re-
sponse to Mn2+ is not well understood, in budding yeast the major source of toxic
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Figure 6.7: Pmr1 does not rescue the other btn1∆ phenotypes. Wild-type (WT), btn1∆,
and btn1∆ + pREP41x.pmr1+ logarithmic cultures were spotted onto YES and incubated
at [A] 30◦C or 37◦C for 3 days or on [B] glucose or glycerol containing media and in-
cubated at 30◦C for 3 days (glucose) or 10 days (glycerol). The most concentrated spot
contains 1x106 cells. v = empty pREP41x vector as a control. Image is representative of 3
independent experiments. [C] Wild-type (WT), btn1∆, and btn1∆ + pREP41x.pmr1+ were
cultured in EMM or EMM lacking the sole nitrogen source (NH4Cl for 72 hrs. Viability
was assessed every 24 hrs using calcofluor-white to identify the total cell population, and
the cell impermeable stain propidium iodide to identify dead cells. Viability was calcu-
lated as the number of alive cells (Nalive) to the total number counted (Ntotal) and expressed
as a percentage ((Nalive/Ntotal)*100). A total of 500 cells were counted per data set, and
the graph shows the mean ± SEM of 4 independent experiments.
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Figure 6.8: Pmr1 does not rescue the btn1∆ Mn2+ hypersensitivity. Wild-type (WT),
btn1∆, and btn1∆ + pREP41x.pmr1+ cells were cultured in EMM (data not shown for clar-
ity) or EMM containing 50 mM Mn2+ for 24 hrs. Viability was assessed using calcofluor-
white to identify the total cell population, and the cell impermeable stain propidium iodide
to identify dead cells. Viability was calculated as the number of alive cells (Nalive) to the
total number counted (Ntotal) and expressed as a percentage ((Nalive/Ntotal)*100). A total
of 500 cells were counted per data set, and the graph shows the mean ± SEM of 4 inde-
pendent experiments. Statistical differences were identified by a one-way ANOVA and
post-hoc Tukey analysis (** = P ≤ 0.01).
manganese is the cell surface inorganic phosphate transporter Pho84. There is, how-
ever, no known down-regulation mechanism for Pho84. Consequently, in addition to
mechanisms that sequester Mn2+ into the vacuole as described above, Pmr1 plays par-
ticularly important role in limiting manganese toxicity by transporting Mn2+ ions into
the secretory pathway to facilitate its elimination from the cell.
Due to the vacuole defects seen in btn1∆ cells, it could be speculated that this
strain is more sensitive to excess manganese because it is less equipped to prevent
Mn2+ accumulation in the cytoplasm. However, since increasing Mn2+ clearance into
the secretory pathway had no effect on cellular survival, this would suggest that the
cytoplasmic accumulation of Mn2+ ions alone is not sufficient to cause the loss of via-
bility observed when btn1∆ is exposed to excess manganese. By extension, this would
suggest that other mechanisms that ordinarily mitigate exposure to manganese remain
impaired.
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Therefore, since rho1+ and rhb1D60K over-expression conferred a complete res-
cue to all other btn1∆ phenotypes, these constructs were also tested for their ability to
support a more wild-type response to 50 mM Mn2+. A one-way ANOVA revealed sig-
nificant differences in viability between the strains following 24 hrs in EMM + 50 mM
Mn2+ (F (7, 23) = 38.63; P <0.0001). Post-hoc Tukey corrections revealed that in the
presence of excess Mn2+, btn1∆ cells over-expressing pREP41x.rho1+ displayed higher
viability than btn1∆ carrying an empty control vector (79.69 ± 3.7% vs 50.68 ± 2.6%;
P ≤ 0.0001). The same was true for btn1∆ cells over-expressing pREP41x.rhb1D60K
(69.29 ± 4.5% vs 50.68 ± 2.6%; P ≤ 0.01). However only pREP41x.rho1+ full res-
cued the sensitivity to manganese, as the viability of btn1∆ + pREP41x.rhb1D60K cells
when exposed to Mn2+ remained significantly reduced compared to wild-type cells un-
der the same condition (69.29 ± 4.5% vs 86.76 ± 4.0%; P ≤ 0.01).
Despite this latter finding, overall it would appear that rather than manganese
dyshomeostasis lying upstream of stress response defects as proposed at the start of
this chapter, the btn1∆ sensitivity to excess Mn2+ is instead another of the downstream
manifestations of compromised stress signalling.
6.4 Btn1 Does not Complement Pmr1
Despite the phenotypic similarities of btn1∆ and pmr1∆, the above results lend little
support to the hypothesis that these two protein are performing a similar or comple-
mentary function. Nonetheless, to further test the hypothesis that Btn1 may be able to
transport Ca2+/Mn2+ ions, the ability of btn1+ to complement the loss of pmr1+ was
also explored.
Like btn1∆ cells, pmr1∆ cell growth is sensitive to high temperature (Cortes et al.,
2004). With respect to Ca2+/Mn2+ homeostasis, the pmr1∆ strain also displays re-
duced growth in the presence of 10 mM EGTA and increased concentrations of Mn2+
ions. The ability of pREP41x.btn1+ (untagged in this instance) to rescue these phe-
notypes was assessed on solid agar. However, in no situation did pREP41x.btn1+
over-expression rescue the phenotypes shown by pmr1∆ cells (Figure 6.10), suggesting
btn1+ cannot complement pmr1+.
There are subtle differences in the localisation of Pmr1 and Btn1, which may be
used as an argument for why btn1+ cannot complement pmr1+ (and vice versa). How-
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Figure 6.9: Rho1 and Rhb1D60K rescue the btn1∆ Mn2+ hypersensitivity. Wild-type
(WT), btn1∆, btn1∆ + pREP41x.rho1+, and btn1∆ + pREP41x.rhb1D60K were cultured
in EMM (data not shown for clarity) or EMM containing 50 mM Mn2+ for 24 hrs. Vi-
ability was assessed using calcofluor-white to identify the total cell population, and the
cell impermeable stain propidium iodide to identify dead cells. Viability was calculated
as the number of alive cells (Nalive) to the total number counted (Ntotal) and expressed as
a percentage ((Nalive/Ntotal)*100). A total of 500 cells were counted per data set, and the
graph shows the mean ± SEM of 4 independent experiments. Statistical differences were
identified by a one-way ANOVA and post-hoc Tukey analysis (** = P ≤ 0.01, **** = P
≤ 0.0001).
ever, protein pumps can supply Mn2+/Ca2+ to the entire secretory pathway, indepen-
dently of their exact localisation within it (Du¨rr et al., 1998). While more extensive
work is needed, the data presented here that Btn1 is unable to rescue the defects arising
upon Pmr1 loss largely reject the hypothesis that btn1+ is able to transport and sequester
these ions into the secretory pathway.
6.5 Summary
btn1∆ shows considerable similarities to pmr1∆ with respect to its phenotypes. Most
notably, yeast lacking pmr1+/PMR1 show compromised cell wall integrity and hyper-
active TORC1 signalling, two defective processes that have emerged during this work
as being apparent in btn1∆ cells. Since both proteins also localise to the membranes
of the secretory system, it was hypothesised that btn1+ might also be involved in Ca2+
and/or Mn2+ homeostasis, and that this primary insult would instigate the stress sig-
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Figure 6.10: Btn1 does not rescue pmr1∆ phenotypes. [A] Wild-type (WT), pmr1∆, and
pmr1∆ + pREP41x.btn1+ logarithmic cultures were spotted onto YES agar and incubated
at either 30◦C or 37◦C for 3 days. [B] The same strains as in [A] were also spotted onto
YES agar and YES containing 10 mM EGTA and incubated at 30◦C for 3 days. [B] The
same strains as in [A] + [B] were also spotted onto EMM agar and EMM containing 10
mM Mn2+ and incubated at 30◦C for 5 days. The most concentrated spot contains 1x106
cells. Images are representative of 3 independent experiments.
nalling defects observed upon btn1+ deletion as would appear to be the case in pmr1∆
cells.
This hypothesis was initially explored by evaluating whether btn1∆ shared the
pmr1∆ sensitivity to alterations in the concentration of Ca2+/Mn2+ ions. This would
expected if btn1+ is ordinarily involved in their homeostasis. Although evidence from
other models suggests CLN3 may be involved in calcium handling, btn1∆ cells were not
found to be sensitive to alterations in Ca2+ concentration. btn1∆ also remained viable
under Mn2+ depletion, but showed an overt sensitivity to excess Mn2+. This suggests
btn1+ is more specifically required for the tolerance to manganese overload, and btn1∆
is unable to maintain appropriate manganese homeostasis.
Complementation assays were then performed to further explore any functional
similarities between btn1+ and pmr1+. It was speculated that if btn1+ loss perturbs
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manganese homeostasis which in turn causes signalling response defects, then ef-
forts to restore manganese homeostasis might also rescue the other phenotypes of
btn1∆ by rectifying the stress signalling defects. In initially encouraging experiments,
pREP41x.pmr1+ fully rescued the vacuole phenotype of btn1∆. It was however unable
to complement the loss of btn1+ with respect to the heat and nutrient sensitivities. Fur-
ther experiments also concluded that pREP41x.btn1+ can not complement the loss of
pmr1+.
Taken together, the data presented here does little to support the hypothesis that
btn1+ loss results in defects in Ca2+/Mn2+ homeostasis which then negatively impacts
upon stress signalling. Furthermore, although btn1+ is required for the tolerance to ex-
cess manganese, it appears unlikely that Btn1 itself is ordinarily involved in the trans-
port of these ions into the secretory system as also initially hypothesised. Two lines
of evidence support this conclusion; firstly, Btn1 is unable to complement the loss of
Pmr1, a bona fide transporter for Ca2+/Mn2+. Secondly, increasing Mn2+ clearance in
btn1∆ cells (through the over-expression of pmr1+) does not allow btn1∆ to maintain
viability when exposed to excess Mn2+, suggesting that a defect in clearance is not
the underlying cause of cell death. Conversely, the over-expression of both rho1+ and
a dominant negative rhb1 did rescue this phenotype. This chapter has therefore ar-
guably come full circle, and suggests the novel Mn2+ sensitivity is another downstream
manifestation of compromised stress signalling rather than a more direct reflection of
the molecular function of btn1+. Although the precise role of btn1+ therefore remains
obscure, the genetic manipulations of the CWI and TORC1 pathways still encourag-
ingly remain the most successful means to rescue btn1∆ phenotypes to date. A revised
working hypothesis is provided in the Discussion (p.194).
This work has shown the ability of genome-wide techniques in simple model or-
ganisms to rapidly provide information about gene function and therapeutic targets.
However, more comprehensive methods may offer yet more information. The pre-
liminary results of a transposon-based mutagenesis system, developed with the aim of
providing complementary data to SGA analysis, is provided in the final Results chapter.
Chapter 7
A Transposon-Based Mutagenesis
System
7.1 Introduction
The SGA performed as part of this work has shown the value of using simple, eukary-
otic models coupled to genome-wide techniques to further understand human disease.
However, as outlined in the Introduction (p. 19), SGAs performed using the Bioneer
library are limited solely to the interrogation of complete null alleles of known, non-
essential coding genes. The use of alternative mutagenesis techniques which allow the
phenotypic contributions of other alleles (e.g. loss-of and gain-of-function) or non-
coding genomic regions to also be investigated may provide additional, illuminating
information about gene function. In a disease model, such information may also re-
veal additional disease modifiers, biomarkers, and therapeutic targets. Of the various
mutagenesis methods detailed in the Introduction, transposon-mediated mutagenesis
provides a particularly helpful means to comprehensively and rapidly generate muta-
genesis libraries that contain a wider range of mutation types than null alleles. It also
offers an attractive benefit over traditional SGAs in terms of cost-effectiveness, as it
is based on freely available plasmids and routine culturing steps thereby avoiding the
need for robotics and expensive reagents.
Two exogenous transposon systems have been developed for S. pombe; one based
on the Hermes transposon originally isolated from the housefly Musca domestica (Ev-
ertts et al., 2007) and a second on the piggyBac transposon from the cabbage looper
moth Trichoplusia ni (Li et al., 2011). The wild-type Hermes transposon is a short
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inverted-repeat eukaryotic class-II (DNA) transposon that belongs to the hAT element
family. It is approximately 3 kb in length and its cut-and-paste movement is mediated
by 17 bp imperfect terminal inverted repeats (TIRs) and an 1800 bp ORF encoding the
Hermes transposase (Warren et al., 1994; Guimond et al., 2003). Many transposons do
not show a random insertion pattern, but instead show highly characteristic preferences
for certain insertion sites, defined either at the primary DNA sequence level, or through
interactions with host proteins (Gangadharan et al., 2010; Ivics and Izsva´k, 2010). This
limits their use as a genome-wide saturating mutagenesis tools as they create both in-
sertion ‘hotspots’ and ‘coldspots’ that lack insertions. Fortunately, the insertion site
preference of the Hermes transposon is based only on a weak and variable 8 bp con-
sensus site that contains a thymine (T) at position 2 and an adenine (A) at position 7
(Evertts et al., 2007). In S. pombe, the analysis of a limited number of insertion mu-
tants has suggested that Hermes is therefore able to target both intergenic and coding
sequences with no apparent bias (Evertts et al., 2007). Further still, a vast majority
(approximately 70%) of mutants investigated only contained one insertion site which
eases the downstream interpretation of its phenotypic consequence. Although more ex-
tensive investigation in S. cerevisiae suggests there is a propensity for Hermes to insert
in intergenic regions near the 5’ end of genes (Gangadharan et al., 2010), this does not
preclude its ability to generate a wide range of mutation types and the characteristics
described in S. pombe support the use of Hermes as a suitable tool for generating close
to genome-wide saturating mutagenesis libraries.
The piggyBac transposon shows a stronger preference for a primary DNA se-
quence of TTAA at its insertion sites, although it has also been shown to insert at
non-canonical sites at a low frequency (Li et al., 2013). The piggyBac transposon ad-
ditionally exhibits a bias toward insertions in genes, promoter regions, and DNaseI
hypersensitive sites (Liang et al., 2009; Ivics and Izsva´k, 2010). Nonetheless, work
in S. pombe has shown that despite these preferences, the piggyBac transposon also
shows a relatively low insertion bias and is capable of generating null, hypomorphic,
and gain-of-function mutations. The piggyBac transposon is therefore also a valid near-
saturating mutagenesis tool for use in S. pombe (Li et al., 2011).
Proof-of-principle experiments using transposon-based mutagenesis have been
performed in wild-type fission yeast in order to assign a measure of gene requirement
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or dispensability under specific conditions (Park et al., 2009; Li et al., 2011; Guo et al.,
2013). Its use for identifying genetic interactions is however largely novel, especially
in its application to fission yeast models of disease. For the reasons outlined at the
beginning of this chapter, the development of such an approach is therefore hoped to
provide a complementary yet competitive resource to conventional SGAs using the
Bioneer deletion library.
7.1.1 Chapter Aims
A secondary aim of this project was to extend the application of a transposon-based
mutagenesis system to allow the identification of btn1+ genetic interactions. There
are benefits to developing such a technique with both the Hermes and piggyBac trans-
posons, as employing their different insertion properties would reduce insertion bias
and the risk of genomic ‘coldspots’. However, due to time constraints this work fo-
cused solely on the use of a Hermes transposon-based approach to directly generate
second site mutations in btn1∆ cells.
As this technique is largely novel, this chapter first introduces the conceptual de-
sign of the Hermes mutagenesis approach before detailing and critically reviewing the
results of preliminary experiments. The work presented in this chapter has been per-
formed in close collaboration with Dr Daniel Jeffares (conceptual design, bioinformat-
ics analysis), Namrata Saha (bioinformatics analysis), and Leanne Greech (mutagenesis
and sequencing library preparation; all University College London, London).
7.2 Conceptual Design
7.2.1 The Creation of Hermes Mutagenesis Libraries
The Hermes transposon is prone to a phenomenon termed local hopping, whereby it
shows a preference for re-integrating into physically linked cis-sites in the vicinity of
the donor locus (Guimond et al., 2003; Bouuaert and Chalmers, 2013). It also leaves a
‘footprint’ on excision due to imprecise repair mechanisms that result in the addition of
supernumerary nucleotides that form short palindromes at the site of excision (Warren
et al., 1994). Both events would be problematic if using the Hermes transposon as a
genome-wide mutagenesis tool should it be mobilised from within the host genome,
but can be circumvented by its mobilisation from a plasmid. Accordingly, the principle
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Figure 7.1: Hermes mutagenesis plasmids. [A] The Hermes donor plasmid (pHL2577)
contains the experimental transposon which consists of a KanMX6 selection cassette
flanked by the Hermes specific 17 bp terminal inverted repeat sequences (TIR-left and
TIR-right). This plasmid is also marked with URA3 to allow for selection in S. pombe.
[B] The expression plasmid (pHL2578) allows the transposase enzyme (which mediates
the transposition of the transposon from the donor plasmid to the S. pombe genome) to
be supplied in trans under a weak nmt81x promotor. Expressing the transposase enzyme
from this weak promotor avoids fluctuations in the proportion of cells that have insertions
(Park et al., 2009) and may help to prevent ‘over-production inhibition (OPI)’; a phe-
nomenon that affects most transposable elements whereby increasing the transposase con-
centration beyond a certain threshold actually decreases transposition efficiency (Mun˜oz-
Lo´pez and Garcı´a-Pe´rez, 2010). The expression plasmid is also marked with LEU2 to
allow for selection in S. pombe. Plasmid maps were designed using Plasmapper software
(wishart.biology.ualberta.ca/PlasMapper/).
starting point of the mutagenesis system used in this work is the sequential transforma-
tion of the btn1∆ strain with two plasmids (Figure 7.1). The first acts as a donor for the
Hermes transposon (defined experimentally as a KanMX6 selection cassette flanked by
the Hermes specific TIRs) while the second plasmid encodes the Hermes transposase
enzyme which is necessary to mediate the transposition reaction.
Following the transformations, the mutagenesis reaction is allowed to occur over
25 generations by removing thiamine from the media, which allows the expression
of the transposase enzyme from the nmt81x promotor. After 25 generations, approxi-
mately 1-2% of cells have a genomic insertion. Although this does not appear imme-
diately efficient, this transposition frequency is suitable for the generation of mutation
libraries as it produces a substantial number of cells with insertions while keeping the
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frequency of double insertions to a minimum (Evertts et al., 2007).
Insertional mutants can subsequently be enriched by placing the cells in me-
dia containing the pyrimidine analogue 5-fluoro-orotic acid (5-FOA). The URA3 se-
lectable marker present on the donor plasmid encodes for orotidine-5’-phosphate de-
carboxylase, and allows cells not only to be selected for in media lacking a source of
uracil but also to metabolise 5-FOA to the toxic 5- fluorouracil. The addition of 5-FOA
to media can therefore be used counter-select cells that have retained a copy of the
URA3 marked donor transposon. Secondly, these cells are cultured in the presence of
G418, the rationale being that since these cells no longer contain the donor plasmid,
any G418-resistant cells must have successfully undergone a transposition event and
now harbour the KanMX6 cassette at a genomic location.
7.2.2 The Identification of Mutants of Interest
In a proof-of-principle experiment performed in wild-type cells by Evertts et al. (2007),
insertional mutants that were rendered defective in adenine biosynthesis were identified
by the formation of pink or red colonies on yeast extract (YE) media, which contains
only a limited amount of adenine for assimilation. Mutations in either ade6+ or ade7+
are known to cause the intracellular accumulation of an adenine intermediate, which
through a series of oxidation and covalent changes gives cells a pink or red pigmenta-
tion (Shadel, 1999). The site of the Hermes insertion in the pink/red colonies identified
by Evertts et al. (2007) was determined by inverse PCR and Sanger sequencing, and
confirmed the disruption of ade6+ or ade7+ in these mutants. Plate-based assays such
as these are however best suited for rapidly screened phenotypes (e.g. colour) or for the
positive selection of mutants that suppress a conditionally lethal phenotype. However,
despite the various conditional sensitivities displayed by btn1∆ cells, no condition was
found during the course of this work that rapidly led to a complete cell death phenotype
and thus no condition was identified that would be suitable as such a selection criteria.
Consequently, separating mutants that have a phenotype of interest (that is, a difference
in colony size) from the many more that do not would be extremely time and resource
consuming. Further more, without the help of an ordered array to determine the location
of the second site mutation (as during the SGA), the use of PCR and Sanger sequenc-
ing to identify genetic interactions in individual double mutants of interest would be
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a tedious and highly time-consuming endeavour. Lastly, plate-based assays performed
in this way also preclude the identification of synthetic lethal interactions as, unlike
during an SGA, there is no way to identify such missing mutants.
An alternative approach is to create the mutagenesis library as described above,
but then pool the cells from any given mutagenesis library, allow them to compet-
itively grow in liquid media, and subsequently analyse them in parallel to provide
a high-throughput fitness profile of genome-wide transposon mutants. In this case,
the genomic location of individual Hermes insertion sites can be mapped using next-
generation sequencing techniques (Figure 7.2).
The relative abundance of reads per insertion site can then also be used as a sur-
rogate for growth rate or fitness, just as colony size is used when assessed on solid
agar. Insertions that cause a growth advantage would be reflected by an increase in se-
quencing reads (as more cells with the same insertion exist by virtue of more division
events), whereas a reduction in sequencing reads would imply that an insertion in that
location is detrimental to the fitness of that cell. When performed in a wild-type strain,
a lack of sequencing reads can therefore be used to identify essential genes despite the
fact that cells carrying such insertions are actually diminished from the competitive
pool (Guo et al. (2013) and Dr Daniel Jeffares, unpublished data). By extension, if a
mutagenesis library is made on a genetic background already harbouring a gene dis-
ruption, regions that can tolerate insertions in a wild-type control but no longer can in
the query strain can be putatively assigned as being synthetic lethal with the primary
gene lesion. Genetic suppressors can be identified by an increase in read abundance
relative to a wild-type control sample. The power of this technique, over the isolation
of individual colonies from solid agar, therefore comes from its ability to detect both
positive and negative interactions, and its sensitivity to even small changes in fitness
that might nonetheless still be biologically relevant. Compared to plate based assays,
parallel analyses performed in this way can also improve the throughput of screens, re-
duce reagents and costs, limit the problem of strain cross-contamination, and decrease
the time for data acquisition (Han et al., 2010).
The next-generation sequencing industry has long been dominated by Illumina,
who offer a sequencing-by-synthesis approach which makes use of fluorescently la-
belled reversible-terminator nucleotides to sequence clonally amplified DNA templates
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Figure 7.2: Schematic showing the mutagenesis library preparation workflow. [A]
The plasmids detailed in Figure 7.1 are provided to cells by sequential lithium acetate
transformations (protocol described in Materials and Methods). [B] The transposition re-
action is allowed to proceed for 25 generations by removing thiamine from the media to
permit the expression of the transposase enzyme. Cultures are then grown in liquid AA +
1 mg/ml 5-FOA to counter-select the donor plasmid, and then in YES + 1 mg/ml 5-FOA
+ 0.5 mg/ml G418 to enrich for insertional mutants. [C] Each library is competitively
grown in liquid media. [D] DNA is extracted from this library and prepared for Illumina
sequencing as described in Figure 7.3. Insertion sites are identified by Illumina sequenc-
ing, and their abundance can be used as a proxy for mutant fitness. Genes of interest
should then be validated in secondary screens.
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that are immobilised on the surface of a so-called flow-cell (Quail et al., 2012). Prepar-
ing Illumina sequencing libraries involves the generation of a random collection of
DNA fragments, all of a uniform size, to which adapters are added to permit binding
to the Illumina flow-cell and subsequent sequencing. Generally this process involves
DNA fragmentation, adapter-ligation, a fragment size-selection step, and a single PCR
step to amplify the library (Quail et al., 2008).
However, in this work, only fragments that contain a Hermes insertion are of inter-
est to sequence. Therefore to adapt the standard Illumina library preparation workflow
to the Hermes approach, a two-step PCR method was instead developed largely based
on a protocol previously developed by Dr Daniel Jeffares (Figure 7.3). In this modified
protocol, DNA from the mutagenesis libraries was first acoustically sheared (as per the
standard Illumina protocol) before fragments were end-repaired and ‘linkers’ (see Ma-
terials and Methods Table 2.2 for linker sequences) were ligated to the terminal ends
(Figure 7.3 A + B). These linkers are not required in the standard approach but were de-
signed to provide a priming site for the forward primer (HermesEnrich For; see Materi-
als and Methods Table 2.2 for primer sequences) in the subsequent PCR step which was
incorporated to specifically enrich Hermes containing fragments. The reverse primer
of this first PCR reaction (HermesEnrich Rev; see Materials and Methods Table 2.2 for
primer sequences) binds within the Hermes right TIR, allowing the 5’ boundary be-
tween the transposon and the genomic region disrupted by its insertion to be amplified
(Figure 7.3 A + B). 10 bp defined barcodes were incorporated into this reverse primer
in order to encode sample identity such that the resulting Illumina sequencing libraries
may be multiplexed to further reduce costs, time, and labour. A second addition to this
barcoded primer was a random, 16 bp sequence that acts as a unique molecular identi-
fier (UMI) (Kivioja et al., 2012). Before PCR amplification, each DNA molecule can
simplistically be taken to have come from a single cell (as the majority of cells only
have one insertion). At this stage, an increased abundance of a certain insertion site
can therefore be intuitively linked to an increased abundance of that mutant within the
pooled population (and vice versa). However, not all sequences amplify with the same
efficiency, therefore the PCR steps can introduce biases which could mask significant
abundance differences. To eliminate this problem, the UMI is used in the first PCR
to make each molecule uniquely identifiable. After sequencing, reads that contain the
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same UMI can be assumed to have arisen from a PCR amplification event. Conversely,
identical insertion sites that have different UMIs can be assumed to have come from
discrete cells, and were therefore both present in the initial, un-amplified sample. By
excluding identical PCR-derived reads, the true number of original DNA molecules
can be determined. Read abundance can therefore be interpreted in a more biologically
accurate and representative manner.
During the second round of PCR, Illumina-defined adapters are incorporated using
commercially available tailed primers as detailed in the Materials and Methods (Figure
7.3 C). The forward primer binds to the linker-derived sequences, while the reverse
primer binds to a priming site incorporated during the previous PCR step via the reverse
primer. These tailed primers provide the necessary sequences to allow the resulting
amplicons to bind the Illumina flow-cell and be sequenced using standard Illumina
sequencing methods. Once the sequences are returned, base pairs that correspond to
known primer-derived sequences can be bioinformatically discarded, and the remaining
genomic sequence can be mapped to the S. pombe genome to determine the Hermes
insertion site.
7.3 Mutagenesis Library Construction
Triplicate mutagenesis libraries were created in the SP5 wild-type and SP19 btn1∆
strains. At each passage during library construction, the transposition frequency was
approximated using a plating assay where the number of colony forming units (CFUs)
on YES agar + G418 + FOA was divided by the CFUs on AA + FOA. This quantita-
tively indicates the percentage of cells that have lost the original pHL2577 donor plas-
mid (determined by negative selection on AA + FOA) but remain resistant to G418, the
assumption being that such cells harbour the KanMX6 cassette on a chromosome fol-
lowing its transposition from the donor plasmid to a genomic location. Of importance,
circular plasmids are not a good substrate for integration so FOA and G418 resistant
cells can be presumed to contain a bona fide transposition event. After 25 generations,
and prior to enriching specifically for insertional mutants, the wild-type libraries had
a mean (± SD) transposition frequency of 2.4 % (± 0.33) (Figure 7.4 A). The btn1∆
libraries had a mean (± SD) transposition frequency of 2.1% (± 0.18) (Figure 7.4
B). These transposition frequencies are consistent with previous reports (Evertts et al.,
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Figure 7.3: Schematic showing the Illumina library preparation workflow. Schematic
begins following DNA extraction, acoustic shearing, and end-repair. [A] Linkers are lig-
ated to the terminal ends of fragmented DNA to provide a priming site for the subsequent
ligation-mediated PCR step which is required to permit the sole amplification of Hermes
containing fragments. [B] Fragments containing the Hermes transposon are specifically
amplified using a sense primer which binds within a linker, and an anti-sense primer which
binds within the Hermes right terminal inverted repeat (TIR). Also shown is the defined
10 bp barcode, and random 16 bp unique molecular identifier (UMI; shown as n...) as
detailed in the main text. [C] The amplicon produced from the ligation-mediated PCR is
used as template in PCR 2. This PCR step is required to add Illumina-defined adapters
through the use of commercially available tailed primers. These adapters provide the se-
quence that allows the final amplicons to bind the Illumina flow-cell and be sequenced.
[D] Once sequences are returned, base pairs that correspond to known primer-derived se-
quences can be discarded, and the remaining genomic sequence can be mapped to the S.
pombe genome to determine the Hermes insertion site.
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2007; Park et al., 2009) and as expected, no transposition events were observed in the
negative control strains lacking the transposase enzyme. Plating assays performed after
the enrichment step confirmed that all the of cells in the mutagenesis libraries no longer
contained the pHL2577 donor plasmid, but remained tolerant to G418 due to a genomic
insertion of the KanMX6 cassette.
7.3.1 Serial Passaging of Mutagenesis Libraries
Disruptions in essential or synthetically lethal genes will most commonly lead to a
rapid loss of such cells in a mixed population of mutants. However, in some cases,
cells carrying these gene disruptions will nonetheless remain at high levels in the pop-
ulation as a result of a large protein pool that is not depleted for several generations
(Guo et al., 2013). Similarly, it is likely that disruptions to certain non-essential genes
will reduce growth rate but to a lesser extent than disruptions to essential genes (Lan-
gridge et al., 2009). These mutants may only become lost from a population after some
time, and therefore may not be immediately apparent but still biologically interesting.
The same can be true for disruptions that are advantageous to fitness, in that they may
only begin to out-compete others and become enriched as the population becomes less
complex over time. Accordingly, it was decided that passaging the final experimental
mutagenesis libraries, and creating Illumina libraries from different time points during
this process (see Figure 7.5), would permit the identification of genes that have more
subtle effects on fitness or might be missed from earlier time points due to large protein
pools. Therefore, after the mutagenesis libraries were constructed and insertional mu-
tants were enriched, aliquots from each library were passaged under normal laboratory
conditions, and maintained in log phase, for a total of ten days. DNA was extracted
from these cultures every two days, and used to create discrete Illumina libraries for
sequencing (described below).
7.4 Proof-of-Principle Screens
To validate the Hermes mutagenesis protocol, cells from the wild-type derived mutage-
nesis libraries (prior to serial passaging) were used in two proof-of-principle screens.
The first proof-of-principle screen took advantage of the characteristic pink/red colony
colour of mutants in ade6+ or ade7+ to identify mutants defective in adenine biosyn-
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Figure 7.4: Transposition frequencies of mutagenesis libraries. [A] Biological tripli-
cate Hermes mutagenesis libraries for the wild-type control strain, including one negative
control. [B] Biological triplicate Hermes mutagenesis libraries for the btn1∆ strain, in-
cluding one negative control. Insertion frequency is defined as the percentage of cells that
have lost the donor plasmid but remain resistant to G418, the assumption being that these
cells harbour the transposon in a genomic location.
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Figure 7.5: Schematic showing the serial passaging of mutagenesis libraries. [A] A
single Hermes mutagenesis library is made in a strain of interest as in Figure 7.2. [B]
Following the enrichment of insertional mutants, the cells are competitively grown in
liquid media and passaged for ten days. [C] DNA is extracted every two days and used
to create discrete Illumina libraries as described in Figure 7.3. These libraries can be
multiplexed and sequenced in parallel to reduce costs, time, and labour. T = time in days
of passaging.
thesis, as performed by Evertts et al. (2007) and described above.
Assuming the Hermes mutagenesis libraries reached complete saturation, out of
the approximately 40,200 screened mutants, seven were expected to be pink or red.
This number is calculated by dividing the total number of coding nucleotides in ade6+
and ade7+ (2559 bp) by the genome size (14.1 Mbp), and multiplying by the number
of cells screened. Four pink colonies were identified on YE agar, each of which also
failed to grow on AA agar lacking adenine (Figure 7.6 A + B). Given that Hermes has a
weak consensus site (therefore libraries will not reach complete saturation) and the in-
accuracies incurred by approximating cell numbers, 4 pink/red colonies is a reasonable
number to have obtained given a randomly distributed insertion pattern. Importantly,
each isolate was able to grow on YES agar + G418, but failed to grow on AA agar lack-
ing uracil. This confirms the loss of the donor pHL2577 plasmid but retention of the
KanMX6 cassette in a genomic isolation (Figure 7.6 C + D). PCR screens to confirm
the locations of Hermes insertions were not performed.
In a second screen to identify mutants resistant to the microtubule depolymerisa-
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Figure 7.6: Proof-of-principle adenine mutant screen. [A] The wild-type parental
strain (WT), a second prototrophic control wild-type strain (972h-), and four mutants
defective in adenine biosynthesis as identified during the proof-of-principle screens were
streaked on to YE agar containing low levels of adenine and grown at 30◦C for 3 days.
As expected, the WT and 972h- cells are white, but the mutants defective in adenine
biosynthesis develop as pink or red colonies. [B] The parental WT strain used for the
mutagenesis is able to grow on agar lacking adenine, while the four mutants described
in panel [A] fail to grow under this condition, supporting the identification of mutants
in adenine biosynthesis. [C] The four pink mutants were able to grow on YES media
containing 0.5 mg/ml G418 but unable to grow on [D] AA agar lacking uracil, indicating
the retention of the KanMX6 selection cassette but not the original donor plasmid which
also harbours the URA3 cassette and would allow cells to grow on media lacking uracil.
klp5+::KanMX6 = a strain containing a genomic integrated KanMX6 selection cassette
which acts as a control for the media containing G418 used in panel [C]. 972h- is used as
a positive control in panel [D].
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Figure 7.7: Proof-of-principle TBZ resistance screen. [A] 16 arbitrarily chosen TBZ
resistant mutants were streaked onto YES + 0.5 mg/ml G418. [B] The same TBZ resistant
mutants were shown to be unable to grow on AA - uracil, indicating the retention of the
KanMX6 selection cassette but not the original donor plasmid which also harbours the
URA3 cassette and would allow cells to grow on media lacking uracil. The wild-type
(WT) parental strain and a positive control for each plate type are indicated.
tion drug thiabendazole (TBZ), 1x107 mutagenised cells were plated from each of three
independent wild-type derived libraries. An average of 130± 60 (mean± SD) TBZ re-
sistant colonies were recovered from each library. All colonies recovered from library
1 (n = 134) were colony purified and confirmed to be stably resistant to 40 µg/ml TBZ
(data not shown). 16 colonies were arbitrarily chosen to be tested for growth on YES
agar + G418, and AA agar lacking uracil. All clones grew well on G418 (Figure 7.7 A)
but were unable to grow on media lacking uracil (Figure 7.7 B), again confirming the
loss of the donor plasmid but genomic retention of the KanMX6 cassette.
Three loss of function alleles are known to cause resistance to TBZ. These include
klp5+, klp6+ (West et al., 2001), and dnm1+ (Jourdain et al., 2009). Although the Her-
mes insertion sites for the TBZ resistant mutants were not determined, no TBZ-resistant
colonies were found when the same number of cells from the negative control library
were screened. This suggests spontaneous resistance to TBZ does not contribute to
the numbers obtained, and that the resistance is highly likely due to a bona fide trans-
position event into one of these three genes. Lastly, the number of resistant mutants
recovered between biological replicates was similar, indicative of the reproducibility of
this method.
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7.5 Illumina Library Construction and Optimisation
In order to optimise the adapted Illumina library workflow introduced above, genomic
DNA from a wild-type culture not exposed to the mutagenesis steps was extracted
and acoustically sheared to approximately 200 bp. This sample was then spiked with
pHL2577 donor plasmid digested with BseYI to a final concentration of 1 ng/µl. BseYI
digests pHL2577 in 2 positions, and generates a fragment size of 4340 bp containing
the Hermes transposon. As this sample therefore contained a single Hermes-containing
species of a known size, it provided a simple way to assess the ability of the linkers to
bind to DNA and the effectiveness of subsequent PCR steps.
In the context of the control sample, the amplicon obtained from the first ligation-
mediated PCR step should consist of 746 bp of plasmid DNA together with the 39
bp linker sequence and an additional 45 bp of reverse primer-derived sequence. The
final PCR amplicon is therefore expected to be 830 bp. As seen in Figure 7.8 A, in
an initial validation test, the amplicon is of this size indicating that the linkers anneal
appropriately, the primers are specific, and the chosen PCR conditions are sufficient
for amplification. With the addition of the sequences provided by the primers used
in the second PCR step, the expected amplicon size increases to 908 bp. As seen
in Figure 7.8 A, an initial attempt at this PCR resulted in a doublet band just under
1000 bp in size. The doublet product may have been indicative of over-amplification
or non-specific priming, but was never seen in additional attempts. Consequently, the
modified Illumina library preparation protocol was deemed to be suitable and a number
of experimental libraries were subsequently developed.
7.6 Critical Appraisal of a Pilot Sequencing Run
In a pilot sequencing experiment, the process of serial passaging and Illumina library
preparation was completed for one wild-type and one btn1∆ biological replicate. Con-
sequently, six libraries were constructed for each strain as each library represented
a different time point during serial passage (T0, T2, T4, T6, T8, and T10). Repre-
sentative Bioanalyser traces for the wild-type libraries are shown in Figure 7.8 B and
indicates that despite some variation, the resulting Illumina libraries were of a suitable
size and concentration for accurate Illumina sequencing. All 12 samples were therefore
multiplexed and sequenced in parallel.
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Figure 7.8: Illumina library optimisation. [A] Agarose gel image shows the successful
shearing of genomic DNA (gDNA) to approximately 200 bp by Covaris shearing, and
the PCR products derived from the optimisation strategy as detailed in the text. Numbers
to left of the gel image correspond to base pairs. [B] Representative Bioanalyzer trace
showing the size and concentration of the Illumina libraries prepared from wild-type (WT)
samples. The timing of DNA extraction during the serial passaging is indicated by T =
number in days.
A total of 23.28 million reads across all libraries were returned. Using the most
common metric for quality, 97.5% of bases showed a Phred quality score greater than
Q30, indicating that the probability of a given base being called incorrectly by the
sequencer was 1 in 1000. That is, the base call accuracy was 99.9%. All reads were
demultiplexed automatically using the NEB barcode, which was successful in assigning
99.5% of reads to a distinct sample.
The total number of insertions, number of unique insertions, and percentage of
unique insertions for all samples are shown in Table 7.1. Of note, the library corre-
sponding to btn1∆ T6 produced very few reads, as very little DNA had been available
for the creation of this Illumina library (reasons remain unknown). Consequently, T6
time points for both strains were excluded from further downstream analysis.
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Table 7.1: Hermes transposon insertion rate. The total and unique numbers of Hermes
insertions found per sample in the pilot sequencing run. Data were analysed by Dr Daniel
Jeffares and Namrata Saha.
Strain
Name
Time Point
(days)
Total Insertions Unique Insertions Percent
Unique
WT T0 1,336,171 90,625 6.78
T2 1,322,424 37,410 2.83
T4 1,492,427 127,847 8.57
T6 1,652,910 122,306 7.40
T8 1,410,071 76,602 5.43
T10 1,597,324 33,040 2.07
btn1∆ T0 971,059 86,946 8.95
T2 732,964 41,881 5.71
T4 1,132,779 85,109 7.51
T6 10,955 5,622 51.32
T8 1,162,698 73,080 6.29
T10 1,077,546 36,657 3.40
As detailed in Table 7.1, only a small proportion of sequencing reads were found
to be unique. In fact, the vast majority (i.e. more than 90%) of sequencing reads
available for each sample were not unique, meaning they arose from re-sequencing the
same insertion site multiple times. The mean number of unique insertion sites across
all ten libraries was 69,920 (5.75 ± 0.02% of total insertions). Taking the genome size
of S. pombe to be 12.57 Mbp, an estimate of the percentage of the genome in which an
insertion was identified per sample (i.e. the genome coverage) was disappointingly low
at just 0.56%. While some degree of re-sequencing is to be expected and is acceptable,
this low percentage of genome coverage would have consequences for the applicability
of this technique to find genetic interactions, and therefore highlighted a need for the
technique to be further improved.
The reasons for the poor percentage of unique insertions could reflect inefficien-
cies introduced either in the development of the Hermes mutagenesis library, or in the
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subsequent development of the Illumina sequencing libraries. That is, a lack of genome
coverage could arise because the initial mutagenesis library is not complex enough (i.e.
other insertion sites are simply not present in cells of the mutagenesis library) or be-
cause the insertions have been created but are then lost due to an inefficiency introduced
at the stage of making the Illumina libraries which are sent for sequencing. However,
since the ten-day passaging process was performed using cultures created following
the enrichment of insertional mutants (i.e. occurred during a time where no more inser-
tions were being created due to the loss of the transposase enzyme) an analysis of the
insertion sites seen at the various time points can be used to determine which of these
possibilities is more likely.
This is logically based on the knowledge that all of the insertion sites that are cre-
ated during the development of any given Hermes mutagenesis library are collectively
present in the cells of the T0 sample. If the creation of the Illumina sequencing libraries
from the DNA of these cultures is performed optimally, it can be understood that all
insertion sites will remain and be identified during the sequencing. Furthermore, since
the Illumina libraries of each subsequent time point were made from cultures that were
derived from the T0 sample, and since no novel insertion sites are created during this
process of serial passaging, no ‘new’ insertion sites should be seen in later time point
samples compared to T0 (although as described above it can be expected that some
insertions sites will be lost as cells die and the culture becomes less complex). If ‘new’
insertion sites are however seen at later time points, it can be assumed that although
they were not sequenced in the T0 sample, they are nonetheless present in the Hermes
mutagenesis library.
As shown in Figure 7.9 an increase in unique insertion sites was seen when sam-
ples corresponding to increasing time points were considered together. These arise
due to the progressive inclusion of insertions that, as discussed above, are present in
the initial Hermes mutagenesis library from which all subsequent samples are derived.
Importantly however, since the T0 samples were sequenced to a sufficient depth to re-
sequence the same insertion sites multiple times, it can be assumed that these ‘new’
insertion sites would not be recovered simply from re-sequencing the T0 Illumina li-
brary again. Instead, these insertion sites were most likely lost during the preparation
of the Illumina sequencing library for sample T0. Optimisation steps to improve the
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efficacy of the Illumina sequencing library preparation are therefore warranted in order
to improve the utility of this technique, and are described below.
Although this analysis indicated that the complexity of the Illumina sequencing
library was less than that of the Hermes mutagenesis library from which it is derived,
it should not be assumed that the Hermes library itself reaches full genome coverage.
As shown in Figure 7.9, the number of unique insertions seen during the progressive
addition of samples begins to plateau, suggesting that the majority of unique insertions
present in the initial Hermes mutagenesis library were eventually identified. A total
of 169,179 unique insertion sites were identified for the WT strain, and 141,963 for
btn1∆. This however still only corresponds to a genome coverage of 1.3% and 1.1%
respectively. By extrapolation, although the Hermes mutagenesis libraries used in this
pilot experience were more complex than the Illumina sequencing libraries developed
from them, the mutagenesis process could also be optimised to increase the number of
unique insertions. Optimising both stages of the workflow to improve the complexity
of the Hermes and Illumina libraries is therefore deemed necessary if this technique
is to successfully identify genome-wide genetic interactions and develop as a comple-
mentary but competitive alternative to SGA analysis.
7.7 Future Improvements and Considerations
Future work to improve the complexity of the Hermes mutagenesis library could come
in the first instance simply from extending the transposition events past 25 generations
in order to increase the likelihood that the transposon has inserted in all genomic po-
sitions. Larger culture volumes to increase the absolute numbers of cells might also
be advantageous. One additional, albeit conceptual, concern raised during this work is
that since the donor plasmid is a multi-copy plasmid, even cells that have had a suc-
cessful genomic insertion may still harbour another intact plasmid. Therefore, during
the steps to enrich for insertional mutants, the addition of 5-FOA might remove such
insertional mutants in addition to cells that carry a plasmid due to a lack of transpo-
sition as reasoned by Park et al. (2009). This would of course reduce the complexity
of the final mutagenesis library, and therefore it may instead be beneficial to explore
whether placing the cells in EMM + uracil (and thiamine to stop transposition events)
to encourage the loss of the plasmid prior to adding 5-FOA might help maintain more
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Figure 7.9: Cumulative number of unique Hermes insertion sites. The number of
unique insertion sites was determined for each sample sent for Illumina sequencing, as
detailed in Table 7.1. The graph shows the cumulative number of unique insertion sites
determined as successive samples derived from serial passaging were analysed together.
T = time in days of serial passage. Of note, samples corresponding to T6 were excluded
from this analysis. Graph and analysis were provided by Namrata Saha.
insertional mutants.
Improvements in the complexity of the Illumina sequencing libraries could also
be simply achieved by increasing the amount of DNA extracted from the mutagene-
sis library. However, although DNA isolation can be achieved by various protocols or
commercial kits, the yield and quality of DNA obtained using the MasterPure Yeast
DNA Purification Kit as used here was acceptable. The preparation method was there-
fore unlikely to be a primary source of inefficiency, and simply increasing the number
of cells used to extract DNA rather than modifying the extraction process may be help-
ful. Similarly, although the fragmentation of DNA can be achieved by various methods,
acoustic fragmentation by Covaris shearing (as used here) is the preferred method as
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it results in sharp, homogeneous, and random fragmentation (Quail et al., 2008). Al-
though an investigation of other methods may prove useful to reduce costs, this was
also not considered a primary source of optimisation.
Further optimisation steps could however include a focus on the linker sequence
and its ligation to the sheared DNA. Although the pilot experiment indicated that the
linker oligonucleotides are capable of ligating to the sheared DNA species, it is possible
that this step is less efficient than presumed. Consequently some sheared Hermes-
containing DNA molecules may not be ligated to linkers, and it turn become unavailable
for sequencing. Ligating DNA in smaller aliquots before re-pooling, increasing the
ligation time, or investigating different temperatures might provide some improvements
in efficiency. Alternatively, the strategy could be modified in order to allow this step
to include a sticky-ended ligation, which is typically more efficient than blunt-ended
ligations as performed here. Of note, one particularly important realisation from the
pilot experiment was that the addition of the 16 bp UMI to the PCR primer meant that
was replaced in each successive PCR cycle, rendering it ineffective. On reflection, the
linker is clearly a far superior component in which to add the UMI, and indeed this has
proved successful in more recent sequencing attempts performed by Dr Daniel Jeffares
and Leanne Greech. The PCR steps could also be performed in multiple aliquots to
reduce the amount of template in each reaction, as excess template can have significant
consequences on the efficiency of PCR (Wilkening et al., 2013).
Lastly, DNA is purified using AMPure XP beads a total of five times during this
Illumina library preparation. The recovery of DNA using AMPure beads is considered
to be higher than other methods, such as column-based purifications. However, some
DNA is inevitably lost and the use of heat inactivation after the digestion, blunt-ending,
and linker ligation steps could avoid sample-loss during excess bead based purification
steps (Wilkening et al., 2013). In turn, this may also maintain the complexity of the
final Illumina library sent for sequencing.
7.8 Summary
This chapter details the initial efforts taken to develop the Hermes transposon as a tool
for the identification of genetic interactions in fission yeast, and the results obtained
from preliminary experiments. While all steps of the protocol were successful to some
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degree, the low genome coverage obtained in these experiments precluded the detailed
identification of interactors. More work is therefore required before this technique is
fully established, and this chapter therefore also suggests some areas of focus for future
improvements. Once these optimisation steps have been introduced and validated, it is
hoped that the genome coverage will be improved and is sufficient enough to allow the
Hermes mutagenesis and SGA approaches to be compared. It is also hoped that a fully,
or close to, saturating mutagenesis approach will reveal disease specific interactions
that cannot be found through conventional, mating-based SGAs and provide insights
into the disease-context role of non-coding RNAs (ncRNAs). There is evidence to sup-
port that this is a worthwhile endeavour and an interesting avenue for future work from
the increasing body of literature describing that various forms of ncRNA are involved
in cellular homeostasis, and therefore that their dysregulation can contribute to human
diseases (Esteller, 2011; Wapinski and Chang, 2011; Harries, 2012), including neu-
rodegeneration (Rege et al., 2013; Salta and De Strooper, 2012). An investigation of
ncRNAs in the context of juvenile CLN3 disease may prove particularly informative
given they have recently been shown to be important for the response to stress in both
yeast (Leong et al., 2014; Sole´ et al., 2014) and mammalian cells (Giannakakis et al.,
2015).
Although mutagenesis systems are conceptually simple, this work has been instru-
mental in developing a deeper understanding of the complexity and pitfalls of extending
the Hermes mutagenesis system to the identification of genetic interactions. If devel-
oped with this knowledge in mind, the technique nonetheless has the potential to be
highly informative and exciting, and can be envisioned to have broad applicability. On-
going efforts to develop this system, initially using the suggestions put forward here, are
therefore desirable and are being performed by Dr Daniel Jeffares and Leanne Greech.
Chapter 8
General Discussion
8.1 Overview
Mutations in CLN3 give rise to juvenile CLN3 disease, a rare lysosomal storage dis-
order and the most common cause of paediatric neurodegeneration. Since its identi-
fication as the causative disease gene in 1995, extensive work in a variety of animal
models has revealed associations between the encoded CLN3 protein and a wide-range
of seemingly disparate pathways. Nonetheless, the precise molecular function of CLN3
and its involvement in juvenile CLN3 disease pathogenesis remains elusive. The ba-
sis of this work was therefore founded on an assumption that taking a non-focused,
hypothesis-free approach in a simple model organism might be a particularity benefi-
cial means by which to address this persistent confusion and complexity.
To this end, the primary aim of this study was to exploit the fission yeast model
of juvenile CLN3 disease to identify genome-wide, genetic interactions of the CLN3
orthologue btn1+. Such information can be used to identify functional relationships
among genes, which in turn can be used to infer gene function and identify therapeutic
targets in the case of disease genes.
This work has been successful in providing novel insights into the cellular role of
Btn1, and therefore by inference CLN3. Further still, the identification and validation
of certain genetic interactions, supported by experimentally derived functional data,
has led to the most complete rescue of disease phenotypes seen in any juvenile CLN3
disease model to date. This work therefore provides important implications for future
therapeutic developments.
Each chapter of this thesis has served to provide some discussion of the particular
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topic of focus, and was done so in order to provide some understanding of the logic
and preamble for subsequent experiments and chapters. This final chapter will act to
supplement these previous discussions by looking at the overall findings more generally
and placing them into the wider context. In doing so, the relevance of this work will
be reiterated and some of the questions put forward in the Introduction (p.19) will
be addressed. Finally, recommendations for future work that should be performed to
continue this work will be discussed.
8.2 New Insights into btn1+ Function
Yeasts are ideal models in which to identify genetic interactions, as their genomic sim-
plicity helps overcome some substantial limitations that prohibit such efforts in other
systems. Importantly, the evolutionary conservation of btn1+ and CLN3, as well wider
basic pathways and molecular mechanisms, allows the work performed in yeast models
to be a valid and informative predictor of human gene function. This is supported fur-
ther by a growing body of evidence that genetic interactions themselves are similarly
conserved among species.
8.2.1 btn1+ is Required for the Tolerance to Environmental Stress
The SGAs performed during this work uncovered a total of 131 negative interactions
and 331 positive interactions with btn1+, the vast majority of which have known hu-
man orthologues. As described in Chapter 3 (p.88), the pattern of genetic interactions
revealed suggest that the function of btn1+ converges with stress response genes, and
therefore is itself required for the appropriate response to exogenous stress. This was
based more specifically on the observation that btn1+ negatively interacts with mem-
bers of the highly-conserved MAPK stress signalling pathways (the stress-associated
protein kinase (SAPK) and cell wall integrity (CWI) pathways) and the kinase compo-
nent of TORC2 (tor1+), in addition to various genes involved in downstream processes
that are similarly needed to support stress responses. That btn1+ is also required for
appropriate stress signalling was further supported by a number of positive interac-
tions with genes that are ordinarily down-regulated by the SAPK pathway, and with a
core component of TORC1 which is similarly repressed under stress. Importantly, and
substantiating the use of fission yeast as an appropriate model, these stress response
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pathways are highly conserved with higher eukaryotes; the SAPK pathway shows high
homology to mammalian p38 kinase and the mammalian specific c-Jun N-terminal ki-
nases (JNK), and the TOR complexes are also both conserved in higher eukaryotes. It
is perhaps most pertinent to note that, despite its name, the cell wall integrity pathway is
also conserved and is orthologous to the extracellular signal-regulated kinases ERK1/2
(p42/p44) of animal cells.
The resulting hypothesis that btn1+ is involved in stress responses is corroborated
by previous studies in the fission yeast model which show that btn1+ is up-regulated
under certain stress conditions (Chen et al., 2003), and that its disruption manifests
with various phenotypes that reflect dysfunctional stress signalling, and are indeed co-
incident with other mutants known to be defective in stress responses. These include
depolarised growth and eventual lysis at 37◦C (Codlin et al., 2008b), multiple septa
which is indicative of delayed cytokinesis (Gachet et al., 2005), morphological alter-
ations such as thickened cell walls and septa, and a hypersensitivity to β -1,3 glucanases
(Codlin et al., 2008a). Notably, this work has shown that the heat phenotype and en-
larged vacuoles of btn1∆ cells, which were first described in 2008, can be rescued by
manipulating the MAPK and TOR pathways, supporting the notion that dysfunctional
stress responses may contribute to these well characterised phenotypes. Importantly,
through the extensive characterisation of the btn1∆ strain developed for this work (as
detailed in Chapter 3 (p. 88)), it is now known that the absence of btn1+ also results
in various novel sensitivities to other environmental stress conditions, including mor-
phological defects and a loss of viability upon both glucose and nitrogen limitation, a
sensitivity to oxidative stress (all Chapter 4 (p. 108)), and a hypersensitivity to excess
Mn2+ (Chapter 6 (p. 151)). All of these novel phenotypes can be fully rescued by the
exogenous over-expression of btn1+, which provides evidence that they manifest as a
direct consequence of btn1+ loss. Chapters 5 (p.129) and 6 (p.151) have also shown that
the nutrient and manganese sensitivities, like the heat and vacuole defects, are similarly
rescued to varying degrees by manipulations to MAPK or TOR signalling. This adds
yet further support to the hypothesis that dysfunctional stress response, arising from
the loss of btn1+, underlie the phenotypic defects of the btn1∆ strain. The relevance of
these findings within the context of the wider literature, and for the function of btn1+,
is discussed in more detail below.
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8.2.1.1 Oxidative Stress
It was shown in Chapter 4 (p. 108) that btn1∆ cells have a reduced ability to tolerate
oxidative stress compared to wild-type cells. This finding is consistent with a body of
work that has previously suggested a role for CLN3 in the response to oxidative stress.
CLN3 over-expression in the Drosophila model has been reported to result in the ac-
tivation of JNK signalling, which is orthologous to the fission yeast SAPK pathway
(Tuxworth et al., 2009). Later, a gain-of-function modifier screen in this same model
revealed that CLN3 genetically interacts with multiple components of stress signalling
pathways, including the MAP kinase kinase kinase (MAPKKK) Mekk1 which acti-
vates the p38 MAP kinase (Tuxworth et al., 2011). The subsequent development of a
lack-of-function cln3 Drosophila model has since revealed a specific hypersensitivity
to oxidative stress when compared with control animals (Tuxworth et al., 2011). Yet
more evidence for a role of CLN3 in the response to oxidative stress comes from the
observation that its over-expression in wild-type flies is sufficient to confer increased
resistance to oxidative damage (Tuxworth et al., 2011). Work in the Cln3-/- knock-out
murine model has also previously demonstrated the widespread presence of oxidative
stress markers in the CNS and the up-regulation of oxidative stress responsive genes,
findings which have been taken to suggest that oxidative stress plays an important role
in the clinical symptoms of juvenile CLN3 disease (Brooks et al., 2003; Benedict et al.,
2007). In patient cell lines, evidence of mitochondrial dysfunction (Jolly et al., 2002)
and altered expression of mitochondria-related molecules (Kang et al., 2013) has also
been used to support the hypothesis that oxidative stress may contribute to pathology.
Indeed, the reduction of oxidative stress by resveratrol has since shown some ben-
efit in patient cell lines through the induction of the antioxidant enzyme superoxide
dismutase-1 (SOD-1) (Yoon et al., 2011). Interestingly, resveratrol can also inhibit
mTOR (Liu et al., 2010). Oxidative stress was not used as a marker phenotype for
the rescue experiments performed in this work, and so it would therefore be of interest
for future work to determine whether manipulations to the TOR pathway can rescue
this phenotype as they can do for the heat, nutrient, and manganese sensitivities and the
vacuole defect. The ability of MAPK signalling manipulations to rescue this phenotype
will also be of interest.
Neuronal cells are known to be sensitive to oxidative stress, and there is also a
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wealth of data mechanistically linking oxidative stress to a wide range of other neurode-
generative disorders such as Alzheimers disease, Parkinsons disease, multiple sclero-
sis, and normal ageing (Bhat et al., 2015). Interestingly however, although Drosophila,
mice, human, and now fission yeast lacking btn1+/CLN3 are reportedly sensitive to ox-
idative stress, the deletion of BTN1 in budding yeast results in resistance to oxidative
stress (Oso´rio et al., 2007). The reasons for this discrepancy are not known, although
this is not the first occurrence of budding yeast displaying an opposing phenotype to
fission yeast - budding yeast lacking BTN1 show abnormally acidic vacuoles (Pearce
et al., 1999a) in contrast to the less acidic phenotype of fission yeast and patients, and
are resistant to D-()-threo-2-amino-1-[p-nitrophenyl]-1,3-propanediol (ANP) (Pearce
et al., 1999a) whereas fission yeast are sensitive.
This work therefore supports the previously postulated role for CLN3 in the tol-
erance to oxidative stress, but also extends this finding by indicating that btn1+/CLN3
may in fact be more broadly involved in a wider and more general physiological re-
sponse to several forms of environmental stress. A particular focus of this work has
been the loss of viability exhibited by btn1∆ cells upon nutrient stress and exposure to
excess levels of manganese, and these phenotypes will therefore also be discussed in
more detail.
8.2.1.2 Nutrient Stress
As shown in Chapter 4 (p. 108), cells lacking btn1+ are unable to undergo the charac-
teristic morphology changes ordinarily seen in wild-type cells upon both glucose and
nitrogen limitation. The inability of btn1∆ cells to tolerate nutrient deprivation is even
more obviously evidenced by the rapid loss of viability under these conditions. It was
also shown in Chapter 5 (p. 129) that these phenotypes can be fully rescued by the
up-regulation of the CWI pathway (through the overexpression of rho1+ or rho5+), the
down-regulation of TORC1 signalling (by the overexpression of rhb1D60K), and par-
tially by the up-regulation of TORC2 activity (thought the overexpression of gad8+).
This again suggests that these btn1∆ phenotypes manifest as a result of a failure to
initiate the usual stress responses needed to tolerate nutrient deprivation, that is (albeit
simplistically) an increase in MAPK and TORC2 activity, and a repression of TORC1
activity. Indeed, the overexpression of pmp1+ to inhibit CWI signalling exacerbated the
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loss of viability upon nitrogen starvation, providing more convincing data to suggest
that this phenotype manifests as a result of compromised stress signalling.
Defects in nutrient sensing have not been widely explored in other models of ju-
venile CLN3 disease, although amino acid homeostasis is already known to be altered
in the fission yeast model, most likely as a result of the vacuolar defects (Pears et al.,
2010). However, perturbations in the ability to respond to nutrient deprivation have
been associated with neurodegeneration in other diseases and ageing through a link to
altered autophagy (Carroll et al., 2013; Nixon, 2013). Nutrient starvation is a potent
activator of autophagy, which occurs via the inhibition of TORC1 in both neuronal and
non-neuronal cells (Young et al., 2009). Under conditions of stress, TORC1 repression
is therefore vitally important to promote an increased activation of autophagy which
is an essential cytoprotective response and needed to provide an alternative supply of
nutrients (Kroemer et al., 2010; Murrow and Debnath, 2012). Tuberous sclerosis com-
plex (TSC) disease is caused by mutations in either TSC1 or TSC2 which ordinarily act
to repress mTORC1 by inhibiting the upstream activator Rheb. Accordingly, TSC is
characterised by a constitutive activation of mTORC1 (Inoki et al., 2005) which results
in a sensitivity to energy starvation and increased rates of apoptosis (Lee et al., 2007).
This work has revealed that the absence of btn1+ is also associated with aberrant
(possibly hyperactive) TORC1 signalling through a positive genetic interaction with
tor2+ and from experiments showing the benefits of repressing TORC1 activity. It
is therefore tempting to speculate that in the absence of btn1+, TORC1 is not fully
repressed and autophagy is not activated upon nutrient withdrawal, leading to the ob-
served loss of viability. Although levels of autophagy were not directly investigated in
this work, this hypothesis is nonetheless supported by previous work in patient derived
fibroblasts which reported an up-regulation of the mTOR pathway leading to disrupted
macroautophagy and decreased protein degradation (Vidal-Donet et al., 2013). Given
that this work has found that the deletion of a TORC1 component, or its pharmaco-
logical inhibition, is beneficial to btn1∆ cells, it can be postulated that the increased
TOR signalling reported by Vidal-Donet et al is indeed a pathological consequence
of CLN3 mutation and contributes to disease development. However, other work has
conversely reported significantly increased activation of autophagy and reduced lev-
els of phospho-mTOR in the brains of 6-month Cln3∆ex7/8 knock-in mice, a finding
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that was also seen in juvenile CLN3 disease patient lymphoblastoid cells (Cao et al.,
2006). In this case, however, it would appear that the observed alterations in mTOR
signalling and autophagy are in fact a compensatory mechanism, as the authors also
reported that the inhibition of autophagy led to cell death. This latter finding is consis-
tent with this work which found that btn1+ negatively interacts with two genes required
for autophagosome formation (atg14+ and atg12+). Therefore, despite the seemingly
contrasting findings of these papers, both pieces of work largely support the findings
and hypothesis reported here that increased TOR signalling, which would lead to re-
duced autophagy, is detrimental in the absence of Btn1/CLN3. They additional raise an
intriguing possibility that the precise alteration in TOR signalling is temporally, or per-
haps species, dependent. Either way, neurons are particularly vulnerable to alterations
in autophagy, and therefore disrupted autophagy arising from aberrant TOR signalling
might make an important contribution to juvenile CLN3 disease, and should be further
investigated in future work.
8.2.1.3 Biometal Stress
As described in Chapter 7 (p. 171), it was initially hypothesised that manganese
dyshomeostasis might lie upstream, and therefore result in, the observed defective
stress signalling seen in btn1∆ cells. However, although more work is needed, it was
later concluded in Chapter 7 that the inability of btn1∆ to tolerate excess manganese is
most likely another downstream manifestation of aberrant stress signalling, which like
other phenotypes explored in this thesis, can be rescued by the inhibition of TORC1
and up-regulation of CWI signalling. Interestingly however, an inability to maintain
biometal homeostasis (which could manifest as a sensitivity to excess levels as seen
here for Mn2+) has been cited as a key feature of several NCL subtypes (Grubman
et al., 2014) as well as several other, common neurodegenerative disorders including
Alzheimers disease, Parkinsons disease, and motor neuron disease (White et al., 2015).
Protein-bound biometals (zinc, copper, manganese, cobalt, and iron) are observed to
pre-symptomatically and progressively accumulate in the CNS of CLN6 deficient sheep
and mice (Kanninen et al., 2013b,a; Grubman et al., 2014), as well as Cln1, Cln3, and
Cln5 deficient mice models (Grubman et al., 2014). Cells inhibited for cathepsin D
(CLN10) activity also undergo greater levels of apoptosis upon manganese exposure
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than healthy controls (Fan et al., 2010).
The brain is exquisitely vulnerable to even subtle perturbations in manganese
homeostasis, which can lead to manganism, a neurodegenerative syndrome resembling
idiopathic Parkinson’s disease (Guilarte, 2013). Manganism also shares some pheno-
typic similarities with the NCLs, including cognitive and visual impairment, and mo-
tor dysfunction (Kanninen et al., 2013b). At the cellular level, excess manganese has
been associated with ER stress (Chun et al., 2001; Xu et al., 2013a), alpha-synuclein
over-expression and aggregation (Xu et al., 2013b, 2014), mitochondrial dysfunction
(Malecki, 2001), oxidative stress, and ultimately apoptosis (Farina et al., 2013); all
of which are similarly seen in juvenile CLN3 disease. It is also interesting to note
that astrocytes, which become activated prior to neuronal loss in juvenile CLN3 dis-
ease, are the primary cell type affected by excess manganese. Although the pre-
cise mechanisms of Mn2+ neurotoxicity are not completely understood, it is thought
to arise in part from Mn2+ mediated mitochondrial dysfunction and energy insuffi-
ciency (Sidoryk-Wegrzynowicz and Aschner, 2013) - features similarly shared in ju-
venile CLN3 disease. Lastly, increased accumulation of manganese in astrocytes also
alters glutamate homeostasis and causes excitatory neurotoxicity (Farina et al., 2013;
Sidoryk-Wegrzynowicz and Aschner, 2013), which again is seen in juvenile CLN3 dis-
ease patients. It remains to be seen whether the neuronal specificity of juvenile CLN3
disease reflects a mutation-specific exacerbation of this fundamental sensitivity, leading
to dyshomeostasis between astrocytes and neurons.
Considering the above information, it is potentially intriguing to speculate that
an inability to respond to, and tolerate, excess Mn2+ might indeed play an important
pathogenic role in juvenile CLN3 disease. However, it should be noted that Grub-
man et al. (2014) did not observe any statistically significant changes in the manganese
concentrations of whole CNS tissue of 6 month or 12 month old Cln3∆ex1-6 knock-out
mice. However, Mn2+ homeostasis in the brain is poorly understood and given the re-
sults reported here, it might be of interest for future work to more precisely measure
manganese concentrations in different cellular components, although this is technically
challenging. An alternative strategy might be to test the function of various enzymes
which use Mn2+ as an integral component or co-factor, including glutamine synthetase,
mitochondrial superoxide dismutase, arginase, and pyruvate carboxylate to name a few.
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Lastly, the manganese concentration used here to challenge the yeast model was 10,000
fold higher than ordinarily experienced when yeast are cultured in EMM media. This
is an extreme increase in concentration, and was used predominately due to the exper-
imental ease with which it was able to rapidly induce a phenotypic difference between
wild-type and btn1∆ cells which formed the basis of the rescue experiments. It would,
therefore, be of interest to test the ability of mammalian systems to tolerate more sub-
tle levels of manganese (and other biometals) that might be more pathophysiologically
relevant. A role for CLN3 (and the other NCL genes) in biometal homeostasis should
be clarified given that metal-targeting therapeutics have shown promising efficacy in
other neurodegenerative diseases (Farina et al., 2013; Grubman et al., 2014).
8.2.1.4 Osmotic Stress
One discrepancy between this work and previously published literature is the role of
btn1+/CLN3 in osmotic stress. As described in Chapter 4 (p.108), btn1∆ cells were
not found to be sensitive to either hypo- or hyper-osmotic stress during the course of
this work. This finding was unexpected however, as CLN3 has previously been sug-
gested to have a role in osmotic regulation in other models. The first such suggestion
came from the observation that culturing human fibroblasts in sucrose, to create osmot-
ically swollen lysosomes, induces the expression of several lysosomal genes including
CLN3 (Helip-Wooley and Thoene, 2004). More notably, experiments using the knock-
in Cln3LacZ/LacZ reporter mouse (Eliason et al., 2007) have shown that Cln3 expression
within the kidney is osmoregulated, and that its expression gradient reflects the os-
motic gradient of the renal medulla (Stein et al., 2010). In the absence of Cln3, this
mouse strain suffers mild defects in renal water balance and K+ secretion, although
no renal symptoms have yet been reported in patients. Hyperosmolarity, achieved by
using NaCl, urea or sucrose, similarly causes CLN3 up-regulation in baby hamster kid-
ney (BHK) cells (Getty et al., 2013). The same condition also alters the sub-cellular
localisation of myc-tagged CLN3 away from the perinuclear region and enhances its
lysosomal localisation (Getty et al., 2013). Although the relevance of attenuated CLN3
expression and localisation was not explored by Getty et al, others have reported an ab-
normal blood-brain barrier response to osmotic stress in the Cln3LacZ/LacZ mouse strain
(Tecedor et al., 2013). Most recently, GFP-Cln3 has been reported to localise to the
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Dictyostelium contractile vacuole system which acts as an osmoregulatory organelle
(Huber et al., 2014). Interestingly however, and in agreement with the findings re-
ported here for btn1∆ yeast, Cln3-deficient Dictyostelium are not sensitive to osmotic
stress. It is therefore possible that while CLN3 expression may well be osmotically
responsive and involved to some extent in osmoregulation, it is largely dispensable for
the complete tolerance to osmotic stress. Indeed, despite the vacuole defects seen upon
deletion of btn1+, it has previously been reported that btn1∆ vacuoles are still capable
of the appropriate fusion response to osmotic stress (Gachet et al., 2005) which may
explain the tolerance to osmotic stress. Alternatively, while many stressors can be re-
layed to the CWI by both Rho1 and Rho2, Pmk1 activation induced by osmotic stress is
channelled solely through Rho2-Pck2 (Barba et al., 2008). One intriguing explanation
for the lack of osmotic stress sensitivity in btn1∆ cells is that only the Rho1 specific
arm of the CWI is dysfunctional when btn1+ is absent, allowing such cells to remain
tolerant to osmotic stress. More in depth experiments, which should also more rigor-
ously challenge cells to osmotic stress, are warranted to confirm the btn1∆ tolerance to
osmotic stress and uncover its molecular basis.
8.2.2 Links to Other Cellular Phenotypes
The main body of this thesis led to the development and exploration of the hypothesis
that btn1+ is required for stress signalling. It has then gone on to show that the inves-
tigated btn1∆ phenotypes can be rescued by manipulations to well understood stress
pathways, implicating their (dysfunctional) involvement in the manifestation of these
phenotypes. The phenotypes investigated can all be considered as sensitivities to en-
vironmental stress conditions (heat, nutrient deprivation, excess biometals etc) but as
explained in the Introduction, juvenile CLN3 disease has been associated with a number
of other cellular phenotypes. These include, but are not limited to defects in autophagy,
cytoskeletal organisation, lipid synthesis/modification, cell polarity and migration, ER
stress, mitochondrial dysfunction, and increased levels of apoptosis. Should the pri-
mary cellular defect arising from btn1+/CLN3 loss truly be compromised stress re-
sponses, then it is not immediately obvious how (or if) these other phenotypes - unlike
the environmental stress defects investigated in most detail here - could arise from de-
fective stress responses. One of the major avenues for future work should therefore
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be to test the involvement of the MAPK and TOR signalling in these phenotypes, and
perhaps more importantly to test the ability of their manipulation to rescue them.
However, and although highly speculative at this stage, there is reason to believe
that altered stress responses could underlie a variety of these phenotypes. For example,
as discussed above, unresolved biometal dyshomeostasis could secondarily lead to a
number of cellular phenotypes and symptoms seen in patients, and the same could be
true for other forms of unresolved stress.
Aberrant stress signalling can also be postulated to lead more directly to some of
these reported defects. There is perhaps most support for this hypothesis with respect to
TOR signalling. Dysregulated mTOR activity, specifically hyperactive mTORC1 activ-
ity, has been reported in numerous neurodegenerative disorders including Alzheimer’s,
Parkinson’s, Huntington’s disease as well as epilepsies (Swiech et al., 2008; Meng
et al., 2013). More specifically, the proper functioning of mTOR is required to control
a myriad of cellular processes, many of which are reported to be defective in juve-
nile CLN3 disease. For example, there is now an increasing recognition of a connec-
tion between TOR signalling and the ER stress response (or unfolded-protein response
(UPR)) (Appenzeller-Herzog and Hall, 2012), a process thought to be involved in the
pathogenesis of juvenile CLN3 disease (Wu et al. (2014) and Dr Davide Marotta (un-
published)) as well as other neurodegenerative disease. Although the cross-talk be-
tween TOR signalling and the UPR is highly complex, for the relevance of this work
it is interesting to note the emerging reports whereby cell toxicity due to ER stress
is coupled to the chronic activation of mTORC1. For example, TSC disease exhibits
hyperactive mTORC signalling and also includes the activation of ER stress pathways
(Appenzeller-Herzog and Hall, 2012), as is juvenile CLN3 disease. Intriguingly, both
disorders present with epileptic seizures. The down-regulation of translation occurs
both as a result of TORC1 inhibition and during the UPR, and as shown in Chapter
5 (p. 129), pharmacologically inhibiting translation partially rescued the heat sensi-
tivity phenotype of btn1∆ strain. This adds yet further support to the hypothesis that
hyperactive, or chronic activation of TORC1 is detrimental in the absence of btn1+, and
potentially strengthens the limited reports linking CLN3 to the ER response (Wu et al.,
2014).
ER stress has also recently been shown to affect budding yeast vacuole morphol-
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ogy in a TORC1 dependent manner (Stauffer and Powers, 2015), and a similar mech-
anism may therefore explain the vacuole defects observed in the btn1∆ fission yeast
strain. Fission yeast that lack tsc1+ or tsc2+ (which ordinarily act to inhibit TORC1 as
mentioned above) have decreased uptake of arginine, as do budding yeast, mice models,
and patients lacking BTN1+/CLN3 (Kim et al., 2003; Ramirez-Montealegre and Pearce,
2005; Chan et al., 2009). The over-expression of a dominant negative rhb1+, which
rescues all btn1∆ phenotypes explored in this work, has also been shown to rescue the
defective arginine transport of tsc2∆ cells (Van Slegtenhorst et al., 2004). mTORC1
signalling has also been implicated in F-actin localisation, polarity, and cell migration
(Li et al., 2008; Morita and Sobueˇ, 2009; Liu and Parent, 2011). Finally, mTOR sig-
nalling also regulates the surface expression of AMPA receptors (Swiech et al., 2008),
a process that is defective in juvenile CLN3 disease patients (Kova´cs et al., 2015) and
is thought to lead to AMPA-type glutamate receptor-mediated toxicity.
8.2.3 Summary
In summary, this work has revealed that btn1+ likely shares a role with stress response
genes, in particular those involved in the MAPK and TOR pathways. btn1∆ cells show
a multitude of phenotypes consistent with dysregulated stress signalling, including an
intolerance to increased heat, enlarged vacuoles, a sensitivity to nutrient starvation, and
a sensitivity to excess manganese. All of these phenotypes are fully rescued by the
overexpression of btn1+. That aberrant stress signalling underlies these phenotypes
is supported by experiments showing that they can be rescued by manipulating the
MAPK or TOR pathways; a finding which has additional implications for therapeutic
developments as discussed in more detail below. Importantly however, this Chapter
has also provided insight into how the dysregulation of stress signalling could not only
give rise to increased cell death upon environmental stress, but could also lead directly
or indirectly (via a failure to maintain cellular homeostasis) to a host of other cellular
and symptomatic findings previously reported in juvenile CLN3 disease models and
patients. These include ER stress, disrupted autophagy, decreased arginine transport,
altered AMPA receptor expression and excitotoxicity, mitochondrial dysfunction, and
epileptic seizures. Although more work is clearly required, it remains tempting to
speculate that the disruption of appropriate stress signalling as a result of a disease
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Figure 8.1: Revised working hypothesis detailing the proposed role of btn1+. In the
absence of btn1+, it is hypothesised that there is a failure to support the normal stress re-
sponses seen in wild-type cells and as detailed in the box on the left hand side of the figure
(CWI = cell wall integrity; SAPK = stress associated protein kinase pathway; TORC1/2
- Tor kinase complexes 1 and 2). Precisely why this occurs is still unknown (see Future
Work in the main text) but it is further hypothesised that defective stress responses lead
to compromised cellular homeostasis and a variety of pleiotropic and seemingly disparate
phenotypes in btn1∆ cells (see main text for explanation). Phenotypes directly investi-
gated as part of this work are shown in bold. The up-regulation of the CWI pathway
and inhibition of TORC1 can fully rescue btn1∆ cells back to wild-type and therefore
represent potential therapeutic options for juvenile CLN3 disease.
mutation could underlie what have long been considered to be disparate phenotypes
and symptoms. A revised working hypothesis is shown in Figure 8.1.
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8.3 Therapeutic Findings
Juvenile CLN3 disease, like all forms of NCLs, currently does not have a satisfactory
treatment that prevents or delays disease development. A lack of understanding of gene
function and disease pathogenesis can complicate therapeutic developments, yet one
path to treatment is to develop extensive genetic networks in which a disease gene or-
dinarily functions, and then target therapies to other genes identified in those networks.
At the outset of this work, it was therefore hoped that the evolutionary conservation
of yeast would allow the network information derived from the SGAs performed with
the btn1∆ model to better focus subsequent work in higher models, which remain a
prerequisite for pre-clinical studies. Accordingly, this work provides the rationale that
therapeutics which are able support normal stress responses may show some benefit in
the treatment of juvenile CLN3 disease. Indeed, as discussed above, that altered stress
signalling may directly or indirectly underlie numerous juvenile CLN3 disease defects
makes this process a particularly attractive target for future work.
This hypothesis was explored in Chapter 5 (p. 129) by using genetic, and where
possible, pharmacological means to manipulate MAPK and TOR signalling in btn1∆
cells. The manipulations of the CWI, SAPK, and both TOR complexes led to varying
degrees of rescue, making all these pathways prospective therapeutic targets. However,
the most promising finding was the firm establishment of two genetic manipulations,
further supported by pharmacological data, that were found to be capable of fully res-
cuing all of the btn1∆ phenotypes investigated; the up-regulation of the CWI pathway
(by the over-expression of rho1+) and the inhibition of TORC1 (by the over-expression
of a dominant negative rhb1+ and through the use of rapamycin). This is the most com-
plete rescue of phenotypes that has been achieved in any juvenile CLN3 disease model
to date.
Encouragingly, that the manipulation of such conserved pathways could be bene-
ficial for the treatment of juvenile CLN3 disease has wider support from other systems.
For example, the activation of the ERK pathway is beneficial in Huntingtons disease
(Apostol et al., 2006; Maher et al., 2011). Perhaps more interestingly, dual-specificity
phosphatases - which de-phosphorylate and inactivate members of the MAP kinase
superfamily - have also been proposed to be suitable therapeutic targets for various hu-
man diseases (Ducruet et al., 2005; Rı´os et al., 2014). Juvenile CLN3 disease patients
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show an up-regulation of DUSP2 mRNA, which encodes for an inducible protein that
negatively regulates ERK1/2, p38, and JNK (Lebrun et al., 2011). Whether this is a
pathological finding is yet to be ascertained, but it could be predicted that increased
DUSP2 levels could adversely impact on MAPK signalling and as of such, a therapy
that inhibits DUSP2 could offer a benefit for juvenile CLN3 disease, just as increasing
MAPK signalling is beneficial in the btn1∆ model. However, caution should be noted
as the constitutive activation of MAPK signalling has also been associated with neu-
ronal death, and pharmacological inhibitors of these pathways (as opposed to activators
which are considered beneficial in this model) have similarly gained attention as poten-
tial therapeutic targets for neurodegeneration (Harper and Wilkie, 2003; Borsello and
Forloni, 2007). The manipulation of these pathways, if helpful, will therefore likely
need to be done in a highly accurate, finely-tuned, and potentially temporal manner.
However, it may be of greater promise for future work to focus on the manipulation
of the TOR signalling pathways. Not only has this work found TORC1 repression to be
highly effective in rescuing btn1∆ phenotypes, but a neuroprotective role for TORC1
repression is also well established in epilepsies and other neurodegenerative diseases.
For example, rapamycin (which, importantly, is able to pass the blood-brain barrier (Se-
hgal et al., 1975)) has been shown to protect against dopaminergic neurodegeneration
in mice models of Parkinson’s disease (Dehay et al., 2010; Malagelada et al., 2010),
enhance mis-folded protein clearance in experimental cellular models of Huntington’s
disease (Ravikumar et al., 2002), protect against neurodegeneration in animal models
Huntington’s disease (Ravikumar et al., 2004), and ameliorate amyloid-β pathology in
mice models of Alzheimer’s disease (Caccamo et al., 2010; Spilman et al., 2010). Ra-
pamycin has similarly shown a therapeutic benefit in rare forms of neurodegeneration
including spinocerebellar ataxia type 3, amyotrophic lateral sclerosis, and HIV demen-
tia (Bove´ et al., 2011), and has gained attention as a possible treatment for epilepsies
(Zeng et al., 2009). Lastly, and with particular relevance to juvenile CLN3 disease,
rapamycin has been shown to limit photoreceptor degeneration and dysfunction arising
from defective mitochondria in mice (Zhao et al., 2011), while mTORC1 inhibition
by other means also exerts cardioprotective effects (Wu et al., 2013). Interestingly,
mTORC1 inhibition has been shown to lead to the activation of the ERK/MAPK path-
way in certain human patients (Carracedo et al., 2008), which from this work could be
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predicted to be an additional benefit from rapamycin treatment given the up-regulation
of the orthologous MAPK pathways in yeast is also advantageous.
Various mechanisms have been proposed to explain the beneficial effects of ra-
pamycin, including increased autophagy and a decrease in protein synthesis. These are
unlikely to be mutually exclusive however, and may instead act in concert to underlie
the therapeutic effects of rapamycin. Indeed, it can be speculated that both processes
would be important targets for the treatment of juvenile CLN3 disease; as shown in
Chapter 5 (p.129), the isolated efforts to reduce protein synthesis partially benefited
btn1∆ cells, and rapamycin alone (which does not induce autophagy in fission yeast
unless in combination with caffeine) was also able to rescue certain phenotypes. This
raises the possibility that other therapies that more specifically target these processes,
as opposed to upstream regulators, could also make good therapeutic options for juve-
nile CLN3 disease. Alternatively, they could be used alongside rapamycin to improve
its effects since rapamycin alone is unable to fully inhibit mTORC1 (Edinger et al.,
2003; Zhou et al., 2013). Indeed, mTOR-independent inducers of autophagy have been
shown to have additive effects with rapamycin at least in terms of clearing aggregate-
prone proteins (Sarkar et al., 2007, 2009), and the use of ER stress alleviating drugs as
an adjunct to rapamycin has previously been proposed for TSC, renal nephropathies,
and type 2 diabetes mellitus (Appenzeller-Herzog and Hall, 2012).
However, it should be noted that the chronic and long-term administration of ra-
pamycin, which is likely to be required for a progressive disease such as juvenile CLN3
disease, does pose some problems. Although rapamycin is considered as a specific in-
hibitor of mTORC1, and does not physically interact with or acutely inhibit mTORC2,
chronic rapamycin treatment can nonetheless reduce mTORC2 function by compromis-
ing complex integrity (Sarbassov et al., 2006). This can be predicted to be detrimental
in the context of juvenile CLN3 disease as this work has shown that reducing TORC2
function in btn1∆ cells (through the deletion of tor1+) reduces fitness, and accord-
ingly that increasing TORC2 activity (through the over-expression of gad8+) is at least
partially protective. Chronic rapamycin treatment can be further predicted to be prob-
lematic as, at least in some cell types, rapamycin reduces mTORC2 activity to levels
below those needed to maintain Akt/PKB signalling, a pro-survival pathway that is re-
quired to counteract neuronal death in experimental models of neurodegeneration (Ries
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et al., 2006; Sarbassov et al., 2006). Indeed, it should be noted that general Tor antago-
nists (e.g. Torin1) which inhibit both TORC1 and TORC2 do not elicit neuroprotective
outcomes (Malagelada et al., 2010). mTOR also has important physiological roles in
development, and in adulthood supports neuronal activity and is essential for synaptic
plasticity (Swiech et al., 2008) and so complete inhibition is unlikely to be beneficial.
Nonetheless, future work should build on the results presented here and continue to
test the ability of mTOR inhibition to evoke beneficial effects in juvenile CLN3 disease
models. The use of mTOR independent drugs to alter autophagy and protein translation
should also be investigated accordingly, and could also help delineate the contributions
of each process to disease pathogenesis. Such work will also need to determine the age
at which treatment should start, its duration, and dose.
One final finding of this work which should be used to inform any future thera-
peutic developments is that certain genetic manipulations (e.g. the over-expression of
wis1DD, gad8+, and pmr1+) were able to restore the vacuole diameter but no other
btn1∆ phenotype. Therefore, while earlier work suggested that juvenile CLN3 diseases
therapies should include a component that promotes lysosome acidification (Codlin
et al., 2008a), it would now seem apparent that a treatment that solely restores the lyso-
somal related features of juvenile CLN3 disease may not be sufficient to reverse the
pathology of this disease.
8.4 Future Work
Some recommendations for future work have already been introduced in this chapter,
for example the need to investigate the potential contributions of stress signalling in the
manifestation of other btn1∆/juvenile CLN3 disease phenotypes not examined in this
work. Similarly, given the profound rescue achieved through CWI and TORC1 manip-
ulations, it will also be of particular interest to determine whether these manipulations
are pervasive enough to rescue other phenotypes as well.
Further suggestions for future work can however also come from recognising that
some questions around the pathogenesis of juvenile CLN3 disease remain unresolved,
and that there are limitations to the work presented here. These will be discussed in
more detail below, together with some final perspectives on the work needed to continue
the findings reported here.
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8.4.1 Unresolved Questions
While the fundamental function of CLN3 is unknown, it was outlined in the Intro-
duction (p. 19) that other questions about juvenile CLN3 disease are unresolved. For
example, what (if anything) mechanistically links the NCL subtypes and why are neu-
rons specifically lost upon the mutation of CLN3 or other NCL genes? Although this
work has done little to resolve these questions, it might be of interest that defects in
JNK signalling have also been associated with infantile NCL (Buff et al., 2007), and
defects in TOR signalling are associated with late-infantile NCL (Vidal-Donet et al.,
2013). Most recently, a significant down-regulation of RhoA (the rho1+ orthologue)
signalling has been reported in the brains of symptomatic mice models of human in-
fantile CLN1 disease (Tikka et al., 2015). The dysregulation of MAPK, and TOR
signalling is also associated more widely with other neurodegenerative disorders, in-
cluding Alzheimer’s, Parkinson’s and Huntington’s disease (Swiech et al., 2008; Kim
and Choi, 2010). Future work to better understand whether impaired stress signalling
indeed represents a broad mechanistic link between the NCLs could reveal important
biology that could accelerate the understanding of each of the distinct subtypes. In
terms of the neuronal specificity, it is possible that neurons and associated cell types
are indeed simply more sensitive to unresolved stress than other cell type by virtue of
their complex, and post-mitotic nature. Indeed, as mentioned above, astrocytes have
a particularly low tolerance to excess manganese, and neurons are well known to be
susceptible to stress-induced damages as they cannot take advantage of the continu-
ous dilution of such damage through cell replication. Future work would benefit from
confirming whether this hypothesis is true, as it may help determine whether therapies
need to focus on neuronal cells, a subset of specific cell types, or act more systemically.
8.4.2 Limitations
Although perhaps an ostensibly unlikely model for a neurodegenerative disease,
this work has shown value by playing to the strengths of the btn1∆ fission yeast
model, namely through exploiting its ability to be used for genome-wide experiments.
Nonetheless, fission yeast does of course have some obvious differences and certain
shortcomings compared to patient cells and other higher eukaryotic models. Firstly,
the work presented here has all been obtained from a complete null model, whereas
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patients most commonly harbour an intragenic deletion which is known to retain some
function. The null model is an appropriate approach given that the primary focus of
this thesis was to determine the fundamental function of btn1+, yet it would be of in-
terest for future work to establish the role of aberrant stress signalling in yeast strains
modelling common CLN3 mutations. The phenotypic characterisation of such mod-
els has previously been done with respect to the cell wall, vacuole, and heat defects,
and it would be of benefit to further clarify the environmental stress phenotypes as
well. Identifying differences and commonalities between the various mutant models
has the power to further identify the functional domains of btn1+, and highlight the
most demonstrable disease phenotype(s) which in turn could be used to narrow down
the pathogenesis of disease and better focus therapeutic options. Indeed, future studies
investigating the therapeutic options presented above would offer the most benefit if
they were performed not only in the null model, but also in the context of a clinically
relevant disease mutation.
Secondly, cellular pathways are conserved between yeast and higher eukaryotes,
meaning that genotype-phenotype information derived from yeast can often be directly
extrapolated to other species. However, it would be naive to ignore the limitation that
arises from yeast being an unicellular model when the neuronal cells most obviously
affected by CLN3 mutations instead exist in a complex milieu of other cell types. The
most obvious avenue for future work is therefore to investigate whether the functional
and therapeutic findings reported in this work hold true in higher eukaryotes.
8.4.3 Other Avenues of Future Work
Based on phenotypic similarities with a strain lacking the Ca2+ ATPase pmr1+, and
supported by other published data, it was hypothesised in Chapter 6 (p.151) that btn1+
might act as a transporter for Ca2+ and/or Mn2+ ions. In turn, it was reasoned that
dyshomeostasis in these ions upon btn1+ deletion could cause compromised CWI and
hyperactive TORC1 signalling, and the resulting phenotypic defects observed in btn1∆
cells. However, the data presented in Chapter 6 did little to support this hypothe-
sis, meaning that the precise molecular mechanism by which the functional loss of
btn1+/CLN3 results in poor stress responses remain elusive.
To help clarify its function, it would be of interest to determine the mRNA and
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protein levels of the various stress responses genes explored in this work and determine
whether their localisation patterns remain as wild-type. This could be done both under
normal and stress conditions, and across a range of time-points. Performing SGAs un-
der multiple stress conditions to identify conditionally synthetic interactions might also
be informative (Martin et al., 2015) as will performing them in a strain harbouring dif-
ferent btn1+ mutations since this could help identify gene function at domain level res-
olution (Braberg et al., 2014). Therefore, although there is a need to translate this work
as mentioned above, the btn1∆ yeast model remains a desirable platform from which
to continue exploring the molecular function of btn1+. Furthermore, the manganese
sensitivity phenotype is already being used in ongoing work to perform chemical/drug
screens to identify additional drugs which may prove as suitable therapeutics (Dr Elisa
Tinelli, University College London).
There is also a wealth of data from the already performed SGA which has, as of
yet, not been exploited. For example, pairs of genes with similar genetic interaction
profiles frequently encode proteins that belong to the same protein complex or work in
the same functional pathway (Roguev et al., 2008; Costanzo et al., 2010; Ryan et al.,
2012). There are a number of different software’s (e.g. FitSearch (Lee et al., 2013)) and
profile similarity measures (Deshpande et al., 2013) which should therefore be used to
find other mutants with similar interaction profiles as revealed here for btn1∆, as such
information may be of particular value. Furthermore, this work focused solely on genes
relating to stress, meaning many other genetic interactions revealed through the SGA
remain unexplored. It may be of particular interest for future work to investigate the
contributions of particularly strong negative (i.e. fully synthetic lethal) and positive
interactions since the information contained in the varying strengths of genetic interac-
tions can be highly useful for determining the organisational structure of the cell and
clarifying gene function (Collins et al., 2006). Particularly strong positive interactions
might also be investigated as alternative therapeutic targets.
Data from genetic interaction mapping can also be integrated with other types of
data such as protein-protein interactions or gene expression data to provide yet more
insight into protein complexes, cellular components, and the higher-order genome or-
ganisation (Bandyopadhyay et al., 2008; van Opijnen and Camilli, 2013). Such infor-
mation could help further narrow the biological context in which btn1+ functions, and
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thus better elude to the fundamental, molecular role of btn1+. It would therefore be of
interest to further generate such data and in doing so develop a multifaceted screening
pipeline of complementary approaches. By considering such data alongside the genetic
data presented here, areas of overlap could be identified in order to help focus future
work and generate hypotheses. It is hoped that data from the optimised Hermes muta-
genesis approach, discussed in Chapter 7 (p.171), could also be incorporated into this
strategy the future.
8.5 Conclusion
This work has been successful in exploiting the fission yeast model for juvenile CLN3
disease in order to allow the accelerated and economical identification of genetic in-
teractions of btn1+ - the orthologue of CLN3. These genetic interactions have been
validated by functional data, and in doing so have led to the increased understand-
ing that btn1+ is required for the appropriate responses to stress. Accordingly, aberrant
stress responses have been implicated in the manifestation of various btn1∆ phenotypes
and, by extrapolation, in the pathogenesis of juvenile CLN3 disease. Stress response
pathways have previously been shown to be dysregulated not only in other NCLs, but
in other more common neurodegenerative diseases, providing strong biological plausi-
bility for the importance of the genetic interactions reported here. Although more work
needs to be done to decisively define the molecular function of CLN3, it is hoped that
this work represents a considerable step in doing so by better elucidating the cellular
defects underlying juvenile CLN3 disease and by offering a more focused avenue for
future work.
Lastly, it is important to reiterate that among the interactions investigated, over-
expressing rho1+ to up-regulate the CWI pathway, and repressing TORC1 function by
a dominant negative rhb1+ allele, led to a complete rescue of all btn1∆ phenotypes
investigated. This noteworthy rescue is the most successful in any model for juvenile
CLN3 disease to date, and therefore this work has notable and important implications
for future therapeutic developments.
Appendix A
btn1∆ Strain Characterisation
The five independent btn1+::NatMX6 strains created as part of this work and described
in Chapter 3 were subjected to a characterisation using a number of phenotypes previ-
ously defined in the btn1+::leu2+ strain Gachet et al. (2005); increased cell length, in-
creased vacuole diameter, and a heat sensitivity. During these characterisation attempts
it was noted that while some isolates recapitulated the btn1+::leu2btn1+ strain, others
showed a varying penetrance of these phenotypes, and one isolate remained indistin-
guishable from the parental wild-type under all conditions tested. It was also revealed
that the majority of these btn1∆ isolates were phenotypically different from parental
strains with regards to nutrient auxotrophies, and therefore also from their supposed
genotype.
Rigorous PCR screens established that these isolates have not retained the full
btn1+ coding sequence so the cause of this disparity is unclear, although it is possible
that the ecoptic retention of a partial coding sequence can protect against deleterious
effects. Alternatively, it has been shown in budding yeast that the loss of a coding se-
quence can be sufficient to rapidly drive adaptive genetic changes (Teng et al., 2013).
It is possible that these isolates may have developed a second site mutation that acts
as a suppressor of the loss of btn1+, and that a high rate of occurrence reflects the
fundamental need for this gene as presumed from its high level of evolutionary con-
servation. It might be of interest for future work to rigorously expose these isolates to
whole-genome sequencing in order to confirm or reject these hypotheses. The charac-
terisation findings are detailed below. Of note, all phenotypes tested and observed in
the btn1∆ isolate (SP29) used for the majority of this work were confirmed to be linked
to the loss of btn1+ through their rescue by the over-expression of pREP41x.GFPbtn1+.
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A.1 Marker Phenotypes
Of the two btn1+::NatMX6 isolates created from the SP23 wild-type strain, only the
first isolate (SP29) showed a significant increase in cell length, vacuole diameter, and
heat sensitivity (Figure A.1 A, B + C). The second isolate (SP30) was indistinguishable
from wild-type, despite lacking the entire btn1+ sequence. None of the btn1+::NatMX6
isolates created from the SP38 wild-type strain showed a change in cell length or vac-
uole size despite also lacking the btn1+ sequence (Figure A.1 A + B). The heat sensi-
tivity was however reproduced in all three isolates (Figure A.1 D).
A.2 Auxotrophic Differences
The loss of btn1+ in fission yeast has previously been linked to metabolic defects, in-
cluding an increased glycolytic flux and amino acid dyshomeostasis (Pears et al., 2010).
However, during the course of this work it was also found that most btn1∆ isolates are
phenotypically different from parental strains with regards to nutrient auxotrophies.
For example, the SP23 wild-type strain is auxotrophic for adenine, leucine and
uracil. However, the first btn1+::NatMX6 isolate made from this background (SP29)
showed a clear reversion from adenine auxotrophy, although remains auxotrophic for
leucine and uracil. The second btn1+::NatMX6 isolate made from this background
(SP30) did however remain indistinguishable form the wild-type with regards to these
auxotrophies. The SP38 wild-type strain is auxotrophic for adenine, leucine, uracil,
and also histidine. After removing the btn1+ coding sequence, btn1+::NatMX6 isolates
1 and 2 (SP35 and 36) appeared phenotypically prototrophic for adenine, histidine and
leucine. Isolate 3 (SP37) also appeared prototrophic for adenine, and partially for his-
tidine, although remained auxotrophic for leucine and uracil.
This striking phenotype has not been reported before, but is not altered by the
over-expression of btn1+ (data not shown). However, the vacuole serves as the major
storage compartment for amino acids, and disrupted vacuole function can lead to the
impaired uptake of several amino acids (Chardwiriyapreecha et al., 2008; Sugimoto
et al., 2010). Sufficient levels of amino acids are in turn required for adequate growth,
stress resistance and chronological longevity (Gomes et al., 2007). Although there are
differences between vacuoles in budding and fission yeast, work in S. cerevisiae has
also shown that even subtle limitations in amino acids can affect vacuolar morphology
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Figure A.1: Marker phenotypes of the btn1+::NatMX6 strains. [A] Strains were grown
overnight in EMM and stained with calcofluor-white to stain the cell wall. The cell length
of 500 cells was determined per data set, and the graph shows the mean ± SEM of three
independent experiments. Statistical differences were identified by a one-way ANOVA
and post-hoc Tukey analysis (*** = P ≤ 0.001). [B] Strains were grown overnight in
EMM and stained with FM4-64 to visualise the vacuoles. The diameter of 300 vacuoles
was determined per data set, and the graph shows the mean ± SEM of three independent
experiments. Statistical differences were identified by a one-way ANOVA and post-hoc
Tukey analysis (**** = P ≤ 0.0001). [C] + [D] 10-fold serial dilutions of logarithmic
cultures were spotted onto YES media and incubated at 30◦C or 37◦C for 3 days. The
most concentrated spot contains 106 cells. Image is representative of 3 independent ex-
periments.
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(C¸akar et al., 2000), further highlighting an intimate relationship between vacuoles and
amino acid availability. Therefore, given that btn1+ has previously been implicated in
vacuole function (Gachet et al., 2005; Kitzmu¨ller et al., 2008), it can be speculated
that vacuolar defects arising from the loss of btn1+ place cells under strong selective
pressure to specifically revert to nutrient prototrophy, making the observed phenotype
an important - and permanent - adaptive change. Whether this arises from changes at
the genetic level is not clear.
Appendix B
SGA Hits Gene List
Table B.1: Negative Interaction Data Set. 131 genes were found to negatively interact
with btn1+. Stress response genes (identified through the AnGeLi software, Pombase, and
Chen et al. (2003)) are shown in bold. Gene names and descriptions were identified using
the Pombase Gene List Search Tool.
Systematic ID Name Description
SPAC1002.07c ats1 N-acetyltransferase Ats1 (predicted)
SPAC11G7.01 SPAC11G7.01 serine-rich Schizosaccharomyces specific
protein
SPAC1250.04c atl1 alkyltransferase-like protein Atl1
SPAC1296.01c SPAC1296.01c phosphoacetylglucosamine mutase (pre-
dicted)
SPAC1399.04c SPAC1399.04c uracil phosphoribosyltransferase (pre-
dicted)
SPAC13D6.01 pof14 F-box protein Pof14
SPAC13D6.02c byr3 translational activator, zf-CCHC type
zinc finger protein (predicted)
SPAC13D6.04c btb3 substrate adaptor for cullin 3 ubiquitin
ligase Btb3
SPAC13F5.01c msh1 mitochondrial MutS protein Msh1
(predicted)
SPAC13F5.03c gld1 mitochondrial glycerol dehydrogenase
Gld1
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Systematic ID Name Description
SPAC13F5.04c vta1 Vps20 associated protein Vta1 (pre-
dicted)
SPAC13F5.05 SPAC13F5.05 thioredoxin family protein (predicted)
SPAC13F5.07c hpz2 zf PARP type zinc finger protein
SPAC13G7.02c ssa1 heat shock protein Ssa1 (predicted)
SPAC13G7.09c SPAC13G7.09c conserved fungal protein
SPAC140.03 arb1 argonaute inhibitor protein 1
SPAC15A10.06 SPAC15A10.06 CPA1 sodium ion/proton antiporter (pre-
dicted)
SPAC1783.01 SPAC1783.01 methionine synthase reductase (pre-
dicted)
SPAC1783.06c atg12 autophagy associated ubiquitin-like
modifier Atg12
SPAC1783.07c pap1 transcription factor Pap1/Caf3
SPAC17A5.09c glc9 protein phosphatase regulatory subunit
Glc9 (predicted)
SPAC17A5.16 ftp105 Ubp5 interacting protein Ftp105
SPAC17A5.18c rec25 meiotic recombination protein Rec25
SPAC17G6.17 pof8 F-box protein Pof8
SPAC17G8.10c dma1 mitotic spindle checkpoint ubiquitin lig-
ase Dma1
SPAC17H9.03c rdl1 RAD51D-like protein 1
SPAC17H9.04c SPAC17H9.04c RNA-binding protein
SPAC17H9.06c SPAC17H9.06c conserved eukaryotic protein
SPAC17H9.11 gmf1 cofilin/tropomyosin family Glia Matura-
tion Factor homolog Gmf1
SPAC17H9.12c SPAC17H9.12c mitochondrial cytochrome c-heme
linkage protein Cyc2 (predicted)
SPAC17H9.14c pdi2 protein disulfide isomerase
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SPAC18G6.01c SPAC18G6.01c chalcone related protein family
SPAC18G6.02c chp1 chromodomain protein Chp1
SPAC18G6.05c SPAC18G6.05c translation elongation regulator Gcn1
(predicted)
SPAC18G6.10 lem2 LEM domain protein Heh1/Lem2
SPAC18G6.12c SPAC18G6.12c ThiJ domain protein (predicted)
SPAC18G6.13 SPAC18G6.13 Schizosaccharomyces specific protein
SPAC19A8.04 erg5 C-22 sterol desaturase Erg5
SPAC1A6.04c plb1 phospholipase B homolog Plb1
SPAC1B3.01c SPAC1B3.01c uracil phosphoribosyltransferase (pre-
dicted)
SPAC1B3.05 not3 CCR4-Not complex subunit Not3/5 (pre-
dicted)
SPAC1D4.03c aut12 autophagy associated protein Aut12 (pre-
dicted)
SPAC20G4.07c sts1 C-24(28) sterol reductase Sts1
SPAC20H4.03c tfs1 transcription elongation factor TFIIS
SPAC20H4.04 fml2 ATP-dependent 3’ to 5’ DNA helicase
(predicted)
SPAC20H4.05c SPAC20H4.05c 5’-methylthioribulose-1-phosphate dehy-
dratase, adducin (predicted)
SPAC20H4.06c SPAC20H4.06c RNA-binding protein
SPAC20H4.09 SPAC20H4.09 ATP-dependent RNA helicase, spliceoso-
mal (predicted)
SPAC20H4.10 ufd2 ubiquitin-protein ligase E4 (predicted)
SPAC20H4.11c rho5 Rho family GTPase Rho5
SPAC22H10.04 ppa3 protein phosphatase type 2A Ppa1
SPAC23C11.01 SPAC23C11.01 ER membrane protein, ICE2 family
SPAC23C11.06c SPAC23C11.06c hydrolase (inferred from context)
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SPAC23C11.07 SPAC23C11.07 Schizosaccharomyces pombe specific
protein
SPAC23C11.14 zhf1 zinc ion transporter Zhf1
SPAC23E2.01 fep1 iron-sensing transcription factor Fep1
SPAC23H3.11c SPAC23H3.11c glucosidase (predicted)
SPAC25A8.02 atg14 autophagy protein Atg14
SPAC32A11.02c SPAC32A11.02c conserved fungal protein
SPAC32A11.03c phx1 stationary phase-specific homeobox
transcription factor Phx1
SPAC3C7.01c sac12 inositol polyphosphate phosphatase (pre-
dicted)
SPAC3C7.02c pil2 meiotic eisosome BAR domain protein
Pil2
SPAC3C7.04 SPAC3C7.04 transcription factor (predicted)
SPAC3C7.05c mug191 alpha-1,6- mannanase (predicted)
SPAC3C7.06c pit1 serine/threonine protein kinase, mei-
otic Pit1
SPAC3C7.07c SPAC3C7.07c arginine-tRNA protein transferase (pre-
dicted)
SPAC3C7.09 set8 lysine methyltransferase Set8 (predicted)
SPAC3C7.10 pex13 peroxin 13 (predicted)
SPAC3C7.12 tip1 CLIP170 family protein Tip1
SPAC3C7.13c SPAC3C7.13c glucose-6-phosphate 1-dehydrogenase
(predicted)
SPAC3H1.06c SPAC3H1.06c membrane transporter (predicted)
SPAC3H1.10 pcs2 phytochelatin synthetase
SPAC3H1.12c snt2 Lid2 complex subunit Snt2
SPAC3H1.13 ppk13 serine/threonine protein kinase Ppk13
(predicted)
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SPAC3H1.14 SPAC3H1.14 cytoplasmic vesicle protein, Vid24 fam-
ily (predicted)
SPAC4G9.02 rnh201 ribonuclease H2 complex subunit
Rnh201 (predicted)
SPAC4G9.06c chz1 histone chaperone Chz1 (predicted)
SPAC4G9.09c arg11 N-acetyl-gamma-glutamyl-phosphate
reductase/acetylglutamate kinase
SPAC4G9.13c vps26 retromer complex subunit Vps26
SPAC4G9.14 SPAC4G9.14 mitochondrial Mpv17/PMP22 family
protein 2 (predicted)
SPAC4G9.20c SPAC4G9.20c mitochondrial carrier with solute car-
rier repeats, organic acid transmembrane
transporter (predicted)
SPAC56F8.02 SPAC56F8.02 AMP binding enzyme (predicted)
SPAC589.05c SPAC589.05c queuosine salvage protein
SPAC607.06c SPAC607.06c metallopeptidase (predicted)
SPAC607.07c SPAC607.07c Schizosaccharomyces specific protein
SPAC607.10 spo3 sporulation protein Spo3
SPAC631.01c acp2 F-actin capping protein beta subunit
Acp2
SPAC631.02 bdf2 BET family double bromodomain protein
Bdf2
SPAC664.01c swi6 HP1 family chromodomain protein Swi6
SPAC6C3.04 cit1 citrate synthase Cit1
SPAC6C3.05 SPAC6C3.05 Schizosaccharomyces specific protein
SPAC6C3.07 mug68 Schizosaccharomyces specific protein
Mug68
SPAC6F12.06 SPAC6F12.06 Rho GDP dissociation inhibitor Rdi1
(predicted)
SPAC6F12.09 rdp1 RNA-directed RNA polymerase Rdp1
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SPAC6G10.06 SPAC6G10.06 FAD-dependent amino acid oxidase in-
volved in late endosome to Golgi trans-
port (predicted)
SPAC732.02c SPAC732.02c fructose-2,6-bisphosphate 2-phosphatase
activity (predicted)
SPAC767.01c vps1 dynamin family protein Vps1
SPAC922.05c SPAC922.05c membrane transporter (predicted)
SPAC9G1.02 wis4 MAP kinase kinase kinase Wis4
SPAC9G1.04 oxa101 mitochondrial inner membrane translo-
case Oxa101
SPAC9G1.05 aip1 actin cortical patch component Aip1
SPAC9G1.06c cyk3 cytokinesis protein Cyk3 (predicted)
SPAC9G1.07 SPAC9G1.07 Schizosaccharomyces specific protein
SPAC9G1.08c SPAC9G1.08c phospholipase (predicted)
SPAC9G1.10c SPAC9G1.10c inositol polyphosphate phosphatase (pre-
dicted)
SPAC9G1.11c spn4 septin Spn4
SPAC9G1.12 cpd1 tRNA (m1A) methyltransferase complex
catalytic subunit Cpd1
SPAP11E10.01 SPAP11E10.01 ornithine cyclodeaminase family (pre-
dicted)
SPAP14E8.04 oma1 metallopeptidase Oma1 (predicted)
SPAP27G11.02 SPAP27G11.02 TPR repeat protein, involved in mito-
chondrial protein turnover (predicted)
SPAPB1A10.05 SPAPB1A10.05 Schizosaccharomyces specific protein
SPAPB1A10.12c alo1 D-arabinono-1,4-lactone oxidase (pre-
dicted)
SPAPB1A10.14 pof15 F-box protein (predicted)
SPBC1105.14 rsv2 transcription factor Rsv2
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SPBC11G11.03 mrt4 mRNA turnover and ribosome assembly
protein Mrt4 (predicted)
SPBC1604.12 SPBC1604.12 Schizosaccharomyces specific phospho-
protein
SPBC1652.02 SPBC1652.02 APC amino acid transporter (predicted)
SPBC1709.11c png2 ING family homolog Png2
SPBC26H8.03 cho2 phosphatidylethanolamine N-
methyltransferase Cho2
SPBC26H8.05c pph3 serine/threonine protein phosphatase,
PP4 complex subunit Pph3 (predicted)
SPBC2D10.17 clr1 cryptic loci regulator Clr1
SPBC2G2.03c sbh1 translocon beta subunit Sbh1 (predicted)
SPBC30D10.10c tor1 phosphatidylinositol kinase Tor1
SPBC409.07c wis1 MAP kinase kinase Wis1
SPBC428.03c pho4 thiamine-repressible acid phosphatase
Pho4
SPBC428.06c rxt2 histone deacetylase complex subunit
Rxt2
SPBC543.03c pku80 Ku domain protein Pku80
SPBC56F2.03 SPBC56F2.03 actin-like protein Arp10 (predicted)
SPCC126.15c sec65 signal recognition particle subunit Sec65
(predicted)
SPCC1902.01 gaf1 transcription factor Gaf1
SPCC24B10.22 pog1 mitochondrial DNA polymerase gamma
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SPAC1006.03c red1 RNA elimination defective protein Red1
SPAC1071.04c spc2 signal peptidase subunit Spc2 (predicted)
SPAC1071.08 rpp203 60S acidic ribosomal protein A2
SPAC1142.07c vps32 ESCRT III complex subunit Vps32
SPAC1142.08 fhl1 forkhead transcription factor Fhl1
SPAC11E3.08c nse6 Smc5-6 complex non-SMC subunit Nse6
SPAC13G6.02c rps101 40S ribosomal protein S3a
SPAC13G6.09 SPAC13G6.09 SSU-rRNA maturation protein Tsr4 ho-
molog 2 (predicted)
SPAC144.04c spe1 ornithine decarboxylase Spe1 (predicted)
SPAC144.11 rps1102 40S ribosomal protein S11 (predicted)
SPAC1486.01 SPAC1486.01 manganese superoxide dismutase (pre-
dicted)
SPAC1527.02 sft2 Golgi transport protein Sft2 (predicted)
SPAC1782.05 ypa2 protein phosphatase type 2A regulator,
PTPA family Ypa2
SPAC1782.11 met14 adenylyl-sulfate kinase (predicted)
SPAC17A5.07c ulp2 SUMO deconjugating cysteine peptidase
Ulp2 (predicted)
SPAC17C9.14 SPAC17C9.14 Pex19 protein (predicted)
SPAC17G8.13c mst2 histone acetyltransferase Mst2
SPAC1851.02 slc1 1-acylglycerol-3-phosphate O-
acyltransferase Slc1 (predicted)
SPAC1851.03 ckb1 CK2 family regulatory subunit Ckb1
SPAC19B12.11c SPAC19B12.11c zinc finger protein, human ZNF593 or-
tholog
SPAC1B2.04 cox6 cytochrome c oxidase subunit VI (pre-
dicted)
Continued on next page
227
Table B.2 – Continued from previous page
Systematic ID Name Description
SPAC1B3.16c vht1 vitamin H transporter Vht1
SPAC1F12.07 SPAC1F12.07 phosphoserine aminotransferase (pre-
dicted)
SPAC20G4.04c hus1 checkpoint clamp complex protein Hus1
SPAC222.08c SPAC222.08c glutamine aminotransferase subunit (pre-
dicted)
SPAC227.01c erd1 Erd1 homolog (predicted)
SPAC227.05 SPAC227.05 prefoldin subunit 4 (predicted)
SPAC22A12.04c rps2201 40S ribosomal protein S15a (predicted)
SPAC22F8.09 rrp16 rRNA processing protein Rrp16 (pre-
dicted)
SPAC22H10.11c SPAC22H10.11c TOR signalling pathway transcriptional
corepressor Crf1 (predicted)
SPAC23C11.04c pnk1 DNA kinase/phosphatase Pnk1
SPAC23C11.13c hpt1 xanthine phosphoribosyltransferase (pre-
dicted)
SPAC23G3.05c SPAC23G3.05c regulator of G-protein signalling (RGS)
domain (predicted)
SPAC23H3.13c gpa2 heterotrimeric G protein alpha-2 subunit
Gpa2
SPAC24B11.13 hem3 hydroxymethylbilane synthase Hem3
(predicted)
SPAC24H6.03 cul3 cullin 3
SPAC25A8.01c fft3 SMARCAD1 family ATP-dependent
DNA helicase Fft3
SPAC25G10.06 rps2801 40S ribosomal protein S28 (predicted)
SPAC25H1.07 emc1 ER membrane protein complex subunit
Emc1 (predicted)
SPAC26A3.06 bud23 rRNA (guanine) methyltransferase
Bud23 (predicted)
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SPAC26H5.05 mga2 IPT/TIG ankyrin repeat containing tran-
scription regulator of fatty acid biosyn-
thesis (predicted)
SPAC30.02c SPAC30.02c elongator complex associated protein
Kti2 (predicted)
SPAC30.03c tsn1 translin
SPAC30C2.07 SPAC30C2.07 Schizosaccharomyces specific protein
SPAC31G5.11 pac2 cAMP-independent regulatory protein
Pac2
SPAC31G5.17c rps1001 40S ribosomal protein S10 (predicted)
SPAC323.05c SPAC323.05c protein methyltransferase Mtq2 (pre-
dicted)
SPAC328.10c rps502 40S ribosomal protein S5 (predicted)
SPAC343.16 lys2 homoaconitate hydratase Lys2
SPAC343.19 lsb6 1-phosphatidylinositol 4-kinase Lsb6
(predicted)
SPAC3A12.10 rpl2001 60S ribosomal protein L20a (predicted)
SPAC3A12.13c SPAC3A12.13c translation initiation factor eIF3j (p35)
SPAC3G9.08 png1 ING family homolog Png1
SPAC3H8.05c mms1 E3 ubiquitin ligase complex subunit
Mms1 (predicted)
SPAC3H8.07c pac10 prefoldin subunit 3 Pac10 (predicted)
SPAC4F10.19c SPAC4F10.19c zf-HIT protein Hit1 (predicted)
SPAC4G9.15 SPAC4G9.15 ketoreductase (predicted)
SPAC521.05 rps802 40S ribosomal protein S8 (predicted)
SPAC56F8.09 rrp8 rRNA methyltransferase Rrp8 (predicted)
SPAC57A10.12c ura3 dihydroorotate dehydrogenase Ura3
SPAC5H10.06c adh4 alcohol dehydrogenase Adh4
SPAC630.14c tup12 transcriptional corepressor Tup12
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SPAC637.10c rpn10 19S proteasome regulatory subunit
Rpn10
SPAC664.02c arp8 actin-like protein, Ino80 complex subunit
Arp8
SPAC6B12.02c mus7 DNA repair protein Mus7/Mms22
SPAC6G10.08 idp1 isocitrate dehydrogenase Idp1 (predicted)
SPAC824.04 SPAC824.04 WD repeat protein (predicted)
SPAC890.05 SPAC890.05 ribosome biogenesis protein, G-patch
domain, PINX1 family (predicted)
SPAC8C9.07 SPAC8C9.07 rRNA processing protein Fyv7 (pre-
dicted)
SPAC8C9.19 SPAC8C9.19 conserved fungal protein
SPAC8F11.02c dph3 diphthamide biosynthesis protein Dph3
(predicted)
SPAC9.12c atp12 F1-ATPase chaperone Atp12 (predicted)
SPAC9.13c cwf16 splicing factor Cwf16
SPAC926.03 rlc1 myosin II regulatory light chain Rlc1
SPAC959.06c SPAC959.06c conserved fungal protein
SPAP27G11.14c SPAP27G11.14c Schizosaccharomyces pombe specific
protein
SPAP7G5.05 rpl1002 60S ribosomal protein L10
SPAP8A3.07c SPAP8A3.07c phospho-2-dehydro-3-deoxyheptonate
aldolase (predicted)
SPAPB1E7.06c eme1 Holliday junction resolvase subunit
Eme1
SPBC106.10 pka1 cAMP-dependent protein kinase catalytic
subunit Pka1
SPBC106.17c cys2 homoserine O-acetyltransferase (pre-
dicted)
SPBC119.12 rud3 Golgi matrix protein Rud3 (predicted)
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SPBC1198.08 SPBC1198.08 dipeptidase Dug1 (predicted)
SPBC1271.15c SPBC1271.15c mitochondrial translation initiation factor
IF-2Mt (predicted)
SPBC12C2.12c glo1 glyoxalase I
SPBC12D12.09 rev7 DNA polymerase zeta Rev7 (predicted)
SPBC13G1.10c mug81 ATP-dependent RNA helicase Slh1 (pre-
dicted)
SPBC1539.10 nop16 ribosome biogenesis protein Nop16 (pre-
dicted)
SPBC15C4.01c oca3 TPR repeat protein Oca3/ ER membrane
protein complex Ecm2 (predicted)
SPBC16D10.11c rps1801 40S ribosomal protein S18 (predicted)
SPBC16E9.12c pab2 poly(A) binding protein Pab2
SPBC16G5.15c fkh2 forkhead transcription factor Fkh2
SPBC16H5.08c SPBC16H5.08c ribosome biogenesis ATPase, Arb family
ABCF2-like (predicted)
SPBC1703.12 ubp9 ubiquitin C-terminal hydrolase Ubp9
SPBC1711.03 aim27 ER membrane protein complex subunit
Aim27 (predicted)
SPBC1718.03 ker1 DNA-directed RNA polymerase I com-
plex subunit Ker1
SPBC1734.12c alg12 dolichyl pyrophosphate Man7GlcNAc2
alpha-1,6-mannosyltransferase Alg12
(predicted)
SPBC17A3.06 SPBC17A3.06 phosphoprotein phosphatase (predicted)
SPBC17D1.06 dbp3 ATP-dependent RNA helicase Dbp3
(predicted)
SPBC18H10.07 SPBC18H10.07 WW domain-binding protein 4 (pre-
dicted)
SPBC18H10.13 rps1402 40S ribosomal protein S14 (predicted)
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SPBC19F8.08 rps401 40S ribosomal protein S4 (predicted)
SPBC19G7.17 SPBC19G7.17 translocon subunit Sec61 homolog (pre-
dicted)
SPBC1D7.04 mlo3 RNA binding protein Mlo3
SPBC20F10.05 nrl1 NRDE-2 family protein (predicted)
SPBC211.06 gfh1 gamma tubulin complex subunit Gfh1
SPBC215.02 bob1 prefoldin subunit 5 (predicted)
SPBC21B10.10 rps402 40S ribosomal protein S4 (predicted)
SPBC21B10.13c yox1 MBF complex corepressor Yox1
SPBC21C3.20c git1 C2 domain protein Git1
SPBC27B12.10c tom7 mitochondrial TOM complex subunit
Tom7 (predicted)
SPBC27B12.11c pho7 transcription factor Pho7
SPBC28E12.04 SPBC28E12.04 Schizosaccharomyces specific protein
SPBC29A3.02c his7 phosphoribosyl-AMP
cyclohydrolase/phosphoribosyl- ATP
pyrophosphohydrolase His7
SPBC2F12.09c atf21 transcription factor, Atf-CREB family
Atf21
SPBC2G5.02c ckb2 CK2 family regulatory subunit Ckb2
(predicted)
SPBC2G5.06c hmt2 sulfide-quinone oxidoreductase
SPBC30D10.16 pha2 phrenate dehydratase
SPBC30D10.18c rpl102 60S ribosomal protein L10a
SPBC32F12.05c cwf12 complexed with Cdc5 protein Cwf12
SPBC32F12.11 tdh1 glyceraldehyde-3-phosphate dehydroge-
nase Tdh1
SPBC32H8.07 git5 heterotrimeric G protein beta subunit
Git5
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SPBC337.04 ppk27 serine/threonine protein kinase Ppk27
(predicted)
SPBC337.09 erg28 Erg28 protein (predicted)
SPBC36.07 elp1 elongator subunit Elp1 (predicted)
SPBC3B9.13c rpp102 60S acidic ribosomal protein A3
SPBC3D6.04c mad1 mitotic spindle checkpoint protein Mad1
SPBC3E7.09 SPBC3E7.09 Sad1-UNC-like protein involved protein
folding in the ER (predicted)
SPBC530.05 prt1 transcription factor (predicted)
SPBC56F2.08c SPBC56F2.08c RNA-binding protein (predicted)
SPBC609.05 pob3 FACT complex subunit Pob3
SPBC651.09c prf1 RNA polymerase II associated Paf1 com-
plex (predicted)
SPBC660.07 ntp1 alpha,alpha-trehalase Ntp1
SPBC6B1.06c ubp14 ubiquitin C-terminal hydrolase Ubp14
SPBC725.01 SPBC725.01 aspartate aminotransferase (predicted)
SPBC725.14 arg6 acetylglutamate synthase Arg6 (pre-
dicted)
SPBC887.17 SPBC887.17 transmembrane transporter (predicted)
SPBC8D2.12c SPBC8D2.12c mitochondrial translational activator of
cytochrome C oxidase I (predicted)
SPBC8D2.17 gmh4 alpha-1,2-galactosyltransferase (pre-
dicted)
SPBC8D2.18c SPBC8D2.18c adenosylhomocysteinase (predicted)
SPBP35G2.08c air1 zinc knuckle TRAMP complex subunit
Air1
SPBP4H10.13 rps2302 40S ribosomal protein S23 (predicted)
SPBP8B7.10c utp16 U3 snoRNP-associated protein Utp16
(predicted)
SPBPB7E8.02 SPBPB7E8.02 PSP1 family protein
Continued on next page
233
Table B.2 – Continued from previous page
Systematic ID Name Description
SPCC1020.06c tal1 transaldolase (predicted)
SPCC1020.07 SPCC1020.07 haloacid dehalogenase-like hydrolase
SPCC1020.10 oca2 serine/threonine protein kinase Oca2
SPCC1020.11c ecm6 ER membrane protein complex subunit 6
(predicted)
SPCC1183.02 SPCC1183.02 glutathione S-transferase (predicted)
SPCC11E10.03 mug1 dynactin complex subunit, dynamitin
(predicted)
SPCC11E10.05c ynd1 nucleoside diphosphatase Ynd1
SPCC11E10.06c elp4 elongator complex subunit Elp4 (pre-
dicted)
SPCC11E10.08 rik1 silencing protein Rik1
SPCC11E10.09c SPCC11E10.09c alpha-amylase homolog (predicted)
SPCC1223.01 SPCC1223.01 ubiquitin-protein ligase E3 (predicted)
SPCC1223.06 tea1 cell end marker Tea1
SPCC1223.12c meu10 GPI anchored cell surface protein in-
volved in ascospore wall assembly
Meu10
SPCC1235.05c fft2 SMARCAD1 family ATP-dependent
DNA helicase Fft2 (predicted)
SPCC1235.13 ght6 hexose transporter Ght6
SPCC1259.03 rpa12 DNA-directed RNA polymerase complex
I subunit Rpa12
SPCC1259.08 SPCC1259.08 conserved fungal protein, DUF2457 fam-
ily
SPCC1259.09c pdx1 pyruvate dehydrogenase protein x com-
ponent, Pdx1 (predicted)
SPCC1259.10 pgp1 mitochondrial metallopeptidase, tRNA
N6-threonyl-carbamoyl-adenosine (t6A),
a modification protein Pgp1
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SPCC1259.11c gyp2 GTPase activating protein Gyp2 (pre-
dicted)
SPCC1259.14c meu27 UPF0300 family protein 5
SPCC1281.04 SPCC1281.04 pyridoxal reductase (predicted)
SPCC1281.07c SPCC1281.07c glutathione S-transferase (predicted)
SPCC1281.08 wtf11 wtf element Wtf11
SPCC132.01c mtr1 microtubule regulator Mtr1
SPCC132.02 hst2 Sir2 family histone deacetylase Hst2
SPCC132.04c gdh2 NAD-dependent glutamate dehydroge-
nase Gdh2 (predicted)
SPCC1322.02 pxd1 structure-specific DNA nuclease regula-
tor Pxd1
SPCC1322.03 trp1322 TRP-like ion channel (predicted)
SPCC1322.06 kap113 karyopherin Kap113
SPCC1322.07c mug150 Schizosaccharomyces pombe specific
protein Mug150
SPCC1322.08 srk1 MAPK-activated protein kinase Srk1
SPCC1322.14c vtc4 vacuolar transporter chaperone (VTC)
complex subunit (predicted)
SPCC1322.15 rpl3402 60S ribosomal protein L34
SPCC1322.16 phb2 prohibitin Phb2 (predicted)
SPCC1393.10 ctr4 copper transporter complex subunit Ctr4
SPCC1393.13 SPCC1393.13 DUF89 family protein
SPCC1450.02 bdf1 Swr1 complex bromodomain subunit
Brf1
SPCC162.10 ppk33 serine/threonine protein kinase Ppk33
(predicted)
SPCC162.12 tco89 TORC1 subunit Tco89
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SPCC1672.06c asp1 inositol hexakisphosphate kinase/inositol
pyrophosphate synthase (predicted)
SPCC1682.14 rpl1902 60S ribosomal protein L19
SPCC16A11.01 SPCC16A11.01 plasma membrane protein involved in
inositol lipid-mediated signalling Sfk1
(predicted)
SPCC16A11.03c SPCC16A11.03c DUF2009 protein
SPCC16A11.04 snx12 sorting nexin Snx12 (predicted)
SPCC16A11.07 coq10 mitochondrial ubiquinone binding pro-
tein Coq10
SPCC16A11.08 atg20 sorting nexin Atg20 (predicted)
SPCC16A11.16c rpn1302 19S proteasome regulatory subunit
Rpn13b
SPCC16C4.04 SPCC16C4.04 Schizosaccharomyces specific protein
SPCC16C4.14c sfc4 transcription factor TFIIIC complex sub-
unit Sfc4
SPCC16C4.17 mug123 Schizosaccharomyces specific protein
Mug123
SPCC1739.06c SPCC1739.06c uroporphyrin methyltransferase (pre-
dicted)
SPCC1753.02c git3 G-protein coupled receptor Git3
SPCC1753.03c rec7 meiotic recombination protein Rec7
SPCC1753.05 rsm1 RNA export factor Rsm1
SPCC1795.03 gms1 UDP-galactose transporter Gms1
SPCC1795.09 yps1 aspartic protease, yapsin Yps1
SPCC1795.10c SPCC1795.10c Sed5 Vesicle Protein Svp26 (predicted)
SPCC18.17c SPCC18.17c proteasome assembly chaperone (pre-
dicted)
SPCC1840.03 sal3 karyopherin Sal3
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SPCC188.02 par1 protein phosphatase regulatory subunit
Par1
SPCC188.08c ubp5 ubiquitin C-terminal hydrolase Ubp5
SPCC188.09c pfl4 cell surface glycoprotein, adhesion
molecule (predicted)
SPCC188.12 spn6 septin Spn6 (predicted)
SPCC18B5.03 wee1 M phase inhibitor protein kinase Wee1
SPCC18B5.06 dom34 peloto ortholog (predicted)
SPCC18B5.11c cds1 replication checkpoint kinase Cds1
SPCC1906.02c cue3 CUE domain protein Cue3 (predicted)
SPCC191.09c gst1 glutathione S-transferase Gst1
SPCC1919.05 SPCC1919.05 Ski complex TPR repeat subunit Ski3
(predicted)
SPCC23B6.01c SPCC23B6.01c oxysterol binding protein (predicted)
SPCC23B6.02c SPCC23B6.02c pre-ribosomal factor (predicted)
SPCC23B6.03c tel1 ATM checkpoint kinase
SPCC23B6.05c ssb3 DNA replication factor A subunit Ssb3
SPCC24B10.02c SPCC24B10.02c NAD/NADH kinase (predicted)
SPCC24B10.10c yta4 mitochondrial outer membrane ATPase
Msp1/Yta4 (predicted)
SPCC24B10.11c mft1 THO complex subunit 7 Mft1 (predicted)
SPCC24B10.13 skb5 Shk1 kinase binding protein 5
SPCC24B10.14c xlf1 xrcc4 like factor, cernunnon
SPCC24B10.15 SPCC24B10.15 RNA endoribonuclease involved in
mRNP quality control (predicted)
SPCC24B10.16c SPCC24B10.16c proteasome assembly chaperone 4 (pre-
dicted)
SPCC24B10.18 SPCC24B10.18 human Leydig cell tumor 10 kDa protein
homolog
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SPCC24B10.19c nts1 Schizosaccharomyces specific protein
SPCC24B10.20 SPCC24B10.20 short chain dehydrogenase (predicted)
SPCC285.09c cgs2 cAMP-specific phosphodiesterase Cgs2
SPCC285.15c rps2802 40S ribosomal protein S28, Rps2802
SPCC285.17 spp27 RNA polymerase I upstream activation
factor complex subunit Spp27
SPCC2H8.05c dbl1 Schizosaccharomyces specific protein,
double strand break localizing Dbl1
SPCC306.07c SPCC306.07c U3 snoRNP-associated protein
Cic1/Utp30 family (predicted)
SPCC306.11 SPCC306.11 Schizosaccharomyces specific protein
SPCC31H12.02c mug73 plasma membrane transmembrane trans-
port regulator (predicted)
SPCC31H12.06 mug111 major facilitator family transmembrane
transporter Mug111 (predicted)
SPCC320.03 SPCC320.03 transcription factor (predicted)
SPCC320.06 SPCC320.06 conserved fungal protein
SPCC320.14 sry1 serine racemase Sry1
SPCC330.02 rhp7 Rad7 homolog Rhp7
SPCC330.06c pmp20 thioredoxin peroxidase Pmp20
SPCC330.07c SPCC330.07c membrane transporter (predicted)
SPCC330.11 btb1 BTB/POZ domain protein Btb1
SPCC330.12c sdh3 succinate dehydrogenase (ubiquinone)
cytochrome b subunit (predicted)
SPCC330.14c rpl2402 60S ribosomal protein L24 (predicted)
SPCC338.02 mug112 Schizosaccharomyces pombe specific
protein Mug112
SPCC338.04 cid2 caffeine induced death protein Cid2
SPCC338.11c rrg1 protein-lysine N-methyltransferase Rrg1
(predicted)
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SPCC338.16 pof3 F-box protein Pof3
SPCC338.18 SPCC338.18 Schizosaccharomyces pombe specific
protein
SPCC417.07c mto1 MT organizer Mto1
SPCC4B3.02c SPCC4B3.02c Golgi transport protein Got1 (predicted)
SPCC4B3.03c SPCC4B3.03c mitochondrial morphology protein (pre-
dicted)
SPCC4B3.06c SPCC4B3.06c NADPH-dependent FMN reductase (pre-
dicted)
SPCC4B3.07 nro1 negative regulator of Ofd1, Nro1
SPCC4B3.08 lsg1 Lsk1 complex gamma subunit (pre-
dicted)
SPCC4B3.11c fra3 mitochondrial transcriptional repressor
protein BolA domain (predicted)
SPCC4B3.12 set9 histone lysine H3-K20 methyltransferase
Set9
SPCC4B3.13 SPCC4B3.13 MatE family transporter (predicted)
SPCC4G3.04c coq5 C-methyltransferase (predicted)
SPCC4G3.10c rhp42 DNA repair protein Rhp42
SPCC550.01c coa4 mitochondrial respiratory chain complex
assembly protein (predicted)
SPCC550.03c SPCC550.03c Ski complex RNA helicase Ski2 (pre-
dicted)
SPCC550.08 SPCC550.08 N-acetyltransferase (predicted)
SPCC550.09 SPCC550.09 peroxin Pex32 (predicted)
SPCC550.10 atd3 aldehyde dehydrogenase Atd3 (pre-
dicted)
SPCC550.11 SPCC550.11 karyopherin (predicted)
SPCC550.15c SPCC550.15c ribosome biogenesis protein (predicted)
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SPCC553.01c dbl2 meiotic chromosome segregation protein
Dbl2
SPCC553.03 pex1 AAA family ATPase Pex1 (predicted)
SPCC553.12c SPCC553.12c transmembrane transporter (predicted)
SPCC584.03c SPCC584.03c Ran GTP-binding protein (predicted)
SPCC584.13 SPCC584.13 amino acid permease (predicted)
SPCC584.15c SPCC584.15c arrestin/PY protein 2
SPCC584.16c SPCC584.16c Schizosaccharomyces specific protein
SPCC594.01 SPCC594.01 DUF1769 family protein
SPCC594.02c SPCC594.02c conserved fungal protein
SPCC594.06c SPCC594.06c vacuolar SNARE Vam7 (predicted)
SPCC594.07c bqt3 bouquet formation protein Bqt3
SPCC61.03 SPCC61.03 NADHX dehydratase (predicted)
SPCC61.05 SPCC61.05 S. pombe specific multicopy membrane
protein family 1
SPCC613.01 SPCC613.01 membrane transporter (predicted)
SPCC613.02 SPCC613.02 membrane transporter (predicted)
SPCC613.06 rpl902 60S ribosomal protein L9
SPCC613.12c raf1 CLRC ubiquitin E3 ligase complex
specificiy factor Raf1/Dos1
SPCC622.01c SPCC622.01c dubious
SPCC622.08c hta1 histone H2A alpha
SPCC622.12c gdh1 NADP-specific glutamate dehydrogenase
Gdh1 (predicted)
SPCC622.14 SPCC622.14 GTPase activating protein (predicted)
SPCC622.15c SPCC622.15c Schizosaccharomyces specific protein
SPCC622.16c epe1 Jmjc domain chromatin associated pro-
tein Epe1
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SPCC622.17 apn1 Major apurinic/apyrimidinic endonucle-
ase
SPCC622.19 jmj4 Jmj4 protein (predicted)
SPCC63.03 SPCC63.03 DNAJ domain protein, DNAJC11 family
SPCC63.04 mok14 alpha-1,4-glucan synthase Mok14
SPCC63.06 SPCC63.06 human WDR89 family WD repeat pro-
tein
SPCC63.14 eis1 eisosome assembly protein eis1
SPCC645.07 rgf1 RhoGEF for Rho1, Rgf1
SPCC645.08c snd1 RNA-binding protein, involved in chro-
matin silencing by small RNA, Snd1
SPCC645.11c mug117 conserved fungal protein Mug117
SPCC645.12c SPCC645.12c Schizosaccharomyces specific protein
SPCC645.13 SPCC645.13 transcription elongation regulator/
ubiquitin-protein ligase (predicted)
SPCC663.03 pmd1 leptomycin efflux transporter Pmd1
SPCC736.04c gma12 alpha-1,2-galactosyltransferase Gma12
SPCC736.07c SPCC736.07c unconventional prefoldin involved in
translation initiation (predicted)
SPCC736.09c SPCC736.09c TRAX
SPCC736.13 SPCC736.13 short chain dehydrogenase (predicted)
SPCC737.06c SPCC737.06c glutamate-cysteine ligase regulatory sub-
unit (predicted)
SPCC74.02c ppn1 PNUTS homologue, mRNA cleavage
and polyadenylation specificity factor
complex associated protein
SPCC757.05c SPCC757.05c peptidase family M20 protein
SPCC757.07c ctt1 catalase
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SPCC757.09c rnc1 RNA-binding protein that suppresses
calcineurin deletion Rnc1
SPCC757.12 SPCC757.12 alpha-amylase homolog (predicted)
SPCC777.03c SPCC777.03c nifs homolog, possible cysteine desul-
furase
SPCC777.13 vps35 retromer complex subunit Vps35
SPCC777.15 SPCC777.15 tRNA dihydrouridine synthase Dus4
(predicted)
SPCC794.09c tef101 translation elongation factor EF-1 alpha
Ef1a-a
SPCC794.11c ent3 ENTH/VHS domain protein Ent3 (pre-
dicted)
SPCC825.04c naa40 histone N-acetyltransferase Naa40 (pre-
dicted)
SPCC825.05c pwi1 splicing coactivator SRRM1 (predicted)
SPCC895.07 alp14 TOG ortholog Alp14
SPCC895.09c ucp12 ATP-dependent RNA helicase Ucp12
(predicted)
SPCC962.04 rps1201 40S ribosomal protein S12 (predicted)
SPCC970.05 rpl3601 60S ribosomal protein L36
SPCP25A2.02c rhp26 SNF2 family helicase Rhp26
SPCP31B10.07 eft202 translation elongation factor 2 (EF-2)
Eft2,B
SPCPB16A4.02c SPCPB16A4.02c conserved fungal protein
SPCPB16A4.03c ade10 bifunctional IMP cyclohydrolase/
SPCPB16A4.04c trm8 tRNA (guanine-N7-)-methyltransferase
catalytic subunit Trm8 (predicted)
SPCPB16A4.05c SPCPB16A4.05c urease accessory protein UREG (pre-
dicted)
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SPCPB16A4.06c SPCPB16A4.06c Schizosaccharomyces specific protein
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